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Abstract 
Rheumatoid arthritis (RA) represents a disease continuum from the pre-clinical 
period, through undifferentiated inflammatory arthritis (IA) to early then established 
RA. Improved patient outcomes in recent years reflect early diagnosis, prompt 
disease-modifying anti-rheumatic drug (DMARD) therapy, treat-to-target strategies 
and use of biological therapies (bDMARDs) particularly following failure of 
conventional synthetic therapies (csDMARDs). Optimal use of bDMARDs in early 
disease, however, has not been established. Early detection in the pre-clinical stage 
is potentially achievable with modern diagnostics but understanding of how to use 
these biomarkers is lacking.  
A systematic literature review on the use of bDMARDs was performed and 
confirmed the efficacy of bDMARDs in patients with established RA. Few studies 
were found addressing their use in early disease.  
Two randomised controlled trials were performed to explore early bDMARD 
intervention. The first, in early DMARD-naïve RA, compared methotrexate and 
infliximab to methotrexate and high-dose intravenous methylprednisolone as 
induction therapy, followed by a treat-to-target strategy; both arms demonstrated 
efficacy with no significant between-group differences. In the second, early DMARD 
naïve IA patients treated with combination etanercept and methotrexate had earlier 
clinical improvement than methotrexate monotherapy; however both groups 
achieved good 12 month outcomes.  
In a longitudinal cohort study conducted in secondary care, 50% of patients with 
musculoskeletal (MSK) symptoms and anti-cyclic citrullinated peptide (anti-CCP) 
antibodies progressed to clinical IA. Use of additional biomarkers including 
rheumatoid factor, shared epitope and ultrasound enabled further risk stratification 
for progression. In a primary care cohort, the anti-CCP antibody was positive in 
2.8% with new nonspecific MSK symptoms with almost half progressing to IA.  
In summary, in early DMARD naïve IA, use of  bDMARD may not be superior to 
csDMARDs with a treat-to-target approach. In patients with MSK symptoms, anti-
CCP testing identifies individuals at risk of developing IA; additional biomarkers 
improve prediction and are feasible for clinical use.  
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Chapter 1 Introduction 
1.1 Background 
Rheumatoid arthritis (RA) can be conceptualised as a continuum of disease - from 
patients at risk, progressing to undifferentiated inflammatory arthritis (IA), through to 
early and established RA (figure 1.1). It is the most common of all the inflammatory 
arthritides, affecting about 1% of the population.3-5 Untreated, RA can have serious 
consequences leading to joint destruction, functional impairment and increased 
mortality.6 7 However, over the past two decades, with the availability of effective 
therapies and the use of early intervention strategies, disease outcomes have 
improved considerably.8 9 The goal of treatment has changed from one of symptom 
control to aiming for suppression of inflammation and remission.10  
In addressing the management of this condition, it is important to note that the 
concept of early IA has evolved over time. First, classification of the phases along 
the IA disease continuum has undergone change with revision of the classification 
of RA and the introduction of the classification of patients ‘at risk’. Second, the 
understanding of the term ‘early’ has also changed over time.  
Until recently RA has been classified according to the 1987 American College of 
Rheumatology (ACR) criteria.11 Whilst accepted classification criteria, it was felt to 
be inadequate for patients with early disease. The 2010 ACR/EULAR classification 
criteria were subsequently designed to identify patients requiring disease-modifying 
antirheumatic drug (DMARD) therapy at an earlier stage.12 Patients with IA who do 
not fulfil criteria for RA are classified as having unclassified or undifferentiated 
arthritis (UA). With research into the phases of the disease prior to detection of 
clinical synovitis, terminologies for individuals ‘at risk’ have also been defined.13 A 
schematic diagram of the IA disease continuum is illustrated in figure 1.1.  
A wide range of definitions have been used in the literature to define early IA or 
early RA. Previously, studies used a cut-off of less than five years to define early 
disease. By the 1990s, symptom duration of less than 12 to 24 months was 
considered early. This duration was chosen because at the end of this period, most 
patients have incurred significant damage when treated conventionally. It is now 
recognised that this period may be limited to weeks or months. There is also 
increasing evidence that very early disease, within the first 12 weeks, may be an 
immunopathologically distinct phase compared to later disease.14  
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Many IA treatment studies now also group patients in terms of previous DMARD 
therapies i.e. those who have had not received previous DMARDs - DMARD-naïve,  
those that may have had DMARD therapy but no methotrexate (MTX) – MTX-naïve, 
methotrexate incomplete responders – MTX-IR and those with incomplete response 
to a tumour necrosis factor inhibitor (TNFi) – TNFi-IR. Where appropriate, the 
recently proposed nomenclature for DMARDs and abbreviations have also been 
used in this thesis: biological- (bDMARD), biosimilar- (bsDMARD), conventional 
synthetic- (csDMARD) and targeted synthetic- (tsDMARD) disease-modifying 
antirheumatic drugs.15  
Although it is widely agreed that patients should be seen and treated at the earliest 
opportunity to achieve optimal disease control, a number of challenges remain. 
These include the decision regarding choice of initial therapy and in particular the 
use and timing of the newer biological therapies in patients with early disease. 
Treating patients in the earlier stages of the disease with early UA has also not 
been widely investigated.  
The importance of early treatment has also placed increasing emphasis on the need 
for early diagnosis. The diagnosis of RA in the earliest phases however can prove 
challenging as patients often present with non-specific symptoms. Several 
biomarkers e.g. rheumatoid factor (RF) have been used. In recent years newer 
serological markers e.g. anti-cyclic citrullinated peptide antibodies (anti-CCP), and 
the use of newer imaging techniques such as ultrasonography have come to the 
fore, but their use in early diagnosis is not yet established.  
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Figure 1.1 Schematic diagram of the inflammatory arthritis disease continuum 
Adapted from Gerlag D. et. al 2012.13 IA, inflammatory arthritis; RA, rheumatoid arthritis; UA, undifferentiated arthritis 
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1.2 Structure of the thesis 
The hypotheses underlying this thesis are that applying the most effective RA 
therapy (bDMARDs) to early IA will improve patient outcomes, and applying modern 
diagnostics will improve early detection (enabling subsequent earlier intervention).  
The structure of the thesis and summary of content of each chapter are outlined 
below. Figure 1.2 depicts the areas along the IA disease continuum that will be 
addressed in each of the chapters. 
Chapter Two: Literature review 
A review of the literature was undertaken to address the current diagnostic and 
treatment strategies for patients with IA. It aimed to address the current 
management principles, providing context to this thesis.  
Chapter Three: A systematic literature review of the efficacy of bDMARDs across 
the IA disease continuum 
A systematic review of the literature (SLR) was undertaken to evaluate the RCT 
evidence for the efficacy of bDMARDs and treatment strategies incorporating 
bDMARDs in patients with IA.  
Chapter Four: A randomised controlled trial of infliximab with methotrexate vs. 
intravenous methylprednisolone with methotrexate as induction therapy in DMARD- 
naïve early RA 
This chapter aimed to compare the use of two induction strategies, (1) using 
infliximab and methotrexate compared to (1) high dose intravenous glucocorticoid 
and methotrexate, together with a treat-to-target approach in patients with early 
DMARD-naïve RA. 
Chapter Five: A randomised controlled trial of etanercept with methotrexate vs. 
methotrexate monotherapy in DMARD-naïve early IA  
In this chapter the use of etanercept and methotrexate was compared to placebo 
and methotrexate in patients with early DMARD-naïve IA. 
Chapter Six: The use of clinical, genetic, serological and imaging biomarkers in anti-
CCP positive patients with nonspecific musculoskeletal (MSK) symptoms to identify 
early IA in secondary care 
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This longitudinal study sought to address the use of several biomarkers in clinical 
practice in secondary care to identify patients with nonspecific MSK symptoms and 
anti-CCP antibodies who are at risk of progression to IA. 
Chapter Seven: The use of anti-CCP antibodies in patients with new nonspecific 
MSK symptoms to identify patients  at risk of early IA in primary care 
In this section the use of anti-CCP antibodies was explored as a biomarker to 
identify individuals at increased risk of developing IA by testing those with new, 
nonspecific MSK symptoms presenting in primary care.  
Chapter Eight: Discussion, conclusions and future directions  
This final chapter reviewed the conclusions drawn from each chapter to provide a 
final summary of the work from this thesis, some of which have been used to inform 
the European League Against Rheumatism (EULAR) guidelines for the treatment of 
RA. The discussion also addressed the limitations of the work that has been done, 
placed it in the context of recent literature, and identified further areas of research in 
the diagnosis and treatment of early IA. 
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Chapter 3   
SLR on the efficacy of bDMARDs across the IA disease continuum16  
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Figure 1.2 Outline of thesis results chapters - addressing the inflammatory arthritis disease continuum 
anti-CCP, anti-cyclic citrullinated peptide antibodies; bDMARD, biological disease-modifying antirheumatic drug; DMARD, disease-
modifying antirheumatic drug; IA, inflammatory arthritis; IV, intravenous; RA, rheumatoid arthritis; RCT, randomised controlled trial; SLR, 
systematic literature review; UA, undifferentiated arthritis
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Chapter 2 Literature Review 
This chapter aimed to review the current management principles of patients with 
inflammatory arthritis, address diagnostic and treatment strategies  across the 
inflammatory arthritis disease continuum, and highlight some of the challenges and 
unanswered questions in this area. 
2.1 The inflammatory arthritis disease continuum 
Inflammatory arthritis is a term used to describe a group of systemic autoimmune 
diseases with predominant joint involvement. The disease affects not only the 
individuals themselves but also has an impact on their families and places a major 
burden on healthcare.21 22 Data from the Arthritis Research UK showed that in 2000, 
there were an estimated 1.9 million general practitioner (GP) consultations in the 
United Kingdom (UK) for IA with almost 46 000 hospital admissions between 1999 
and 2000.23 Of the inflammatory arthritides, RA is the most common. Untreated it 
can have serious consequences, causing irreversible joint damage, functional 
impairment and increased mortality.6 7 24 The focus of this thesis will therefore be on 
the IA pathway leading to the development of RA, which may be describe as a 
continuum of disease - from patients at risk, developing undifferentiated arthritis 
(UA), progressing to early and then established RA (figure 2.1).  
 
Figure 2.1 Inflammatory arthritis disease continuum 
IA, inflammatory arthritis; RA, rheumatoid arthritis; UA, undifferentiated 
arthritis 
At risk 
Symptoms 
without 
clinical 
arthritis 
UA RA  
Remission 
IA other than 
RA 
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This thesis will focus, in particular, on the early stages of the disease continuum. 
From clinical studies there is evidence confirming that joint damage and loss of 
function occur early in the disease process. Radiographic outcome studies have 
shown that 70% of patients with recent onset RA develop bony erosions within the 
first 3 years25 and erosions have been reported in 25% of patients within 3 months 
of disease onset. 26  Newer and more sensitive imaging techniques such as 
magnetic resonance imaging (MRI) and ultrasound have confirmed evidence of 
damage within weeks of symptom onset.27 28 Early radiographic erosions have also 
been shown to predict the future development of further lesions and those seen on 
ultrasound and MRI shown to correlate with later radiographic erosions.29  
The concept of a ‘window of opportunity‘ for the treatment of RA suggests that there 
is a phase early in the disease during which there may be the potential to alter or 
possibly even reverse the disease course with a complete return to normality.30 
Treatment during this period is thought to have a much more profound effect in 
terms of halting disease progression and achieving remission than treatment at a 
later stage (figure 2.2).   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Altering the course of early inflammatory arthritis. 
Adapted from Breedveld FC.31 DMARD, disease-modifying antirheumatic drug 
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presentation). The average time interval between early and late therapy was 9 
months. After a median of 3 years of observation, radiographic progression was 
33% lower in those who received early treatment compared to those in which 
treatment was delayed. 9 Disease duration at the time of starting treatment is 
therefore a significant predictor of response to therapy. 
It has been suggested that the window for early treatment may be much shorter, 
possibly within 12 weeks of symptom onset. 32 In a study by Green et al. in which a 
single dose of glucocorticoid was administered to patients with mild early IA, 
disease duration less than 12 weeks at time of therapy was noted to be the 
strongest predictor of remission at six months. 33 In a SLR by van Nies et al. 34, a 
meta-analysis of three early arthritis datasets also showed symptom duration to be 
independently associated with DMARD-free sustained remission (the outcome 
chosen as deemed the closest proxy of cure in RA) with a hazard ratio (HR)(95%CI) 
0.989 (0.983 to 0.995) and a HR 0.88 using 12 weeks at treatment initiation. 
Radiographic progression was also lower with shorter symptom duration. In a sub-
analysis of the COMET study, a RCT of 417 early RA patients, treatment with 
etanercept and methotrexate in patients with disease duration less than 4 months 
was associated with significantly higher proportions reaching remission and low 
disease activity than when the same treatment was used with a longer disease 
duration.35  
With evidence that joint damage occurs early and that early treatment has a 
significant impact on outcomes, increasing emphasis has been place on the early 
phases of the IA disease continuum.  
The first few weeks or months of symptoms, therefore, represent a potentially 
important therapeutic window in patients with early IA. In practice, these patients 
should be seen early and treated at the earliest opportunity. However, managing 
patients within the early stages presents several challenges: 
1. Identifying and assessing patients with IA early. Seeing patients at the earliest 
opportunity requires early recognition and referral to rheumatology services for 
assessment and decisions regarding therapy. In the earliest phases of the 
disease, however, patients may present with nonspecific MSK symptoms. 
2. Predicting which patients with early IA will develop RA and thus require DMARD 
therapy. As rheumatologists continue to see patients earlier in the course of 
disease, it has also become clear that a proportion of patients, who present with 
an IA, may have UA – a form of arthritis that does not fulfil criteria for a more 
definitive diagnosis. Whilst a proportion will progress to RA, 36 some may 
undergo spontaneous remission whilst others  may progress to other diseases 
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(e.g. systemic lupus erythematosus (SLE) or a spondyloarthropathy) 37 (figure 
2.1). 
3. Determining how such patients should be treated.  
2.2 Classification  
In moving towards earlier patient identification, there have been some changes in 
the nomenclature within the IA continuum.  
1. The classification criteria for RA have been revised with the 2010 ACR/ 
EULAR RA classification criteria12 replacing the 1987 ACR RA classification 
criteria,11 and  
2. New terminology have been developed within the group of individuals at 
risk.13  
2.2.1 Classification of rheumatoid arthritis 
2.2.1.1 1987 ACR RA classification criteria 
As there is no single marker for patients with RA, a combination of clinical features 
and laboratory tests are used for the classification of the disease. Until recently the 
1987 ACR classification criteria have been used for patients with RA.11 They were 
based on seven criteria (table 2.1).  A patient was classified with RA if he/she has 
satisfied at least four of the seven criteria, with criteria 1 to 4 being present for at 
least six weeks. However, as these criteria were developed in populations with long-
standing disease, studies have found that they did not perform as well for the 
diagnosis of recent-onset RA. A SLR found that sensitivity and specificity of the 
1987 ACR criteria in early RA was 77% (68% to 84%) and 77% (68% to 84%) 
respectively using the list format.38 With the relatively poor sensitivity, patients with 
early RA may not fulfil these criteria and may therefore be misclassified. The 
relatively low specificity means that non-RA conditions such as post-viral 
arthropathies, early spondyloarthropathies and other self-limiting arthritides may 
satisfy the classification criteria.   
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Table 2.1 1987 ACR RA classification criteria   
Criterion Definition 
1. Early morning 
stiffness 
Early morning stiffness in and around the joints, lasting at least 
1 hour before maximal improvement.  
2. Arthritis of 3 
or more joint 
areas 
At least 3 joint areas simultaneously have had soft tissue 
swelling or fluid (not bony overgrowth alone) observed by a 
physician. The 14 possible areas are right or left PIP, MCP, 
wrist, elbow, knee, ankle, and MTP joints.  
3. Arthritis of 
hand joints 
At least 1 area swollen (as defined above) in a wrist, MCP, or 
PIP joint.  
4. Symmetric 
arthritis 
Simultaneous involvement of the same joint areas (as defined 
in 2) on both sides of the body (bilateral involvement of PIPs, 
MCPs, or MTPs is acceptable without absolute symmetry).  
5. Rheumatoid 
nodules 
Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxta-articular regions, observed by a physician.  
6. Rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive in 
<5% of normal control subjects.  
7. Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on antero-
posterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in or 
most marked adjacent to the involved joints (osteoarthritis 
changes alone do not qualify).  
 
MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal 
interphalangeal 
 
2.2.1.2 2010 ACR-EULAR RA classification criteria 
The 2010 ACR/EULAR RA classification criteria were later developed through a 
collaborative initiative between the ACR and EULAR aiming to define RA at an 
earlier stage. 12 The aim of these classification criteria was to identify patients with 
an IA with relatively short symptom duration who would benefit from early diagnosis 
and early institution of DMARD therapy (table 2.2). 
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For the classification criteria to be applied, patients must meet two mandatory 
requirements. First, there must be clinical evidence of synovitis (i.e. swelling) in at 
least one joint. All joints of a full joint count may be assessed for this purpose with 
the exception of the distal interphalangeal (DIP) joints, the first metatarsophalangeal 
(MTP) joints, and the first carpometacarpal (CMC) joints as these joints are typically 
involved in osteoarthritis. Second, the synovitis should not be better explained by 
another diagnosis (e.g. SLE, psoriatic arthritis, and gout). Classification as definite 
RA is then based on achieving a total score of 6 or more out of 10 from individual 
scores in four domains. These are the: 
 number and site of involved joints (score range 0–5);  
 serological abnormality (score range 0–3);  
 elevated acute phase response (score range 0–1); and  
 symptom duration (score range 0–1).  
As a caveat, patients with RA type erosions on X-ray with a typical history of RA 
may also be classified as such and the scoring system need not be applied. 
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Table 2.2 2010 American College of Rheumatology/ European League Against 
Rheumatism classification criteria for rheumatoid arthritis 
Joint involvement1  
1 large2 joint 0 
2–10 large joints  1 
1–3 small3 joints (with or without involvement of large joints) 2 
4–10 small joints (with or without involvement of large joints)  3 
>10 joints4 (at least one small joint) 5 
Serology5 (at least one test result is needed for classification)  
Negative RF AND negative ACPA 0 
Low positive RF OR low positive ACPA 2 
High positive RF OR high positive ACPA 3 
Acute phase reactants6 (at least one test result is needed for classification)  
Normal CRP AND normal ESR  0 
Abnormal CRP OR abnormal ESR  1 
Duration of symptoms7 
<6 weeks 0 
≥6 weeks 1 
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(1) Joint involvement refers to any swollen or tender joint on examination, 
which may be confirmed by imaging evidence of synovitis. Categories of joint 
distribution are classified according to the location and number of the involved 
joints, with placement into the highest category possible based on the pattern 
of joint involvement.(2) Large joints refer to shoulders, elbows, hips, knees and 
ankles.(3) Small joints refer to the wrists, metacarpophalangeal (MCP) joints, 
proximal interphalangeal (PIP) joints, thumb interphalangeal (IP) joints, and 
metatarsophalangeal (MTP) joints 2–5. (4) In this category, at least one of the 
involved joints must be a small joint; the other joints can include any 
combination of large and additional small joints, as well as other joints not 
specifically listed elsewhere (eg, temporomandibular, acromioclavicular, and 
sternoclavicular joints).(5) Negative refers to international unit (IU) values that 
are ULN for the lab and assay. Low titre refers to IU values that are >ULN but 
3X ULN for lab and assay. High titre positive is >3X ULN for lab and assay. 
Where RF is only available as positive or negative, a positive results should be 
scored as ‘low positive’ for RF. (6) Normal/abnormal is determined by local 
laboratory standards. (Other causes for elevated acute phase reactants should 
be excluded) (7) Duration of symptoms refers to patient self-report of the 
duration of signs or symptoms of synovitis (e.g. pain, swelling, tenderness) of 
joints that are clinically involved at the time of assessment, regardless of 
treatment status. ACPA, anti-citrullinated protein/peptide antibodies; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; 
ULN, upper limit of normal. Reproduced with permission from Aletaha et al 12. 
 
2.2.2 Classification of undifferentiated arthritis 
There are currently no specific criteria for undifferentiated or unclassified arthritis. 
This term is generally used to define cases in which there is clinical synovitis not 
fulfilling RA classification criteria and not due to another disease e.g. crystal 
arthropathy, reactive arthritis, a spondyloarthropathy or SLE.34 It is important to 
note, particularly when reviewing the literature that patients not fulfilling the 1987 
ACR RA classification criteria who were previously classified as UA may now fulfil 
the 2010 ACR/EULAR classification criteria for RA. 
 
2.2.3 Classification of individuals at risk  
Increasingly work has also been done looking at the phases prior to the 
development of clinical synovitis aiming to identify patients at the very earliest 
stages. Research into these early stages had led to the formation of a ‘Study Group 
for Risk Factors for Rheumatoid Arthritis’.13 The group has published recommended 
terminology to define the specific phases up to the development of RA in order to 
phenotype/ characterise these and to standardise further research in the field (table 
2.3). 
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Table 2.3 Recommendation for terminology to be used to define specific phases up 
to the development of RA 13 
 
Phases up to the development of RA 
In prospective studies individuals would be described as having: 
a. Genetic risk factors for RA 
b. Environmental risk factors for RA 
c. Systemic autoimmunity associated with RA 
d. Symptoms without clinical arthritis 
e. Unclassified arthritis 
f. RA 
The term ’arthritis’ is used to denote clinically apparent soft tissue swelling or fluid 
(not bony overgrowth alone). 
(a) to (e) can be used in a combinatorial manner for example, an individual may 
have (a)+(b), or (a)+(b)+(c) or (a)+(b)+(d) etc. 
The prefix ‘pre-RA with:’ can be used before any/any combination of (a) to (e) but 
only to describe retrospectively a phase an individual was in once it is known that 
they have developed RA. 
 
2.3 Epidemiology  
2.3.1 Incidence and prevalence 
Recognising the need to diagnose patients with IA early led to the development of 
Early Arthritis Clinics. These enabled patients with suspected IA rapid access to 
rheumatology services.39 Data from these clinics together with that from the general 
population have provided information on the incidence of early IA, UA and RA, and 
the proportions and risk factors for the progression from UA to RA.40   
Three population based studies have reported on the incidence of early IA, including 
RA and UA. In Finland the reported annual incidence of clinically observed early IA 
was 271/100 000 adult population, with that of RA of 36/100 000 and that of UA 
149/100 000 adults.41 Data from a study in South Sweden estimated an annual 
incidence of new IA in adults of 115/100 000 - 24/100 000 for RA and 41/100 000 
for UA.42 In a Spanish study, early arthritis (defined as > 1 painful or swollen 
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metacarpophalangeal (MCP) or MTP  joint with early morning stiffness (EMS) > 30 
minutes and the presence of symptoms > 1 month and < 1year)43 was estimated to 
occur in 25/100 000 population.44 After 6 months follow up, 8/100 000 adults were 
diagnosed with RA (1987 ACR criteria) and 3/100 000 were regarded to have UA.  It 
is likely that the difference in the definitions used for early IA account in part for the 
differences in incidence rates between these populations. It is also know that the 
incidence of RA varies according to geographic location.45  
RA, the most common IA, has a worldwide prevalence of approximately 0.5-1%. 3-5 
46 In Northern Europe and the USA, the reported prevalence according to the 1987 
ACR RA classification criteria  was between 500-100/100 000 population with an 
annual incidence of approximately 40/100 000. It was estimated that about 387 000 
adults in the UK have RA 4 with approximately 12 000 new cases per year. In 
Southern Europe, China and South America, reported prevalence has been slightly 
lower (<500/100 000).45 Age of onset is commonly over 50 years, however it may 
occur at any age. 4 47 From the Rochester Epidemiology Project, there was a rise 
with age with a peak incidence in patients between 65-74 years of age (89/100 
000).48 The female-to-male ratio is about 3:1. 
With the change in the RA classification criteria, the incidence of RA in the UK was 
reviewed using data from the Norfolk Arthritis Register (NOAR).49 This primary care 
inception cohort comprised patients ≥ 16 years with IA in two or more swollen joints, 
notified between 1990 - 1995 with symptom onset in 1990. The incidence of RA was 
40/100 000 applying the 2010 ACR/EULAR criteria and 32/100 000 using the 1987 
ACR criteria at baseline. Applying the criteria cumulatively over 5 years, incidence 
rates were similar for both criteria (48/100 000 for the 2010 ACR/EULAR criteria and 
44/100 000 for the 1987 ACR criteria) suggesting that whilst both classified similar 
patients with RA over this period, the new criteria identified patients with RA who 
presented with an IA earlier in the course of their disease.  
 
2.3.2 Aetiology 
The exact aetiology of IA leading to RA is unknown. As with other autoimmune 
diseases, the hypothesis is that it occurs in a genetically susceptible individual with 
an environmental exposure or ‘trigger’.50  
Twin studies have shown concordance rates of 5% among dizygotic twins and 15-
30% among monozygotic twins.51 The human leucocyte antigens (HLA-DRB1) 
alleles is the main genetic risk factor for inflammatory polyarthritis with the HLA-
DRB1*0404 conferring the greatest risk.52 Other genetic factors have also been 
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identified and will be discussed in more detail later in the chapter. The heritability of 
RA has been estimated to be 60%, suggesting that 40% of the risk of developing 
RA may be determined by environmental factors.51 53  
Several environmental risk factors have been identified.54 Of these, cigarette 
smoking is the most significant and is associated with an increased risk of RA and 
the development of RF.55 56 Smokers who possess the shared epitope genes in 
particular are at increased risk of ACPA-positive RA.57 Smoking is estimated to be 
responsible for 35% of ACPA-positive RA and in homozygous patients, 55% of 
ACPA-positive RA was attributable to smoking.58 Use of the oral contraceptive pill 
and pregnancy have been associated with a lower incidence or RA.59  
More recently studies have suggested that the initiating site of inflammation in IA 
may take place in areas outside the joint, with particular focus on mucosal sites.60 
An association between periodontitis and RA has been described in several clinical 
studies.61-63  Porphymonas gingivalis, an oral pathogen and a common cause of 
periodontitis, is one mucosal pathogen that has been implicated in the disease 
pathogenesis. 64 It is capable of expressing the enzyme peptidyl arginine deiminase, 
type IV (PADI4) which is needed to generate citrullinated peptides. Increases in 
intestinal Prevotella copri have also been described in patients with new-onset 
untreated RA.65 
The trigger for the subsequent loss of systemic tolerance is still unclear. Local 
biomechanical, micro-trauma, microvascular and neurologic-related mechanisms 
have been suggested as possible factors. 50 The subsequent immune dysregulation, 
with release of pro-inflammatory cytokines and chemokines, neoangiogenesis, 
activation of endothelial cells and fibroblasts and leucocyte infiltration into the 
synovium, lead to the inflammation of synovial tissue. Perpetuation of this immune 
response results in cartilage and bone destruction and the systemic consequences 
seen in patients with RA. 
 
2.3.3 Natural history 
It has been suggested that in one third of patients with recent onset IA it may not be 
possible to come to a definitive diagnosis at presentation.66 The outcome of these 
patients may vary and the diagnosis may change over the period of follow-up. Some 
patients will progress to RA, and some to other rheumatic diseases. Others will 
remain undifferentiated or enter into remission. Data from several inception cohorts 
have suggested that of the patients that present with UA, 40-50% will remit and 30% 
will evolve into RA (based on the 1987 ACR criteria). 37 66 67 It is almost certain that 
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proportions classified as UA will be lower and those with RA higher using the newer 
classification criteria. 
In patients with RA spontaneous remission is rare. In a cohort of 458 patient with 
RA followed up for 1131 patient years, 14% achieved remission without treatment.68 
In another study of 183 RA patients with a follow-up of 5 years, a remission rate of 
20% was described; 11% were spontaneous and 9% were drug-induced.69 In the 
majority of patients therefore who progress to RA, the disease persists. In many, 
untreated this results in joint damage, functional decline and may lead to premature 
mortality.  
2.4 Diagnosis  
There is no single diagnostic test for patients with early IA. Evaluation requires a 
combination of clinical features and laboratory tests. The key issue when seeing 
these patients is determining their prognosis - differentiating those with self-limiting 
disease from those at risk of developing persistent inflammatory and erosive arthritis 
to allow the initiation of appropriate DMARD therapy for those that will progress and 
prevent unnecessary treatment for those that will resolve. 
The following steps have been suggested as an approach to evaluate patients with 
early arthritis:70  
 Recognise the presence of IA  
 Exclude diseases other than RA or UA that present as an early IA (e.g. SLE, 
psoriatic arthritis or other spondyloarthropathies). 
 Estimate the risk of developing persistent or erosive irreversible arthritis in 
patients with RA or UA using a combination of clinical features, laboratory 
tests and imaging techniques.  
The development of the 2010 ACR/EULAR RA classification criteria are based on 
these principles and have helped to identify patients with RA at a early stage. 
All new patients with symptoms of an IA should be referred to a rheumatologist as 
early as possible, ideally within 6 weeks of symptom onset.71 As a proportion of 
patients will have normal/ negative results at disease onset, they should be referred 
regardless of blood test results or radiographic findings. If tests are done in primary 
care referral should not be delayed while waiting for results.  
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2.4.1 History  
The clinical evaluation remains the cornerstone for evaluating early IA - determining 
whether arthritis is present or not, differentiating between inflammatory or non-
inflammatory disease and deciding aetiology of the arthropathy. Articular symptoms 
may be the presenting manifestation of many infectious, inflammatory or malignant 
conditions. The clinical feature may also provide clues to identify those at risk of 
developing persistent erosive disease (table 2.3).  
A thorough history includes the distribution of the symptomatic joints, duration of 
symptoms and early morning stiffness, response to non-steroidal anti-inflammatory 
drugs (NSAIDS), any prodromal illness and associated symptoms. Family history is 
important for RA, psoriasis and other autoimmune diseases. Personal and past 
medical histories including smoking history should also be noted.  
 
2.4.2 Clinical features  
The clinical finding of joint swelling not caused by trauma or bony swelling suggests 
a diagnosis of early IA, especially if it includes involvement of at least two joints 
and/or EMS lasting 30 minutes or more. Hand or foot involvement is common in 
inflammatory arthropathies. A positive MCP or MTP ‘squeeze test’ has been used to 
identify patients at risk of developing RA early (figure 2.4). 43 
 
 
 
Figure 2.3 Metacarpophalangeal squeeze test 
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While joint symptoms predominate early in disease, extra-articular manifestations of 
RA (e.g. nodules, keratoconjunctivitis sicca) are seldom present early. In other 
forms of polyarthritis, extra-articular manifestations may be present early and may 
precede the onset of synovitis, providing clinical clues to the diagnosis. This is 
particularly true with SLE (malar rash, serositis), reactive arthritis (urethritis, 
conjunctivitis), psoriatic arthritis (psoriasis, nail pitting or other nail changes) and 
sarcoidosis (lung involvement, fever) 72 (table 4).  
 
2.4.3 Investigations 
Laboratory investigations and imaging are ancillary measures for the diagnosis and 
prognosis of patients presenting with early IA and should be tailored to the 
individual. These have their limitations - in the early phases of the disease in 
particular tests can be within normal limits. Imaging techniques are potentially 
helpful in this setting.  
Most cases of suspected IA will warrant a complete blood count, inflammatory 
markers, basic serology including RF, ACPA and antinuclear antibodies, renal and 
liver function tests and a urine analysis. 
More specific tests may be directed by the clinical presentation including tests for 
uric acid, cultures where infection may be suspected, serology for atypical infections 
e.g. Lyme disease, virology e.g. hepatitis B, C or B19 parvovirus (immunoglobulin M 
(IgM) antibodies), serum angiotensin-converting enzyme, specific autoantibodies 
and genetic markers. In cases of suspected crystal arthropathy or infection, an 
aspirate of a joint effusion will be of value in making a definitive diagnosis. Findings 
on X-rays may further assist in making the diagnosis of a specific arthropathy e.g. 
the presence of cartilage calcification in calcium pyrophosphate dihydrate deposition 
disease (CPPD). Large asymmetric erosions with periosteal reaction and late 
development of “pencil in cup” deformities may be seen in psoriatic arthritis, joint 
space narrowing with sclerosis and hook like osteophytes of MCP 2 and 3 in 
hereditary hemochromatosis, large asymmetric, erosions with sclerotic rims in gout 
and joint space narrowing with subchondral sclerosis and osteophyte formation 
sparing MCP joints in osteoarthritis. 
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Table 2.4 Differentiating diseases that present as an early inflammatory arthritis 73 
Arthritis History Typical pattern of 
joint involvement 
Joints commonly 
affected 
Associated  features Laboratory tests 
Undifferentiated 
Arthritis 
F>M  Insidious 
Oligoarthritis 
PIP,MCP, wrist, 
MTP, knee, ankle 
EMS ↑CRP/ESR 
Rheumatoid Arthritis F>M 
35-50 years  
Insidious, progressive 
Symmetrical 
PIP,MCP, wrist, 
MTP, knee, ankle 
EMS ↑CRP/ESR, RF+, 
ACPA+ 
Spondyloarthropathy Psoriasis, urethritis 
or cervicitis, IBD  
Family history of 
psoriasis or IBD 
Persistent 
Asymmetric 
Oligoarticular 
DIP, PIP, knee, 
feet, 
spine 
 
Psoriasis, nail pitting, 
uveitis, 
Enthesitis, dactylitis  
ESR/ CRP may be 
normal 
More severe course 
in HLA B27 +  
Systemic lupus 
erythematosus 
 
F > M, young 
 
Polyarticular 
Symmetric 
Usually non-erosive 
PIP, knee 
 
Rash, serositis 
 
Anaemia, 
↑ESR/CRP, 
proteinuria,  
ANA+, dsDNA+ 
Rubella  Rubella epidemic 
and no previous 
Acute  
Symmetric  
PIP, MCP, wrist, 
knee 
Rash, 
lymphadenopathy, 
Rubella serology 
(IgM) 
2
1
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vaccination 
Recent (2-3 weeks) 
rubella vaccination 
Oligoarthritis or 
polyarthritis 
fever Virus isolation from 
nasopharynx or joint 
tissue 
Alpha viruses Mosquito-borne RNA 
viruses in endemic 
areas (Asia and 
Africa)  
Acute  
Polyarthritis 
PIP, wrist, MTP, 
ankle,  
Rash, fever, tendinitis 
and peri-articular 
involvement 
Serology for alpha 
viruses 
Viral (HBV, HCV) 
 
Hepatitis risk factors 
 
Acute 
Polyarthritis 
PIP, MCP, wrist, 
knee, ankle 
Jaundice ↑ESR/CRP, ↑ LFTs, 
Hepatitis B and C 
serology 
Septic Arthritis 
(non-gonococcal) 
Peak incidence in 
elderly 
Reduced host 
immunity 
Joint prostheses 
Acute 
Mono-articular 
(may be polyarticular) 
Often extremely painful 
 
Knee – most 
common 
Hip, shoulder, 
ankle, wrist 
Systemic symptoms 
common 
Commonest cause 
Staphylococcus 
aureus 
Synovial fluid is gram 
stain positive in 50% 
and culture positive 
in 90% 
Gonococcal 
 
F > M  
young, sexually 
Acute  
Oligo- or poly-arthritis 
Wrist, knee 
 
Fever, rash, skin 
blisters/pustules, 
↑ESR/CRP, ↑WBC 
Synovial fluid gram 
2
2
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active  tenosynovitis  stain positive in 25% 
and culture positive 
in 50% of cases 
Osteoarthritis 
 
F > M  
Men with knee or hip 
involvement 
↑age 
Progressive   
Asymmetric or 
symmetric, 
bony swelling  
Oligo- or poly-articular 
DIP, PIP, first 
CMC1, knee, hip, 
MTP, spine 
 
 Normal laboratory 
tests 
  
Gout 
 
Men 
Postmenopausal 
women 
Diuretic use 
(especially  in 
elderly) 
Sudden onset 
Severe pain with 
attacks 
Oligoarticular early, 
polyarticular later 
MTP, ankle, knee 
 
Tophi Synovial fluid – urate 
crystals 
↑uric acid level – 
normal levels in 40% 
of acute attacks 
Pseudogout 
 
M=F 
↑age 
Chronic 
Oligo- or polyarticular 
Acute monoarticular 
(25%) 
Knee, wrist, MCP, 
MTP 
 
Associated conditions 
include: 
Hypomagnesaemia, 
Hypophosphataemia, 
Haemochromatosis, 
↑CRP, ↑WBC 
2
3
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Wilson’s disease,  
Hyperparathyroidism 
Polymyalgia 
rheumatica 
 
M = F  
Older  
Caucasian 
Prolonged morning 
stiffness   
 
Hip and shoulder 
girdle, PIP, wrist, 
knee occasionally 
RS3PE 
 
Anaemia, ↑ESR/CRP 
 
Sarcoidosis 
 
F>M 
 
Acute symmetrical 
Chronic uncommon 
Knee, ankle Fever, 
Erythema nodosum,  
hilar 
lymphadenopathy with 
acute sarcoid 
↑ESR/CRP 
Serum ACE 
Scleroderma F>M Acute or occasionally 
insidious 
Symmetric or 
asymmetric 
MCP, PIP 
 
Tendon friction rubs 
(diffuse disease) 
CRP/ESR 
ANA +, Scl-70+, 
ACA+ 
ACA, anticentromere antibody;  ACPA, anti-citrullinated protein antibody; ANA, antinuclear antibody;  CMC1, first carpometacarpal joint; CRP, 
C-reactive protein;   ESR, erythrocyte sedimentation rate; F, female;  HBV, hepatitis B virus; HCV, hepatitis C vírus;   IBD, inflammatory bowel 
disease; LFT, liver function test; M, male;  MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint;  PIP, proximal interphalangeal 
joint;  RA,  rheumatoid arthritis; RF, rheumatoid factor; UA, undifferentiated arthritis; WBC, white blood cells.  
2
4
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2.5 Prognosis  
After excluding other diseases and making a diagnosis of probable RA or UA, the 
next step is to determine which patients are at risk of developing persistent and/ or 
erosive arthritis. This prognostic assessment is important for guiding treatment 
strategies. Predictors of persistence and disease progression include demographic, 
genetic, clinical, serological and radiological factors. 74 Several of these have been 
incorporated into the 2010 RA classification criteria.12 
2.5.1 Disease persistence  
The potential for spontaneous remission of synovitis in patients with early IA 
(particularly those with symptoms of less than 3 months duration) means that a 
therapeutic approach which targets all patients with very early synovitis, will 
needlessly expose some patients to potentially toxic therapies. The ability to 
distinguish resolving disease from synovitis that persists and develops into RA is 
thus essential. Female gender, cigarette smoking, duration of symptoms, the tender 
and swollen joint count, hand involvement, the level of acute phase response, 
presence of RF and ACPA, and the fulfilment of 1987 ACR diagnostic criteria for RA 
are factors associated which have been associated with disease persistence (table 
2.5). 
On the other hand, seronegativity for rheumatoid factor (RF) and fewer active joints 
at baseline in early RA have been cited as markers of a favourable outcome. 69 
Other studies have shown a relationship with male gender and absence of erosions 
with higher remission rates. 68 
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Table 2.5 Candidate predictors of disease persistence in early inflammatory arthritis 
Predictors of disease persistence  
 Female gender 
 Duration of symptoms  (more than 12 weeks) 
 High tender and swollen joint count 
 Hand involvement 
 Cigarette smoking 
 Elevated acute phase response 
 Positive rheumatoid factor 
 Positive anti-citrullinated protein antibodies 
 Erosions on X-ray 
 Fulfilment of 1987 ACR classification criteria for RA  
 
ACR, American college of rheumatology 
 
2.5.2 Disease severity 
In clinical practice, treatment of early RA is often commenced and increased 
according to the disease activity. An alternative approach would be to initiate the 
most appropriate treatment based on prognostic stratification, differentiating 
between those with a more benign disease from those at risk of developing severe 
erosive disease who would benefit from more aggressive, and more expensive, 
treatment early on to prevent severe outcomes.  
Many of the factors predicting disease persistence are also markers of disease 
severity. Joint damage and functional disability are the two most common outcome 
measures of disease severity.   
Prognostic factors of radiographic damage are a high acute phase response, the 
presence and titre of RF and ACPA at baseline, the genetic marker HLA-
DRB1*0401 allele subtype, and early erosions or a high radiographic score at 
disease onset. Factors that have been found to predict future disability include a 
high baseline health assessment questionnaire disability index (HAQ-DI) score, 
high Ritchie articular index, elevated erythrocyte sedimentation rate (ESR) and C-
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reactive protein (CRP), and the presence of erosions on X-rays. Female gender, 
older age, the number of damaged joints, RF positivity and the presence of nodules 
(although usually a later finding in RA) at baseline are other documented factors 
(table 2.6). 
 
Table 2.6 Candidate predictors of disease severity in early inflammatory arthritis 
Predictors of disease severity  
    
• Female gender b 
• High tender b and swollen joint a counts 
• High HAQ-DI score b   
• Elevated acute phase reactants  a, b 
• Positive rheumatoid factor  a  
• Positive anti-citrullinated protein antibody a 
• Shared Epitope a 
• Erosive disease a, b 
 
      a  Predictors of joint damage 
      b  Predictors of functional disability  
 
HAQ-DI, health assessment questionnaire disability index 
 
2.5.3 Individual factors predicting disease persistence and 
severity  
2.5.3.1 Disease duration  
Several studies have shown symptom duration at first visit to be a good predictor of 
disease persistence. 67 75 In a study by Green et al, 63 patients with mild untreated 
early IA were given a single dose of glucocorticoid at presentation. At 6 months, 49 
patients (78%) had persistent inflammatory joint disease and 14 (22%) were in 
clinical remission. The strongest predictor of persistence was disease duration of 12 
weeks.33 With disease duration less than 12 weeks, the chance of remission was 
increased five-fold.  
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A further study examined the use of a similar protocol of intra-articular 
glucocorticoid injections in patients with early oligoarthritis (i.e. involvement of four 
or less joints) followed by an early review to assess for the presence of persistent 
synovitis.76 At least 50% of patients with oligoarthritis had complete response at two 
weeks. The best predictor of response at 12 and 26 weeks was the presence or 
absence of synovitis on examination at 2 weeks follow-up. Failure to respond by 
two weeks indicated a high likelihood of persistent disease and the need for 
DMARD therapy.  
Disease duration is also an important predictor of severity, with better clinical and 
radiographic outcomes seen in patients with shorter disease duration. 77 78 
 
2.5.3.2 Early morning stiffness 
EMS is an early symptom of IA. It is a complex symptom and may be difficult to 
interpret and to discriminate from pain and functional limitation. It has been used in 
some models as a clinical marker of disease persistence.79 80 Interestingly, 
however, during the first phase development of the 2010 ACR/EULAR RA 
classification criteria EMS, using the traditional cut-off of one hour, was not found to 
be predictive of starting methotrexate in patients with early IA and was therefore 
subsequently not included in the final classification criteria.81 
 
2.5.3.3 Joint involvement 
The number of affected joints has also been associated with disease persistence. In 
a cohort of 121 patients with early arthritis followed up for a median duration of 5 
years, those with polyarticular disease and hand involvement were more likely to 
have persistent disease. 75 These findings have been confirmed by several other 
studies. 82 83 
Persistent joint inflammation leads to joint destruction. A high joint count is also a 
marker of disease severity with the number of swollen joints correlating better with 
radiographic progression than the number of tender joints. 
 
2.5.3.4 Functional disability 
Functional disability as measured by the Stanford HAQ-DI has also been found to 
be a reliable predictor of disease outcomes in early arthritis. 84  A high baseline 
HAQ-DI is an important risk factor for the development of future functional disability 
and has been predictive of both all-cause and cardiovascular mortality in patients 
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with early disease, as well as quality of life and work disability85 86 in patients with 
early RA. Analysis from a primary care-based inception cohort of patients with 
recent –onset polyarthritis has found the one year HAQ-DI score to be a better 
predictor of subsequent outcome than the baseline HAQ-DI score87.  
 
2.5.3.5 The acute phase response  
A rise in the level of acute-phase reactants such as the ESR and CRP provide 
surrogate measures of inflammation. Both elevated ESR and CRP levels, especially 
if sustained, are predictive of long term radiographic progression. In a study of 130 
patients with early RA (median disease duration 3 months), logistic regression 
analysis of baseline variables revealed that a high CRP level ( 20mg/L) was an 
independent predictor of severe progressive radiographic joint damage at 1 year 
(odds ratio(OR) (95% CI) 3.59 (1.53, 8.39).88 CRP levels at presentation have also 
been found to be an independent predictor of functional ability assessed by the 
HAQ-DI.  
High sensitivity CRP (hs-CRP) assays may be used to identify mild disease activity 
that is not detectable by routine CRP testing. 89  
 
2.5.3.6 Serological markers  
2.5.3.6.1 Rheumatoid Factor 
Rheumatoid factor (RF) is a polyclonal antibody against the Fc portion of 
immunoglobulin G (IgG). It is both a marker of persistence in patients with early IA 
67 90 and a predictor of radiographic progression. 91 92 Studies have shown 
sensitivities ranging from 41%–66% and specificities between 87%–97% for the 
diagnosis of early RA. 93  
In a prospective cohort study of 9712 Danish individuals aged 20-100 years, an 
elevated RF level was associated with a 26-fold greater long term risk of developing 
RA. The absolute risk was highest at 32% in women between 50-69 years of age 
who smoked and had RF levels > 100 IU/mL. A doubling in RF level was 
associated with a 3.3 fold (95% CI 2.7 to 4.0) increased risk of RA.94 
2.5.3.6.2 Anti-citrullinated protein antibodies  
Research into autoantibodies other than RF in sera of RA patients led to the 
discovery of antibodies to citrulline, a non-standard amino acid is generated by the 
post-translational modification of arginine residues by the enzyme peptidylarginine 
deiminase (PAD). The assay using the second generation cyclic citrullinated 
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peptide (anti-CCP 2) as an artificial auto-antigen is currently the most commonly 
used test in clinical practice to identify ACPA. A review of data has shown that anti-
CCP 2 has a similar sensitivity to RF in early RA cohorts, but a greater specificity.93 
Anti-CCP positivity has also been shown to be an independent predictor of 
radiographic damage and progression.95    
A SLR evaluating the diagnostic value of anti-CCP and RF for the diagnosis of RA, 
in which data from 24 studies were pooled, showed that positivity for both anti-CCP 
and RF yielded a sensitivity (95% CI) of 57% (55% to 59%), specificity (95% CI) 
96% (96% to 97%), positive likelihood ratio (LR) (95% CI) 13.84 (10.56 to 18.12), 
negative LR (95% CI) 0.46 (0.40 to 0.52) and odds ratio (OR) (95% CI)  33.02 
(23.89 to 45.64). When either anti-CCP antibody or RF were positive, results were 
as follows: sensitivity (95% CI) 78% (76% to 80%), specificity (95% CI)  82% (81% 
to 84%), positive LR (95% CI) 4.24 (3.61 to 4.97), negative LR (95% CI) 0.27 (0.22 
to 0.34), OR (95% CI) 16.95 (12.96 to 22.18).96 The performance of RF and anti-
CCP 2 in early RA cohorts are summarized in table 2.7.  
 
Table 2.7 Performance of immunoglobulin M-rheumatoid factor and anti-citrullinated 
peptide antibodies (anti-CCP 2) assays in early rheumatoid arthritis cohorts. 
 
 Anti-CCP 2 IgM-RF Anti-CCP 2 or 
IgM-RF 
Anti-CCP 2 
and IgM-RF 
Sensitivity 
range (%) 
41–63 41–66 52–67 33–58 
Specificity 
range (%) 
91–100 81–97 72–82 98–100 
 
Adapted from Aggarwal et al. 93 
Anti-CCP 2, second generation anti-cyclic citrullinated peptide antibody; IgM-
RF, Immunoglobulin M rheumatoid factor 
 
2.5.3.6.3 Other serological and immune markers 
Despite the diagnostic value of ACPA and RF, a proportion of patients with IA will 
still be classified as seronegative RA. Research has led to the finding of several 
other autoantibodies including antibodies to carbamylated antigens (anti-CarP).97 
These autoantibodies recognise carbamylated but no citrullinated protein antigens. 
IgG anti-CarP and IgA anti-CarP antibodies have been described in 16% and 30% 
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of ACPA negative individuals with IA and the presence of these antibodies have 
been associated with greater radiographic progression.98  
In addition to autoantibodies, levels of cytokines and chemokines, including 
interleukin (IL)-1α, IL-1β,IL-6, IL10 and tumour necrosis factor alpha (TNF–α), have 
also been shown to be elevated in pre-clinical RA with increasing numbers present 
in cases nearer to the time of RA diagnosis. 99 
These findings add to the armamentarium of potential biomarkers for the diagnosis 
of early arthritis. Further studies will determine their use in clinical practice. 
 
2.5.3.7 Genetic markers  
Genetic factors play an important role in the development of RA. Twin studies have 
estimated heritability to account for about two-thirds of the risk for ACPA-positive as 
well as ACPA-negative disease. 53  
A group of the major histocompatibility complex class II, DR beta 1 (HLA-DRB1) 
alleles provides the strongest genetic associated with RA. A number of these alleles 
in particular DRB1*0401 and *0404 share a similar amino acid sequence which is 
important in antigen presentation - the shared epitope. Several studies have shown 
a correlation between shared epitope and disease persistence. 33 100 Others, 
however, have found the presence of shared epitope of less value as an 
independent predictor of disease persistence 80 101 but rather an indicator of disease 
severity in patients with RA. 101 102  
Among the different HLA-DRB1 alleles, HLA-DRB1*401 and DRB1*0404 have also 
been associated with radiographic erosions in different ethnic groups. This 
association appears to be dose dependent with patients with two RA-associated 
alleles (DRB1*04 or DRB1*01) having had more radiographic erosions and more 
joint replacements than those with non-disease associated-alleles. 103 Studies have 
shown that individuals who were homozygous for HLA-DRB1*0404 were 4 times 
more likely to develop erosions than those who were shared epitope negative. 100 104 
A number of other genetic polymorphisms have been identified including PTPN22, 
a negative regulator of T-cell activation. 105 106 This is the first non-HLA (human 
leucocyte antigen) genetic variation associated with the susceptibility to a number 
of autoimmune diseases including RA. Other genetic markers include TRAF-1 C5 
107 and STAT4 108. The 150V IL4 single-nucleotide polymorphism and the TNFA-308 
polymorphism have also been shown to be markers for early radiographic bone 
erosions, suggesting that functional alterations in cytokine regulation are also 
involved in the disease pathogenesis and may have an effect on disease 
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persistence and damage. More recently, the functional leukocyte immunoglobulin-
like receptor A3 (LILRA3) gene has been found to be associated with RA in a 
Northern and Southern Han Chinese cohort.109 
 
2.5.3.8 Smoking 
Smoking is the most recognised environmental risk factor for the development of 
RA.55 56 There is also a strong association between smoking and the development 
of rheumatoid nodules in early seropositive RA. 
Studies addressing the role of smoking in the pathogenesis of RA, have shown that 
smoking increases the risk of the development of ACPA. In the presence of the 
shared epitope alleles, this risk is further increased – up to 20 times in 
homozygotes as compared to shared epitope negative non-smokers. 110 111 It is 
possible that, smoking, in a genetically predisposed individual, induces apoptosis 
and protein-citrullination, followed by an anti-citrulline specific immune response. 
Former smokers are also at an increased risk for RA up to 20 years after smoking 
cessation with a gradual decreasing risk over time. 112 
Outcomes of studies assessing the effect of smoking on disease severity, however, 
vary. Several cross sectional studies have demonstrated significant associations 
between radiographic joint damage and smoking 113 114 and disease activity, 
response to treatment and smoking, with poorer outcomes seen in smokers 
compared to non-smokers 115. Others, including a large observational study of 2004 
RA patients,116 have found no effect of overall current or past smoking, 117 118 
suggesting that smoking may be more important in the initiation of RA than in the 
perpetuation of the erosive disease process.  
 
2.5.3.9 Imaging  
2.5.3.9.1 Conventional radiographs  
Conventional radiographs remain the most widely used imaging modality in many 
centres given the low cost and availability. Radiographic erosions have a high 
specificity in discriminating between self-limiting and persistent arthritis.79 Early 
radiographic changes are also predictive of disease progression. In a cohort of 
patients with UA, the presence of two or more erosive joints at baseline had a 
positive predictive value for persistent disease of 68%. 119 
Radiographic examination should include the assessment of the hands and the feet 
as erosions may start in the feet, and in approximately 14-18% of cases are only 
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detected in the feet. 120 In general antero-posterior views are done. Other views e.g. 
lateral or oblique views may be requested if clinically indicated.  
Radiographic damage at baseline is also the best predictive factor of poor structural 
outcome. Irrespective of the scoring systems used (e.g. Larsen121, Sharp122 or 
modified Sharp scores123), the initial radiographic score consistently predicts future 
radiographic damage.88 
X-rays are however not very sensitive for detecting change in early RA. Joint 
erosions and joint space narrowing seen on X-rays are generally late findings. 
Newer imaging modalities e.g. MRI and ultrasound have both been shown to be 
more sensitive for visualizing early inflammatory and destructive change and 
predicting future radiographic damage. 
2.5.3.9.2 Magnetic resonance imaging  
MRI can assess all structures of the inflamed joint. Synovitis and bone oedema are 
two features of early IA seen on MRI. Histopathology and mini-arthroscopy have 
confirmed that these findings represent true inflammation. 124 125 Bone oedema, 
which is a specific MRI finding and probably represents a cellular infiltrate within 
bone,126 occurs in various arthritides and is common in early RA. 127 
MRI is a sensitive indicator of active disease 128 and more sensitive than clinical 
examination for detecting synovitis. 129 Erosions are also detected earlier on MRI 
than conventional radiographs,130 and may help classify patients with 
undifferentiated IA as having RA. In a cohort of patients with undifferentiated 
polyarthritis followed up over 2 years, MRI of the most symptomatic hand and 
whole-body scintigraphy correctly classified RA according to the 1987 classification 
criteria and non-RA in 39 of 41 patients.131 The positive and negative predictive 
values for the development of RA of were 1.0 and 0.87 respectively. In another 
study assessing the diagnostic value of MRI, the presence of symmetric 
periarticular enhancement in the wrists, MCP or proximal interphalangeal (PIP) 
joints increased the sensitivity for the clinical diagnosis of RA from 77% to 96%. 132  
There is also evidence that MRI findings (synovitis, bone oedema, and bone 
erosions) may predict subsequent radiographic progression. Notably, however, 
changes resembling mild synovitis or small bone erosions are occasionally found in 
the joints of healthy subjects.133 
The use of MRI has recently been addressed in patients with symptoms of an IA but 
no synovitis. In a cohort of 93 patients with arthralgia and inflammatory symptoms, 
44% had subclinical MRI inflammation. Patients with MRI inflammation were more 
frequently anti-CCP antibody positive than those without MRI inflammation (p= 
34 
 
 
0.049). Ten out of 29 patients (34.5%) with MRI inflammation developed an IA 
within at least two months of follow-up.134 
Higher costs, longer examination times and lower availability in some centres 
however are some disadvantages of MRI compared to conventional radiographs.  
2.5.3.9.3 Ultrasound  
The use of ultrasonography for the management of patients with early IA has 
increased over the years. Similar to MRI, studies have shown ultrasound to be 
more sensitive than clinical examination for detecting synovitis. Use of the Doppler 
technique can further assist in detecting inflammation. Power Doppler (PD) 135 in 
particular is suited for assessing tissues with low velocity blood flow, such as the 
synovium. When compared to findings on MRI scans, PD findings have proven 
reliable for detecting joint inflammation.  
Ultrasound is also more sensitive than conventional radiography for detecting joint 
erosions in patients with RA. In one study 6.5 fold more MCP erosions were 
documented using ultrasound compared to X-rays. 28 The higher sensitivity relates 
to the multi-planar capability of ultrasound (compared to the two-dimensional image 
with conventional radiography) and its ability to detect smaller erosions.  
Ultrasound has also been shown to be of value in determining persistence of very 
early IA. 136 Of a cohort 50 of patients with ≤ 12 weeks of inflammatory symptoms, 
in those who were RF and CCP negative, the use of this imaging modality raised 
the probability of IA from 30% using clinical and radiographic features to 94% with 
the addition of ultrasound.  
Ultrasound, in particular the use of PD, has also been found to be a sensitive and 
reliable method for longitudinal assessment of the inflammatory activity in early 
RA.137 In patients on DMARDs in clinical remission, ultrasound synovitis may still be 
found suggesting that it may be a more accurate measure of disease activity than 
currently used clinical scores.138 139 
The advantages of ultrasound are that it is relatively inexpensive, non-invasive and 
allows many joints to be assessed at any one time. The main disadvantage is that it 
is operator-dependant.  
2.5.3.9.4 Hand bone densitometry 
With newer therapies for RA, erosion progression is lower, requiring more sensitive 
measures to assess treatment outcomes. In RA, bone loss, particularly in the 
hands, takes place early in the disease process. Measuring hand bone loss may 
therefore be useful for diagnosis and as a marker of disease activity. Dual energy x-
ray absorptiometry (DEXA) measures bone density with high precision, making it 
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sensitive enough to detect even small changes in bone mass. Studies in RA 
assessing bone mineral density (BMD) have shown good correlation between BMD 
loss in the spine 102 and hand 140 with disease activity. In a study comparing the role 
of hand DEXA and conventional radiography in 58 patients with early RA (mean 
disease duration 8.5 months), DEXA was found to be a more sensitive tool for 
measuring disease related bone damage. Fifty percent of patients demonstrated 
significant loss of hand BMD after 24 weeks compared to only 22% showing 
radiographic deterioration as measured by the modified Sharp score at 48 weeks.141  
 
2.5.3.10 Histology  
Studies using arthroscopy have confirmed imaging findings of subclinical synovitis 
examining asymptomatic joints of newly diagnosed RA. Distinct macroscopic 
vascular patterns have been seen in early RA and psoriatic arthritis. Comparison of 
histopathological features of synovial tissue in early RA and non-RA synovitis has 
shown subtle differences in histological features, cytokine and protease expression 
patterns, as well as apoptosis. An analysis of synovial biopsies of 95 patients with 
early arthritis showed that the higher scores for the number of CD38+ plasma cells 
and CD 22+ B cells in RA were the best discriminating markers comparing RA to 
non-RA patients. The number of CD68+ macrophages in the synovial tissue of 
patients with RA was also increased.142 Features in synovial tissue biopsies in 
patients with early RA fulfilling the 2010 ACR/EULAR RA classification criteria were 
found to be similar to those fulfilling the 1987 ACR classification criteria.143 Thus far, 
the clinical value of the histopathological characteristics of synovial tissue in early 
arthritis is yet to be proven.144 Widespread use of synovial biopsies in the clinical 
setting is still limited by its invasiveness. 
 
2.5.3.11 Biomarkers of joint destruction 
 Molecular markers that reflect synovial, bone and cartilage turnover have been 
studied as potential tools for early identification of patients with RA at high risk of 
rapid disease progression.74 These include urinary glucosyl-galactosyl-pyridinoline, 
a marker of destruction of the synovium, and C-terminal crosslinking telopeptides of 
type I and type II collagen (CTX-I and CTX-II), markers of bone and cartilage 
destruction. High baseline levels of CTX-I and CTX-II have been shown to predict 
an increased risk of radiographic progression. Elevated levels have also been 
described in patients with no radiographic evidence of joint destruction at baseline 
suggesting that they may be useful for detecting patients at risk of joint damage 
early in the course of the disease. 
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Raised levels of matrix metalloproteinases (MMP), enzymes involved in the 
degradation of articular cartilage in RA, have been found in tissue, synovial fluid 
and the systemic circulation of patients with RA. Studies have shown a correlation 
with increased MMP levels and progression of joint damage.145 
Osteoclasts play a key role in the mechanism of joint destruction in RA. Receptor 
activator of nuclear factor kappa-B ligand (RANKL) and its receptor RANK are 
central in the stimulation of osteoclast formation and activation. The soluble 
receptor-like molecule osteoprotegerin (OPG) is a natural inhibitor of RANKL.  Bone 
resorption is regulated by the balance between RANKL and OPG. The ratio 
between OPG: RANKL may be another marker of joint destruction with low levels 
predictive of more rapid progression.146  
An analysis of cartilage and bone biomarkers in predicting 10 year radiographic 
progression in RA have shown a weak association between CTX-1 and 
radiographic damage.  Neither this nor any of the other tested biomarkers however 
were found to be more useful than current predictors e.g. ACPA and the presence 
of early radiographic damage.147 In daily clinical practice therefore, the role of these 
biomarkers is yet to be demonstrated.  
 
2.5.4 Models to predict disease persistence  
In general, a combination of predictive factors has been found to be superior to 
single variables in predicting those who will develop a persistent erosive IA. Several 
models have been developed using a combination of the most reliable markers to 
determine which patients with UA will progress to develop RA (defined by the 1987 
ACR classification criteria) 80, and to predict disease severity148, radiographic 
progression149 150 and functional outcome.151  
Several studies have been done evaluating the performance of the 2010 
ACR/EULAR criteria for the classification of RA.152 A SLR by Radner et al. has 
shown a pooled sensitivity of 82% (95% CI 0.79-0.84) and specificity of 61% (95% 
CI 0.59-0.64) for RA (defined by different reference standards).153 Excluding other 
diagnoses, the sensitivity of the 2010 ACR/EULAR RA classification criteria was 
21% higher than the 1987 ACR RA classification criteria but the specificity 16% 
lower. Similar results were found in another SLR and meta-analysis.154 Thus whilst 
the 2010 ACR/EULAR criteria have enabled the classification of a greater 
proportion of patients with RA, it is balanced by the risk of over-classifying patients 
without the disease. There are also a proportion of patients with RA not fulfilling the 
2010 criteria – these are often patients who are seronegative.155 It has been 
suggested that clinical judgment and other tools e.g. imaging with ultrasound156 or 
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MRI and other biomarker assays may be useful to better refine these criteria for use 
in clinical practice.157 Further work is also required to determine the value of the 
criteria prospectively in clinical practice and the effect on  long-term outcomes e.g. 
radiographic damage and disability.152 155 Thus far  one retrospective cohort study 
has shown the ability of the 2010 criteria for identifying patients at increased risk of 
mortality by identifying a higher proportion of at-risk patients soon after their 
presentation to a healthcare service (HR 1.37 vs. 1.24 for the 2010 ACR/EULAR vs. 
the 1987 ACR RA classification criteria).158 Data from another cohort study 
suggested that patients identified using the 2010 classification criteria have a milder 
disease with patient fulfilling these criteria demonstrating lower radiographic 
progression (p=0.023). There was also trend towards achieving DMARD free 
sustained free remission more often than those fulfilling the 1987 criteria (HR(95% 
CI) 1.18 (0.93 to 1.50)).159 
Work has also been done in the earlier phases of the disease looking at the 
development of IA in patients with seropositive arthralgia. 160  In a prospective 
cohort of 374 patients seropositive for anti-CCP and/ or IgM RF, a prediction rule 
was developed consisting of nine variables: first degree relative (FDR) with RA, 
alcohol non-use, symptom duration < 12 months, upper and lower extremity 
arthralgia, presence of intermittent symptoms, pain visual analogue scale (VAS) 
≥50, EMS ≥ 1 hour, patient reported joint swelling and antibody status. Using a 
composite score based on these variables, patients were categorised into three 
groups: low (0-4 points), intermediate (5-6 points) and high risk (7-13) groups. The 
hazard ratio (HR; 95% CI) for the intermediate risk group was 4.52 (2.42-8.77) and 
for the high risk group 14.86 (8.40-28.32) for the development of IA compared to 
the low risk group. 
2.6 Treatment  
The primary goal of treating the patient with early IA is to maximize long-term 
health-related quality of life through symptom control, prevention of structural 
damage and normalization of function. 10 To achieve this, requires early effective 
therapy and regular monitoring, adjusting treatment to minimize the burden of 
disease. Patients require care from a multi-disciplinary team using a combination of 
pharmacological and non-pharmacological therapy.2 161 162  
 
2.6.1 Non-pharmacological treatment 
General lifestyle measures are important. Smoking cessation in particular should be 
advised. Ensuring an appropriate body weight by following a healthy diet and 
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maintaining physical activity are necessary for general wellbeing and can also 
improve symptoms. 
Several other non-pharmaceutical interventions - such as dynamic exercises, 
occupational therapy, physiotherapy and hydrotherapy – have shown beneficial 
symptom relieving effects in established RA. These are also recommended in 
patients with early disease. 
As part of the management of any chronic disease, patients should be provided 
with information concerning the disease and its treatment. Education programmes 
may be used as adjunctive measures, aimed at coping with pain and disability and 
the maintenance of work ability.  
Patients with an IA who do not meet criteria for a specific diagnosis and do not have 
poor prognostic factors are more likely to do well. Although patients may feel 
disappointed when a specific diagnosis is lacking, they may be reassured of a 
better outcome.  
 
2.6.2 Pharmacological treatment 
The first principle of pharmacological therapy is early intervention with effective, 
appropriate treatment. The second is one of treating to target 10 to achieve tight 
control of disease activity. In practice, this means that therapy is increased if 
disease activity is not suppressed below a predefined level (ideally remission). 
A suggested algorithm for the management of patients with early IA is shown in 
figure 2.5. The principles of management and different treatment approaches will be 
discussed below. Chapter 3 will provide a systematic review of the literature 
addressing the efficacy of the bDMARDs across the IA disease continuum. 
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Figure 2.4 An algorithm for the management of early inflammatory arthritis 
 
2.6.2.1 Pharmacological treatment of RA 
2.6.2.1.1 Glucocorticoids 
Glucocorticoids have demonstrated disease-modifying as well as anti-inflammatory 
properties. 163 Rapid clinical improvements have been seen with high dose oral 
steroid use. 164 Intravenous (IV) steroid, whilst less widely studied, has shown high 
remission rates in a small group of patients who were MTX-naïve but may have 
failed other csDMARDs.165   
In established RA, several RCTs and SLRs 166 167 have shown that systemic low 
dose glucocorticoids, typically prednisone  10 to 15 mg/day, are effective in 
relieving short-term signs and symptoms in patients. They are therefore often used 
as bridging therapy at the start of DMARD therapy or when switching from one 
DMARD to another to improve symptom control until treatment with the new drug 
has become effective. Studies have also shown that glucocorticoids – either alone 
or in combination with other DMARD therapy – are effective in slowing radiographic 
progression in early and established RA. 164 168-170. They have also been used as 
part of tight control treatment strategies, the concept of which will be discussed later 
in this chapter. 
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Concerns, however, are often raised about the side effects of glucocorticoids.  
Evidence suggests the side effect profile depends on the dose used and the 
disease being treated. A review of the published literature has shown that in RA, 
low doses of glucocorticoids may have very few side effects. 171 Those known to 
occur in other diseases treated with higher doses of glucocorticoids may not occur 
when low dose glucocorticoids are used to treat RA. These include increased 
cardiovascular risk, lipid abnormalities and osteoporosis.  
Newer glucocorticoids and glucocorticoid analogues that will target inflammatory 
tissues or specific gene activations have been investigated, aiming to obtain the 
anti-inflammatory effect of the drug with minimal or no increased risk of adverse 
reactions. 172-174  
2.6.2.1.2 Conventional synthetic DMARDs 
Early treatment with DMARDs is one of the key principles in the management of 
early IA. There is good evidence that patients with recent onset polyarthritis who 
receive earlier DMARD treatment have better outcomes in terms of  radiographic 
progression, function, and ability to work than those in whom DMARD treatment is 
delayed by a few months .8 9 26 34  
Conventional synthetic DMARDs have an effect on the disease process within 
weeks to months. Methotrexate, sulphasalazine, and leflunomide are commonly 
used csDMARDs which have been shown to improve clinical outcomes and delay 
radiographic progression. Of the csDMARDs, methotrexate is considered the 
anchor drug and is generally used as part of the first-line treatment strategy 
because of its clinical and radiographic efficacy, relatively beneficial safety profile 
as well as its benefit in treatment combinations with other csDMARDs and 
biological DMARDs (bDMARDS). 175 176  Leflunomide and sulphasalazine have 
similar clinical efficacy and are considered good alternatives. 
Despite early treatment, substantial structural damage may still occur in some early 
RA patients treated with csDMARDs alone. 92 177 In a cohort of very early RA 
patients with symptom duration of less than 3 months, 64% developed erosive 
disease by 3 years. 
2.6.2.1.3 Biological DMARDs 
The first bDMARD for the treatment of RA, infliximab, was discovered in the 
1990’s.178 Infliximab exerts its effect by blocking TNF-α, a cytokine central to the 
inflammatory cascade. It has modulatory effects on many aspect of cellular and 
humoral immunity and has an important role in persistence of early RA. Since its 
discovery there has been a rapid expansion of bDMARDs used in RA. Within the 
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tumour necrosis factor alpha inhibitor (TNFi) class of agents, these include the 
monoclonal TNFi, adalimumab and the soluble recombinant TNF receptor fusion 
protein, etanercept as well as the newer therapies, golimumab - a fully human 
antibody - and certolizumab-pegol - a humanised recombinant antibody conjugated 
with a polyethylene glycol chain. Two other cytokine inhibitors are the IL-1 receptor 
antagonist, anakinra and the IL-6 receptor blocking monoclonal antibody, 
tocilizumab. Therapies targeting alternative pathways include the anti-CD20 B-cell 
depleting agent, rituximab and the cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
fusion protein, abatacept.   
From systematic reviews of the literature, all of the bDMARDs, particularly when 
combined with methotrexate, have been shown to provide rapid control of 
inflammation and have proven efficacy both in terms of clinical outcomes and 
structural damage in RA. Results of these findings will be detailed in chapter 3. 
Even in cases in which clinical activity have not been optimally suppressed (‘poor 
response’), radiographic progression appeared to be significantly retarded with 
bDMARD use compared to methotrexate monotherapy. 179 
Of these RCTs, the Combination of Methotrexate and Etanercept (COMET) study 
180 was the first major study looking at remission as the primary endpoint in patients 
with early RA. Patients with symptom duration of 2 years or less were randomised 
to receive methotrexate or methotrexate and etanercept for a year. At week 52, 
remission as defined by a DAS 28<2.6 was achieved in 49.8% with methotrexate 
plus etanercept vs. 27.8% with methotrexate alone (p< 0.001) (figure 2.6). 
Radiographic progression at week 52 was also significantly lower in the group 
receiving combination therapy. No differences were seen between the two groups 
in terms of serious adverse events, serious infections or malignancies. No cases of 
tuberculosis were reported in either group.  
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Figure 2.5 Percentage of patients achieving DAS28 remission (primary endpoint) 
and DAS remission at Week 52 in the groups receiving methotrexate vs. 
methotrexate plus etanercept in the COMET trial. 180  
2.6.2.1.4 Biological DMARD strategies 
Biological DMARDs have not only been studied in patients who have failed DMARD 
therapies, but as treatment induction. The therapeutic approach of induction and 
maintenance has been used in several fields of medicine including oncology and 
transplant medicine.181 There are several principles governing this treatment 
approach. The first is that the period of greatest immune reactivity occurs early. 
This is the time when the most intensive therapy is required then settling on the 
lowest maintenance dose required to maintain immunosuppression but minimise 
drug toxicity. The second is to use low doses of several drugs with toxicities that do 
not overlap rather than higher doses of fewer drugs. The third is to avoid 
immunosuppression which can have numerous side effects including the risk of 
infection. 
The placebo controlled RCT by Quinn et al 182 was one of the first studies 
addressing the use of TNFi therapy in DMARD-naïve RA, introducing the concept of 
induction with a bDMARD and methotrexate followed by methotrexate 
maintenance.  In this study of 20 RA patients with poor prognostic factors, 
treatment with infliximab and methotrexate results in less MRI detected erosions at 
12 months than treatment with methotrexate alone. Function and quality of life 
benefits achieved with infliximab after one year was sustained at two years without 
further infliximab therapy. This study provides evidence for the rationale for early 
intensive therapy with a bDMARD and methotrexate with the potential for treatment 
de-escalation.  
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Another study that compares the use of these various therapeutic options and 
addresses the optimal treatment paradigms for early RA is the Behandel 
Strategieёn (BeSt) trial. This multi-centre single blinded trial of 508 RA patients with 
less than 2 years of symptoms, compared four treatment strategies including a 
sequential monotherapy (group1), step-up combination therapy (group2), a triple 
step-down strategy with methotrexate, sulphasalazine, and high dose prednisone 
(group3), and initial combination therapy with infliximab plus methotrexate 
(group4).183 Treatment was adjusted at three monthly intervals with a goal of 
achieving a DAS of 2.4 or less. The two groups with initial intensive treatment 
(groups 3 and 4) showed a more rapid clinical response and a better radiographic 
outcome than groups 1 and 2 at two years. Progression of joint damage remained 
better suppressed in groups 3 and 4 (median Sharp-van der Heijde scores of 2.0, 
2.0, 1.0 and 1.0 in groups 1, 2, 3 and 4 respectively (p=0.004)). In addition, less 
treatment adjustments were required in groups 3 and 4 to achieve suppression of 
disease activity. No significant differences in toxicity were noted between the 
groups.  
After 8 years, 68% of patients continued follow up within the study. Of these 52% 
were in clinical remission (DAS44 <1.6) with 29%, 22%, 45% and 66% in groups 1-
4 respectively still on the initial treatment step (p<0.001). Radiographic progression 
was lower in the initial combination groups in first 2 years of treatment. Thereafter, 
between years 3-8 annual progression was comparable across the groups. By year 
8, joint damage progression remained low in all groups. The proportions of patients 
on infliximab was not significantly different between groups (21%, 10%, 13% and 
24% in groups 1-4 (p=0.06)). Drug free remission was achieved in 10%, 19%, 17% 
and 15% of groups 1-4 respectively (p=0.90).184 
A further analysis from the BeSt trial comparing patients who received initial 
infliximab treatment (group 4) with patients receiving infliximab at a later stage 
(groups 1-3) showed that 56% of patients in group 4 were able to successfully stop 
infliximab compared to only 15% in the other groups at 2 years. This suggests that 
by achieving remission within the ‘therapeutic window of opportunity’, patients may 
require less treatment later on in the disease course. 185 
Discontinuation of infliximab after achieving low disease activity (LDA) has also 
been evaluated in several other studies including the RRR (remission induction by 
Remicade in RA) study. 186 The mean disease duration of 114 RA patients was 5.9 
years, mean DAS28 5.5 and mean van der Heijde modified total Sharp score 
(mTSS) 63.3. Infliximab was discontinued in 102 patients after maintaining LDA for 
>24 weeks. At 1 year, 55% continued to have DAS28<3.2 after stopping infliximab. 
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Radiographic non-progression (ΔmTSS <0.5) was achieved in 67% and 44% of the 
RRR-achieved and RRR-failed groups, respectively. 
These studies provide evidence for the rationale for early intensive treatment 
strategies, with the potential to de-escalate therapy when optimal disease control is 
achieved. 
2.6.2.1.5 Biological DMARD safety  
The issue of bDMARD safety has been reviewed in a SLR187 informing the 2010 
EULAR RA treatment recommendations188 and recently updated.189 Safety data 
was evaluated from observational studies and registry data which included a 
comparator arm (either patients on non-bDMARD therapy or the general 
population) rather than RCTs as their duration of follow-up are relatively short and 
results may be potential biased as patients with significant co-morbidities are often 
excluded.  
Compared to patients on csDMARDs, patients on TNFi have been shown to be at 
higher risk of serious infections (adjusted HR 1.1-1.8)190-192 and tuberculosis.193 194 
Some studies suggested an increased risk of herpes zoster,195 196 although this has 
not been confirmed in all.197 There has been no signal of increased risk of 
malignancy,198 199 lymphoma200 201 or non-melanoma skin cancer201 202 in patients on 
TNFi therapy. There was a suggestion that the risk of melanoma may be slightly 
increased (adjusted HR 1.5 (1.0-2.2)).203 The absolute risk however was relatively 
low, corresponding to an additional 20 cases per 100 000 person years.  
Information from the majority of non-TNFi biological observational studies that have 
been published have not had a comparator arm. Data from these registries suggest 
similar safety profiles to those of the TNFi therapies.204-206 
2.6.2.1.6 Summary of bDMARD therapy in RA 
 The use of bDMARDs has changed the face of RA.  For many rheumatologists, 
bDMARD therapy has become part of routine clinical practice. They are however 
substantially more expensive than traditional csDMARDs. With cost remaining an 
important point of consideration, 207 many guidelines place them after failure of one 
or more csDMARD. 162 208 209  
 
2.6.2.2 Pharmacological treatment of UA 
Recognising that there is a potential window of opportunity for the treatment of RA, 
studies have aimed to address treatment at the earlier phase of the disease, that of 
UA. 
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2.6.2.2.1 Glucocorticoids 
An approach for patients who present with very early UA (less than 12 weeks of 
symptoms) may be to give a single dose of glucocorticoid to provide rapid 
improvement of symptoms and demonstrate the reversibility of disease.33 Results of 
an open study of 100 patients with UA suggest that a single dose of intramuscular 
or intra-articular steroids may induce remission in these patients.210  
Two RCTs also investigated the benefits of a limited course of intramuscular (IM) 
steroids in patients with early UA. The steroids in very early arthritis (STIVEA) 
trial211 212 aimed to determine whether treatment of recent onset inflammatory 
polyarthritis with 3 weekly injections of IM glucocorticoids could suppress evolution 
to RA. Two hundred and sixty-five patients with 4–11 weeks of symptoms, two or 
more tender and swollen joints and hand involvement were enrolled and 
randomised to receive 3 weekly doses of methylprednisolone 80 mg IM or placebo. 
Patients were followed up for 12 months and assessed for the initiation of DMARD 
therapy. At 6 months, 76% of the placebo group and 61% of the steroid group had 
either started or been referred for DMARD therapy [OR (95% CI) 2.11 (1.16, 3.85), 
p=0.015]. At 12 months, the arthritis had resolved in 20% (22/111) of patients in the 
glucocorticoid arm compared with 10% (11/111) in the placebo arm.  
In the SAVE study, a similar patient population, however, a single dose of 
intramuscular methylprednisolone 120mg was not effective in inducing remission or 
delaying development of RA. Of 383 patients, 17.0% (65/383) achieved persistent 
remission: 17.8% (33/185) of the placebo group and 16.2% (32/198) of the patients 
receiving methylprednisolone (OR (95% CI) 1.13 (0.66 to 1.92), p=0.6847). 
DMARDs were started in 162 patients: 56.7% in the placebo arm and 50.3% 
methylprednisolone arm (OR (95% CI) 0.78 (0.49 to 1.22), p=0.30). Significantly 
more patients with polyarthritis than with oligoarthritis received DMARDs (OR(95% 
CI) 2.84 (1.75 to 4.60), p<0.0001).  
Although study outcomes differed, results suggest that the use of IM steroids in 
some patients with very early inflammatory polyarthritis may postpone the initiation 
of DMARD therapy.  
2.6.2.2.2 Conventional synthetic DMARDs 
Use of csDMARD therapy in patients with UA before the stage of fulfilling 1987 
ACR RA classification criteria was first addressed in the PROMPT study. In this 
double-blind RCT, 110 patients were randomized to treatment with methotrexate or 
placebo for 12 months.  Forty percent (22/55) of patients in the methotrexate group 
progressed to RA compared with 53% (29/55) in the placebo group. In the 
methotrexate group patients also fulfilled the 1987 ACR classification criteria for RA 
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at a later time point than in the placebo group (P = 0.04) and fewer patients showed 
radiographic progression over 18 months (P = 0.046). This study suggests that 
methotrexate may also delay the development of RA and retard radiographic joint 
damage in UA patients. Further analysis showed that these findings were mainly 
seen in the subgroup of patients who demonstrated the presence of ACPA.213 
2.6.2.2.3 Biological DMARDs 
Studies have also started to address the role of bDMARDs in patients with UA. A 
pilot RCT by Saleem et al. aimed to assess the ability of a TNFi to induce remission 
and prevent progression to RA in patients with poor prognosis UA. 214 Seventeen 
patients with UA who had relapsed after a single parenteral glucocorticoid injection 
were randomized to receive infliximab (n=10) or placebo (n=7) at week 0, 2, 6 and 
14. Methotrexate was added if no clinical response was achieved. At week 26 only 
three patients were in clinical remission (2 in the infliximab and 1 in the placebo 
groups). By week 52 all patients in the infliximab arm and 71% (5/7) in the placebo 
arm developed RA (1987 ACR classification criteria). The study was stopped early 
due to the poor patient outcomes. More recently larger studies have been 
performed using bDMARDs in patients with UA. These will be discussed in Chapter 
3. 
 
2.6.2.3 Pharmacological treatment of individuals at risk 
Treating patients with inflammatory arthritis in the pre-clinical stages requires early 
identification of subclinical disease. To date there have been no clinical trials 
published on the use of DMARD therapy in these patients. 
 
2.6.2.4 Monitoring of disease activity and achieving tight control  
Regular monitoring and increasing treatment aiming at specific therapeutic targets 
has improved outcomes and reduced the risk of organ damage in several areas of 
medicine (e.g. diabetes mellitus and hypertension). A similar approach has been 
adopted in patients with early IA.  
In the Tight Control in Rheumatoid Arthritis (TICORA) study, 110 RA patients with 
less than 5 years disease duration were randomly assigned to receive intensive 
treatment or routine clinical care. 215 Patients in the intensive TICORA group were 
examined monthly and DMARD therapy escalated according to a predefined 
strategy if DAS44 >2.4. Those in the routine care group were seen three monthly 
without formal assessment and treatment was adjusted according to clinician 
judgment. The group receiving more intensive monitoring and treatment had 
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significantly greater EULAR and ACR responses and higher remission rates than 
the control group at 18 months (figure 2.7).  Radiographic damage was also lower 
in the TICORA group. This strategy also resulted in higher treatment retention rate, 
a lower discontinuations due to side effects, and lower costs per patient (based on 
lower admission costs) than routine care. Of note, more intra-articular steroids were 
used in this treatment group.  
 
 
Figure 2.6 Intensive versus routine monitoring - results from the Tight Control in 
Rheumatoid Arthritis (TICORA) study. 
Adapted from Grigor et al. 215 ACR, American College of Rheumatology; 
EULAR, European League Against Rheumatism 
 
The CAMERA (computer-assisted management of early RA) trial 216 also showed 
intensive treatment and monitoring to be more beneficial than routine care. Two 
hundred and ninety nine patients with early RA were randomised to intensive 
treatment or routine treatment, with oral methotrexate. If necessary, therapy was 
changed to subcutaneous methotrexate and cyclosporine added to achieve disease 
control. Patients in the intensive treatment group were seen more frequently in 
clinic and dosages were adjusted based on predefined criteria and tailored to 
achieve remission using a computer assisted programme. At 2 years, results 
showed that more patients in the intensive-management group achieved sustained 
remission for at least 3 months than in the routine care group (50% vs. 37%: 
p<0.03). Median area under the curve for all clinical variables (ESR, early morning 
stiffness, visual analogue scale for pain, visual analogue scale for general 
wellbeing, number of swollen joints and number of tender joints) were significantly 
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better in the intensive-management group than in the routine-care group. Patients 
in the intensive-management group also used less NSAIDs anti-inflammatory drugs 
than the routine care group. 
Results of the BeSt study,183 discussed earlier in this chapter, showed good clinical 
outcomes in all patients irrespective of the initial treatment group and sustained 
clinical and functional benefit for up to 5 years, reinforcing the importance of early 
intervention and tight control in the treatment of RA.217 Several other trials have also 
shown better outcomes where intensive care was based on regular monitoring of 
disease activity and treatment to target. 218-220  
Regular monitoring of disease activity and adverse events, therefore, should guide 
decisions on choice and changes in treatment strategies. This includes both 
csDMARDs and bDMARDs. Based on evidence from a SLR221 and expert opinion 
on best practice, recommendations for achieving optimal therapeutic outcomes 
using treat-to-target approach have been developed and recently updated for the 
management of RA.10 222 It is suggested that when monitoring treatment, measures 
of disease activity should be obtained and documented regularly, as frequently as 
monthly for patients with high/moderate disease activity or less frequently (e.g. 
every 3–6 months) for patients in sustained low disease activity or remission. 
Assessments should include composite disease activity measures which include 
joint counts. Structural damage should be assessed with X-rays approximately 
every 12 months during the first few years. Functional assessment (e.g. using the 
HAQ-DI) may be used to complement the disease activity and structural damage 
monitoring. Drug therapy should be adjusted at least every 3 months until the 
desired treatment target is reached. The patient should be appropriately informed 
about the treatment target and the strategy planned to reach this target under the 
supervision of the rheumatologist. The desired treatment target should be 
maintained throughout the remaining course of the disease (figure 2.8). 
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Figure 2.7 Algorithm for treating rheumatoid arthritis to target based on European 
League Against Rheumatism treat-to-target recommendations. 
Adapted from Smolen et al.10  The main target (remission and sustained 
remission), indicated by the red arrows, and the alternative target (low 
disease activity in patients with long-term disease) indicated by the blue 
arrows are shown as separate threads. Remission, defined as the absence of 
signs and symptoms of significant inflammatory disease activity, is the primary 
target for treatment of RA. In certain instances (e.g. in established long-
standing disease), low disease activity may be an acceptable alternative 
therapeutic goal. The approach to attain the targets and sustain them are 
similar. (RA, rheumatoid arthritis) 
2.7 Summary 
A review of the literature on early IA, of which RA is the most common, confirms the 
importance of early diagnosis and treatment. With increasing treatment options 
available and improved strategies for treating RA with regular monitoring and tight 
disease control, remission and prevention of structural damage are achievable 
goals.  
In terms of treatment, non-pharmacological and lifestyle measures form part of the 
treatment strategy. Of these, reduction or cessation of smoking is a known factor 
that could and prevent the development of early RA and decrease the risk of 
cardiovascular complications of the disease and should therefore be strongly 
encouraged. 
Early institution of effective pharmacological  therapy forms the cornerstone of 
treatment for patients with early IA. Disease-modifying therapy should be 
commenced in all patients with early IA in whom the disease is likely to develop into 
a persistent and/or erosive arthritis classifiable as RA. In terms of the risk –benefit 
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ratio and the cost effectiveness of these therapies, initial treatment with csDMARD 
therapy are advocated with glucocorticoids as adjunctive therapy. In most cases 
methotrexate is considered as part of first-line treatment. Other DMARDs e.g. 
sulphasalazine and leflunomide are suitable alternatives. The use of bDMARDs in 
clinical practice, particularly in RA patients failing csDMARDs, is supported by 
evidence from many clinical studies confirming their efficacy. 187 223 In patients with 
significant disease activity and/ or risk factors for adverse outcome e.g. (high titre) 
rheumatoid factor or ACPA, earlier use of a more intensive strategy including the 
use of bDMARDs may be necessary.  Whilst the concept of bDMARD induction and 
maintenance with csDMARDs is an attractive treatment option, their role in early 
DMARD-naïve RA and UA is still unconfirmed.  
With the need for early treatment, increasing emphasis is also being placed on 
importance of early diagnosis. In the early stages of the disease patients may 
present with UA. A combination of clinical, imaging and laboratory measures allows 
the clinician to differentiate different causes of IA, identify those who will progress to 
RA and determine their severity. Conventional radiography is the mainstay imaging 
modality although the use of ultrasound and MRI are coming to the fore. At present, 
non-HLA genetic markers, histology and biochemical markers remain more 
research based tools rather than investigations for day to day patient care. The 
development of the 2010 ACR/EULAR classification criteria have helped to aid 
earlier identification of patients with RA. At an even earlier phase patients may 
present with arthralgia or non-specific MSK symptoms. The role of the different 
biomarkers in patients at risk presenting without clinical synovitis are yet to be 
determined.  
The following chapters will review the use of bDMARDs across the IA disease 
continuum, address the use of bDMARDs in early DMARD-naïve RA and UA and 
explore the use of ACPA together with other biomarkers in order to identify patients 
with early IA in the ‘pre-clinical’ phase. 
2.8 Thesis Aims 
This body of work initially aims to examine the literature on the efficacy of 
bDMARDs across the IA disease continuum. Second, the thesis aims to investigate 
the use of treatment strategies with bDMARDs in DMARD-naïve early RA and IA in 
RCTs. Last, through a longitudinal study, it will assess the use of anti-CCP together 
with other biomarkers available in clinical practice to enable the identification of 
patients with IA patients with MSK symptoms but without clinical synovitis. 
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Chapter 3 Systematic literature review of the efficacy of 
biological DMARDs across the inflammatory arthritis 
disease continuum 
This chapter presents the results of a systematic literature review of RCTs 
addressing the efficacy of bDMARDs with inflammatory arthritis across the disease 
spectrum from early undifferentiated arthritis to rheumatoid arthritis. 
3.1 Introduction 
The use of bDMARDs has changed the outlook for patients with IA. Review of the 
literature in Chapter 2 showed that achieving remission, normal function and 
prevention of joint damage is now possible for patients with these therapies.  
In 2010, EULAR recommendations were initially developed to guide the 
management of RA with cs- and bDMARDs to address the increasing number of 
therapeutic options available.188 SLRs was performed to inform these 
recommendations. These included one on bDMARD efficacy and safety,187 and 
another on treatment strategies in RA, some of which incorporated bDMARD 
therapy. 223 Results from these literature reviews showed good efficacy and safety 
profiles for bDMARDs in both in early and established disease and highlighted the 
benefit of treat-to-target type strategies. Data were available mainly for patients who 
had previously had at least one DMARD. There were fewer studies addressing their 
efficacy in DMARD-naïve RA.182 183  
Since then, several additional bDMARD studies have been published. There have 
also been an increasing number of studies evaluating, not only the efficacy of 
bDMARDs vs. csDMARDs, but also addressing different treatment approaches 
using bDMARDs (strategy-type studies). Data are also emerging on biosimilar 
DMARDs (bsDMARDs) 224 and tofacitinib, a new tsDMARD inhibiting Janus kinase. 
In addition, trials have also addressed the use of bDMARDs earlier in the 
inflammatory arthritis disease continuum – in patients with UA.  
3.2 Aims 
This SLR aimed to review the evidence for the efficacy of bDMARDs in patients with 
RA to inform the updated EULAR Task Force treatment recommendations.209 The 
search also aimed to investigate the use of these therapies in patients presenting 
earlier with UA.  
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3.3 Methods   
3.3.1 Literature search strategy 
The requirements for the literature search were discussed and performed with a 
librarian with expertise in the field (JL with LN). The titles and abstracts of articles 
retrieved from the search were then reviewed independently by two of the authors 
(JLN and SR). A search of ACR abstracts and EULAR abstracts were also 
performed (JLN and MLG). Potential articles were then obtained for detailed review 
and decision regarding inclusion. Discrepancies were resolved by discussion. Data 
from relevant articles were then extracted and checked by two of the authors (JLN 
and KT).  
The search was performed for trials evaluating one of nine bDMARDs: infliximab, 
etanercept, adalimumab, certolizumab pegol, golimumab, anakinra, abatacept, 
rituximab and tocilizumab. Information was also sought on bsDMARDs in phase 3 
development and tsDMARDs in studies comparing these to bDMARDs. The 
previous SLR included studies to 2009.187 This updated literature review was 
therefore done for the period from January 2009 to February 2013. The databases 
used were Medline, Embase and Cochrane. The search terms used in Medline are 
provided in table 3.1. Conference abstracts from ACR 2011–2012 and EULAR 
2011-2013 were also reviewed. Where full papers of these abstracts were found, 
the latter were used for data extraction.
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Table 3.1 Medline search terms and limits 
 
1. arthritis, rheumatoid/ or caplan's 
syndrome/ or felty's syndrome/ or 
rheumatoid nodule/  
16. mabthera.mp.  
2. rheumatoid arthritis.mp.  17. anakinra.mp.  
3. (early adj2 arthritis).mp.  18. kineret.mp.  
4. inflammatory arthritis.mp  19. tocilizumab.mp.  
5. Biological Therapy/  20. actemra.mp.  
6. biologic$.mp.  21. golimumab.mp.  
7. infliximab.mp.  22. certolizumab.mp.  
8. remicade.mp.  23. cimzia.mp.  
9. etanercept.mp.  24. biosimilar.mp  
10. enbrel.mp  25. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
or 13 or 14 or 15 or 16 or 17 or 18 or 19 
or 20 or 21 or 22 or 23 or 24  
11. adalimumab.mp.  26. 1 or 2 or 3 or 4 
12. humira.mp.  27. 26 and 25 
13. abatacept.mp.  28. limit 27 to English language 
14. orencia.mp.  
29. limit 28 to yr=“2009-2013” 
15. rituximab.mp.  
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3.3.2 Outcome measures and data extraction  
 
The criteria for study selection were as follows: 
1.RCTs. As in the previous SLRs,187 223 these were double-blind for RCTs evaluating 
a bDMARD vs. a csDMARD; for strategy-type trials, open label studies were also 
included.  
2.patients with RA  defined according to the 1987 ACR11 or the 2010 ACR/EULAR 
RA classification criteria12 or patients with UA, at risk of developing RA  
3.trials evaluating one of the nine bDMARDs or a bsDMARD in phase 3 
development or a tsDMARD of compared with a bDMARD 
4.trials of 6 months’ duration or greater  
5.trials with at least 50 patients  
6.publications in English  
Published SLRs and meta-analyses were also reviewed and considered for 
inclusion where relevant.  
In order to reflect current clinical practice and trial design, studies were grouped 
according to the following categories: (1) no previous DMARD therapy (DMARD-
naive); (2) no previous methotrexate therapy (MTX-naive); (3) inadequate response 
to methotrexate (MTX-IR); (4) inadequate response to any csDMARD, not 
necessarily methotrexate (mixed DMARD-IR) and (5) inadequate response to a 
TNFi (TNFi-IR).  
For each trial, information on the demographic features, disease duration, baseline 
disease activity scores and function (measured by the HAQ-DI),225  treatment 
allocation and follow-up duration were recorded. The Cochrane risk of bias 
assessment tool for RevMan 5.1 was used to assess the quality of the trials.226  
Data were extracted for clinical, patient reported and radiographic outcomes. For 
clinical signs and symptoms, measures included the ACR response criteria 
(20/50/70), changes in the DAS44 and DAS28 and EULAR-response criteria. 
Patient reported outcomes included the  HAQ-DI for measure of function, the 
Physical Component Score and Mental Component Score of the Short Form-36227 
for quality of life and the FACIT 228 229 and fatigue visual analogue scale (FAS) 
scores for fatigue. For evaluation of structural damage, change in radiographic 
scores and the proportion of patients achieving radiographic non-progression 
(defined within individual studies) were collected.  
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Careful consideration was taken of the inherent biases when comparing studies of 
different patient populations, using different compounds, each powered for different 
endpoints and using different statistical analysis plans. The heterogeneous nature 
of the studies evaluating different treatment strategies introduced additional 
challenges when analysing and the interpreting the results. Where possible, meta-
analyses of studies comparing combination bDMARD and csDMARD to csDMARD- 
monotherapy or combination therapy were performed. Due to the differences in the 
strategy-type studies, data for these are presented in tables.  
The Oxford Centre for Evidence-based Medicine levels of evidence (http:// 
www.cebm.net/index.aspx?o=1025) was used to assign levels of evidence using 
these data. 
3.4 Results  
The search yielded 10,265 articles for title and abstract screening, of which 123 
were selected for detailed review. With the additional conference abstracts and full-
papers obtained from a hand search, 50 full-papers and 57 abstracts fulfilled the 
inclusion criteria (figure 3.1). 
The data are summarised addressing three main areas of bDMARD use: (1) 
bDMARD efficacy (in combination therapy with csDMARDs or as monotherapy, 
head-to-head bDMARD studies and bDMARD switching); (2) treatment strategies 
using bDMARDs and addressing the possibility of bDMARD stopping or dose 
reduction; and (3) studies including bDMARDs and new therapies (bsDMARDs and 
tsDMARDs).  
Preliminary analyses and abstracts of the IDEA17 and EMPIRE18 studies were 
available at the time the SLR was performed and have been included. Both studies 
investigated the use of bDMARDs as part of an induction strategy and with the 
potential to de-escalate or stop therapy. In the IDEA study this was in patients with 
early DMARD-naïve RA and the EMPIRE study included patients with UA.  Both 
have now been published as full manuscripts and will be discussed in detail in 
Chapters 4 and 5.
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Medline 
n = 2519 
(Jan 2009 to Jan Week 5 2013) 
Embase 
n = 7337 
(Jan 2009 to 2013 Week 9) 
Cochrane Central 
n = 410 
(Jan 2009 to Feb 2013)  
Total  
n = 10 265 
 
After initial deduplication 
n = 7458 
 
For detailed review 
n = 123 
 
Included 
n = 48 
articles n=44; abstracts n=4 
Duplicates 
n=2807 
 
Excluded by titles/abstracts: 
• Not adult RA (n=1590) 
• Not  intervention of interest 
(n=486) 
• Not outcome of interest 
(n=2852) 
• Reviews, case reports, 
observational  data (n=2229) 
• Non-human (n=57) 
• Duplicates (n=121) 
Excluded 
n=75 
 
Additional ACR 2011- 2012 
and EULAR 2011-2013 
abstracts not found in main 
search 
n =53 
 
Hand  
search 
n = 6 
Total Included in the SLR 
n = 107 
(articles n=50;abstracts n=57) 
Figure 3.1 Systematic literature review flow chart 
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3.4.1 Risk of bias assessments 
Risk of bias for the clinical trials was assessed using the  Cochrane risk of bias 
assessment tool for RevMan 5.1.226 This addresses seven aspects of clinical 
studies, namely (1) random sequence generation, (2) allocation concealment, (3) 
blinding of participants and personnel, (4) blinding of the outcome assessment, (5) 
incomplete outcome data, (6) other bias and (7) selective reporting, This information 
can be found in tables 3.2 to 3.13. 
Overall the risk of bias was found to be low across the studies that were selected. 
There were some in which the information in the reported trials were not sufficient to 
assess all domains of the Cochrane risk of bias assessment tool.230-236 Some 
studies were open label, leading to a high risk of bias in these domains.237-240 A few 
studies reported difficulty with recruitment which may have  affected the power of 
the studies.240-242 In some of these the main analyses were also completer- only 
analyses which may have contributed to a high risk of bias in terms of incomplete 
outcome data.241 242 It was however noted in these studies that similar results 
obtained when other sensitivity analyses were performed. The findings from the risk 
of bias assessments of all of the studies were taken into account when interpreting 
and drawing conclusion from the clinical trial data. 
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Table 3.2 Cochrane risk of bias assessment: Biological DMARDs in RA patients who are DMARD naïve 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Detert 2013 
(HIT HARD)230  
ADA  U  U  U  U  L  L  L  
 
ADA, adalimumab, ROB, risk of bias 
a = abstract only, H= high risk; L = low risk; U = unclear risk  
5
8
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Table 3.3 Cochrane risk of bias assessment 5.1: Biological DMARDs in RA patients who are MTX naïve 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Westhovens 
2009231  
ABT  U  U  L  L  L  L  L  
Kavanaugh 
2013 
(OPTIMA)232  
ADA  L  L  L  U  L  L  L  
Emery 2009  
(GO-
BEFORE)233  
GLM  L  L  L  U  L  L  L  
Emery 2011 
(GO-BEFORE 
and  
GO-
FORWARD)243  
GLM  o  o  o  L  o  o  o  
Tak 2011 
(IMAGE)244  
RTX  L  L  L  L  L  L  L  
Burmester 
EULAR 2013 
(FUNCTION)245  
TCZ  a  a  a  a  a  a  a  
 
ADA, adalimumab; GLM, golimumab; ROB, risk of bias; RTX, rituximab; TCZ, tocilizumab  
a = abstract only, o= refer to original manuscript; H= high risk; L = low risk; U = unclear risk  
5
9
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Table 3.4 Cochrane risk of bias assessment 5.1: Biological DMARDs in RA patients who are MTX inadequate responders (MTX IR) 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Bao 2011234   ANA  U  U  L  U  U  L  L  
Yamamoto 
ACR 2011246  
CZP  a  a  a  a  a  a  a  
Choy 2012247  CZP  L  L  L  L  L  L  L  
Kang EULAR 
2012248  
CZP  a  a  a  a  a  a  a  
Keystone 2010 
(GO-
FORWARD)249  
GLM  o  o  o  L  o  o  o  
Emery 2011 
(GO-BEFORE 
and GO-
FORWARD)243  
GLM  o  o  o  L  o  o  o  
Tanaka 2012 
(GO-FORTH)250  
GLM  U  U  L  U  L  L  L  
Tanaka EULAR 
2012 (GO-
FORTH)235  
GLM  a  a  a  a  a  a  a  
Li EULAR 
2013251  
GLM  a  a  a  a  a  a  a  
Kremer 2010252  IV GLM  L  L  L  L  U  L  L  
Weinblatt 
EULAR 2013253  
IV GLM  a  a  a  a  a  a  a  
6
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Emery 2010 
(SERENE)254  
RTX  U  U  L  U  L  L  L  
Kremer 2011 
(LITHE)255  
TCZ  U  U  L  L  L  L  L  
 
ANA anakinra; CZP,certolizumab pegol; GLM, golimumab; ROB, risk of bias; RTX, rituximab; TCZ, tocilizumab; IV, intravenous  
a = abstract only, o= refer to original manuscript, H= high risk; L = low risk; U = unclear risk  
 
6
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Table 3.5 Cochrane risk of bias assessment 5.1: Biological DMARDs in RA patients who are mixed DMARD IR 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Smolen 
EULAR 2011 
(CERTAIN)256  
CZP  a  a  a  a  a  a  a  
Smolen 
EULAR 2012 
(CERTAIN)257  
CZP  a  a  a  a  a  a  a  
Yamomoto 
ACR 2011258  
CZP  a  a  a  a  a  a  a  
Takeuchi 
EULAR 2011 
(GO-MONO)259  
GLM  a  a  a  a  a  a  a  
Takeuchi ACR 
2011 (GO-
MONO)260  
GLM  a  a  a  a  a  a  a  
Takeuchi 
EULAR 2012 
(GO-MONO)261  
GLM  a  a  a  a  a  a  a  
Jones 2010 
(AMBITION)262  
TCZ  U  U  L  L  L  L  L  
Yazici 2013 
(ROSE)263 
TCZ  U  U  L  U  L  L  L  
CZP,certolizumab pegol; GLM, golimumab; ROB, risk of bias; TCZ, tocilizumab  
a = abstract only, H= high risk; L = low risk; U = unclear risk  
6
2
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Table 3.6 Cochrane risk of bias assessment 5.1: Biological DMARDs in RA patients who are TNF IR 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Smolen 2009 
(GO-AFTER)264  
GLM  L  L  L  U  L  L  L  
Keystone 2009 
(REFLEX)265  
RTX  o  o  o  L  L  L  L  
 
GLM, golimumab; ROB, risk of bias; RTX, rituximab  
a = abstract only; o= refer to original manuscript; H= high risk; L = low risk; U = unclear risk  
6
3
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Table 3.7 Cochrane risk of bias assessment 5.1: Biologic monotherapy vs. biological DMARD + MTX in RA patients who are MTX IR 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Kameda 2010 
(JESMR)266  
ETN  U  U  H *  U  L  L  L  
Kameda 2011 
(JESMR)237  
ETN  o  o  H *  L  o  L  L  
Dougados 
ACR 2011  
(ACT-RAY)267  
TCZ  a  a  a  a  a  a  a  
Dougados 
EULAR 2012 
(ACT-RAY)268  
TCZ  a  a  a  a  a  a  a  
Dougados 
ACR 2012  
(ACT-RAY)269  
TCZ  a  a  a  a  a  a  a  
Dougados 
2013 (ACT-
RAY)270  
TCZ  U  L  L  L  L  L  L  
Takeuchi 
EULAR 2013 
(SURPRISE)271  
TCZ  a  a  a  a  a  a  a  
ETN, etanercept ; NR, not recorded ; ROB, risk of bias; TCZ, tocilizumab  
a = abstract only; o= refer to original manuscript; H= high risk; L = low risk; U = unclear risk; * = not blinded  
6
4
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Table 3.8 Cochrane risk of bias assessment 5.1: Head to head biological DMARDs in RA patients who are MTX IR 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Weinblatt 2013 
(AMPLE)239  
ABT vs. 
ADA  
U  U  H *  L  L  L  L  
Fleischmann 
EULAR 2013 
(AMPLE 
work)272  
ABT vs. 
ADA  
a  a  a  a  a  a  a  
Fleischmann 
EULAR 2013 
(AMPLE)273  
ABT vs. 
ADA  
a  a  a  a  a  a  a  
Schiff EULAR 
2013 
(AMPLE)274  
ABT vs. 
ADA  
a  a  a  a  a  a  a  
Gabay 2013 
(ADACTA)275  
TCZ vs. 
ADA  
L  L  L  L  L  L  L  
Kavanaugh 
ACR 2012 
(ADACTA)276  
TCZ vs. 
ADA  
a  a  a  a  a  a  a  
 
ADA, adalimumab; ABT, abatacept ; eow, every other week; ROB, risk of bias; TCZ, tocilizumab  
a = abstract only, H= high risk; L = low risk; U = unclear risk, * = not blinded  
6
5
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Table 3.9 Cochrane risk of bias assessment 5.1: Biological DMARDs strategies RCTs without treat-to-target 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Emery 2010 
(ADJUST)236  
ABT  U  U  U  U  U  L  L  
Moreland 2012  
(TEAR)277  
ETN  L  L  L  L  H**  U***  L  
van der Kooij 
2009 (BeSt)278  
IFX  o  o  o  o  L  L  L  
van 
Vollenhoven 
2009 
(SWEFOT)240  
IFX  L  L  H*  H*  H**  L  L  
van 
Vollenhoven 
2012 
(SWEFOT)279  
IFX  L  L  H*  H*  H**  L  L  
Kavanaugh 
2013 
(OPTIMA)232  
ADA  L  L  L  U  L  L  L  
Fleischmann 
ACR 2012 
(OPTIMA)1  
ADA  a  a  a  a  a  a  a  
Kavanaugh 
ACR 2011 
(OPTIMA)280  
ADA  a  a  a  a  a  a  a  
6
6
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Emery 2010  
(COMET)281  
ETN  L  L  L  L  L  L  L  
O'Dell ACR 
2012 
(RACAT)282  
ETN  a  a  a  a  a  a  a  
O'Dell EULAR 
2013 
(RACAT)283  
ETN  a  a  a  a  a  a  a  
O'Dell 2013  
(RACAT)242  
ETN  U  U  L  L  H**  U***  L  
Li EULAR 
2013251 §  
GLM  a  a  a  a  a  a  a  
 
ABT, abatacept : ADA, adalimumab ; ETN, etanercept ; GLM, golimumab ; IFX, infliximab; ROB, risk of bias 
a = abstract only, o= refer to original manuscript ; H= high risk; L = low risk; U = not blinded, * = open label study,** = difficulty with 
recruitment, trial ended early – possible effect on power of the study, *** main analysis = completer- only analysis, although noted that 
similar results obtained with other statistical analyses, § MTX arm: cross-over from MTX to MTX + GLM  
6
7
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Table 3.10 Cochrane risk of bias assessment 5.1: Biological DMARDs strategies RCTs with treat-to-target 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Heimans 
EULAR 2012 
(IMPROVED)284  
ADA  a  a  a  a  a  a  a  
Heimans 2013 
(IMPROVED)285  
ADA  L  L  H*  U  L  L  L  
Horslev-
Petersen ACR 
2011 
(OPERA)286  
ADA  a  a  a  a  a  a  a  
Horslev-
Petersen 2013 
(OPERA)287  
ADA  L  L  L  U  L  L  L  
Van Eijk 2012 
(STREAM)288  
ADA  U  U  U  L  L  L  L  
Villeneuve 
ACR 2011 
(EMPIRE)289  
ETN  a  a  a  a  a  a  a  
van der Kooij 
2009 (BeSt)290  
IFX  o  o  o  L  o  L  L  
van der Kooij 
2009 (BeSt)291  
IFX  o  o  o  o  o  L  L  
van der Kooij 
2009 (BeSt)278  
IFX  o  o  o  o  L  L  L  
6
8
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Klarenbeek 
2011 (BeSt )217  
IFX  o  o  L  o  L  L  L  
Rantalaiho 
EULAR 2012 
(NEO-RACo)292  
IFX  a  a  a  a  a  a  a  
Leirisalo-Repo 
2013 (NEO-
RACo)293  
IFX  L  L  L  U  L  L  L  
Nam ACR 2011 
(IDEA)294  
IFX  a  a  a  a  a  a  a  
Nam EULAR 
2012 (IDEA)295  
IFX  a  a  a  a  a  a  a  
Nam 2013 
(IDEA)296  
IFX  L  L  L  L  L  L  L  
 
ADA, adalimumab; ETN, etanercept; IFX, infliximab; ROB, risk of bias 
a = abstract only, o= refer to original manuscript ; H= high risk; L = low risk; U = unclear risk, * = not blinded  
6
9
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Table 3.11 Cochrane risk of bias assessment 5.1: RCTs addressing Biological DMARD stopping or dose reduction 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Detert ACR 
2011 (HIT 
HARD)2973  
ADA  a  a  a  a  a  a  a  
Detert 2013 
(HIT HARD)230  
ADA  U  U  U  U  o  o  o  
Horslev-
Petersen 
EULAR 2013298  
ADA  a  a  a  a  a  a  a  
van der Kooij 
2009 (BeSt)291  
IFX  o  o  o  o  o  o  o  
Dirven 2011 
(BeSt)299  
IFX  a  a  a  a  a  a  a  
Klarenbeek 
2011 (BeSt )300  
IFX  o  o  o  o  o  0  0  
van den Broek 
2011 (BeSt)301  
IFX  o  o  H*  L  L  L  L  
Nam 2013 
(IDEA)296  
IFX  L  L  L  L  L  L  L  
Kavanaugh 
EULAR 2012 
(OPTIMA)302  
ADA  a  a  a  a  a  a  a  
Smolen 
EULAR 2012 
ADA  a  a  a  a  a  a  a  
7
0
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(OPTIMA)303  
Emery EULAR 
2013 (PRIZE)304  
ETN  a  a  a  a  a  a  a  
Smolen ACR 
2011 
(PRESERVE)305  
ETN  a  a  a  a  a  a  a  
Smolen 
EULAR 2012 
(PRESERVE)306  
ETN  a  a  a  a  a  a  a  
Smolen 2013 
(PRESERVE)307  
ETN  L  L  L  L  L  L  L  
Huizinga 
EULAR 2013 
(ACT-RAY)308  
TCZ  a  a  a  a  a  a  a  
Fautrel ACR 
2012 
(STRASS)309  
ADA & 
ETN  
a  a  a  a  a  a  a  
Fautrel EULAR 
2013 (STRASS) 
(1)310  
ADA & 
ETN  
a  a  a  a  a  a  a  
Fautrel EULAR 
2013 (STRASS) 
(2)311  
ADA and 
ETN  
a  a  a  a  a  a  a  
Smolen ACR 
2011 
(CERTAIN)312  
CZP  a  a  a  a  a  a  a  
Smolen 
EULAR 2012 
(CERTAIN)257  
CZP  a  a  a  a  a  a  a  
van 
Vollenhoven 
ETN  a  a  a  a  a  a  a  
7
1
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ACR 2012 
(DOSERA)313  
van 
Vollenhoven 
EULAR 2013314  
ETN  a  a  a  a  a  a  a  
 
ADA, adalimumab, CZP, certolizumab pegol, ETN, etanercept, IFX, infliximab; ROB, risk of bias; TCZ, tocilizumab  
a = abstract only, o= refer to original manuscript ; H= high risk; L = low risk; U = unclear risk, * = not blinded   
7
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Table 3.12 Cochrane risk of bias assessment 5.1: RCT that included both Biological and targeted synthetic DMARDs 
 
Study  Targeted 
synthetic 
and 
Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
van 
Vollenhoven 
EULAR 2012315  
Tofa and 
ADA  
a  a  a  a  a  a  a  
van 
Vollenhoven 
ACR 201131688  
Tofa and 
ADA  
a  a  a  a  a  a  a  
vanVollenhove
n 2012 (ORAL-
STANDARD)317  
Tofa and 
ADA  
L  L  L  U  L  L  L  
 
ADA, adalimumab; ROB, risk of bias; Tofa, tofacitinib  
a = abstract only, H= high risk; L = low risk; U = unclear risk  
7
3
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Table 3.13 Cochrane risk of bias assessment 5.1: RCT that included both Biological and targeted synthetic DMARDs 
 
Study  Biological 
DMARD  
ROB1:  
Random 
sequence 
generation  
ROB2:  
Allocation 
concealment  
ROB3:  
Blinding of 
participants 
and 
personnel  
ROB4:  
Blinding of 
outcome 
assessment  
ROB5:  
Incomplete 
outcome 
data  
ROB6:  
Other bias  
ROB7:  
Selective 
reporting  
Yoo EULAR 
2012 (CT-
P13)318  
CT-P13 vs. 
IFX  
a  a  a  a  a  a  a  
Yoo 2013 
(PLANETRA)319  
CT-P13 vs. 
IFX  
U  U  U  U  L  L  L  
Yoo EULAR 
2013 
(PLANETRA)320  
CT-P13 vs. 
IFX  
a  a  a  a  a  a  a  
 
IFX, infliximab; ROB, risk of bias; 
a = abstract only, H= high risk; L = low risk; U = unclear risk 
7
4
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3.4.2 Biological DMARD efficacy 
The efficacy outcomes in this group will focus mainly on those relating to signs and 
symptoms with the ACR70 responses shown by way of example in the forest plots. 
The ACR responses remain one of the most frequently reported measure of 
efficacy. Of these, the ACR70 was chosen as it was felt to be the most clinically 
meaningful response, most closely representing low disease activity 321.   
 
3.4.2.1 Biological DMARD and methotrexate combination vs. 
conventional synthetic DMARD 
3.4.2.1.1 DMARD-naïve RA 
In the SLR performed in 2010 there were no studies fulfilling the inclusion criteria 
comparing a bDMARD and methotrexate to methotrexate or another csDMARD 
monotherapy in patients with newly diagnosed IA who were DMARD naive.187  One 
study showed benefit of methotrexate and infliximab vs. methotrexate due to the 
sample size (n=20) was not included in the analysis.182 In this updated SLR one 
RCT was identified. In the HIT HARD study,230  patients with early active DMARD-
naïve RA were randomised to receive adalimumab 40mg subcutaneously every 2 
weeks and methotrexate 15mg subcutaneously weekly or placebo and 
methotrexate 15mg subcutaneously for 24 weeks. Thereafter, the adalimumab and 
placebo were stopped and patients continued with methotrexate monotherapy to 
week 48. The results from the first 24 weeks confirm the efficacy of bDMARD and 
methotrexate combination therapy compared to methotrexate monotherapy in 
patients DMARD-naïve RA. Whilst the ACR 20 were not significantly different 
between the two groups, the ACR50 and ACR 70 responses were also higher in the 
methotrexate and adalimumab group (ACR 20/50/70: 79% vs. 67.6% (p=0.10), 
63.8% vs. 49.7% (p=0.049) and 48.0% vs. 26.8% (p=0.006) in the methotrexate and 
adalimumab vs. methotrexate and placebo groups respectively). Patients who 
received methotrexate and adalimumab also achieved lower DAS28 scores than 
those with moderate dose methotrexate monotherapy (15mg weekly) at 6 months 
(mean (SD) 3.0 (1.2) vs 3.6 (1.4) in the methotrexate and adalimumab vs. 
methotrexate and placebo groups respectively; adjusted difference (95% CI)  0.53 
(0.13 to 0.93), p = 0.009). DAS28 remission and improvement in function were also 
significantly greater in the group receiving combination therapy (DAS28 remission 
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47.9% vs 29.5%, p=0.021 and HAQ-DI 0.49±0.6 vs 0.72±0.6, p=0.0014 in the 
methotrexate and adalimumab vs. methotrexate and placebo groups).  
 
3.4.2.1.2 MTX-naïve RA 
RCTs of seven bDMARDs (abatacept,231 adalimumab,232 322 323 etanercept,180 
golimumab,233 infliximab324 , rituximab244 and tocilizumab245) were included in the 
MTX-naïve RA group. These confirmed superior efficacy of starting methotrexate 
and bDMARD vs. starting methotrexate monotherapy (pooled RR (95% CI)  1.68 
(1.54, 1.84) for ACR 70 responses) (figure 3.2) (level of evidence 1A). 
DAS28 remission rates were also higher with methotrexate and bDMARD 
combination therapy in this group with a pooled RR for DAS28 remission at 12 
months (95% CI) of 1.77 (1.56 to 2.00). Radiographic data showed less progression 
for abatacept,231 adalimumab,232 etanercept,180 golimumab,243 infliximab,324 rituximab 
244 and tocilizumab 245 in combination with methotrexate than for methotrexate  
monotherapy and radiographic non-progression was higher for abatacept,231 
adalimumab,323 etanercept 180 and golimumab. 243 Improvements in HAQ-DI at 12 
months were also greater for abatacept,231 adalimumab,322 323 etanercept,325 
infliximab,324 rituximab 244 and tocilizumab 245 in combination with methotrexate. 
3.4.2.1.3 MTX-IR and Mixed DMARD-IR RA 
From the SLR performed in 2010, there were data for all nine bDMARDs in patients 
with MTX-IR.234  Since then, additional studies for this group and the mixed 
DMARD-IR group have been published foranakinra,234 certolizumab pegol,247 248 and 
golimumab 235 251-253. All confirm efficacy of a bDMARD and methotrexate vs. 
placebo and methotrexate in MTX-IR (pooled RR (95% CI) 4.07 (3.21, 5.17)) (figure 
3.3) and bDMARD and a csDMARD vs. csDMARD in mixed DMARD –IR (pooled 
RR (95% CI) 4.74 (2.63, 8.56)) (figure 3.4) (level of evidence 1A).  
3.4.2.1.4 TNFi-IR RA 
In a SLR and meta-analysis of four RCTs in TNFi-IR, 326-330 which were included in a 
previous SLR,187 the pooled RR for ACR 70 (95% CI) was 5.40 (2.93, 9.98)  (figure 
3.5) (level of evidence 1A). Whilst there were no new RCTs fulfilling inclusion 
criteria in this group, approximately 40% of patients in the 12-week REALISTIC 
RCT in which were TNFi-IR and sub-analysed accordingly, confirming clinical 
efficacy of certolizumab pegol.331 
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Figure 3.2 Risk ratios for the ACR 70 responses comparing a biological disease-
modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) versus 
MTX monotherapy in patients with early rheumatoid arthritis who are MTX-
naïve. 
ACR, American College of Rheumatology; *additional study since the 2010 
systematic literature review 187; † ACR 70 responses at 6 months for 
Kavanaugh 2013 OPTIMA, Emery 2009 GO-BEFORE and Burmester  EULAR 
2013 FUNCTION; all other ACR 70 responses are at 12 months.  
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Figure 3.3 Risk ratios for the ACR70 responses comparing the use of a biological 
disease-modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) 
versus MTX monotherapy in patients with rheumatoid arthritis (RA) who are 
MTX incomplete responders.  
ACR, American College of Rheumatology; *additional study since the 2010 
systematic literature review 187; †ACR 70 response at 12 months for Kremer 
2011 LITHE; all other ACR 70 responses are at 6 months.  
 
 
 
Figure 3.4 Risk ratios for the ACR70 responses comparing the use of a biological 
disease-modifying antirheumatic drug (bDMARD) plus synthetic disease-
modifying antirheumatic drug (csDMARD) versus csDMARD monotherapy in 
patients with rheumatoid arthritis for whom a csDMARD (not necessarily MTX) 
has failed. 
ACR, American College of Rheumatology; *additional study since the 2010 
systematic literature review. 187; † ACR 70 response at 12 months for 
Klareskog 2004 TEMPO; all other ACR 70 responses are at 6 months.  
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Figure 3.5 Risk ratios for the ACR 70 responses comparing a biological disease-
modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) versus 
MTX monotherapy in patients with rheumatoid arthritis who have failed a TNF-
inhibitor. 
ACR, American College of Rheumatology 
 
3.4.2.2 Biological DMARD monotherapy vs. conventional synthetic 
DMARD 
From the previous SLR, bDMARD monotherapy was not superior to csDMARD 
monotherapy.187 Reviewing the literature again, results for this group have varied 
with no clear benefit from sub-assessments of these patients in three recent 
golimumab RCTs.237 243 252 332 In the FUNCTION study, which addressed the efficacy 
and safety of tocilizumab with/without methotrexate vs. methotrexate in MTX- naive 
early RA, the primary endpoint was met (DAS28 ESR remission at 6 months: 38.7% 
vs. 15% in the tocilizumab 8mg/kg monotherapy vs. methotrexate monotherapy 
respectively, p≤0.0001). This endpoint however favours therapies that, like 
tocilizumab, interfere with the acute phase responses. The  ACR responses and 
changes in physical function, however, which do not, were similar between the two 
groups. At 12 months, radiographic progression was lower in patients receiving 
81 
 
 
tocilizumab than those receiving methotrexate,  and  lowest  in the tocilizumab 
8mg/kg and methotrexate combination therapy group.245 
 
3.4.2.3 Biological DMARD and methotrexate combination vs. biological 
DMARD monotherapy 
Several previously published clinical trials have demonstrated better clinical and 
radiographic outcomes with bDMARD and methotrexate than with bDMARD 
monotherapy.323 333 This has been confirmed in more recent RCTs in MTX-naïve RA 
(figure 3.6). 243 245 334  
 
 
Figure 3.6 Risk ratios for the ACR70 responses comparing the use of a biological 
disease-modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) 
versus bDMARD monotherapy in patients with rheumatoid arthritis who are 
MTX-naïve. 
ACR, American College of Rheumatology; *additional study since the 2010 
systematic literature review 187 ; † ACR 70 response at 12 months for 
Breedveld 2006 PREMIER; all other ACR 70 responses are at 6 months. 
 
In a 16-week open label study of patients with MTX—IR RA however, similar clinical 
and patient reported outcomes were seen with etanercept and methotrexate 
compared to etanercept monotherapy.335 336 In this SLR there were three studies, all 
in the MTX-IR group, comparing bDMARD and methotrexate combination therapy 
vs. bDMARD monotherapy.  In the open label JESMR study, combination therapy 
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with etanercept and methotrexate was superior to etanercept monotherapy for 
clinical outcomes. Although there was less radiographic progression with 
combination therapy, the between group difference was not statistically 
significant.237 266 Two studies compared adding tocilizumab to methotrexate 
(combination therapy) to switching from methotrexate to tocilizumab monotherapy 
(methotrexate-withdrawal). In the ACT-RAY study 270 and the non-inferiority 
SURPRISE study, 271 ACR 70 responses were similar in both groups at 6 months 
(figure 3.7). However, in contrast to the 6 month outcomes, 12 month results from 
the ACT-RAY study showed higher proportions of remission and radiographic non-
progression in the tocilizumab and methotrexate combination group (DAS28 
remission 37% vs. 46%, p=0.03 and radiographic non-progression 86% vs. 92%, 
p=0.007 in the tocilizumab monotherapy and tocilizumab and methotrexate  groups 
respectively)268 (figure 8). 
 
 
Figure 3.7 Risk ratios for the ACR70 responses comparing the use of a biological 
disease-modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) 
versus bDMARD monotherapy in patients with rheumatoid arthritis who are 
MTX incomplete responders. 
ACR, American College of Rheumatology; *additional study since the 2010 
systematic literature review 187; ACR 70 responses are at 6 months; †† open 
label studies 
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Figure 3.8 Risk ratios for the DAS28 remission comparing the use of a biological 
disease-modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) 
versus bDMARD monotherapy in patients with rheumatoid arthritis who are 
MTX incomplete responders. 
*Additional study since the 2010 systematic literature review. 187 ; † DAS28 
remission at 6 months for Kremer 2010 IV Golimumab and Takeuchi EULAR 
2013 SURPRISE and ACR 70 at 12 months for Keystone 2010 GO-
FORWARD and DOUGADOS EULAR 2012 ACT-RAY; †† open label study 
 
The possibility of stepping down from bDMARD and methotrexate to bDMARD 
monotherapy was addressed in one study. In the COMET trial, patients were 
randomised at baseline for a 2-year period to methotrexate for a year then 
continuing with methotrexate monotherapy or adding etanercept, or to methotrexate 
and etanercept for one year then continuing or stopping methotrexate. 281 At 2 years 
DAS28 remission in the group continuing methotrexate and etanercept (EM/EM) 
and the group stepping down to etanercept monotherapy (EM/E) was 45% and 37% 
respectively. In both groups radiographic non-progression was high, but higher in 
those on combination therapy (EM/EM vs. EM/E 90% vs. 75%, p 0.008) (table 4). 
 
3.4.2.4 Head to head biological DMARD studies 
Two studies, both in the group of patients with MTX-IR RA, have done ‘head-to-
head’ comparisons, directly comparing two different bDMARDs. The non-inferiority 
study AMPLE study compared combination therapy abatacept and methotrexate to 
adalimumab and methotrexate in patients with early RA (less than 2 years). 239The 
study met its primary end-point (ACR20 response at 12 months). The ACR50 and 
70 responses between the two groups were also similar (ACR20, 50 and 70 
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responses: 65%, 46% and 29% vs. 63%, 46% and 26% in the abatacept and 
methotrexate and adalimumab and methotrexate groups, respectively). In the 
ADACTA study tocilizumab monotherapy was compared to adalimumab 
monotherapy.275 There was a significantly greater change in DAS28 from baseline 
to 6 months in the tocilizumab 8mg/kg monotherapy vs. adalimumab 40mg 
subcutaneous (SC) monotherapy group (difference (95% CI): -1.5 (-1.8 to -1.1), 
p<0.0001) in this superiority study. The 6 month ACR responses were also higher 
with tocilizumab monotherapy (ACR20, 50 and 70 responses: 65%, 47% and 33% 
vs. 49%, 28% and 18% in the tocilizumab and adalimumab monotherapy groups 
respectively) as was the change in clinical disease activity index (CDAI) (which 
does not include an acute phase reactant) (table 3.2). 
 
3.4.2.5 Switching between biological DMARDs  
No RCTs were found fulfilling inclusion criteria for switching between bDMARDs.
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Table 3.14 ACR responses of head-to head biological DMARD RCTs  
 
Trial 
(reference) 
Treatment group Patients 
evaluated (n) 
Time-point 
evaluated 
(months) 
ACR 20 
(%) 
p ACR50 
(%) 
p ACR70 
(%) 
p 
Weinblatt 2013 
(AMPLE) 
239
 
  
MTX + ABT 125mg 
weekly  
318 12 64.8 referent 46.2 referent 29.2 referent 
MTX + ADA 40mg 
every 2 weeks 
328   63.4 NS 46.0 NS 26.2 NS 
Gabay 2013 
(ADACTA) 
275
 
  
ADA 40mg every 2 
weeks 
162 6 49.4 referent 27.8 referent 17.9 referent 
TCZ 8mg/kg every 
4 weeks 
163   65.0 0.0038 47.2 0.0002 32.5 0.0023 
 
ABT, abatacept; ACR, American College of Rheumatology; ADA, adalimumab; MTX, methotrexate; RCTs, randomised controlled trials; 
TCZ, tocilizumab  
All RCTs are in MTX incomplete responders 
8
5
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3.4.3 Strategy trials with biological DMARDs 
Increasingly, with the number of treatment options and evidence of the benefit of 
regular monitoring to optimise disease control (treat-to-target approach),10 studies 
have looked, not only at direct comparisons between a bDMARD and methotrexate 
vs. methotrexate monotherapy but use of bDMARDs in different treatment 
strategies. The BeSt trial,183 identified in one of the EULAR SLRs done in 2010223 
and discussed in the previous chapter, was one of the pioneering studies to do so. 
Since then several strategy studies, using different trial designs and primary 
outcome measures, have been published aiming to address the place of bDMARD 
therapy in treating patients with IA. For purposes of discussion, these can broadly 
be divided into two groups addressing (1) stepping up to or induction with a 
bDMARD compared to other treatment strategies and (2) the possibility of bDMARD 
withdrawal or dose reduction. Some studies have addressed both aspects and will 
be discussed in both groups. Within each group studies have also addressed the 
use of bDMARDs in both (a) RA and (b) UA. These will be discussed as 
subsections within each group. 
 
3.4.3.1 Strategy trials addressing stepping up to or induction with a 
biological DMARD  
3.4.3.1.1 Strategy trials addressing stepping up to or induction with a bDMARD in 
RA 
These have addressed (i) initial methotrexate monotherapy then stepping up to 
csDMARD combination therapy vs. methotrexate and bDMARD in the case of MTX- 
incomplete response (SWEFOT,240 TEAR,241 RACAT242 ), (ii) induction with 
csDMARD combination therapy or methotrexate and a bDMARD (TEAR241), (iii) 
methotrexate monotherapy then stepping up to methotrexate and a bDMARD vs. 
methotrexate and bDMARD as induction therapy (TEAR,241 OPTIMA,1 2 232 COMET 
281) (iv) induction with a bDMARD and methotrexate vs. csDMARD within a treat-to-
target approach, in which patients were seen at regular intervals with treatment 
changes if the desired outcome (e.g. low disease activity or remission) was not met 
(Neo-RACo,293 OPERA,337 IDEA17).  Table 3.3 provides a schematic diagram of the 
different types of study designs illustrating some of the RCTs by way of example. 
A number of RCTs which compared a bDMARD and methotrexate vs. methotrexate 
monotherapy also incorporated a cross-over arm from methotrexate monotherapy to 
combination therapy with methotrexate and bDMARD. These provided further 
information on induction therapy with a bDMARD and methotrexate vs. initial 
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methotrexate monotherapy then stepping up to a bDMARD and methotrexate.243 251 
253 260
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Table 3.15 Schematic of strategy-type designs in RA 
Study design Example RCT Comparator groups  
MTX step up to csDMARD combination vs. 
MTX step up to MTX + bDMARD  
SWEFOT (van 
Vollenhoven 2009)
240 279
 
MTX then MTX + SSZ+ HCQ   
MTX then MTX + IFX  
Induction with csDMARD combination vs. 
Induction with MTX + bDMARD  
TEAR (Moreland 
2012)
241
 * 
MTX+ SSZ + HCQ  
MTX + ETN  
MTX step up to MTX + bDMARD vs. 
Induction with MTX+ bDMARD  
OPTIMA (Fleischmann 
ACR 2012
1 , Smolen 
2014
2
)**  
MTX then MTX + ADA   
MTX+ ADA   
Induction with csDMARD + T2T vs. 
Induction with a bDMARD + MTX +T2T 
NeoRA-Co (Leirisalo-
Repo 2013)
293
 
MTX + SSZ+ HCQ+ Pred+ T2T  
MTX + SSZ+ HCQ+ Pred+T2T+ 
IFX for 26 weeks then stop IFX 
 
Legend:  
ADA, adalimumab (      ); ETN, etanercept (      ); HCQ hydroxychloroquine (      ); IFX, infliximab (      ); MTX, methotrexate (      );  
Pred, prednisolone (       ); RA, rheumatoid arthritis; SSZ, sulphasalazine (      ); T2T, treat–to-target (      ), *only two of the four treatment arms 
in the TEAR trial are illustrated here; the other two arms are similar in design to the two arms in the SWEFOT trial; For the OPTIMA trial, the 
ACR abstract by Fleichmann et al. 1 was used for the published manuscript, the data in this thesis has been updated using the data from the 
published manuscript by Smolen et al.2 
8
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3.4.3.1.2 Initial methotrexate monotherapy then stepping up to csDMARD 
combination therapy vs. methotrexate and bDMARD in the case of 
methotrexate - incomplete response 
 
The SWEFOT240 study was a 24 month study in which 487 patients were enrolled 
and received initial treatment with methotrexate monotherapy. Of a group of 258 
who did not achieve LDA (DAS 28 ≤ 3.2) after three to four months, 130 were 
randomised to receive triple csDMARD therapy with methotrexate, sulphasalazine, 
and hydroxychloroquine and 128 to methotrexate and infliximab.  At 12 months, a 
significantly greater clinical response was seen in the group receiving bDMARD 
therapy (EULAR good response 50/128 (39%) vs. 32/130 (25%), RR (95% CI) 1.59 
(1.10 to 2.30), p=0.0160 in the methotrexate and infliximab vs. the methotrexate, 
sulphasalazine and hydroxychloroquine groups respectively).240 At 24 months these 
were similar between the two groups (EULAR good response 49/128 (38%) vs. 
40/130 (31%), p=0.204) however radiographic progression remained lower in the 
methotrexate and infliximab group (mean (SD) change in mTSS 4.00 (10.0) vs. 7.23 
(12.72), p=0.009)279 (table 3.4). 
The TEAR study was a double blind 2x2 factorial design RCT in which four 
treatment strategies were compared.241  Similar to the SWEFOT study, there were 
two step- up treatment groups: ST (step-up from methotrexate monotherapy to triple 
therapy) and SE (step-up from methotrexate monotherapy to methotrexate and 
etanercept) if DAS28 ESR ≥ 3.2 at week 24. The study also aimed to address 
induction therapy with combination csDMARD therapy with methotrexate, 
sulphasalazine and hydroxychloroquine (IT [immediate triple therapy]) and induction 
with a bDMARD (IE [immediate methotrexate and etanercept]). Eight percent of 
patients in this study were DMARD-naïve. The primary end-point, DAS28-ESR from 
week 48 to week 102, and DAS28-ESR remission at week 102 were similar 
between groups (IE/IT/SE/ST:   56.5 %/ 59.1 %/ 52.9%/ 56.5%, p=0.93). Remission 
was achieved earlier with both of the initial combination therapy groups with 
methotrexate and etanercept and triple csDMARDs (IE+IT vs. SE+ST p<0.0001). 
Greater depth of response however was seen in the etanercept therapy groups 
(week 102 ACR70: IE+SE vs. IT+ST 18.25 vs. 11.3%, p=0.01). Radiographic non-
progression was not significantly different comparing each of the four groups 
however those receiving etanercept (IE+SE) had less progression than those 
receiving triple csDMARD therapy (IT+ST) (p=0.02)(table 3.4). 
It has been suggested that confounding by low recruitment (and therefore 
insufficient power) and other factors need to be considered for these trials240 241 and 
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that perhaps more significant between-group differences may have been seen if this 
was not the case.338 Never-the-less, findings suggest that more rapid achievement 
of clinical outcomes are achieved with more intensive treatment strategies seen with 
significantly more patients achieving ACR 70 responses and less radiographic 
progression with bDMARD therapy. 
The RACAT study was a 48-week, double blind, non-inferiority study comparing 
methotrexate and etanercept to triple csDMARD therapy (methotrexate, 
sulphasalazine and hydroxychloroquine) in MTX-IR RA. The original primary 
endpoint was the difference in proportion of participants with DAS28 ≤ 3.2 at week 
48. Due to unexpected low recruitment, this was changed to a continuous outcome 
– that of change in DAS28 at week 48. In the completers-only analysis of 309 
patients, the mean (SD) difference between the two groups this was 0.17 (0.15). 
With the 95% upper confidence interval limit (0.41) below the non-inferiority margin 
of 0.60, triple therapy was found to be non-inferior to methotrexate and etanercept. 
There was also no significant difference in radiographic progression between the 
two groups (table 3.6). 
3.4.3.1.3 Induction with csDMARD combination therapy or methotrexate and a 
bDMARD 
The TEAR trial 241 was the only RCT found comparing induction therapy with triple 
csDMARDs (methotrexate, sulphasalazine and hydroxychloroquine) to 
methotrexate and a bDMARD, in this case, etanercept. The results are detailed 
above and in table 3.4 showing similar clinical responses with the two treatment 
strategies but lower radiographic progression with methotrexate and etanercept. 
3.4.3.1.4 Methotrexate monotherapy then stepping up to methotrexate and a 
bDMARD vs. methotrexate and bDMARD as induction therapy  
The results of the first year of the COMET study,180 which were included in the SLR 
done in 2010187 and discussed in the previous chapter, showed that clinical and 
radiographic responses were superior with methotrexate and etanercept 
combination therapy than with methotrexate monotherapy. During the second year 
of the COMET study, patients in the methotrexate group were randomised to 
receive methotrexate (M/M) alone or methotrexate and etanercept (M/EM) and 
those in the methotrexate and etanercept group to continue with combination 
therapy (EM/EM) or to receive etanercept alone (EM/E). At year 2 clinical outcomes 
were superior in the groups that received etanercept compared to the group 
receiving methotrexate alone. DAS28 remission was achieved in 62/108 (57%) and 
51/88 (58%) for the EM/EM and M/EM groups respectively – this was significantly 
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greater than that in the M/M group (33/94 [35%]) (p = 0.002 for the EM/EM group 
vs. the M/M group; p = 0.003 for M/EM group vs. the M/M group) but not 
significantly greater than that in the EM/E group (54/108 [50%]) (table 3.5). 
Radiographic progression was also lower in those who received etanercept with the 
lowest rate of progression seen in the groups treated with etanercept early (figure 
3.9).77  
In the OPTIMA study, induction therapy with methotrexate and adalimumab was 
compared to methotrexate monotherapy for 26 weeks in achieving stable low 
disease activity (LDA: DAS28 (CRP) ≤ 3.2 at weeks 22 and 26).339 Patients 
completing period 1 were then re-randomised in period 2 according to response to 
therapy. Responders in the combination therapy group either continued or stopped 
adalimumab and those on methotrexate monotherapy continued treatment. These 
results will be discussed later in the chapter. Incomplete responders received open 
label rescue-therapy with adalimumab. The primary endpoint was a composite 
score of DAS28 ≤ 3.2 and radiographic non-progression between weeks 0 and 78. 
A significantly higher proportion of patients in the methotrexate and adalimumab 
group achieved this combined measure compared to those receiving methotrexate 
monotherapy (70% (73/105) vs. 54% (61/112), mean difference (95% CI) 15% (2-
28%), p=0.0225, in the methotrexate and adalimumab and methotrexate 
monotherapy groups respectively) (table 4). In the methotrexate monotherapy group 
who did not achieve sustained low disease activity in period 1 and received 
additional treatment with adalimumab (adalimumab-rescue), clinical improvements 
between weeks 26 and 52 were similar to those of patients who received induction 
therapy with methotrexate and adalimumab during period 1 at week 26 (mean (SD) 
DAS28 3.27 (1.27) vs 3.32 (1.44) with adalimumab-rescue at week 78 vs. induction 
with methotrexate and adalimumab at week 26. As in the COMET study, 
radiographic progression with methotrexate monotherapy at week 26 (mean (SD) 
ΔmTSS 1.2 (4.22)) was reduced with the addition of a bDMARD (mean ΔmTSS 0.1 
with methotrexate and adalimumab) (table 3.5). 
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Table 3.16 Biological DMARD strategy RCTs in early DMARD-naïve RA without a treat-to-target approach –study outcomes 
Outcome Result 
van Vollenhoven 2009/ 2012 (SWEFOT) 240 279 
EULAR good response at 12 months* MTX+ SSZ +HCQ  vs. MTX+ IFX : 25% vs. 39%, (RR 1.59 [95% CI 1.1-2.3]), p=0.016 
EULAR good response at 24 months   MTX+ SSZ +HCQ  vs. MTX+ IFX : 31% vs. 38%, p=0.204 
Mean radiographic progression (SD) at 2 years   MTX+ SSZ +HCQ  vs. MTX+ IFX : 7.23 (12.72) vs. 4 (10.05), p=0.009 
Moreland 2012 (TEAR) 241 ** 
DAS28-ESR from week 48 to week 102* 
  
IE (n=244) vs. IT (n=132) vs. SE(n=255) vs.ST (n=124); completers only analysis: No 
difference between groups (p=0.28)  
MTX + ETN (IE+SE) vs. TT (IT+ST), p=0.48; Immediate (IE+IT) vs. step up (SE+ST), p=0.55 
DAS28 ESR at week 24 IE+IT vs. SE+ST p<0.0001 
DAS28 ESR remission (%) at week 102 IE/IT/SE/ST : 56.5/ 59.1/ 52.9/ 56.5, p=0.93 
ACR responses (%) at week 102  IE/IT/SE/ST : ACR20 and ACR 50, p=NS; ACR70: IE+SE vs. IT+ST: 18.25 vs. 11.3%, p=0.01 
Radiographic non-progression (%) at week 102 IE/IT/SE/ST: 79.4/64.9/71.1/68.3, p=0.33; IE+SE vs. IT+ST: 76.8 vs. 66.4, p=0.02 
DMARD, disease modifying antirheumatic drug ETN, etanercept; HCQ, hydroxychloroquine; IFX, infliximab; MTX, methotrexate; SD, 
standard deviation; SSZ, sulphasalazine; TT, triple therapy (MTX, SSZ and HCQ)  
IE, immediate treatment with MTX and ETN; IT, immediate oral triple therapy (MTX, SSZ and HCQ); SE, step-up form MTX monotherapy 
to MTX plus ETN; ST, step up from MTX monotherapy to MTX, SSZ and HCQ; *primary endpoint; **80% of patients were DMARD naive   
9
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Table 3.17 Biological DMARD strategy RCTs in early MTX-naïve RA without a treat-to-target approach – study outcomes 
Outcome Result 
Emery 2009 (COMET) 281 
Remission (DAS28<2.6) at 2 years  EM/EM, EM/E, M/EM, M/M 62/108, 54/108, 51/88 and 33/94 (p<0.01 for EM/EM and M/EM vs. M/M) 
Radiographic non-progression 
(mTSS ≤ 0.5) at 2 years   
EM/EM (n=111), EM/E (n=111), M/EM (n=90), M/M (n=99): 89/99, 74/99, 59/79 and 56/83 (p<0.01 
EM/EM vs. other groups) 
Kavanaugh 2013, 232 Fleischmann ACR 2012 1, Smolen 20142 (OPTIMA) 
Stable LDA at weeks 22 and 26 ADA+MTX (n=517) vs. Placebo+MTX (n=515): 44% vs. 24% (p<0.001)  
Composite score: DAS28(CRP)<3.2 
at week 78 mTSS ≤ 0.5 at week 78* ADA+MTX (n=105) vs. Placebo+MTX (n=112): 70% vs. 54% (p=0.025)  
Mean (SD) DAS28CRP in ADA-
rescue at week 78 MTX then MTX+ADA if not in LDA at week 26: ADA+MTX from week 0 to 26: 3.27 (1.27) vs. 3.32 (1.44) 
Mean ∆mTSS week 26 and weeks 
26-78 in ADA-rescue MTX then MTX+ADA if not in LDA at week 26: 1.2 (4.22) then 0.1 
ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; E, etanercept; EM, etanercept and methotrexate; ETN, etanercept; 
LDA, low disease activity; mTSS, van der Heijde modified total Sharp score; M, methotrexate; MTX,  methotrexate; * primary endpoint; 
SD, standard deviation
9
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Figure 3.9 Radiographic progression over 2 years in the COMET trial 
Adapted from Emery et al, Ann Rheum Dis 2010281  
Mean changes in van der Heijde modified Sharp score (mTSS) from week 0 to week 104, based on the last observation carried forward 
analysis. (ETN = etanercept: MTX = methotrexate. * = 1 subject did not have a valid radiograph at week 52 but did at baseline and week 
106; changes from week 52 to week 104 cannot be assessed.) 
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Table 3.18 Biological DMARD strategy RCT in MTX IR RA without a treat-to-target approach – study outcomes 
 
Outcome Result 
O'Dell 2013 (RACAT) 242 (n=353) 
Mean (SD) ∆DAS28 at week 48* 
MTX+SSZ+HCQ vs. ETN+MTX (completers only analysis): -2.12 (1.28) vs. -2.29 (1.30) 
(p=0.26) 
Mean (SD) ∆DAS28 at week 24   -1.79 (1.20) vs. -2.06 (1.35) (p=0.06)  
Mean (SD) ∆mTSS at week 24   0.42(1.91) vs. 0.003 (3.62) (p=0.20) 
Mean (SD) ∆mTSS at week 48   0.54 (1.93) vs. 0.29(3.32)  (p=0.43) 
 
DMARD, disease-modifying antirheumatic drug; ETN, etanercept; HCQ, hydroxychloroquine; mTSS, van der Heijde modified total Sharp 
score; MTX,  methotrexate; * primary endpoint; SD, standard deviation; SSZ, sulphasalazine
9
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3.4.3.1.5 Induction with a bDMARD and methotrexate vs. csDMARD within a treat-
to-target approach  
The Neo-RACo was one of the RCTs addressing bDMARD induction within a treat-
to-target setting.293  Patients received methotrexate, sulphasalazine, 
hydroxychloroquine  and prednisolone 7.5mg daily (the Fin-RACo regime) and 
placebo or the Fin-RACo regime and infliximab 3mg/kg for 26 weeks.  Additional 
glucocorticoids were permitted during the study period. The modified ACR 
remission at 2 years (study primary endpoint) was 66% in the Fin-RACo and 
infliximab group and 53% in the Fin-RACo + placebo groups (p=0.19). DAS28 
remission for both groups was 82%. Radiographic progression however was lower 
and the proportion achieving non-progression higher in the group receiving 
infliximab (24 month mean ∆mTSS: 0.2 vs. 1.4 (p=0.0058) and ∆mTSS ≤0.5: 80% 
vs. 53% (p=0.006) in the Fin-RACo and infliximab vs. the Fin-RACo and placebo 
groups respectively). The proportion of patients in remission at 5 years remained 
high (modified ACR remission (95% CI): FIN-RACo and infliximab vs. FIN-RACo 
and Placebo 59% (43 to 73) vs. 60% (45 to 74) (p=0.87), DAS28 remission (95% 
CI) 83% (69 to 92) vs. 88% (75 to 95))292 (table 3.7). 
The other studies addressing bDMARD use within a treat-to-target setting were 
OPERA337 and IDEA17.  Both used a monoclonal TNFi with methotrexate – 
adalimumab in OPERA and infliximab in IDEA.  In the OPERA study, induction with 
methotrexate and adalimumab combination was compared to methotrexate 
monotherapy with intra-articular glucocorticoids as part of the treat-to-target 
strategy. At each visit swollen joints were injected with triamcinolone (maximum of 
four joints per visit). Additional DMARDs were also prescribed if LDA was not 
achieved. LDA at 12 months, the primary endpoint, was similar between groups 
(methotrexate and adalimumab 80% vs. methotrexate monotherapy 76% (p=0.65)). 
Proportions of patients achieving remission was higher in the methotrexate and 
adalimumab group (methotrexate and adalimumab 74% vs. methotrexate 
monotherapy 49% (p=0.0008)) (table 3.7). Further details on the IDEA17 study will 
be provided in Chapter 4.
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Table 3.19 Biological DMARD strategy studies* with a treat-to-target approach – study outcomes 
 
Outcome Result 
Leirisalo-Repo 2012 (NEO-RACo) 293 
Modified ACR remission** 2 year MTX SSZ+HCQ+Pred + IFX vs. MTX+SSZ+HCQ+Pred + Placebo:66% vs. 53% (p=0.19) 
Sustained modified ACR remission# 2 year MTX+SSZ+HCQ+Pred + IFX vs. MTX+SSZ+HCQ+Pred + Placebo:26% vs. 10% (p=0.042) 
DAS28 remission  Both groups:  82% (NS) 
Mean ∆mTSS 2 year MTX+SSZ+HCQ+Pred + IFX vs. MTX+SSZ+HCQ+Pred + Placebo:-0.2 vs. 1.4 (p=0.0058) 
Radiographic non-progression 2 year MTX+SSZ+HCQ+Pred + IFX vs. MTX+SSZ+HCQ+Pred + Placebo:80% vs. 53% (p=0.006)  
Horslev-Petersen 2013 (OPERA) 337 (n=180) 
DAS28CRP < 3.2 at 1 year** ADA + MTX vs. Placebo + MTX: 80% vs. 76% (p=0.65) 
DAS28CRP (median (95% CI) at 1 year ADA + MTX vs. Placebo + MTX: 2.0 (1.7 to 5.2) vs. 2.6 (1.7 to 4.7 ) (p=0.009) 
DAS28 CRP < 2.6 at 1 year   ADA + MTX vs. Placebo + MTX: 74% vs. 49% (p=0.0008), NNT 4.0 (2.6 to 9.1) 
Nam 2013 (IDEA)17  (n=112)  
∆mTSS score (mean) at 1 year** IFX + MTX vs. IV steroid + MTX: 1.20 vs. 2.81 (p=0.132) 
mTSS <2.0 at 1 year** IFX + MTX vs. IV steroid + MTX: 81% vs. 71% [OR (95% CI) 1.77 (0.56, 5.61); p=0.328] 
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DAS44 remission at 1 year    IFX + MTX vs. IV steroid + MTX: 49% vs. 36% [OR (95% CI)  2.13 (0.91, 5.00); p=0.082) 
DAS44 remission at 1.5 year (week 78) IFX + MTX vs. IV steroid + MTX : 48% vs. 50% [OR (95% CI) 1.12 (0.47, 2.68); p=0.792] 
 
ADA, adalimumab; DAS, disease activity score; FIN-RACo = methotrexate, sulphasalazine, hydroxychloroquine and prednisolone; IFX, 
infliximab; MTX, methotrexate; mTSS = van der Heijde modified total Sharp score; *all DMARD-naïve RA studies; **primary endpoint; # 
Sustained  remission = remission at each visit from 6 to 24 months 
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3.4.3.1.6 Strategies trials addressing stepping up to or induction with a bDMARD in 
UA 
Studies have also begun to focus on patients at earlier stages of the IA disease 
continuum. These have aimed to address the use of bDMARDs in patients 
presenting with UA or in those fulfilling the 2010 ACR-EULAR  classification 
criteria12 but not all fulfilling the 1987 ACR criteria11 for RA (ADJUST,236 STREAM, 
288 IMPROVED,238 EMPIRE 18 289). Table 3.8 provides a schematic of the different 
types of the different study designs in this group of patients and table 3.9 the 
results. 
In the two year randomised double blind controlled ADJUST trial, 56 anti-CCP 
positive patients with undifferentiated arthritis (not fulfilling the 1987 ACR RA 
classification criteria) were randomised to receive IV abatacept or placebo for six 
months.236 Treatment was then discontinued. At 1 year, a smaller proportion in the 
abatacept group developed RA (1987 criteria) (46% (1/26) vs. 67% (16/34) in the 
abatacept and placebo groups respectively).  Radiographic progression was also 
lower with abatacept (total Genant-modified Sharp scores: 0 vs. 1.1 in the abatacept 
and placebo groups).  
In the STREAM 288 study, 82 patients were randomised to conventional care or 
aggressive treatment with regular monitoring and treatment escalation.  In the 
aggressive group, 19 (45%) received adalimumab. Two year remission were similar 
between the groups (median 66% vs. 49% (NS) in the aggressive and conventional 
care groups respectively) and with minimal radiographic progression (median 
(interquartile range(IQR)) ∆mTSS (0 (0-1.1) vs. 0.5 (0-2.5) (NS)). One of the main 
reasons suggested by the authors for the lack of difference in outcomes between 
groups was the gradual intensification of treatment in the conventional care group 
during the course with a higher number of glucocorticoid injections used, resulting in 
a lower than expected rate of radiographic damage.  
In the single-blind IMPROVED study all patients were treated with methotrexate and 
high dose oral prednisolone for four months.238 In those who achieved early 
remission (DAS44 <1.6 at 4 months), prednisolone was tapered and for those with 
persistent remission after 8 months methotrexate was tapered and stopped. Those 
not in early remission were randomized to receive methotrexate, sulphasalazine 
and hydroxychloroquine (arm 1) or methotrexate and adalimumab (arm 2). For 
those in remission after 8 months, treatment was tapered to methotrexate 
monotherapy. For those not in remission after 8 months, triple therapy was changed 
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to adalimumab (arm 1) and in those already receiving adalimumab the treatment 
dose was increased (arm 2). DAS remission (DAS<1.6) at 1 year was 68 % in the in 
early DAS remission group, 25% in arm 1 and 41% in arm 2 (p<0.001).  
Radiographic non-progression was high in all groups (∆mTSS< 0.5: early remission 
group: 95%; Arm 1 96% and Arm 2 92%). Few patients who required treatment 
escalation however were able to achieve drug free remission (0% and 1% in arms 1 
and 2 respectively). Details on the EMPIRE study will be provided in Chapter 5. 
 
 
 
 
 
101 
 
 
Table 3.20 Schematic of strategy-type designs in UA 
Study design Example RCT Comparator groups 
 
Placebo vs. 
Induction with a bDMARD  
ADJUST (Emery 2010) 
236
 PBO  
ABT  
Conventional care vs. 
Induction with MTX then protocol step up 
with a T2T approach 
STREAM (van Eijk 2012)
288
 HCQ** then SSZ then MTX then LEF  
MTX then MTX + ADA then MTX + SSZ 
+ HCQ 
 
Induction with MTX + high dose prednisolone 
then step up to csDMARD combination vs. 
MTX + bDMARD 
IMPROVED (Heimans 2014)
238
 MTX + Prednisolone then MTX + SSZ + 
HCQ 
 
MTX + Prednisolone then MTX + ADA  
MTX vs.  
Induction with MTX+ETN then step down to 
MTX monotherapy 
EMPIRE (Nam 2014)
18
 MTX  
MTX + ETN   
Legend:  
ABT, abatacept (      ); ADA, adalimumab (      ); ETN, etanercept (      ); HCQ hydroxychloroquine (      ); MTX, methotrexate (      );  
PBO, placebo (       ), Pred, prednisolone (       ); RA, rheumatoid arthritis; SSZ, sulphasalazine (      ); T2T, treat-to-target (      ), ** from August 
2005, MTX could be used as first-line therapy 
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Table 3.21 Biological DMARD strategy RCTs in UA – study outcomes 
Outcome Result 
Emery 2010 (ADJUST)236 (n=56) 
Development of RA (ACR criteria) at 1 year* ABT vs. placebo: 1/26 (46%) vs. 16/24 (67%) 
van Eijk 2012 (STREAM ) 288 (n=82)  
Median (IQR ) ∆mTSS at 2 years* aggressive vs. conventional care: 0 (0-1.1) vs. 0.5 (0-2.5) NS 
Median remission (DAS<1.6) at 2 years 66% vs. 49% NS 
Heimans 2013 (IMPROVED) 238 (n=610)  
DAS44 remission at 1 year 
MTX + high dose prednisolone§ vs. MTX+HCZ+SSZ vs. MTX+ADA: 68 %; 25%; 41% 
(MTX+HCZ+SSZ vs. MTX+ADA p<0.001) 
DFR remission at 1 year MTX + high dose prednisolone§; MTX+HCZ+SSZ; MTX+ADA: 32%;  1%; 0%  
 ∆mTSS< 0.5  MTX + high dose prednisolone§;; MTX+HCZ+SSZ; MTX+ADA: 95%; 96% ; 92%  
Villeneuve ACR 2011289/ Nam 201418 (EMPIRE) (n=110) 
Remission (NTSJ) at 1 year ETN + MTX vs. Placebo + MTX : 31% vs. 29% (p=0.835) 
ABT, abatacept; ACR, American College of Rheumatology; ADA, adalimumab; DFR, drug free remission; DMARD, disease-modifying 
antirheumatic drug; ETN, etanercept; HCQ, hydroxychloroquine; IFX, infliximab; IQR, interquartile range; mTSS, van der Heijde modified 
total Sharp score; MTX, methotrexate; NTSJ, no tender or swollen joints (RAI +SJC= 0); SD, standard deviation; SSZ, sulphasalazine;* 
primary endpoint; § early DAS remission arm
1
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3.4.3.2 Strategy trials addressing biological DMARD stopping or dose 
reduction  
The placebo controlled RCT by Quinn et al. 182 was one of the first studies 
introducing the concept of induction with methotrexate plus bDMARD combination 
therapy and stepping down to maintenance methotrexate.  In this study of 20 
DMARD-naïve RA patients with poor prognostic factors, erosions on MRI were less 
with methotrexate and infliximab therapy than with methotrexate monotherapy at 12 
months.  
In this SLR, eleven studies were found evaluating bDMARD stopping or bDMARD 
dose reduction after achieving low disease activity or remission.230 232 280 289 291 296 298 
308 309 340-342  
In DMARD-naïve patients, long-term data from  the BeSt study showed that 
bDMARD discontinuation was possible and more likely in those receiving 
methotrexate and infliximab as induction therapy compared to those receiving 
delayed methotrexate and infliximab combination therapy (56% vs. 29%, p=0.008 in 
the initial vs. delayed groups respectively.278 In the HIT HARD study however, 6 
months after methotrexate and adalimumab induction therapy, stopping 
adalimumab in an open label manner, clinical outcomes were similar to those in 
group receiving methotrexate monotherapy (mean (SD) DAS28 :3.2 (1.4) vs. 3.4 
(1.6), p=0.41 at 1 year), suggesting that not all patients may be able to stop their 
bDMARD therapy.230 Similarly in the OPERA study in which patients received 
methotrexate and adalimumab or methotrexate and placebo for the first year, then 
methotrexate monotherapy in the second year, there were no significant differences 
in clinical findings or function between the two groups298 (table 3.10). 
In the MTX-naïve group, results from the OPTIMA study showed that a high 
proportion of patients who achieved low disease activity using a 28 joint count 
(LDAS28) at 6 months were able to maintain this even after withdrawing the TNF-
inhibitor. Maintenance however was somewhat higher in patients continuing 
adalimumab compared to those who stopped the bDMARD (18 month LDAS28: 
91% vs. 81% in the ADA-continue vs. the ADA-stop groups, p=0.004 
respectively).280  The possibility of dose reduction has also been addressed. In the 
PRIZE study, 306 patients were treated with methotrexate and etanercept 50mg 
weekly for 52 weeks. Seventy percent achieved DAS28 remission. One hundred 
and ninety four patients were then randomised to receive placebo (drug-free group), 
methotrexate monotherapy (bDMARD-free group) or methotrexate and etanercept 
25mg/week (dose-reduction group). After 39 weeks, approximately two-thirds of 
patients were able to maintain this response at 2 years with methotrexate and 
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etanercept 25 mg weekly (sustained DAS 28 remission [DAS28<2.6 at weeks 76 
and 91 with no steroid boost]: 63.5% vs. 40% vs. 23.1% in the methotrexate and 
etanercept 25mg weekly vs. methotrexate monotherapy vs. placebo groups 
respectively) 340 (table 3.11). 
 Maintenance of response in patients with MTX-IR RA who reduced their etanercept 
dose was similarly shown in the PRESERVE study. 232 In this RCT 834 patients with 
moderate disease activity were included in a 36-week open label study and treated 
with methotrexate and etanercept 50mg/week. Of these 604 (72.4%) achieved 
sustained LDA and were therefore eligible for the double-blind phase. Patients were 
randomised to receive either methotrexate and etanercept 50mg weekly, 
methotrexate and etanercept 25mg weekly or methotrexate and placebo. At week 
88, maintenance of LDA was greater in the dose-reduction group than in those who 
stopped etanercept (82.6% vs. 79.1% vs. 42.6% in methotrexate and etanercept 
50mg weekly, methotrexate and etanercept 25 mg weekly and methotrexate and 
placebo groups respectively). DAS28 remission at week 88 was 66.7% vs. 60.2% 
vs. 29.4% in methotrexate and etanercept 50mg weekly, methotrexate and 
etanercept 25 mg weekly and methotrexate and placebo groups.  
The ACT-RAY308 and CERTAIN256 341 studies also looked at bDMARD 
discontinuation in patients with MTX-IR RA. In ACT-RAY patients were randomised 
to either adding tocilizumab 8mg/kg IV to methotrexate or switching to tocilizumab 
8mg/kg IV and placebo with additional DMARDs as part of a treat-to-target strategy 
during the first year. In those who achieved sustained remission in year 2, treatment 
was de-escalated by first stopping the tocilizumab then withdrawing other DMARDs. 
A high proportion of patients experienced a flare on stopping tocilizumab (86% 
before the end of year 2). Only a small proportion of patients achieved drug free 
remission. In the CERTAIN study, patients with low to moderate disease activity 
who achieved sustained remission after 24 weeks of certolizumab pegol stopped 
bDMARD therapy and continued with their csDMARDs. Few patients remained in 
remission at week 52 (CDAI remission in 3/17 and 2/6 in the prior certolizumab 
pegol and prior placebo groups respectively) (table 3.12). 
Studies have also addressed the possibility of tapering bDMARDs in patients with 
established RA. In the STRASS study, patients in stable DAS28 remission (DAS28 
≤ 2.6 for ≥ 6 months) on etanercept or adalimumab for ≥ 1 year with no structural 
damage progression on X-rays since their last X-ray assessments were randomised 
to one of 2 arms:  S (spacing adalimumab and etanercept injections) vs. M 
(maintain adalimumab and etanercept as full regimen).309 343 After 18 months, 73.4% 
of patients in the S-arm tapered bDMARD of whom 37.5% stopped. Mean DAS28 
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and HAQ-DI were not significantly different between the two groups but relapses 
were more frequent in the S than in the M group (81 % vs. 56%, p=0.0009). 
Radiographic progression was not significantly different between the groups. In the 
DOSERA study, patients on methotrexate and etanercept 50mg weekly and in LDA 
or DAS28 remission for  ≥ 11 months were randomised to continuing methotrexate 
and etanercept 50mg weekly (n=23), methotrexate and etanercept 25mg weekly 
(n=27) or methotrexate and placebo (n=23). The primary endpoint was the 
proportion of non-failures at week 48, with failure defined by DAS28 ≥ 3.2 and an 
increase in DAS28 ≥ 0.6. The proportion of non-failures was significantly higher in 
those continuing full dose etanercept (52%) and those receiving half-dose 
etanercept (44%) than in patients on methotrexate monotherapy (13%) (p=0.007 
and p=0.044, for etanercept 50 mg weekly and etanercept 25mg weekly 
respectively vs. placebo)344 (table 3.13). 
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Table 3.22 Biological DMARD strategy studies in DMARD-naïve RA addressing biological DMARD dose reduction or stopping – study 
outcomes 
Outcome Result 
van der Kooij 2009 291 / van der Kooij 2009 278/ Klarenbeek 2011 217/ Dirven 2011 184/ van den Broek 2011 (BeSt) 301  (n=508) 
DFR (%) at year 4; year 8 184 Groups 1 to 4‡: 14/12/8/18 (p=0.14); 18/19/17/15 (p=0.9) 
Joint damage progression > SDC (%) at 4 years 
Groups 1 to 4‡: 51/54/38/31 (p<0.05 for groups 4 vs. 1 and 3, and 3 
vs. 2) 
Discontinuation of IFX due to sustained DAS44 ≤2.4 2 years after IFX 
initiation (%)278 
Initial vs. delayed IFX: 56 vs. 29 (OR(95% CI)  2.56 (1.27 to 5.16) 
p=0.008))  
Discontinuation of IFX due to sustained DAS ≤ 2.4 (for 6 months) (n) 301 Initial vs. delayed IFX: 77/120 vs. 27/109 
Sustained DAS remission after IFX cessation (n (%))301 Initial vs. delayed IFX: 43/77 (56) vs.11/27 (41)  
DFR (n (%))301  Initial vs. delayed IFX: 15 (27) vs. 0 after at least 1 year of follow up 
Predictor of restarting IFX (for DAS > 2.4) 301 Initial vs. delayed IFX: HR (95% CI) 1.8 (0.9 to 3.7) 
Detert 2013 (HIT HARD) 230 (n=172) 
Mean (SD) DAS28 at week 48* 
ADA+MTX/ MTX vs. Placebo + MTX/MTX§: 3.2 (1.4) vs. 3.4 (1.6) 
(p=0.49) 
ACR responses (%) at week 48 
ADA+MTX/ MTX vs. Placebo + MTX/MTX§: ACR 50: 52.6 vs. 51.4 
1
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(p=0.88), ACR 70: 40.5 vs. 34.0 (p=0.40) 
DAS28 remission (%) at week 48 ADA+MTX/ MTX vs. Placebo + MTX/MTX§: 42.4 vs. 36.8 (p=0.47) 
Horslev-Petersen EULAR 2013 (OPERA) 337 (n=180) 
Median (95% CI) DAS28CRP at year 2 
ADA + MTX/ MTX vs. Placebo + MTX/MTX† : 2.0 (1.7-4.4) vs. 2.0 
(1.7 - 4.5)(p=0.97)  
Remission (DAS28CRP<2.6) at year 2 ADA + MTX/ MTX vs. Placebo + MTX/MTX†: 66% vs. 69% (p=0.79) 
Median (95% CI) HAQ-DI at year 2 
ADA + MTX/ MTX vs. Placebo + MTX/MTX†: 0.13 (0-1.63) vs 0.13 
(0-1.5) (p=0.37) 
Nam 2013 (IDEA)296 (n=112) 
Week 78: Stopped IFX due to sustained remission (n (%)) *  14/55 (25) of the IFX group 
ACR , American College of Rheumatology; ADA, adalimumab, DFR, drug free remission; CI, confidence interval; IFX, infliximab, MTX, 
methotrexate; SD, standard deviation; SDC, smallest detectable change 
§HIT HARD comparator groups: ADA+ MTX vs. Placebo + MTX for 24 weeks. After 24 weeks both groups treatment with MTX only 
† OPERA comparator groups: ADA+ MTX vs. Placebo + MTX for 1 year. After 1 year both groups treatment with MTX only 
‡BeSt comparator groups: Group 1 Sequential monotherapy; Group 2 Step-up combination therapy; Group 3 Initial combination with 
prednisone; Group 4 Initial combination with IFX 
*Sustained remission = DAS< 1.6 for 6 months 
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Table 3.23 Biological DMARD strategy studies in MTX-naïve RA addressing biological DMARD dose reduction or stopping – study outcomes 
Outcome Result 
Smolen EULAR 2012 (OPTIMA) 303/ Emery  EULAR 2011 (OPTIMA) 345 (n=1032) 
Maintenance of DAS28<3.2 (%) from week 52 to 78 303  ADA _continue vs. ADA withdrawal§ : 87 vs. 65 (p=0.002) 
ACR20/50/70 (%) at week 78345      ADA_ continue vs. ADA_withdrawal§: 95/89/77 vs. 94/80/65 (p = 0.72/ 0.11/ 0.05)  
DAS28 <3.2(%) at week 78 345     ADA_ continue vs. ADA_withdrawal§: 81 vs. 91 (p=0.04) 
DA28<2.6(%) at week 78 345     ADA_ continue vs. ADA_withdrawal§: 66 vs. 86 (p=0.001) 
∆mTSS ≤ 0.5(%)at week 78345      ADA_ continue vs. ADA_withdrawal§: 89 vs. 81 (0.06)  
Emery EULAR 2013 (PRIZE) 340 (n=306) 
Sustained DAS remission at week 39 after achieving  
remission     
ETN25+MTX vs. MTX vs. placebo: 63.5 vs. 38.5 vs. 23.1 (ETN25+MTX vs. MTX p= 
0.0051; ETN25+MTX vs. placebo p<0.0001, MTX vs. placebo 0.0595) 
∆mTSS ≤ 0.5(%) at week 39 after achieving  remission       
ETN25+MTX vs. MTX vs. placebo: 87.9 vs. 96.4 vs. 89.8 (ETN25+MTX vs. MTX 
0.1124; ETN25+MTX vs. placebo 0.7609; MTX vs. placebo 0.1929) 
ADA, adalimumab, ETN, etanercept; ETN25, etanercept 25mg weekly, MTX, methotrexate  
§OPTIMA comparator groups: ADA_ continue vs. ADA_withdrawal: in patients who achieved LDA at with ADA + MTX at weeks 22 and 26
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Table 3.24 Biological DMARD strategy studies in csDMARD IR RA addressing biological DMARD dose reduction or stopping – study outcomes 
Outcome Result 
Smolen 2013 (PRESERVE) 341 (n=834) § 
Week 88 LDAS28 (%) in patients who achieved  
sustained LDA with ETN 50 mg weekly + MTX for 
36 weeks 
ETN50+ MTX vs.ETN25+MTX vs. PBO+MTX: 82.6 vs. 79.1 vs. 42.6 
ETN50+ MTX vs. PBO+MTX (mean difference (95% CI)  40.8 (32.5-49.1, p<0.0001) 
ETN25+MTX vs. PBO+MTX  (mean difference (95% CI) 35.9  (27.0 to 44.8), p<0.0001) 
Huizinga EULAR 2013 (ACT-RAY)  308 (n=556) § 
TCZ discontinuation after achieving the protocol- 
defined sustained remission (%) at Week 104 
TCZ add-on vs. switch: 57 vs. 47 (p=0.13)  
Flare (%) at Week 104   TCZ add-on vs. switch: 85 vs. 87 (p=0.075) 
Study DFR (%) at Week 104 TCZ add-on vs. switch: 5.1 vs. 1.8 (0.037) 
Smolen EULAR 2011 / EULAR 2012 (CERTAIN) 256 341 (n=194) † 
CDAI remission at Week 52 in patients who 
achieved CDAI remission at both weeks 20 and 24  Remission retained in 3/17 prior CZP vs. 2/6 placebo patients  
§ MTX IR; † mixed csDMARD IR; CI, confidence interval; CZP, certolizumab pegol; DFR, drug free remission; csDMARD, conventional 
synthetic disease-modifying antirheumatic drug; ETN, etanercept; IR, incomplete responder; LDA,  low disease activity, LDAS28, low 
disease activity score using the 28 joint count; MTX, methotrexate; PBO, placebo; SDC, smallest detectable change; TCZ, tocilizumab 
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Table 3.25 Biological DMARD strategy studies in established RA addressing biological DMARD dose reduction or stopping – study outcomes 
Outcome Result 
Fautrel ACR  2012 / EULAR 2013 (STRASS) 309 311 343 (n=137) 
Taper and stopping TNFi (n (%)) at 18 months    S: 47 (73.4) tapered TNFi, of whom 24 (37.5) stopped 
Relapse occurred at least once (%) at 18 months    S vs. M: 81 vs. 56, p=0.0009 
Structural damage progression (n (%)) at 18 months    S vs. M: in 4 (6.7) and 3 (4.5) patients (p=0.3)  
van Vollenhoven ACR 2012/ EULAR 2013 (DOSERA) 342 344 (n=91) 
Non-failure# (%) at week 48*  
ETN50 vs.ETN25 vs. placebo: 52  vs. 44  vs. 13 (ETN50 vs. placebo*: OR  7.2 (1.7-29.8 
(p=0.007), ETN25 vs. placebo: OR 4.2 (1.0 – 17.0 ( p=0.44), ETN50 vs. ETN25 NS) 
ADA, adalimumab; ETN, etanercept; ETN25, etanercept 25mg weekly; ETN50, etanercept 50mg weekly; IFX, infliximab, LDA, low 
disease activity, MTX, methotrexate; TNFi, tumor necrosis factor inhibitor 
S =spacing ADA and ETN injections; M =maintain full dose ADA and ETN; # Failure = DAS28 ≥ 3.2 and an increase of SDAS28 ≥ 0.6 or 
disease progression as determined by the investigator or patient; * primary endpoint 
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3.4.4 Biosimilar DMARDs   
The PLANETRA study was the first phase 3 RCT to compare the bsDMARD CTP-
13 to infliximab. In this multicentre study 606 patients with MTX-IR RA were 
randomised to receive CTP-13 (n=302) or infliximab (n=304). The study met its 
primary endpoint - the ACR 20 response at week 30 (61% vs. 59% (95% CI -6% to 
10%) for methotrexate and CT-P13 vs. methotrexate and infliximab respectively).346 
ACR50 and ACR70 responses were also similar in the two groups with no 
significant between-group differences at one year320 (table 3.14). 
 
3.4.5 Targeted synthetic DMARDs in the context of existing 
biological DMARDs 
Tofacitinib is an oral targeted synthetic DMARD, selectively inhibiting Janus kinase 
(JAK) 1 and JAK 3, and to a lesser extent JAK 2.  In the ORAL-STANDARD study, 
tofacitinib and adalimumab were compared to placebo in patients with MTX-IR 
RA317 .  The three primary endpoints were the ACR 20 responses at 6 months, the 
change from baseline to 3 months in HAQ-DI and the proportion of patients in 
DAS28-ESR remission at 6 months. ACR 20 responses for tofacitinib 5mg and 10 
mg, and adalimumab were both significantly higher than placebo (51.5% vs. 52.6% 
vs. 47.2% vs 28.3% in the tofacitanib 5mg, tofacitanib 10mg, adalimumab and 
placebo groups respectively)(table 3.14). HAQ-DI and DAS28-ESR remission was 
significantly higher in the groups receiving tofacitinib and adalimumab compared to 
placebo.
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Table 3.26 RCTs comparing a bDMARD to a biosimilar or a targeted synthetic DMARD –ACR responses 
 
Treatment group 
Patients 
evaluated (n) 
Time-point 
evaluated (months) 
ACR20(%) p ACR50(%) p ACR70(%) p 
Yoo ARD 2013 (PLANETRA)346  
MTX + CT-P13 3mg/kg  302*/248**  7 60.9*/73.3** referent 42.3** referent 20.2** referent 
MTX + IFX 3mg/kg 304*/251**   58.6*/69.7**  NS 40.6** NS 17.9**  NS 
                  
van Vollenhoven 2012 (ORAL STANDARD) 317 (n=717) 
Placebo 106 6 28.3 referent   referent   referent 
Tofacitinib 5mg twice daily 196   51.5 <0.001   ≤0.05   ≤0.05 
Tofacitinib 10mg twice daily 196   52.6 <0.001   ≤0.05   ≤0.05 
ADA 40mg every 2 weeks 199   47.2 <0.001   ≤0.05   ≤0.05 
ACR, American College of Rheumatology; ADA, adalimumab; bDMARD, biological disease-modifying antirheumatic drug; DMARD disease-
modifying antirheumatic drug; IFX infliximab; MTX, methotrexate; RCTs, Randomised controlled trials;*intention-to-treat population;** per 
protocol population 
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3.5 Discussion 
With the increasing use of bDMARDs as well as the introduction of newer therapies 
including the tsDMARD tofacitinib and emerging bsDMARDs, a systematic review of 
the literature was warranted.  
This SLR confirmed the efficacy of all the classes of bDMARDs in patients with MTX 
naïve, MTX-IR and TNF-IR RA. There is also data for TNFi for patients with 
DMARD-naïve RA and emerging data for the TNFi and abatacept in patients with 
UA. .  With studies showing superior long-term clinical and radiographic outcomes 
using a bDMARD with methotrexate, this remains the optimal treatment approach 
and preferred option to bDMARD monotherapy. In situations where patients may not 
tolerate methotrexate or another csDMARD, however, bDMARD monotherapy may 
be considered. 245 275 281  
There have been an increasing number of RCTs addressing the efficacy of 
bDMARDs in different study populations across the IA disease continuum – looking 
at RA according to the 1987 ACR and the 2010 ACR/EULAR classification criteria, 
as well as patients in the earlier phases of the disease spectrum that did not fulfil 
these criteria. Different study designs have also been used aiming to address the 
optimal treatment approach and timing of bDMARD use. In essence studies have 
shown earlier improvement in signs and symptoms with the more intensive 
strategies compared to step-up approaches. Outcomes however were similar once 
bDMARDs were added in patients with insufficient response to methotrexate 1 240 241 
279 281 339.  In RCTs addressing different step-up therapies in patients with MTX-IR 
RA, combination csDMARD therapy with methotrexate, sulphasalazine and 
hydroxychloroquine reported similar clinical efficacy to step up bDMARD therapy.241 
242 279 Low recruitment (and therefore possibly insufficient power) however were 
noted in some of these studies. Nevertheless, greater depth of response (higher 
proportions achieving ACR 70 responses (equivalent to low disease activity) 321 or 
remission) was seen with the use of bDMARD therapy. 293 337 347 Radiographic 
progression was also lower and proportions achieving radiographic non-progression 
were higher with combination therapies which included a bDMARD. 1 278 281 339 These 
were mainly due to the early effects of treatment. 184 281 High clinical response rates 
and low radiographic progression were also seen in the clinical trials which 
incorporated treat-to-target type strategies - many of these also included 
glucocorticoids. 293 296 337  
Studies have also looked at the possibility of bDMARD dose reduction or stopping 
once achieving control of disease activity. While clinical responses were higher 
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when continuing the bDMARD than when stopping treatment, there was evidence 
responses could be maintained with bDMARD dose reduction. Biological DMARD- 
and drug-free remission was achievable in some, particularly with earlier bDMARD 
use.  
This literature search confirmed an absence of RCT evidence to guide decisions on 
switching from one bDMARD to another after failure of a TNFi. 
Newer therapies have also emerged with trials showing efficacy of CT-P13, the 
infliximab bsDMARD and tofacitinib, the tsDMARD.  Drug developments continue 
with several other new agents on the horizon.348 349 
3.6 Limitations 
The literature review has its limitations. One relates to the heterogeneous nature of 
the studies. The different inclusion criteria, trial designs and primary endpoints in 
particular, pose inherent challenges to ensuring accurate interpretation of the data. 
Whilst the main clinical outcomes on bDMARD efficacy were addressed, other 
outcomes e.g. the impact of bDMARDs on work ability was beyond the scope of this 
SLR. Standard definitions of disease activity (e.g. DAS28 < 2.6 for remission) were 
used, however recent insights suggest that these patients may still have ongoing 
disease activity despite achieving this target, highlighting the deficiencies of such 
measures. This review also focused on evidence from RCTs. Whilst these trials are 
regarded as the highest level of evidence, they reflect a select patient population, so 
results may potentially be less applicable to a real-life population. Non-randomised 
studies and evidence from clinical practice (e.g. from national registries) would 
provide valuable information to complements these data.  Another aspect of 
bDMARD therapy that needs consideration is that of safety. Given its importance, 
this area was reviewed in a separate SLR.189  
3.7 Conclusions 
In conclusion, this SLR confirmed the efficacy of bDMARDs across the IA disease 
continuum in patients with UA and RA. It evaluated different treatment strategies  
addressing the issue regarding when to start bDMARD therapy and the potential for 
treatment reduction, particularly when early disease control has been achieved. It 
also highlighted new emerging therapies in this field.  
Finally, this review identified some areas for further research. These included the 
need for more studies investigating the benefit of initial induction therapy with a 
bDMARD compared to stepping up to a bDMARD following a csDMARD, 
115 
 
 
particularly in very early disease.  Related research areas include the identification 
of predictors of  response to targeted therapies, the search for prognostic risk 
factors (e.g. the presence of erosions on X-ray at baseline) 339 identifying those 
patients who may benefit most from a more intensive, initial bDMARD treatment 
strategy,  as well as the search for factors predicting successful treatment 
withdrawal.230 303 340 345 Data from registries will also be an invaluable source of 
information, providing ‘real-life’ data on patients who may be excluded from RCTs.
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Chapter 4 Infliximab vs. intravenous methylprednisolone with 
methotrexate as induction therapy in DMARD-naïve early 
RA 
In this chapter, a RCT aimed to compare the use of induction therapy using 
methotrexate and infliximab to methotrexate and an intravenous glucocorticoid 
together with a treat-to-target approach in DMARD-naïve early RA. 
4.1 Introduction 
From the results of the systematic literature review detailed in chapter 4, it is clear 
that biological therapies are efficacious in treating patients with RA.16 The benefit of 
bDMARDs is well established in patients who have had incomplete response to one 
or more csDMARD 180 187 323 324 or bDMARD.326-329 Some studies have also 
confirmed efficacy in DMARD-naïve RA.182 183 230 In clinical practice, however, 
particularly with cost considerations, bDMARDs are usually prescribed after failure 
of one or more csDMARD.162  
There is evidence that achieving low levels of disease activity early, particularly 
within the first three months of therapy, predicts remission at one year350 and is also 
associated with better long-term radiographic outcomes.351 Optimising disease 
control in the early phases of the disease is therefore important. The optimal 
strategy however still remains to be determined.223  
Treatment options for patients with RA include the use of csDMARDs, bDMARDs 
and glucocorticoids or combinations of these therapies. Of the csDMARDs, 
methotrexate is generally recommended as part of first-line therapy given its 
efficacy and safety profile. 209 As noted in chapter 4, bDMARDs have been used in 
clinical trials for treatment induction.182 183 230 293 Glucocorticoids have also 
demonstrated anti-inflammatory as well as disease-modifying properties.163 Rapid 
clinical improvements have been documented with high dose oral steroids.164 Whilst 
less widely studied, IV glucocorticoids, have shown high remission rates in a small 
group of patients with MTX-naïve RA.165  In addition to the therapeutic 
considerations, there is also evidence for the benefit of regular monitoring of 
disease activity and escalating therapy until a treatment goal is achieved – so called 
‘treating to target’. 10 215 216 221 
The Infliximab as induction therapy in early rheumatoid arthritis (IDEA) study was a 
RCT in patients with DMARD-naïve early RA. It aimed  to compare the efficacy of 
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methotrexate and a TNFi to methotrexate with an IV steroid for remission induction, 
followed by a treat-to-target approach in both groups. Infliximab was chosen as the 
bDMARD given the short- and long-term clinical and radiographic efficacy data 
available at the time of study design.183 324 Intravenous methylprednisolone was 
chosen as the comparator – the use of IV steroid for its rapid onset of action and 
potential impact on endothelial adhesion molecules as seen with TNFi,352 as well as 
ease of blinding versus infliximab.  As varying degrees of subclinical disease and 
subsequent structural progression have been documented with clinical remission, 
138 and the trial was open after 26 weeks, an objective primary outcome looking at 
structural progression was chosen.   
4.2 Patients and methods 
4.2.1 Patients 
Patients included in this study were aged 18 to 80 and who fulfilled the 1987 ACR 
classification criteria for RA with symptom duration between 3 and 12 months, 
active disease defined by DAS44 > 2.4 and were DMARD-naïve.  The following 
were exclusion criteria: treatment with a prior DMARD, glucocorticoid use within one 
month prior to baseline, pregnancy or planned pregnancy within 24 months of 
screening, an opportunistic infection within six months or a serious infection within 
three months of screening, HIV infection, positive hepatitis B or C serology, relevant 
co-morbidities or important concurrent medical conditions, a history of 
lymphoproliferative disease, or any other malignancy within the previous 5 years 
(with the exception of basal cell or squamous carcinoma of the skin that had been 
treated with no evidence of recurrence). Screening for tuberculosis was carried out 
in accordance with local recommendations.  
 
4.2.2 Treatment allocation and intervention 
The IDEA study was an 18-month multicentre, double-blind, randomised (1:1), 
phase 4, superiority study. It was designed by consensus of the regional 
rheumatologists in West Yorkshire, UK and conducted across four sites. These 
were Leeds, Huddersfield, Harrogate and Bradford.  
Patients were randomised to receive either methotrexate and infliximab or 
methotrexate and IV steroid. Patient consent was obtained, after which the research 
nurse telephoned central pharmacy for allocation consignment.  The personnel at 
central pharmacy were independent of the recruitment process. They assigned 
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subject numbers according to a block randomisation programme which was 
generated using random number tables, stratified by site.  
Both groups of patients received methotrexate 10mg weekly. This was increased to 
20mg or the maximum tolerated dose by week 6. Folic acid 5 mg daily except the 
day of methotrexate was also prescribed. Patients, clinical staff and assessors were 
blinded to the treatment allocation during the first 26 weeks. All patients received 
infusions over a 2-hour period from visually identical 250ml bags during this double 
blind phase. Those in the infliximab group received: infliximab 3mg/kg (maximum 
dose 1000mg) at weeks 0, 2, 6, 14 and 22. Those in the IV steroid group received 
IV methylprednisolone 250mg at week 0 followed by placebo infusions at weeks 2, 
6, 14 and 22. Disease activity was measured at the following time points: weeks 0, 
6, 14, 22, 26, 38, 50, 68 and 78. During the open label observation period, from 
week 26, patients continued treatment according to a predetermined study 
escalation protocol. If low disease activity was not achieved (DAS44>2.4) at those 
visits, infliximab dose adjustments or DMARD changes were made in the infliximab 
group and DMARD escalated in the IV steroid group as shown in figure 4.1.  
A treat-to-target approach was used throughout the study. If  low disease activity 
was not attained at weeks 6, 14, 22, 38, 50 and 62, IM methylprednisolone 120mg 
was administered for both groups. Intra-articular steroid could be given up to an 
equivalent dose of methylprednisolone 120mg if a joint required aspiration and 
injection. if a smaller amount was used, the remainder was given as an IM injection. 
In patients with a DAS28 ≥ 5.2 who had failed 2 DMARDs, bDMARDs could be 
considered according to NICE guidelines.353  
Infliximab infusions were stopped in all patients in the infliximab arm at week 78 
(study endpoint) or if they withdrew from the study. In patients on infliximab who 
achieved sustained remission (DAS44 <1.6 at all consecutive visits for 6 months), 
infliximab could be stopped early. Patients who withdrew but who were still willing to 
attend for clinical assessments continued follow up according to the study visit 
schedule. Prophylaxis for osteoporosis was administered at the discretion  of the 
treating physician, guided by local guidelines.
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Figure 4.1 IDEA study design 
DMARD, disease-modifying antirheumatic drug, IFX, infliximab , * IM methylprednisolone if DAS44 > 2.4 
**DMARD escalation protocol: sulphasalazine (SSZ) 500mg daily increasing to 1g bd over a 4 week period and hydroxychloroquine 
(HCQ) 200mg - 400mg daily to a maximum of 6.5mg/kg, then stop SSZ and HCQ and add leflunomide (LEF)10mg daily for 1 month, then 
increase to 20mg daily, then one of the following: subcutaneous (s/c) methotrexate (MTX) and LEF or MTX and ciclosporin 2.5mg/kg/day 
or MTX, LEF and prednisolone 5-7.5mg daily. If DAS 28 ≥5.2, assess for other biological DMARD therapy according to NICE criteria or 
other trials and potential to exit trial.  
6* 14* 22* 50* 38* 62* 46 
Randomise 
IFX 3mg/kg + MTX 
IV MP 250mg +MTX,  Placebo  +MTX 
DAS44 ≤ 2.4 – Continue treatment  
DAS44 ≤ 2.4 – Continue treatment  
WEEK 
0 78 
UNBLIND 
26 
DAS44 > 2.4 – Increase IFX dose     
 then change DMARD** 
DAS44 > 2.4 – Escalate 
DAS44 ≤ 1.6 x 6/12  - Stop IFX 
• IFX 6mg/kg then 10mg/kg 
• Stop IFX  and change 
DMARDS 
 Add SSZ + HCQ 
 Stop SSZ + HCQ and start 
LEF 
 Change oral MTX to s/c MTX 
 Stop LEF and add ciclosporin 
 Add low dose oral 
prednisolone 
2 
1
1
9
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4.2.3 Efficacy and safety outcomes 
Radiographic progression, defined by the change in total mTSS at week 50, was the 
study primary outcome. 354 Secondary radiographic outcomes included the changes 
in joint space narrowing (JSN)  and erosion (ERO) scores and the proportions of 
patients achieving radiographic non-progression (change < 0.5 units355 and change 
< the smallest detectable change (SDC) for this study). X-rays  were read in time 
order and scored independently by two experienced radiographers who were 
blinded to treatment allocation. 
Secondary clinical outcomes included the proportion of patients achieving clinical 
remission (DAS44<1.6), and the proportion in sustained remission (DAS44<1.6 for 6 
months) and were therefore eligible to stop infliximab. Patient reported outcomes 
included the HAQ-DI225 and the RA Quality of Life score (RAQoL) which were 
measured at baseline and weeks 26 and 78. The proportion of patients remaining in 
paid employment was also calculated.  
The subgroup of patients recruited in Leeds had ultrasound assessments for 
synovitis. These were performed using a Philips HDI 5000 machine, employing a 
15-8 MHz transducer at baseline, weeks 50 and 78 by four rheumatologists trained 
in MSK ultrasound, with good intra- and inter-reader reliability (data not shown). The 
findings in 22 joints (wrists, MCP  joints 2 and 3, PIP joints 2 and 3, and MTP joints 
1 to 5 bilaterally) were compared between the two groups. OMERACT definitions 
were used to define synovitis.356 The EULAR-OMERACT scoring system, a 0-3 
semi-quantitative scale, was used to score grey scale change and power Doppler 
signal.357 The clinical assessors were unaware of the ultrasound findings. 
Post hoc analyses included the ACR 20/50/70 responses358 and proportions of 
patients achieving low disease activity (DAS44 <2.4 and DAS28 <3.2), 3-variable 
DAS28 remission (<2.6) and remission based on the 2010 ACR/EULAR criteria 
(tender joint count ≤ 1, swollen joint count ≤ 1, patient global assessment (PGA)cm 
≤ 1 and CRP mg/dL≤1) or SDAI remission (≤3.3)).359 The proportion of patients in 
clinical remission (DAS44<1.6) at week 78 no longer on infliximab/placebo infusions 
and  duration of biologic-free remission, in patients who were able to stop biological 
therapy early, were calculated. (Loss of this state was defined by an increase in 
DAS44 of 1.2, a DAS44 >1.6 or any change in disease activity score requiring an 
increase in therapy).360  Differences in steroid requirements in each group were also 
assessed. In a subset of patients, post hoc regression analyses were also 
conducted to determine the association between baseline factors and outcome at 
78 weeks (clinical remission (defined by DAS44<1.6), annualised radiographic 
progression).  
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Patients were asked to report new adverse events at each visit. Clinical and 
laboratory adverse events were documented using standard medical terms.  
 
4.2.4 Sample size  
The sample size for the study was calculated to detect a significant difference in 
damage progression, measured by the mTSS, between the two treatment groups. 
Estimated radiographic progression in each group was based on that observed in 
the BeSt study183 in which 508 patients with early DMARD-naïve RA were allocated 
to one of four treatment groups. The change in mTSS in the step-up (mean (SD) 4.3 
(6.5)) and the methotrexate and infliximab (mean (SD) 1.3 (4.0)) combination 
therapy groups were thought to best reflect the magnitude of expected response, 
and were used to power this study. With an 80 percent power to detect a difference, 
at a  5% two-sided significance level, 56 patients were required per group, 
assuming that the use of non-parametric statistics may be required if the primary 
outcome were skewed.   
 
4.2.5 Statistical methods 
4.2.5.1 Numbers analysed 
All patients (n=112) were included in the multiple imputation analyses. For the 
complete case analyses, the number of patients with available data for each 
outcome varied. The number of patients included has been provided for each of the 
comparisons. There were safety data for all 112 patients. 
 
4.2.5.2 Statistical analyses 
Efficacy and safety analyses were performed on subjects who received at least one 
dose of the study drug. Patient data were analysed according to the groups to which 
they were originally assigned i.e. on an intention to treat (ITT) basis.  
The SDC in mTSS was calculated according to the Bland-Altman 95% limits of 
agreement method. Intra-class correlation coefficients were used to quantify 
agreement between the change in scores of the two readers. For disease activity, 
values presented are for the 3-variable DAS44-CRP (lower limit for CRP = 5 mg/L). 
For patients where ESR measurements were more complete than the CRP 
measurements, values for ESR were converted to CRP using a published 
nomogram361 prior to calculation of the DAS score. Where possible, provided the 
data were found to fit the Rasch model (lack of local dependency and differential 
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item functioning, demonstrating unidimensionality and achieving sufficient person 
separation), questionnaire scores were transformed to quasi interval scaling prior to 
analysis using RUMM2030. 
Categorical outcomes were analysed using logistic regression and continuous 
outcomes (Rasch-transformed HAQ-DI, RAQoL) were analysed using linear 
regression. Baseline values and study site were controlled for in each analysis. 
Non-parametric quantile regression models were also constructed for severely 
skewed variables. Amongst the secondary outcomes, the threshold for statistical 
significance was adjusted for multiple comparisons using the Holm method. There 
were no adjustments made for the exploratory analyses.   
Multiple imputation362 by chained equations was performed to account for missing 
data. These results were combined according to Rubin’s rules. This was based on 
the assumption that data was missing at random (MAR). For continuous variables, 
missing baseline data were imputed using the mean and missing indicator method. 
For categorical variables, a separate category was created for missing values. Data 
that were missing at later visits were imputed in each treatment group separately. 
This was done using logistic regression for categorical variables and predictive 
mean matching for continuous variables. Derived variables (mTSS, radiographic 
progression>SDC, remission) were computed passively after imputation of the 
component variables prior to analysis.  
A sensitivity analysis which only included patients with available data (complete 
case, CC) was also performed. This assuming data were missing completely at 
random (MCAR). Further sensitivity analyses were conducted to challenge the MAR 
assumption in the primary analysis. This was done by increasing or decreasing the 
imputed values in each treatment group in order to mimic various missing not at 
random (MNAR) patterns. For the complete case analysis of radiographic data, only 
patients with baseline and follow-up radiographs were included. Annualised 
progression scores were analysed using linear regression of the change scores, 
controlling for natural log-transformed baseline values and for study site, which was 
entered as a fixed factor. Robust standard errors were used to account for 
heteroskedasticity. Because the primary outcome was right-skewed, the primary 
analysis was supplemented with non-parametric quantile regression, minimising 
differences from the median, rather than the mean. In addition to this, a per-protocol 
analysis was performed. Analyses were conducted in Stata 12.1. 
Descriptive results are presented for harms. In cases of recurring events, only the 
most severe occurrence was counted in each patient. Absolute and relative 
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frequencies are presented together with the number of occurrences per 100 patient-
years of follow-up. 
4.3 Results 
In total 112 patients were recruited from the 4 sites in West Yorkshire, U.K. between 
September 2006 to July 2009. The majority (81%) were from Leeds which was the 
main centre. The remaining patients were from Harrogate, Huddersfield and 
Bradford. Patients attended for screening (within 4 weeks prior to baseline), at the 
time of randomisation (baseline) and for subsequent visits for 78 weeks according to 
the study protocol (figure 4.2).  
The demographic and baseline characteristics are presented in table 4.1. The 
clinical features were similar between the two groups. The methotrexate and IV 
steroid group had a slightly higher proportion of RF and anti-CCP positivity 
compared to the methotrexate and infliximab group (60.7% vs. 49% and 75% vs. 
64% in the methotrexate and IV steroid an methotrexate and infliximab groups 
respectively). The mean radiographic scores were also somewhat higher in the 
methotrexate and IV steroid group at baseline (mTSS 9.23 (18.31) vs. 6.05 (10.83)).  
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Figure 4.2 IDEA study patient disposition 
AE, adverse event; bDMARD, biological disease-modifying antirheumatic 
drug; LEF, leflunomide; LOE, loss of efficacy; LTFU, lost to follow up; SW, 
subject withdrawal 
Assessed for eligibility (n=130) 
Excluded  (n=18) 
- Inclusion criteria not met (n=17) 
- Declined participation (n=1) 
Allocated to MTX+ IV steroid 
(n=57) 
Allocated to MTX + infliximab 
(n=55) 
 
Randomised (n=112) 
Enrolment 
Discontinued intervention (n=9) 
 
- LTFU: reasons unknown 
(n=2) 
- LOE:  fulfilled NICE criteria for    
bDMARDs (n=3)  
did not fulfill NICE 
criteria for bDMARDs 
(n=1) 
- AE:   related to LEF (n=1) 
- SW: too many tablets (n=1) 
Discontinued intervention (n=6) 
 
- LTFU: reasons unknown 
(n=1) 
   moved away (n=1) 
- LOE: fulfilled NICE criteria for    
bDMARDs (n=1) 
- AE: tuberculosis (n=1) 
pulmonary embolism; 
death (n=1) 
- SW: recurrent LRTIs (n=1) 
Allocation 
Discontinued intervention 
(cumulative) (n=14) 
 
- LTFU: reasons unknown 
(n=3) 
   new job (n=1) 
- LOE:  fulfilled NICE criteria for    
bDMARDs (n=5) 
did not fulfill NICE 
criteria for bDMARDs 
(n=2) 
- AE:  thought related to 
leflunomide (n=1) 
- SW: too many tablets (n=1) 
poor venous access  
(n=1) 
 
Completed study (n=43) 
Discontinued intervention 
(cumulative) (n=11) 
 
- LTFU: reasons unknown 
(n=2) 
   moved away (n=1) 
- LOE: fulfilled NICE criteria for    
bDMARDs (n=3) 
did not fulfill NICE 
criteria for bDMARDs 
(n=1) 
- AE: tuberculosis (n=1) 
suspected respiratory 
involvement (n=1) 
pulmonary embolism; 
death (n=1) 
- SW: recurrent LRTIs (n=1) 
 
Week 50 
Week 78 
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Table 4.1 Baseline characteristics of patients in each treatment group 
  MTX + IV steroid 
(n=57)  
MTX + IFX     
(n=55) 
Site:                                      
 
Leeds
Huddersfield 
Harrogate 
Bradford 
n=45                      
n=3                        
n=6                        
n=3 
n=44                      
n=3                         
n=5                             
n=3 
Age (years):                                                                             mean(SD)  
range 
52.9 (12.8)  
19 to 77 
53.7 (13.0) 
28 to 78 
Female:                                      n (%) 41 (71.9%) 36 (65.5%) 
Disease duration 
(months):     
median (IQR) 1.2 (0.7, 2.1) 1.2 (0.7, 1.7) 
Symptom duration 
(months):  
median (IQR) 6.9 (4.8, 9.8) 7.2 (5.1, 10.7) 
ESR:                                          median (IQR) 47 (21, 80) (n=56) 35 (19, 52) (n=54) 
CRP (mg/L):                              median (IQR) 18 (10, 51) 16 (7, 61) 
DAS44:                              mean (SD) 3.56 (0.98) 4.05 (1.04) 
RF positive:                            n (%) 34/56 (60.7%) 27 (49.1%) 
Anti-CCP positive:  n (%) 39/52 (75.0%) 32/50 (64.0%) 
HAQ-DI:                              mean (SD) 1.3 (0.54) (n=56) 1.4 (0.53) (n=55) 
RAQoL:                              mean (SD) 15.9 (4.7) (n=56) 17.9 (5.3) (n=53) 
ERO:                                        
                                         
mean (SD)  
median (IQR) 
3.51 (8.73) (n=50) 
0.50 (0.00, 3.50) 
1.36 (2.91) (n=43) 
0.00 (0.00, 1.50) 
JSN:                                         
                                         
mean (SD)  
median (IQR) 
5.72 (9.93) (n=50) 
2.00 (0.50, 7.00) 
4.69 (8.38) (n=43) 
2.00 (0.00, 7.50) 
mTSS:                                        
                                         
mean (SD)  
median (IQR) 
9.23 (18.31) (n=50) 
2.50 (1.00, 10.00) 
6.05 (10.83) (n=43) 
3.00 (0.50, 9.50) 
Anti-CCP, anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; 
DAS44CRP, 3-variable disease activity score based on CRP, RAI and SJC44; 
ERO, erosion; ESR, erythrocyte sedimentation rate; HAQ-DI, Rasch-
transformed health assessment questionnaire disability index score; IFX, 
infliximab; IV, intravenous; JSN, joint space narrowing; mTSS, MTX, 
methotrexate; van der Heijde modified total Sharp score; RAQoL, Rasch-
transformed rheumatoid arthritis quality of life score; RF, rheumatoid factor 
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4.3.1 Radiographic outcomes 
There was excellent agreement between the two readers’ changes scores 
(ICC=0.8). The calculated SDC for this study was 2 units. 
Baseline JSN, ERO and total mTSS scores in the methotrexate and IV steroid and 
the methotrexate and infliximab groups are presented in table 4.1. At week 50, the 
mean (SD) changes in total mTSS (ΔmTSS) (primary endpoint) were 2.81 (6.88) 
and 1.20 (2.27) in the methotrexate and IV steroid and the methotrexate and 
infliximab groups respectively, with no significant between group difference 
(adjusted difference (95% CI) -1.45 (-3.35, 0.45), p=0.132) (table 4.2). Figure 4.3 
shows a cumulative probability plot of radiographic progression at week 50. The 
findings were similar for JSN and ERO scores at week 50 and for JSN, ERO and 
total scores at weeks 26 or 78. Non-parametric analysis did not change the overall 
conclusions.  
At week 78 radiographic non-progression, defined by ΔmTSS <0.5, was 46.7% in 
the methotrexate and IV steroid group and 61.9% in the methotrexate and infliximab 
group (p=0.116)]. Using ΔmTSS <2.0 (change <SDC) to define radiographic non-
progression, this was  achieved in 71.0% and 80.6% of the methotrexate and IV 
steroid and methotrexate and infliximab groups respectively (p=0.328). 
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Table 4.2 Multiple imputation analysis of radiographic changes at weeks 26, 50 and 78; results were adjusted for baseline values and study 
site. 
Radiographic outcome MTX + IV Steroid 
(n=57) 
MTX + IFX       
(n=55) 
Unadjusted difference 
(95% CI) 
Adjusted difference 
(95% CI) 
p 
Change at week 26 
ERO mean (SD)
 median (IQR) 
0.74 (1.94) 
0.00 (0.00, 0.65) 
0.35 (0.89) 
0.00 (0.00, 0.38) 
-0.39 (-1.03, 0.26) 
0.00 (-0.13, 0.13) 
-0.26 (-0.82, 0.30) 
0.00 (-0.12, 0.12) 
0.357 
1.000 
JSN  mean (SD)
 median (IQR) 
0.78 (2.63) 
0.00 (0.00, 0.57) 
0.48 (1.02) 
0.00 (0.00, 0.64) 
-0.31 (-1.09, 0.48) 
0.00 (-0.17, 0.17) 
-0.29 (-0.99, 0.42) 
0.00 (-0.12, 0.12) 
0.420 
1.000 
mTSS  mean (SD)
 median (IQR) 
1.52 (4.25) 
0.04 (0.00, 1.18) 
0.83 (1.69) 
0.00 (0.00, 1.02) 
-0.69 (-1.99, 0.60) 
-0.04 (-0.34, 0.42) 
-0.59 (-1.70, 0.52)  
-0.20 (-0.29, 0.25) 
0.291 
0.880 
Change < SDC 
82.5% 85.1% OR 1.23 (0.35, 4.31) OR 1.18 (0.31, 4.51)* 0.806 
Change ≤ 0.5 63.5% 68.5% OR 1.25 (0.52, 3.04) OR 1.35 (0.46, 3.95) 0.579 
Change at week 50 
ERO mean (SD)
 median (IQR) 
1.28 (3.26) 
0.14 (0.00, 0.87) 
0.49 (1.21) 
0.00 (0.00, 0.64) 
-0.79 (-1.83, 0.26) 
-0.14 (-0.68, 0.40) 
-0.58 (-1.53, 0.37) 
0.00 (-0.21, 0.21) 
0.224 
1.000 
JSN  mean (SD)
 median (IQR) 
1.53 (3.95) 
0.07 (0.00, 1.51) 
0.71 (1.31) 
0.00 (0.00, 0.97) 
-0.82 (-1.99, 0.34) 
-0.07 (-0.55, 0.40) 
-0.80 (-1.87, 0.27) 
-0.03 (-0.38, 0.32) 
0.141 
0.878 
1
2
7
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mTSS  mean (SD)
 median (IQR) 
2.81 (6.88) 
0.65 (0.00, 2.37) 
1.20 (2.27) 
0.11 (0.00, 1.55) 
-1.61 (-3.69, 0.47) 
-0.53 (-1.36, 0.29) 
-1.45 (-3.35, 0.45) 
-0.16 (-0.85, 0.54) 
0.132 
0.651 
Change < SDC 
71.0% 80.6% OR 1.68 (0.57, 4.95) OR 1.77 (0.56, 5.61)* 0.328 
Change ≤ 0.5 46.7% 61.9% OR 1.96 (0.77, 4.47) OR 2.13 (0.83, 5.46)* 0.116 
Change at week 78 
ERO mean (SD)
 median (IQR) 
1.32 (3.46) 
0.07 (0.00, 0.80) 
0.75 (2.03) 
0.01 (0.00, 1.07) 
-0.57 (-1.83, 0.70) 
-0.06 (-0.49, 0.38) 
-0.33 (-1.46, 0.81)  
0.00 (-0.28, 0.28) 
0.564 
1.000 
JSN  mean (SD)
 median (IQR) 
1.87 (4.58) 
0.31 (0.00, 1.90) 
0.94 (1.69) 
0.03 (0.00, 1.26) 
-0.93 (-2.35, 0.48) 
-0.28 (-0.93, 0.36) 
-0.90 (-2.22, 0.42) 
-0.04 (-0.48, 0.40) 
0.178 
0.856 
mTSS  mean (SD)
 median (IQR) 
3.19 (7.75) 
0.66 (0.00, 2.59) 
1.69 (3.28) 
0.43 (0.00, 2.17) 
-1.50 (-4.01, 1.01) 
-0.23 (-1.16, 0.71) 
-1.31 (-3.59, 0.96) 
-0.11 (-0.85, 0.63) 
0.253 
0.769 
Change < SDC 
66.4% 74.4% OR 1.50 (0.50, 4.55) OR 1.53 (0.45, 5.14)* 0.492 
Change ≤ 0.5 51.1% 54.5% OR 1.15 (0.46, 2.89) OR 1.22 (0.45, 3.32)* 0.699 
 
ERO, erosion; IFX, infliximab ; IV, intravenous; JSN, joint space narrowing; mTSS, van der Heijde modified total Sharp score; MTX, 
methotrexate; SDC, smallest detectable change in mTSS (2 units) 
*Not adjusted for site because for at least 1 site the outcome was the same for all patients therefore odds ratio could not be calculated  
 
 
1
2
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Figure 4.3 Cumulative probability plot showing radiographic progression at week 50 
Patients treated with methotrexate and IV methylprednisolone (open symbols, 
n=44) and methotrexate and infliximab (closed symbols, n=40) 
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4.3.2 Clinical outcomes 
4.3.2.1 Remission and low disease activity 
There was no significant difference between the two treatment groups in the 
proportions of patients achieving DAS44 remission at weeks 26, 50 or 78 (table 
4.3).  
From the exploratory outcomes, a greater proportion of patients who received 
methotrexate and infliximab achieved early clinical responses compared to those 
who received methotrexate and IV steroid. At week 6, LDAS44 was 30.4% vs. 
46.0% in the methotrexate and IV steroid and methotrexate and infliximab groups 
respectively (adjusted OR=3.75 (1.46, 9.62), p=0.006). Remission at week 6 was 
also higher with methotrexate and infliximab (DAS44 remission: 7.1% vs. 18.3%, 
adjusted OR=5.02 (1.30, 19.33), p=0.019,  and DAS28 remission: 7.5% vs. 22.3% 
adjusted OR=6.16 (1.61, 23.54), p=0.008, in the methotrexate and IV steroid and 
the methotrexate and infliximab groups respectively). However by week 14 the 
differences between the two treatment groups were no longer apparent. There were 
few substantive differences between the groups at the later study time points in the 
proportions of patients achieving ACR 20/50/70 responses, LDAS28, LDAS44, 
DAS28 remission, 2010 ACR/EULAR remission (Boolean definition) or SDAI 
remission (table 4.3).  
Sustained remission, defined by DAS44 < 1.6 maintained for ≥ 6 months, was 
achieved in 30.8% and 37.9% of the methotrexate and IV steroid and methotrexate 
and infliximab groups respectively. Assuming non-response for patients who 
withdrew early, the results were similar for the observed data (27.3% (15/55) vs. 
34.6% (19/52)). There was no significant difference between the groups in terms of 
time to achieving sustained remission (unadjusted mean 60.98 vs. 59.27 weeks, 
site- and baseline DAS44-adjusted HR 1.48 (-0.76, 2.87), p=0.251). Sustained 
remission was maintained if patients remained at DAS44<1.6 at subsequent time-
points, had no evidence of increase in DAS44>1.2, and no changes in treatment. Of 
those who achieved sustained remission in the observed data, flare occurred in 
three patients in the methotrexate and IV steroid group (one each at weeks 50, 62 
and 78) and in four patients in the methotrexate and infliximab group (at weeks 50 & 
62, two at week 78). 
In the methotrexate and infliximab group, 24.5% (14/55) of patients stopped 
infliximab due to sustained remission (> 6 months) and of these 78.6% (11/14) 
maintained remission during the remainder of the study period. There was one 
patient who achieved sustained remission after week 26 but did not discontinue 
infliximab before week 78. This was due to an error in DAS44 calculation at week 
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38. The patient was not included in this total. In the majority of patients who 
achieved sustained remission and stopped infliximab did so within the first year of 
treatment (11/14). The earliest was at week 30 (7.5 months from baseline). 
 
4.3.2.2 ACR 20%, 50% and 70% responses 
The proportions of patients achieving ACR 20, 50 and 70 responses at weeks 26 
and 78 were similar in the two treatment groups (table 4.3). Approximately half of 
the patients achieved an ACR70 response by week 78 (50.1% vs. 46.2% in the 
methotrexate and IV steroid and methotrexate and infliximab groups respectively). 
 
4.3.3 Patient-reported outcomes 
4.3.3.1 Patient-reported function and quality of life 
There were substantive improvement in both groups at week 26 with continued 
improvement to week 78. At week 78, the mean change in HAQ-DI was -0.79  and -
0.85 in the methotrexate and IV steroid and methotrexate and infliximab groups 
respectively (adjusted difference (95% CI) -0.03 (-0.26, 0.21), p=0.826). (table 4.3) 
 
4.3.3.2 Maintenance of paid employment  
At baseline 57.1% (32/56) of patients in the methotrexate and IV steroid group and 
57.4% (31/54) in the methotrexate and infliximab group were in full-time or part-time 
paid employment. At week 78 there were data available for 26 patients in the 
methotrexate and IV steroid group who  were in paid employment at baseline, 4 of 
whom had retired and 29 patients in the methotrexate and infliximab group, 5 of 
whom had retired. Of the remaining patients, 81.8% (18/22) in the methotrexate and 
IV steroid group  compared to 91.7% (22/24) of those in the methotrexate and 
infliximab group remained in paid employment at week 78 (OR (95% CI)=2.44 (0.40, 
14.91), p=0.333). In eight patients, employment status was unknown at week 78. Of 
these, four patients (3 methotrexate and IV steroid and 1 methotrexate and 
infliximab) remained in paid employment at week 62 and one in the methotrexate 
and IV steroid group was unemployed at week 62. In those who were in paid 
employment at week 78, no difference was seen in the proportion of patients who 
reported taking sick leave because of their arthritis within the previous 3 months 
(11.1% (2/18) vs. 18.2% (4/22), OR 1.78 (0.29, 11.04), p=0.537). 
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Table 4.3 Multiple imputation analysis of secondary and exploratory clinical and patient-reported outcomes at weeks 2, 14, 26, 50 and 78; 
results were adjusted for baseline values and study site. 
 
Week Clinical outcome MTX + IV Steroid 
(n=57) 
MTX + IFX   
(n=55) 
Unadjusted OR (95% CI) Adjusted OR (95% CI) p 
6 DAS44 remission 
7.1% 18.3% OR 2.93 (0.86, 10.00) OR 5.02 (1.30, 19.33)* 0.019 
DAS44 LDAS 
30.4% 46.0% OR 1.95 (0.89, 4.25) OR 3.75 (1.46, 9.62) 0.006 
DAS28 remission 
7.5% 22.3% OR 3.56 (1.07, 11.80) OR 6.16 (1.61, 23.54)* 0.008 
DAS28 LDAS 
23.9% 33.5% OR 1.60 (0.69, 3.69) OR 2.63 (1.00, 6.93)* 0.051 
SDAI remission 
3.6% 4.4% OR 1.19 (0.16, 8.66) OR 1.54 (0.21, 11.48)* 0.674 
14 DAS44 remission 
31.0% 34.8% OR 1.19 (0.53, 2.65) OR 1.89 (0.78, 4.62)*  0.161 
DAS44 LDAS 
61.4% 66.8% OR 1.27 (0.58, 2.77) OR 3.44 (1.21, 9.76) 0.020 
DAS28 remission 
40.0% 42.3% OR 1.10 (0.52, 2.35) OR 1.68 (0.70, 4.05)* 0.250 
DAS28 LDAS 
54.1% 55.4% OR 1.061 (0.50, 2.24) OR 1.61 (0.670, 3.83)* 0.285 
SDAI remission 
16.7% 24.5% OR 1.61 (0.58, 4.44) OR 2.04 (0.70, 5.92)* 0.191 
26 DAS44 remission 
40.0% 31.6% OR 0.69 (0.31, 1.54) OR 0.82 (0.36, 1.88) 0.644 
DAS44 LDAS 
68.4% 65.9% OR 0.89 (0.40, 2.00) OR 1.48 (0.57, 3.84) 0.422 
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DAS28 remission 50.8% 40.6% OR 0.66 (0.31, 1.42) OR 0.76 (0.34, 1.70) 0.510 
DAS28 LDAS 
66.6% 64.6% OR 0.92 (0.41, 2.04) OR 1.32 (0.54, 3.27)* 0.545 
SDAI remission 
24.1% 29.6% OR 1.32 (0.56, 3.14) OR 1.55 (0.63, 3.79) 0.340 
ACR EULAR remission 
19.3% 14.5% OR 0.71 (0.26, 1.93) OR 0.75 (0.27, 2.08) 0.587 
ACR20 
ACR50 
ACR70 
75.2% 
55.1% 
31.8% 
71.0% 
54.0% 
32.7% 
OR 0.81 (0.35, 1.89) 
OR 0.96 (0.45, 2.03) 
OR 1.04 (0.47, 2.32) 
OR 0.81 (0.35, 1.89)* 
OR 0.95 (0.45, 2.03) 
OR 1.04 (0.46, 2.33)  
0.626 
0.898 
0.927 
Change in HAQ-DI mean (SD) 
-0.61 (0.47) -0.70 (0.56) -0.09 (-0.29, 0.11) -0.05 (-0.23, 0.13) 0.568 
Change in RAQoL mean (SD) 
-6.29 (5.83) -7.87 (6.58) -1.57 (-3.96, 0.81) -0.88 (-3.19, 1.44) 0.454 
50 DAS44 remission 
36.1% 48.5% OR 1.67 (0.75, 3.72) OR 2.13 (0.91, 5.00)* 0.082 
DAS44 LDAS 
70.6% 70.4% OR 0.99 (0.42, 2.32) OR 1.26 (0.51, 3.12) 0.617 
DAS28 remission 
49.6% 55.7% OR 1.28 (0.59, 2.76) OR 1.71 (0.73, 3.99) 0.218 
DAS28 LDAS 
63.4% 68.7% OR 1.27 (0.55, 2.91) OR 1.68 (0.68, 4.19) 0.264 
SDAI remission 
27.2% 45.3% OR 2.23 (0.96, 5.18) OR 2.98 (1.18, 7.56) 0.021 
 
ACR EULAR remission 
19.4% 16.5% OR 0.82 (0.31, 2.17) OR 0.84 (0.31, 2.25)* 0.729 
78 DAS44 remission 
50.0% 47.7% OR 0.91 (0.40, 2.09) OR 1.12 (0.47, 2.68)* 0.792 
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DAS44 LDAS 
80.4% 72.7% OR 0.65 (0.23, 1.87) OR 0.92 (0.29, 2.93)* 0.888 
DAS28 remission 
65.3% 54.3% OR 0.63 (0.27, 1.46) OR 0.74 (0.31, 1.76)* 0.488 
DAS28 LDAS 
76.4% 63.6% OR 0.54 (0.22, 1.35) OR 0.60 (0.23, 1.53)* 0.282 
SDAI remission 
49.4% 37.6% OR 0.62 (0.27, 1.40) OR 0.73 (0.30, 1.76) 0.480 
ACR EULAR remission 
15.9% 15.7% OR 0.99 (0.34, 2.87) OR 1.04 (0.35, 3.08)*  0.950 
ACR20 
ACR50 
ACR70 
71.1% 
63.4% 
50.1% 
70.7% 
64.3% 
46.2% 
OR 0.98 (0.39, 2.46) 
OR 1.04 (0.44, 2.45) 
OR 0.85 (0.39, 1.89) 
OR 0.98 (0.39, 2.46)* 
OR 1.03 (0.43, 2.48) 
OR 0.84 (0.37, 1.88) 
0.973 
0.953 
0.669 
Change in HAQ-DI mean (SD) 
-0.79 (0.54) -0.85 (0.60) -0.06 (-0.31, 0.19) -0.03 (-0.26, 0.21) 0.826 
Change in RAQoL mean (SD) 
-7.96 (6.32) -9.71 (7.80) -1.75 (-4.77, 1.28) -0.62 (-3.34, 2.09) 0.650 
 
DAS28, disease activity score based on a 28-joint count; DAS44, disease activity score based on RAI and SJC44; HAQ-DI=Rasch-
transformed health assessment questionnaire disability index score; IFX, infliximab; IV, intravenous; LDAS, low disease activity score; MI, 
multiple imputation, MTX, methotrexate; RAQoL=Rasch-transformed rheumatoid arthritis quality of life score; SDAI, simplified disease 
activity index,  
 
* Not adjusted for site because for at least 1 site the outcome was the same for all patients therefore OR could not be calculated 
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4.3.4 Use of glucocorticoids, methotrexate and other DMARDs 
The unadjusted mean additional glucocorticoid requirement over the study period 
(total cumulative dose divided by months of follow-up) was 21.1mg 
methylprednisolone/month in the methotrexate and IV steroid group (n=57) and 
16.0mg/month in the methotrexate and infliximab group (n=55) (adjusted mean 
difference (95% CI) -4.96 (-10.31, 0.38), p=0.069). Assessment of glucocorticoid 
use at different points in time was measured by dividing the study into six 12-week 
intervals (table 4.4). Overall, glucocorticoid use was greater during the earlier parts 
of the study. There was some evidence of greater additional IA/IM glucocorticoid 
use in the methotrexate and IV steroid group between weeks 13 and 26, but 
subsequently the amounts used in each group was comparable. 
In terms of DMARD therapy, 55 patients in the methotrexate and IV steroid group 
achieved a maximum methotrexate dose of 20mg, and two achieved a dose of 
25mg. In the methotrexate and infliximab group 53 patients achieved a maximum 
methotrexate dose of 20mg, one withdrew at week 2 prior to dose escalation, and 
another was maintained on 15mg due to abnormal liver function tests during dose 
escalation.  
The proportions of patients requiring additional DMARD therapy treatment are 
presented in table 4.5. In total 38 (66.7%) patients in the methotrexate and IV 
steroid group and 32 (58.2%) in the methotrexate and infliximab group required a 
change in medication during follow-up.
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Table 4.4 : Intramuscular and intra-articular steroid doses with mean and median 
doses of methylprednisolone (mg) per study period 
Study period Summary MTX + IV steroid 
n=57 
MTX + IFX          
n=55 
Weeks 1-12 Mean (SD) 
  Median (IQR) 
  N patients injected 
  N injections 
85 (9) 
0 (0, 120) 
38 
40 
77 (59)  
0 (0, 120) 
35 
35 
Weeks 13-26 Mean (SD) 
  Median (IQR) 
  N patients injected 
  N injections 
120 (99)  
0 (0, 240) 
39 
57 
84 (92)  
0 (0, 120) 
28 
40 
Weeks 27-39 Mean (SD) 
  Median (IQR) 
  N patients injected 
  N injections 
46 (66)  
0 (0, 120) 
21 
22 
41 (72)  
0 (0, 120) 
15 
19 
Weeks 40-52 Mean (SD) 
  Median (IQR) 
  N patients injected 
  N injections 
42 (69)  
0 (0, 120) 
18 
21 
20 (47)  
0 (0, 0) 
10 
13 
Weeks 53-65 Mean (SD) 
  Median (IQR) 
  N patients injected 
  N injections 
15 (40)  
0 (0, 0) 
8 
9 
24 (58)  
0 (0, 0) 
9 
11 
Weeks 66-78 Mean (SD) 
  Median (IQR) 
  N patients injected 
  N injections 
- 
- 
0 
0 
5 (3)  
0 (0, 0) 
4 
4 
IQR, interquartile range; N, number; SD, standard deviation 
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Table 4.5 Escalation of DMARDs 
 
DMARD 
 
MTX + IV Steroid 
n=57 
MTX + IFX 
n=55 
IFX initiated 
4 (7.0%) 55 (100.0%) 
IFX 3 > 6mg/kg 
0 (0.0%) 29 (52.7%) 
IFX 6 > 10mg/kg 
0 (0.0%) 15 (27.3%) 
Sulphasalazine initiated 
35 (61.4%) 7 (12.7%) 
Hydroxychloroquine initiated 
34 (59.6%) 5 (9.1%) 
Leflunomide initiated 
21 (36.8%) 1 (1.8%) 
Cyclosporine initiated 
2 (3.5%) 0 (0.0%) 
Oral steroids prescribed 
7 (12.3%) 6 (10.9%) 
Etanercept initiated 
2 (3.5%) 2 (3.6%) 
Rituximab initiated 
0 (0.0%) 1 (1.8%) 
Total N patients requiring change in 
arthritis medication 
38 (66.7%) 32 (58.2%) 
 
DMARD, disease-modifying antirheumatic drug; IFX, Infliximab; IV, 
intravenous; MTX, methotrexate
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4.3.5 Ultrasound 
Eighty-nine patients (45 methotrexate and IV steroid and 44 methotrexate and 
infliximab) had ultrasound assessments. At baseline all 39 patients in the 
methotrexate and IV steroid group (100%) and 36/41 (87.8%) in the infliximab group  
who had ultrasound scans at baseline had grey scale (GS)>1 and PD>0 in at least 
one joint. From multiple imputation analysis, at week 50, 78.7% of patients in the 
methotrexate and IV steroid group compared to 40.5% of patients in the 
methotrexate and infliximab group has ultrasound disease activity (adjusted OR 
(95% CI) 0.18 (0.07, 0.50), p=0.001). At week 78 this was seen in 43.6% and 32.2% 
respectively (adjusted OR 0.62 (0.24, 1.58), p=0.314). 
 
4.3.6 Factors associated with response to therapy 
In the seropositive patients, rates of non-progression (ΔmTSS <SDC) at week 78 
were 59% vs. 74% in the methotrexate and IV steroid and methotrexate and 
infliximab groups. In the seronegative patients the trend was reversed; with 96% 
and 76% and in the methotrexate and IV steroid and methotrexate and infliximab 
groups respectively  achieving non-progression.  
 
4.3.7 Sensitivity analyses  
The analyses of the radiographic and clinical outcomes were repeated using only 
the available data (tables 4.6 and 4.7). Clinical outcomes were also analysed 
assuming non-response in patients who withdrew (table 4.8). The between group 
differences of each of these analyses were of comparable magnitude to those of the 
multiple imputation datasets. In particular, the adjusted mean change in the ΔmTSS 
according to the multiple imputation analysis was 1.45 compared to 1.21 in analysis 
of the observed data. 
To test the robustness of the study conclusions to conditions under which data were 
missing not at random (MNAR), the imputed values were altered to investigate a 
range of alternatives.  To achieve a mean difference in ΔmTSS of 3 units, the 
interval used to power the study, was only possible if it was assumed that patients in 
the methotrexate and IV steroid group with missing radiographic at week 50 week 
progressed by ≥ 16 units than the values that were imputed by the model, whilst 
patients with missing data in the methotrexate and infliximab group retained the 
scores that were originally imputed (range 0 to 11). Of note, change ≥16 units in the 
observed data occurred in only two patients. The majority (70%) progressing by <1 
unit.  
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Table 4.6 Complete case analysis of radiographic changes at weeks 26, 50 and 78; results were adjusted for baseline values and study site. 
Radiographic outcome MTX +IV Steroid MTX +IFX Unadjusted difference 
(95% CI) 
Adjusted difference (95% 
CI) 
p 
Change at week 26 n=48 n=41    
ERO mean (SD) 
 median (IQR) 
0.72 (1.97) 
0.00 (0.00, 0.68) 
0.24 (0.79) 
0.00 (0.00, 0.00) 
-0.48 (-1.13, 1.17) 
0.00 (-0.16, 0.16) 
-0.27 (-0.75, 0.21) 
0.00 (-0.09, 0.09) 
0.270 
1.000 
JSN  mean (SD) 
 median (IQR) 
0.82 (2.83) 
0.00 (0.00, 0.48) 
0.31 (0.85) 
0.00 (0.00, 0.00) 
-0.51 (-1.42, 0.40) 
0.00 (-0.11, 0.11) 
-0.45 (-1.26, 0.35) 
0.00 (-0.10, 0.10) 
0.267 
1.000 
mTSS  mean (SD) 
 median (IQR) 
1.54 (4.51) 
0.00 (0.00, 1.18) 
0.55 (1.50) 
0.00 (0.00, 0.42) 
-0.99 (-2.45, 0.48) 
0.00 (-0.27, 0.27) 
-0.79 (-1.98, 0.41) 
-0.02 (-0.24, 0.19)  
0.194 
0.832 
Change < SDC 
83.3% 90.2% OR 1.85 (0.51, 6.66) OR 1.67 (0.45, 6.11)* 0.441 
Change ≤ 0.5 66.7% 78.1% OR 1.78 (0.69, 4.61) OR 1.48 (0.52, 4.23) 0.463 
Change at week 50 
n=44 n=40    
ERO mean (SD) 
 median (IQR) 
1.24 (3.38) 
0.00 (0.00, 0.82) 
0.42 (1.10) 
0.00 (0.00, 0.43) 
-0.83 (-1.74, 0.29) 
0.00 (-0.20, 0.20) 
-0.40 (-1.19, 0.39) 
0.00 (-0.16, 0.16) 
0.318 
1.000 
JSN  mean (SD) 
 median (IQR) 
1.63 (4.32) 
0.00 (0.00, 1.45) 
0.53 (1.24) 
0.00 (0.00, 0.42) 
-1.10 (-2.51, 0.31) 
0.00 (-0.30, 0.30) 
-0.77 (-1.90, 0.36) 
0.00 (-0.33, 0.33) 
0.178 
1.000 
1
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mTSS  mean (SD) 
 median (IQR) 
2.88 (7.38) 
0.49 (0.00, 2.01) 
0.95 (2.21) 
0.00 (0.00, 0.91) 
-1.93 (-4.34, 0.49) 
-0.49 (-1.01, 0.02) 
-1.21 (-3.03, 0.62) 
0.00 (-0.41, 0.41) 
0.192 
1.000 
Change < SDC 
75.0% 85.0% OR 1.89 (0.63, 5.70) OR 1.72 (0.56, 5.27)* 0.341 
Change ≤ 0.5 52.3% 72.5% OR 2.41 (0.97, 5.99) OR 2.12 (0.83, 5.42)* 0.115 
Change at week 78 
n=42 n=35    
ERO mean (SD) 
 median (IQR) 
1.25 (3.63) 
0.00 (0.00, 0.49) 
0.57 (1.82) 
0.00 (0.00, 0.70) 
-0.68 (-2.03, 0.67) 
0.00 (-0.18, 0.18) 
-0.22 (-1.25, 0.81) 
0.00 (-0.25, 0.25)* 
0.674 
1.000 
JSN  mean (SD) 
 median (IQR) 
1.90 (5.09) 
0.00 (0.00, 1.49) 
0.61 (1.53) 
0.00 (0.00, 0.45) 
-1.29 (-3.07, 0.48) 
0.00 (-0.19, 0.19) 
-1.08 (-2.48, 0.32) 
0.00 (-0.30, 0.30) 
0.130 
1.000 
mTSS  mean (SD) 
 median (IQR) 
3.15 (8.49) 
0.47 (0.00, 2.30)  
1.18 (3.09) 
0.00 (0.00, 0.94) 
-1.97 (-4.99, 1.04) 
-0.47 (-1.09, 0.14) 
-1.35 (-3.62, 0.92) 
0.00 (-0.58, 0.58) 
0.239 
1.000 
Change < SDC 
71.4% 85.7% OR 2.40 (0.75, 7.65) OR 2.21 (0.63, 7.76) 0.216 
Change ≤ 0.5 59.5% 68.6% OR 1.48 (0.58, 3.81) OR 1.57 (0.57, 4.35) 0.383 
ERO, erosion; IFX, infliximab; IV, intravenous; JSN, joint space narrowing; mTSS, van der Heijde modified total Sharp score; MTX, 
methotrexate; SDC, smallest detectable change in mTSS (2 units) 
*Not adjusted for site due to problems of model separation and/or collinearity
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Table 4.7 Complete case analysis of secondary and exploratory clinical and patient-reported outcomes at weeks 26, 50 and 78 (observed 
values only); results were adjusted for baseline values and study site. Values presented are % (n/N) unless otherwise stated. 
Week Clinical outcome MTX + IV Steroid 
(n=57) 
MTX + IFX 
(n=55) 
Unadjusted OR (95% 
CI) 
Adjusted OR (95% CI) p 
6 DAS44 remission 
7.1% (4/56) 18.5% (10/54) 2.95 (0.87, 10.08) 4.97 (1.29, 19.18)* 0.020 
DAS44 LDAS 
30.4% (17/56) 46.3% (25/54) 1.98 (0.91, 4.32) 3.73 (1.45, 9.61) 0.006 
DAS28 remission 
7.1% (4/56) 22.2% (12/54) 3.71 (1.12, 12.36) 6.22 (1.61, 24.01)* 0.008 
DAS28 LDAS 
23.2% (13/56) 33.3% (18/54) 1.65 (0.71, 3.83) 2.61 (0.98, 6.94)* 0.055 
SDAI remission 
3.6% (2/55) 4.0% (2/50) 1.10 (0.15, 8.15) 1.36 (0.18, 10.42)*  0.765 
ACR EULAR remission 
1.8% (1/57) 1.9% (1/53) 1.08 (0.07, 17.66) 1.44 (0.08, 25.23)* 0.805 
14 DAS44 remission 
30.4% (17/56) 34.6% (18/52) 1.21 (0.54, 2.72) 1.85 (0.75, 4.57)* 0.181 
DAS44 LDAS 
60.7% (34/56) 67.3% (35/52) 1.33 (0.60, 2.93) 3.51 (1.22, 10.15) 0.020 
DAS28 remission 
39.3% (22/56) 42.3% (22/52) 1.13 (0.53, 2.44) 1.62 (0.67, 3.93)* 0.288 
DAS28 LDAS 
53.6% (30/56) 55.8% (29/52) 1.09 (0.51, 2.33) 1.54 (0.65, 3.70)* 0.323 
SDAI remission 15.4% (8/52) 17.8% (8/45) 1.19 (0.41, 3.48) 1.46 (0.48, 4.45)* 0.505 
ACR EULAR remission 
8.9% (5/56) 3.8% (2/53) 0.40 (0.07, 2.16) 0.46 (0.08, 2.53)* 0.371 
26 DAS44 remission 
40.0% (22/55) 31.4% (16/51) 0.69 (0.31, 1.53) 0.85 (0.37, 1.97) 0.703 
1
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DAS44 LDAS 
69.1% (38/55) 66.7% (34/51) 0.89 (0.40, 2.02) 1.60 (0.60, 4.22) 0.346 
DAS28 remission 
50.9% (28/55) 41.2% (21/51) 0.68 (0.31, 1.46) 0.80 (0.36, 1.78) 0.579 
DAS28 LDAS 
66.3% (37/55) 64.7% (33/51) 0.89 (0.40, 1.99) 1.29 (0.52, 3.20)* 0.582 
SDAI remission 
24.1% (13/54) 29.4% (15/51) 1.31 (0.55, 3.13) 1.54 (0.62, 3.78) 0.350 
ACR EULAR remission 
18.2% (10/55) 15.1% (8/53) 0.80 (0.29, 2.21) 0.89 (0.32, 2.53)*  0.834 
ACR20 
ACR50 
ACR70 
76.4% (42/55) 
54.6% (30/55) 
32.7% (18/55) 
73.1% (38/52) 
55.8% (29/52) 
33.3% (17/51) 
0.84 (0.35, 2.01) 
1.05 (0.49, 2.25) 
1.03 (0.46, 2.31) 
0.84 (0.35, 2.01)* 
1.05 (0.49, 2.26) 
1.03 (0.46, 2.31) 
0.541 
0.900 
0.945 
Change in HAQ-DI mean 
(SD) 
-0.61 (0.47), n=54 -0.68 (0.53), n=53 -0.08 (-0.27, 0.12) -0.06 (-0.24, 0.12) 0.502 
Change in RAQoL mean 
(SD) 
-6.42 (5.82), n=54 -7.99 (6.51), n=52 -1.57 (-3.95, 0.81) -0.94 (-3.24, 1.36) 0.421 
50 DAS44 remission 
38.0% (19/50) 48.9% (22/45) 1.56 (0.69, 3.53) 1.97 (0.82, 4.70)* 0.128 
DAS44 LDAS 
74.0% (37/50) 71.1% (32/45) 0.86 (0.35, 2.13) 1.08 (0.42, 2.80) 0.874 
DAS28 remission 
50.0% (25/50) 57.8% (26/45) 1.37 (0.61, 3.08) 2.04 (0.82, 5.07) 0.123 
DAS28 LDAS 
64.0% (32/50) 68.9% (31/45) 1.25 (0.53, 2.93) 1.74 (0.68, 4.47) 0.250 
SDAI remission 
27.1% (13/48) 46.7% (21/45) 2.36 (0.99, 5.60) 3.44 (1.31, 9.01) 0.012 
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ACR EULAR remission 
20.8% (11/53) 18.0% (9/50) 0.84 (0.31, 2.23) 0.85 (0.31, 2.31)* 0.750 
78 
DAS44 remission 
54.4% (25/46) 47.7% (21/44) 0.77 (0.33, 1.76) 0.96 (0.40, 2.29)* 0.922 
DAS44 LDAS 
87.0% (40/46) 75.0% (33/44) 0.45 (0.15, 1.35) 0.68 (0.21, 2.23)* 0.526 
DAS28 remission 
69.6% (32/46) 59.1% (26/44) 0.63 (0.26, 1.51) 0.75 (0.30, 1.87)* 0.540 
DAS28 LDAS 
80.4% (37/46) 68.2% (30/44) 0.52 (0.20, 1.37) 0.58 (0.22, 1.55)* 0.275 
SDAI remission 
52.2% (24/46) 39.5% (17/43) 0.60 (0.26, 1.39) 0.74 (0.30, 1.79)* 0.503 
ACR EULAR remission 
17.4% (8/46) 17.8% (8/45) 1.03 (0.35, 3.02) 1.06 (0.35, 3.18)*  0.920 
ACR20 
ACR50 
ACR70 
77.1% (37/48) 
72.9% (35/48) 
58.3% (28/48) 
76.1% (35/46) 
73.9% (34/46) 
58.7% (27/46) 
0.95 (0.36, 2.46) 
1.05 (0.42, 2.63) 
1.02 (0.45, 2.31) 
0.95 (0.36, 2.46)* 
1.05 (0.42, 2.63)* 
1.02 (0.45, 2.31)* 
0.909 
0.913 
0.972 
Change in HAQ-DI mean 
(SD) 
-0.77 (0.52), n=47 -0.81 (0.55), n=46 -0.04 (-0.26, 0.18) -0.04 (-0.25, 0.17) 0.703 
Change in RAQoL mean 
(SD) 
-7.33 (5.71), n=38 -9.72 (7.69), n=42 -2.39 (-5.43, 0.65) -1.61 (-4.31, 1.10) 0.240 
ACR, American College of Rheumatology; DAS28, disease activity score based on a 28-joint count; DAS44_3-variable, disease activity 
score based on RAI and SJC44; EULAR, European League Against Rheumatism; HAQ-DI=Rasch-transformed health assessment 
questionnaire disability index score; IFX, infliximab; IV, intravenous; LDAS, low disease activity score; MTX, methotrexate; 
RAQoL=Rasch-transformed rheumatoid arthritis quality of life score; SDAI, simplified disease activity index 
*Not adjusted for site because for at least 1 site the outcome was the same for all patients therefore OR could not be calculated
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Table 4.8 Complete case analysis of secondary and exploratory clinical outcomes at weeks 26, 50 and 78 where non-response was assumed 
for those who withdrew early; results were adjusted for baseline values and study site. Values presented are % (n/N) unless other 
 
Week Clinical outcome MTX + IV 
Steroid (n=57) 
MTX + IFX  
(n=55) 
Unadjusted OR (95% 
CI) 
Adjusted OR (95% CI) p 
6 DAS44 remission 
7.1% (4/56) 18.2% (10/55) 2.89 (0.85, 9.85) 4.97 (1.29, 19.23)* 0.020 
DAS44 LDAS 
28.6% (16/56) 45.5% (25/55) 2.08 (0.95, 4.57) 4.18 (1.58, 11.07)* 0.004 
DAS28 remission 
7.1% (4/56) 21.2% (12/55) 3.63 (1.09, 12.06) 6.22 (1.61, 24.08)* 0.008 
DAS28 LDAS 
23.2% (13/56) 32.7% (18/55) 1.61 (0.70, 3.72) 2.60 (0.98, 6.94)* 0.056 
SDAI remission 
3.6% (2/55) 3.9% (2/51) 1.08 (0.15, 7.98) 1.36 (0.18, 10.42)*  0.765 
ACR EULAR remission 
1.8% (1/57) 1.9% (1/54) 1.06 (0.06, 17.33) 1.43 (0.08, 25.23)* 0.805 
14 DAS44 remission 
29.8% (17/57) 34.0% (18/53) 1.21 (0.54, 2.70) 1.92 (0.78, 4.73)* 0.158 
DAS44 LDAS 
59.7% (34/57) 66.0% (35/53) 1.32 (0.60, 2.86) 3.69 (1.28, 10.67) 0.016 
DAS28 remission 
38.6% (22/57) 41.5% (22/53) 1.13 (0.53, 2.42) 1.69 (0.70, 4.08)* 0.248 
DAS28 LDAS 
52.6% (30/57) 54.7% (29/53) 1.09 (0.51, 2.30) 1.62 (0.68, 3.84)* 0.276 
SDAI remission 
15.1% (8/53) 17.4% (8/46) 1.18 (0.41, 3.46) 1.49 (0.49, 4.55)* 0.480 
ACR EULAR remission 
8.8% (5/57) 3.7% (2/54) 0.40 (0.07, 2.16) 0.47 (0.08, 2.58)* 0.382 
1
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26 DAS44 remission 
39.3% (22/56) 30.2% (16/53) 0.67 (0.30, 1.48) 0.82 (0.36, 1.89) 0.645 
DAS44 LDAS 
67.9% (38/56) 64.2% (34/53) 0.85 (0.38, 1.87) 1.50 (0.58, 3.87) 0.406 
DAS28 remission 
50.0% (28/56) 39.6% (21/53) 0.66 (0.31, 1.40) 0.76 (0.35, 1.68) 0.501 
DAS28 LDAS 
66.1% (37/56) 62.3% (33/53) 0.85 (0.39, 1.86) 1.20 (0.50, 2.87)* 0.688 
SDAI remission 
23.6% (13/55) 28.3% (15/53) 1.28 (0.54, 3.02) 1.50 (0.61, 3.68) 0.377 
ACR EULAR remission 
17.9% (10/56) 14.6% (8/55) 0.78 (0.28, 2.16) 0.88 (0.31, 2.47)*  0.804 
ACR20 
ACR50 
ACR70 
75.0% (42/56) 
53.6% (30/56) 
32.1% (18/56) 
70.4% (38/54) 
53.7% (29/54) 
32.1% (17/53) 
0.79 (0.34, 1.84) 
1.01 (0.48, 2.13) 
1.00 (0.45, 2.23) 
0.79 (0.34, 1.84)* 
1.01 (0.48, 2.13) 
1.00 (0.45, 2.24) 
0.457 
0.986 
0.999 
50 DAS44 remission 
35.2% (19/54) 46.0% (23/50) 1.57 (0.71, 3.45) 2.05 (0.88, 4.79)* 0.096 
DAS44 LDAS 
64.8% (35/54) 64.0% (32/50) 0.97 (0.43, 2.16) 1.34 (0.56, 3.22) 0.512 
DAS28 remission 
46.3% (25/54) 54.0% (27/50) 1.36 (0.63, 2.95) 1.98 (0.83, 4.70) 0.122 
DAS28 LDAS 
55.6% (30/54) 62.0% (31/50) 1.31 (0.60, 2.86) 1.89 (0.78, 4.44) 0.159 
SDAI remission 
25.0% (13/52) 44.0% (22/50) 2.36 (1.02, 5.46) 3.40 (1.33, 8.68) 0.010 
ACR EULAR remission 
19.6% (11/56) 18.2% (10/55) 0.91 (0.35, 2.35) 0.91 (0.35, 2.40)* 0.855 
78 DAS44 remission 
43.6% (24/55) 39.6% (21/53) 0.85 (0.39, 1.82) 1.12 (0.49, 2.53)* 0.789 
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DAS44 LDAS 
69.1% (38/55) 69.1% (33/53) 0.74 (0.33, 1.64) 1.16 (0.47, 2.82)* 0.749 
DAS28 remission 
54.6% (30/55) 54.6% (26/53) 0.80 (0.38, 1.71) 1.03 (0.46, 2.30)* 0.952 
DAS28 LDAS 
63.6% (35/55) 63.6% (30/53) 0.75 (0.34, 1.61) 0.89 (0.40, 2.00)* 0.782 
SDAI remission 
41.8% (23/55) 41.8% (17/52) 0.68 (0.31, 1.49) 0.88 (0.38, 2.04)* 0.766 
ACR EULAR remission 
14.6% (8/55) 14.6% (9/54) 1.18 (0.42, 3.31) 1.22 (0.43, 3.52)* 0.708 
 
ACR20 
ACR50 
ACR70 
59.7% (34/57) 
57.9% (33/57) 
45.6% (26/57) 
63.6% (35/55) 
61.8% (34/55) 
49.1% (27/55) 
1.18 (0.55, 2.54) 
1.18 (0.55, 2.51) 
1.15 (0.55, 2.42) 
1.18 (0.55, 2.54)* 
1.18 (0.55, 2.51)*  
1.15 (0.55, 2.42)* 
0.665 
0.672 
0.713 
 
ACR, American College of Rheumatology; DAS28, disease activity score based on a 28-joint count; DAS44_3-variable, disease activity 
score based on RAI and SJC44; EULAR, European League Against Rheumatism; HAQ-DI=Rasch-transformed health assessment 
questionnaire disability index score; IFX, infliximab; IV, intravenous; LDAS, low disease activity score; MTX, methotrexate; 
RAQoL=Rasch-transformed rheumatoid arthritis quality of life score; SDAI, simplified disease activity index 
*Not adjusted for site because for at least 1 site the outcome was the same for all patients therefore OR could not be calculated 
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4.3.8 Adverse events 
In total 94.7% (54/57) in the methotrexate and IV steroid group compared to 98.2% 
(54/55) in the methotrexate and infliximab group reported adverse events (AEs). Of 
the AEs, the most common were non-infectious gastrointestinal events (18.3% 
(68/372) in the methotrexate and IV steroid group and 15.7% (58/369) in the 
methotrexate and infliximab group). Upper respiratory tract/ pulmonary infections  
were reported in 13.8% (51/372) of the methotrexate and IV steroid and 11.3% 
(42/369) of the methotrexate and infliximab groups. There were 11.0 AEs per 100 
patient years in the methotrexate and IV steroid group and 25.3 in the methotrexate 
and infliximab group. There were 9 serious adverse events (SAEs) recorded for 9 
patients in the methotrexate and IV steroid group (15.8%) and 20 events recorded 
for 13 patients in the methotrexate  and infliximab group (23.6%). A higher 
proportion of SAEs in the methotrexate and infliximab group (9.1% (5/55)) were due 
to admissions for surgical procedures unrelated to the RA or study medication. 
During the study period, one patient in the methotrexate and infliximab arm died due 
to a suspected pulmonary embolus. Serious infections were documented in two 
patients (3.5%) in the methotrexate and IV steroid group and two (3.6%) in the 
methotrexate and infliximab group. One person in the methotrexate and infliximab 
group had pulmonary tuberculosis which presented as a pleural effusion and 
another patient had an empyema. In the methotrexate and IV steroid group, one 
patient had a lung abscess and another had herpes zoster. There were no 
malignancies reported during the study period (table 4.9).
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Table 4.9 Summary of adverse events 
 
 
MTX + IV Steroid  MTX + IFX  
Number of patients who 
experienced an AE 
54/57 (94.7%) 54/55 (98.2%) 
Maximum severity of AE 
experienced 
  
- Mild 
5/57 (8.8%) 10/55 (18.2%) 
- Moderate 
40/57 (70.2%) 31/55 (56.4%) 
-Severe (including SAEs) 
9/57 (15.8%) 13/55 (23.6%) 
Total number of AEs 
372 369 
Total patient-years of 
follow-up 
81.9 79.1 
Number of AEs per 100 
patient-years 
454.0 466.3 
Patient expectation of 
event 
  
-Expected (listed in PIS) 
294/372 (79.0%) 270/369 (73.2%) 
Severity 
  
-Mild 
230/372 (61.8%) 226/369 (61.2%) 
-Moderate 
133/372 (35.8%) 122/369 (33.1%) 
-Severe (including SAEs) 
9/372 (2.4%) 21/369 (5.7%) 
Relation to study drug 
  
-Not related 
120/372 (32.3%) 96/369 (26.0%) 
-Probably not related 
160/372 (43.0%) 197/369 (53.4%) 
-Possibly related 
77/372 (20.7%) 61/369 (16.5%) 
-Probably related 
15/372 (4.0%)  15/369 (4.1%) 
Number of patients who 
experienced an SAE 
9/57 (15.8%) 13/55 (23.6%) 
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Total number of SAEs 
9 20 
Number of SAEs per 100 
patient-years 
11.0 25.3 
Relation to study drug 
  
-Not related 
1/9 (11.1%) 8/20 (40.0% 
-Probably not related 
6/9 (66.7%) 7/20 (35.0%) 
-Possibly related 
2/9 (22.2%) 4/20 (20.0%) 
-Probably related 
0 1/20 (5.0%) 
SAEs by category: 
  
-Blood/bone marrow 
0  1 in 1/55 patients (1.8%) 
-Cardiac arrhythmia 
0  1 in 1/55 patients (1.8%) 
-Cardiac general 
2 in 2/57 patients (3.5%) 2 in 1/55 patients (1.8%) 
-Gastrointestinal 
1 in 1/57 patients (1.8%) 0  
-Hepatobiliary/pancreas 
1 in 1/57 patients (1.8%) 1 in 1/55 patients (1.8%) 
-Infection - gastrointestinal 
1 in 1/57 patients (1.8%) 0  
-Infection - pulmonary/ 
upper respiratory 
1 in 1/57 patients (1.8%) 2 in 2/55 patients (3.6%) 
-Injury, poisoning or 
procedural complications 
2 in 2/57 patients (3.5%) 1 in 1/55 patients (1.8%) 
-Pain - musculoskeletal 
0  2 in 2/55 patients (3.6%) 
-Pain - neurology 
1 in 1/57 patients (1.8%) 0  
-Pain - pulmonary/ upper 
respiratory 
0  1 in 1/55 patients (1.8%) 
-Pulmonary/upper 
respiratory 
0  4 in 4/55 patients (7.3%) 
-Surgical and medical 
procedures 
0  5 in 5/55 patients (9.1%) 
 
AE, adverse event; IFX, infliximab; IV, intravenous; PIS, patient information 
sheet; SAE, serious adverse event  
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4.4 Discussion 
The IDEA study was the first double-blind RCT comparing two rapid remission 
induction strategies, using either methotrexate and IV steroid or methotrexate and 
infliximab in early DMARD-naïve RA, and incorporating a treat-to-target approach in 
both groups.  
No significant difference in radiographic progression (the primary outcome) was 
seen between the groups. Proportions of patients achieving radiographic non-
progression in both groups were high, and at study end approximately 50% in both 
groups were in remission. The treatment benefits were seen across all aspects of 
care including function.  
Several factors may explain the high proportion of radiographic non-progression in 
the methotrexate and IV steroid group which was similar to that observed in the 
methotrexate and infliximab group. Glucocorticoids, like the TNFi, are known to 
inhibit osteoclastic activity. The initial IV steroid administration may have minimised 
bone damage in the early stages of the disease. In these patients the subsequent 
potential for damage is likely to have been reduced by the additional treat-to-target 
approach, suppressing inflammation which drives joint damage. In a smaller study 
of MTX-naïve RA which also compared IV methylprednisolone to infliximab, but 
without a treat-to-target approach, clinical benefits were also seen in both treatment 
groups.  Progression of MRI-detected erosions however was significantly higher in 
the group receiving IV steroid compared to the those in the infliximab group.165 (In 
this study, ultrasound demonstrated greater sensitivity than clinical measures of 
disease activity with significant benefit seen on synovitis in the methotrexate and 
infliximab group.)  
Whilst the efficacy of methotrexate monotherapy is well documented in patients with 
RA (20-40%), 183 240 a proportion still have ongoing disease with radiographic 
progression138 177 and require additional therapy.183 240 This study confirms the 
benefit of methotrexate and a bDMARD as induction therapy in early DMARD-naïve 
RA182 183 with the potential for treatment de-escalation. In addition, the study 
demonstrates the benefit of combination therapy with methotrexate and a 
glucocorticoid,164 165 168 220 given here as an initial single IV dose. The results of this 
study also supports the call to treat-to-target.10 The target aiming to achieve low 
disease activity was applied throughout the study. This treatment target was similar 
to that in several other studies including BeSt183, OPTIMA232 and SWEFOT,240 but 
perhaps a more stringent target e.g. aiming for remission as was the target in the 
NeoRACo study,293 would have led to even better clinical outcomes.In addition to 
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the DMARD escalation protocol, the  additional IA/IM glucocorticoid would have also 
been an important part of the treat-to-target approach, minimising the differences 
between the groups. The additional glucocorticoid was marginally higher in the 
methotrexate and IV steroid group compared to the methotrexate and infliximab 
group, suggesting that combination therapy with methotrexate and IV steroid may 
be somewhat more dependent on regular monitoring and treating to target than 
combination therapy with methotrexate and infliximab. In the OPERA study337 which 
compared methotrexate and adalimumab to methotrexate and placebo, IA 
glucocorticoids were used as part of a treat-to-target strategy. There was no 
difference in the primary endpoint (LDAS) or in the ACR20. Greater improvements 
however were seen at the higher clinical endpoints (remission, ACR50 and ACR70) 
as well as in DAS28-CRP, quality of life and function in the group receiving 
bDMARD therapy. Similar to the IDEA study, although there was a trend toward 
greater glucocorticoid use in the placebo group, the cumulative dose was not 
significantly different between the two treatment groups.  
The use of glucocorticoids often raise the concerns of side effects, particularly with 
high dose glucocorticoid therapy. In this study, whilst the boluses of steroid used 
may have appeared large (methylprednisolone 120mg if not in LDAS at the given 
time points), this dose is used in clinical practice as part of standard care. In the 
tREACH study this has been shown to be an efficient way of administering 
glucocorticoids.363 In both groups in the IDEA study, the greatest glucocorticoid use 
occurred at the beginning of the study when patients had the highest disease 
activity. The total dose used however was equivalent to low dose oral prednisolone: 
0.89 mg/day in the methotrexate and IV steroid groups and 0.67 mg/day in the 
methotrexate and infliximab group over the course of the study period.  
Exploratory analysis suggests that earlier remission is achievable with infliximab 
(week 6 DAS44 remission in 7.1%  vs 18.3% in the methotrexate and IV steroid and 
methotrexate and infliximab groups respectively).  This is worth noting as previous 
clinical trials have shown that earlier control of disease activity, particularly during 
the first three months of therapy, predicted achievement of remission at a later time-
point.350 In the OPTIMA study, the only measures of disease activity after 12 weeks 
predicted clinical outcomes at week 26, 232 supporting the rationale for the use of 
early intensive treatment strategies.350   
Adverse events, in particular serious infections, are of concern with both bDMARD 
and glucocorticoid use. In this study both treatment strategies were generally well 
tolerated, with no unexpected adverse events. The number of serious infections was 
low, with two cases (3.6%) reported in each group. The infections were similar to 
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those described in clinical practice and in registries. 197 364 365 There was one case of 
tuberculosis in the methotrexate and infliximab group, three pulmonary infections 
(one in the methotrexate and IV steroid and two in the methotrexate and infliximab 
groups) and one gastrointestinal infection in the methotrexate and IV steroid group. 
A case of herpes zoster manifesting as a Ramsay Hunt syndrome was recorded in 
the methotrexate and IV steroid group. Serious adverse events (excluding 
admissions for procedures unrelated to the RA or to study treatment) were similar 
between the groups. 
Cost considerations are also important when considering the treatment of RA. 
Identifying  prognostic factors would help determine which patients would benefit 
most from more intensive strategies with early bDMARD therapy. A post hoc 
analysis of this study showed less radiographic progression in seropositive patients 
receiving methotrexate and infliximab compared to methotrexate and IV steroid. 
4.5 Limitations 
Our study has its limitations. Missing data was one which needed careful 
consideration, particularly in terms of the potential effect on the lack of difference in 
radiographic progression seen between the two groups. Sensitivity analyses using 
multiple imputation were done to account for this. The adjusted means for 
radiographic progression at week 50 were consistent in the multiple imputation and 
complete case datasets (1.45 and 1.21 respectively). Results from both analyses 
were lower than the value used to power the study (3 units), and both were within 
the measurement error of 2 units. In both groups radiographic progression was less 
than expected and, as is often the case, a minority of patients accounted for this. 
The median (IQR) change in the methotrexate and IV steroid group this was 0.65 
(0.00, 2.37) which is comparable to the change recorded in patients treated with 
infliximab in the BeSt study [0.50 (0.00, 2.30)].183 In the methotrexate and infliximab 
group this was 0.11 (0.00, 1.55). Based on the unadjusted results of this study (a 
difference in change in the observed mTSS at week 50 of 1.93), calculations 
showed that even if the study was twice the size it would not show a significant 
difference in the primary outcome. The changes seen would still fall within the 
calculated smallest detectable difference of 2 units and therefore would not 
represent a clinically meaningful difference. Data for the secondary and exploratory 
outcomes were complete in more than 90% of patients, assuming non-response in 
those who withdrew. There were no substantive differences between the groups in 
these analyses. 
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No increase in adverse events was seen in the methotrexate and IV steroid group 
however, bone density was not one of the specific outcomes measured in the study. 
Per protocol, osteoporosis prophylaxis was prescribed at the treating physician’s 
discretion guided by local guidelines.  
Induction using other routes of glucocorticoid administration was also not 
investigated in this study. Oral, intramuscular and intra-articular steroids are widely 
used in clinical practice and have demonstrated efficacy in recently published 
clinical trials.337 363  Tapering and stopping is potentially less difficult when given 
intravenously rather than orally. 
4.6 Conclusions 
In summary, the IDEA study has shown that first-line therapy with methotrexate and 
high dose IV steroid in DMARD-naïve RA, together with a treat-to-target approach, 
resulted in little structural damage. Although methotrexate and infliximab was not 
superior in inhibiting radiographic progression, there was a trend towards earlier 
clinical responses, significantly earlier achievement of DAS28 remission and greater 
reduction in  synovitis on ultrasound.  
 
 
154 
 
 
Chapter 5 Etanercept with methotrexate vs. methotrexate 
monotherapy in DMARD-naïve early IA  
In this chapter, a RCT aimed to compare the use of methotrexate and etanercept  to 
methotrexate monotherapy in DMARD-naïve early IA. 
5.1 Introduction 
Remission is a primary goal for patients with IA.180 Whilst this may be possible at 
any time during the course of the disease, the evidence suggests that this is best 
achieved with early DMARD therapy.1 366   
Identifying patients with IA early is therefore paramount. RF and anti-CCP - both 
antibodies of which are included in the 2010 ACR/EULAR RA classification criteria12 
90-92 95 367 – as well as genetic markers, in particular shared epitope,33 100 102 have 
been found to be markers of persistent inflammation and progression to RA.  
In early IA the optimal induction therapy is still unknown. As discussed in previous 
chapters, methotrexate is generally used as part of first-line therapy in RA .209 In 
patients with ACPA-positive UA, methotrexate has also been shown to delay the 
progression to RA. 213 In a study of early DMARD-naïve RA, the use of 
methotrexate and etanercept has proven effective for remission induction. 180 
Efficacy was superior to methotrexate monotherapy, particularly in patients with 
early disease (RA disease duration ≤ 4 months). 1 The role of this combination 
however has not been examined in patients with early IA.   
The aim of the EMPIRE (Etanercept and Methotrexate in Patients to Induce 
Remission in Early Arthritis) study was to compare the clinical, radiographic and 
functional outcomes of methotrexate and etanercept to methotrexate monotherapy 
in patients with DMARD-naïve early IA, with at least one joint with clinical synovitis.  
5.2 Patients and methods 
5.2.1 Patients  
Patients between 18 - 80 years, with at least one tender and swollen joint - within 
three months of diagnosis of an IA - RF, anti-CCP or shared epitope positive, and 
DMARD-naïve were eligible to take part in the study. Exclusion criteria included 
current crystal or infective arthritis, important concurrent medical diseases or 
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relevant co- morbidities, glucorticoids within 28 days of screen and previous 
treatment with any cs- or bDMARD.  
 
5.2.2 Treatment allocation and intervention 
This was an 18-month, randomised, double-blind, placebo-controlled phase 3 
superiority trial.  The multicentre study was conducted across 4 sites in West 
Yorkshire, UK (Harrogate, Huddersfield, Leeds and York).  
Randomisation (1:1) took place according to a computer generated list in blocks of 
four. There was no stratification. Treatment was assigned by central pharmacy. 
Patients, nurses, clinicians, local pharmacists and assessors were blinded to the 
treatment allocation throughout the study. The protocol and amendments received 
independent ethics committee and regulatory review and approval. Patient informed 
consent was obtained prior to study enrolment.  
Patients either received methotrexate plus placebo or methotrexate plus etanercept. 
The etanercept 50mg SC injections or visually identical placebo (sterile lyophilized 
powder similar in appearance to the etanercept) SC injections were administered 
once weekly. The study injections were continued to week 52. In patients with no 
tender and no swollen joints (NTSJ) (Ritchie articular index (RAI) = 0 and 44-
swollen joint count (SJC44) = 0) for 26 weeks, injections could be stopped earlier. In 
both treatment groups, methotrexate was started at a dose of 10mg weekly. This 
was increased by 5 mg every 4 weeks to 20mg. In patients who did not achieve 
NTSJ, the methotrexate dose could be increased further to 25 mg/week at or after 
week 12. In patients who achieved NTSJ by week 4, the methotrexate dose was 
maintained at 15mg weekly. Study subjects also received folic acid 5mg orally at 
least twice a week. In patients achieving sustained NTSJ for 12 weeks after 
stopping etanercept or placebo injections, methotrexate was weaned (figure 5.1). 
Where possible, data collection continued and included patients who withdrew from 
the trial but were still able to attend for follow up.   
NSAIDS were permitted during the study. Patients were also allowed an 
intramuscular or intra-articular glucocorticoid injection to a maximum dose of 120mg 
of methylprednisolone once within the first nine months of the trial and as clinically 
indicated thereafter. Oral steroids were not permitted. Additional DMARD therapy 
was allowed after week 52 at the discretion of the investigator if there were features 
of ongoing disease activity.
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Figure 5.1 EMPIRE study design 
ETN, etanercept; MTX, methotrexate; SC, subcutaneous; 1°= primary outcome at week 52 
8 12 52 32 62 46 
Randomise 
ETN 50mg SC weekly  + MTX  
 Placebo + MTX 
WEEK 
0 78 26 
Week 52: all patients stop ETN/ placebo 
From week 32: can stop ETN/ placebo if in sustained remission 
If in remission for ≥ 12 weeks after stopping ETN/placebo, MTX is weaned 
4 
1° 
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5.2.3 Efficacy and safety outcomes 
The primary outcome of the study was NTSJ at week 52.  Secondary outcomes 
included NTSJ at week 78, DAS44-CRP, remission according to the 2010 
ACR/EULAR criteria, physician global assessment of disease activity, patient pain 
and fatigue VAS, HAQ-DI, SF36 and EQ5D at weeks 52 and 78. Other secondary 
outcomes were the proportions of patients in etanercept-free NTSJ (for those in the 
methotrexate and etanercept arm) and in drug-free NTSJ.  
Secondary radiographic outcomes were the change in JSN , ERO and total 
mTSS,354 and the proportions of patients achieving radiographic non-progression 
(change ≤0.5 units355 or change less than the calculated SDC for this study) at 
weeks 52 and 78. The radiographs were scored in time order, independently by two 
experienced readers, who were blinded to treatment allocation. 
The following were exploratory outcomes of the study:  NTSJ at weeks 2, 12 and 
26; other clinical responses (DAS44-CRP <1.6, DAS28-CRP <2.6, DAS44-CRP 
≤2.4, DAS28-CRP ≤3.2) at weeks 2, 12, 26, 52 and 78; functional outcomes 
including the proportions of patients achieving a minimal clinical important 
difference (MCID) in HAQ-DI (decrease of ≥ 0.22 units from baseline) 368 and normal 
HAQ-DI status (≤0.5 369); additional DMARD therapy and additional glucocorticoids 
required during the study. In patients who were able to stop injections with/ without 
methotrexate early, duration of bDMARD free- and drug free- NTSJ was determined 
(loss of this state was defined by any change in disease activity requiring an 
increase in therapy, RAI>0 or SJC44> 0).360 In addition we aimed to identify 
baseline variables which were predictive of clinical and radiographic outcome, whilst 
also testing for potential moderators of the treatment effect.  
Ultrasound assessments were performed at baseline, weeks 52 and 78 in the 
subgroup of patients recruited in Leeds. These were done (Philips HDI 5000, 
employing a 15-8 MHz transducer) by three experienced rheumatologists trained in 
MSK ultrasound who were blinded to treatment allocation. Intra- and inter-reader 
reliability tests between the sonographers had been done prior to this study and 
shown to be good. Findings in 20 joints (bilateral wrists, MCPs 2 and 3, PIPs 2 and 
3, and MTPs 1 to 5) were compared between the two groups. The OMERACT 
definitions were used to define synovitis.356 The EULAR-OMERACT scoring system 
(a 0-3 semi-quantitative scale) was used to measure grey scale and power Doppler 
signal.357 The number of ultrasound detected erosions in each joint was also 
determined. 
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At every visit, patients were asked to report any new adverse events. Clinical and 
laboratory adverse events were recording using standard medical terms.  
 
5.2.4 Sample size 
The study primary outcome was the proportion of patients with no symptoms and 
signs of IA, defined by no NTSJ at 12 months. The study null hypothesis was that 
there was no difference between the proportions of patients in each of the treatment 
groups with NTSJ. Based on previous data, 35 it was anticipated that 30% of 
patients receiving methotrexate monotherapy would achieve NTSJ at 12 months, 
compared to 60% of patients receiving methotrexate and etanercept. The sample 
size required to show a significant difference between these two groups, with 80% 
power and at the 5% significance level, was 50 per group. To allow for a 10 percent 
drop-out, the number of patients required was 55 per group (110 patients in total). 
 
5.2.5 Statistical methods 
Efficacy and safety analyses were performed on subjects who received at least one 
dose of study drug. The primary analysis was done according to the groups to 
which patients were originally randomised (intention-to-treat).  
Multiple imputation by chained equations (Stata command: mi imputed chained) 
was used to account for missing data. Twenty  complete datasets were generated. 
The size of the dataset precluded full imputation of all variables simultaneously. 
Separate imputation models were created for joint counts, DAS44, DAS28, SDAI 
and ACR remission, radiographic outcomes, patient reported outcomes (HAQ-DI, 
short form 36 (SF-36), EQ5D), VAS, EMS and ultrasound. Imputation models 
included auxiliary variables if they were substantively associated with the variable 
imputed or with the likelihood that the data were missing. Anti-CCP was found to be 
associated with the likelihood that data were missing at weeks 52 (OR 3.0) and 78 
(OR 3.8) and was included in all the imputation models. Data on the 1987 ACR and 
2010 ACR/EULAR RA classification criteria were included in DAS and DAS28 
imputation models as these were to be used in exploratory analyses of response to 
treatment. Age was associated with the radiographic outcomes, particularly 
progression of erosion score (r>0.3 at both time-points). Males were slightly more 
likely to be missing radiographic outcome data (OR≈1.5 at both time-points). RAI 
and HAQ-DI were associated with EMS, global pain VAS, abnormal fatigue VAS 
and physician VAS at both time-points (all r>0.3) and were more complete so were 
included in the VAS imputation model. Binary variables were imputed using binary 
159 
 
 
logistic regression. Predictive mean matching was used to impute all other 
variables. For continuous variables with missing values at baseline, the mean of the 
observed values was imputed and an indicator variable coded 1 for missing was 
also included in the imputation model and subsequent analysis models. For 
categorical variables with missing values at baseline, missing values were given a 
unique code prior to imputation and analysis. DAS28 remission, LDAS28, SDAI 
remission and TSS were all computed passively following imputation of DAS28, 
SDAI, and JSN/ erosion scores respectively. 
During the analysis of the imputed datasets the Monte Carlo errors were examined 
to ensure these met the conditions defined by White et al. (2010):370 
(1) The Monte Carlo error of ?̂? is approximately 10 per cent of its standard error. 
(2) The Monte Carlo error of the test statistic ?̂?/𝑠𝑒(?̂?) is approximately 0.1. 
(3) The Monte Carlo error of the p-value is approximately 0.01 when the true p-
value is 0.05, and 0.02 when the true p-value is 0.1. 
Additional sensitivity analyses of the primary outcome at week 52 were also done 
imputing non-response for patients who withdrew or were lost to follow-up. A 
complete case analysis was also done and included observed data only. This 
included patients who may have been followed up after withdrawal from study 
treatment.  
In addition to this, a per-protocol analysis was also performed, excluding patients 
who withdrew or were lost to follow up, or deviated from the study protocol in any 
other way that could have affected the outcome. Analyses were conducted using 
Stata 12.1.  
The SDC in mTSS was calculated based on the change scores of both readers 
according to the Bland-Altman 95% limits of agreement method.371  
Linear regression was used to analyse continuous interval outcomes. Non-
parametric quantile regression models with heteroscedasticity-robust standard 
errors were used if non-normality or heterogeneity of residuals were identified in the 
linear models. Binary logistic regression was used for analysis of categorical 
outcomes. In each analysis,  baseline values and study site were controlled for.  
Proportions estimated from the combined multiple imputation datasets could not be 
summarised in terms of the number of patients exhibiting each characteristic as 
these vary between the imputed sets. Numerators and denominators for proportions 
are therefore only presented for the observed data. The threshold for statistical 
significance was adjusted for multiple comparisons in the secondary outcomes 
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using the Holm method. There were no adjustments made for the exploratory 
analyses.   
Descriptive results are presented for harms. Where events recurred over time, only 
the most severe was counted for each patient. Absolute and relative frequencies 
are presented with the number of occurrences per 100 patient-years of follow-up. 
5.3 Results 
In total, 110 patients were recruited from four sites in West Yorkshire, UK from 
October 2006 to May 2009 (figure 5.2). Demographics and baseline disease 
characteristics are summarised in table 5.1. Seventy six percent of patients were 
female with a mean (SD) age of 48.6 (13.3) years and median symptom duration of  
seven months.  Fifty three percent were RF positive, 77% anti-CCP positive and 
82% shared epitope positive. Forty one percent (45/110) fulfilled the 1987 ACR RA 
classification criteria and 94% (103/110) fulfilled the 2010 ACR EULAR criteria. 
Mean (SD) baseline DAS44-CRP was 2.94 (0.91). 12   
During the study the median (IQR) maximum methotrexate dose in each group was 
25 (20, 25) mg/week in both groups. Five patients in the methotrexate and placebo 
group (9.1%) and three patients in the methotrexate and etanercept group (5.5%) 
were not prescribed at least 20 mg/week. Of these, two patients (one in the 
methotrexate and placebo and one in the methotrexate and etanercept groups) 
experienced adverse events which limited their tolerated dose, three patients (two in 
the methotrexate and placebo and one in the methotrexate and etanercept group) 
withdrew from the study during the treatment escalation phase, and three patients 
(two in the methotrexate and placebo and one methotrexate and etanercept groups) 
achieved NTSJ before reaching 20 mg/week.
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Figure 5.2 EMPIRE study patient disposition 
 ETN, etanercept; MTX, methotrexate 
Assessed for eligibility (n=132) 
Excluded                               (n=22) 
- Inclusion criteria not met (n=18) 
- Declined participation      (n=4) 
Allocated to MTX+ placebo 
(n=55) 
Allocated to MTX + ETN 
(n=55) 
 
Randomised (n=110) 
Enrolment 
Discontinued intervention (n=12) 
 
- Lost to follow-up  (n=1) 
- Adverse event (n=0) 
- Lack of efficacy (n=7) 
- Missed medication (n=0) 
- Patient self-withdrew (n=4) 
 
Included in analysis of primary 
outcome: 
Intention-to-treat (n=55) 
Available data (n=51) 
Per protocol (n=39) 
 
Discontinued intervention (n=14) 
 
- Lost to follow-up  (n=2) 
- Adverse event (n=2) 
- Lack of efficacy (n=2) 
- Missed medication (n=3) 
- Patient self-withdrew (n=5) 
 
Included in analysis of primary 
outcome: 
Intention-to-treat (n=55) 
Available data (n=48) 
Per protocol                    (n=35) 
Allocation 
Discontinued intervention 
(cumulative)       (n=13) 
 
- Lost to follow-up  (n=2) 
- Adverse event (n=0) 
- Lack of efficacy (n=7) 
- Missed medication (n=0) 
- Patient self-withdrew (n=4) 
 
Completed study             (n=42) 
 
Discontinued intervention 
(cumulative)                    (n=15) 
 
- Lost to follow-up  (n=3) 
- Adverse event (n=2) 
- Lack of efficacy (n=2) 
- Missed medication (n=3) 
- Patient self-withdrew (n=5) 
 
Completed study             (n=44) 
 
Week 52 
Week 78 
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Table 5.1 Baseline characteristics of patients randomised to receive methotrexate 
and placebo or methotrexate and etanercept 
 
  MTX+PBO 
(n=55)  
MTX+ETN 
(n=55) 
Site:                                                                                                                                                                                           Leeds 
Huddersfield 
Harrogate     
York 
n=46 
n=4 
n=2 
n=3 
n=48 
n=3 
n=4 
n=0 
Age (years):                         mean 
(SD),range 
48.38 (13.34), 26-
79 
47.91 (13.58), 18-
80 
Female:                                     % (n)
72.7% (40/55) 80.0% (44/55) 
Symptom duration 
(months):  
median (IQR), 
range 
8 (6, 11), 3-18 6 (4, 9). 1-21 
DAS44-CRP:                             mean (SD) 
2.95 (0.91) 2.94 (0.92) 
DAS28-CRP: mean (SD) 
4.17 (1.10) 4.10 (1.14) 
RF-positive:                             % (n)
55.6% (30/54) 56.4% (31/55) 
Anti-CCP-positive:                        % (n)
80.8% (42/52) 72.2% (39/54) 
SE positive (1 copy):               
SE positive (2 
copies):            
% (n)
% (n) 
63.5% (33/52) 
21.2% (11/52) 
43.4% (23/53) 
35.8% (19/53) 
HAQ-DI:                                    mean (SD) 
1.00 (0.43), n=53 1.01 (0.47), n=53 
SF-36 MCS:                              mean (SD) 
42.45 (12.23), 
n=49 
46.82 (10.19), 
n=51 
SF-36 PCS:                               mean (SD) 
35.51 (7.90), 
n=49 
36.00 (8.04), 
n=51 
EQ-5D-3L:      mean (SD) 
  
median (IQR) 
0.569 (0.252), 
n=53 
0.587 (0.516, 
0.760) 
0.578 (0.245), 
n=52 
0.620 (0.516, 
0.760) 
ERO:                                                       mean (SD)
1.36 (2.95), n=49 1.10 (1.84), n=40 
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median (IQR)     
0.0 (0.0, 1.5) 0.0 (0.0, 1.5) 
JSN:                                                       mean (SD)
median (IQR) 
6.65 (6.03), n=49 
4.5 (2.3, 9.5) 
5.59 (4.28), n=40 
5.3 (1.8, 9.3) 
mTSS:      
                                                  
mean (SD)    
median (IQR)     
8.01 (8.06), n=49 
5.5 (2.8, 11.3) 
6.69 (5.04), n=40 
5.5 (2.8, 10.0) 
 
Anti-CCP, anti-cyclic citrullinated peptide antibody; DAS44CRP, disease 
activity score based on RAI and SJC44; EQ-5D-3L, Euroqol 5-dimensional 3-
level response standardised health outcome tool; ERO, rosion; ESR, 
erythrocyte sedimentation rate; ETN, etanercept; HAQ-DI, Rasch-transformed 
health assessment questionnaire disability index score; JSN, joint space 
narrowing; mTSS, van der Heijde modified total Sharp score; MTX, 
methotrexate; RAI, Ritchie Articular Index; RAQoL, Rasch-transformed 
rheumatoid arthritis quality of life score; RF, rheumatoid factor; SE, shared 
epitope 
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5.3.1 Clinical outcomes   
5.3.1.1 Primary clinical outcome: NTSJ 
The proportions of patients achieving NTSJ at week 52 were similar between the 
two groups (28.1% vs. 32.5% adjusted OR (95% CI) 1.32 (0.56, 3.09), p=0.522 in 
the methotrexate and placebo and methotrexate and etanercept groups respectively 
(table 5.2)). Findings were similar with the different sensitivity analyses -  imputing 
non-response for patients who discontinued the intervention, using complete case 
data and the per protocol data - with no significant differences between the groups 
(tables 5.3 to 5.6). 
 
5.3.1.2 Secondary clinical outcomes  
5.3.1.2.1 Remission according to the 2011 ACR/EULAR remission criteria359   
At week 52, remission using the 2011 ACR/EULAR Boolean-based definition was 
22.5% in the methotrexate and placebo and 26.7% in the methotrexate and 
etanercept groups. In both, remission was achieved in a higher proportion of 
patients when defined by SDAI≤3.3 (37.0% vs. 47.5%). No statistically significant 
between-group differences were seen for both outcomes at week 52 and 78 (table 
5.2). 
5.3.1.2.2 Drug free remission  
Of those in the methotrexate and placebo group, 9.1% (5/55) stopped placebo 
injections after achieving sustained NTSJ. In the methotrexate and etanercept 
group, 7.3% (4/55) achieved sustained NTSJ (>26 weeks) by week 52; two of whom 
stopped etanercept early. There were also two patients in the methotrexate and 
etanercept group who stopped injections prematurely - each had one tender joint 
one swollen joint. In each group, 3.6% (2/55) had NTSJ and were drug free at week 
78. 
5.3.1.2.3 Exploratory clinical outcomes: DAS28-CRP  
Earlier clinical responses were seen in patients receiving methotrexate and 
etanercept. By week 2, the proportion of patients achieving DAS28 remission and 
low disease activity was significantly higher in the group receiving combination 
therapy (DAS28-CRP <2.6: 9.2% vs. 38.5% (adjusted OR (95% CI) 8.87 (2.53, 
31.17), p=0.001 and DAS28-CRP≤3.2: 22.2% vs. 55.5% (adjusted OR (95% CI) 
6.03 (2.22, 16.36), p<0.001 in the methotrexate and placebo and methotrexate and 
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etanercept groups respectively) (figure 5.3 table 5.5). For DAS28-CRP<2.6, this 
difference was maintained at week 12 (43.8% vs. 65.1% (adjusted OR (95% CI) 
2.49 (1.12, 5.54), p=0.026) for the methotrexate and placebo and methotrexate and 
etanercept groups respectively). There was no significant difference in proportions 
achieving DAS28-CRP≤3.2 at this time-point. By week 52, the proportions of 
patients achieving DAS28-CRP<2.6 and DAS28-CRP≤3.2 in both groups were high 
(62.5% vs. 68.8% (adjusted OR (95% CI) 1.32 (0.58, 3.04), p=0.508) and 75.1% vs. 
84.5% (adjusted OR (95% CI) 1.84 (0.65, 5.24), p=0.250) in the methotrexate and 
placebo and methotrexate and etanercept groups respectively) (figure 5.3). 
Of the patients in the methotrexate and etanercept group, 57.7% maintained 
DAS28-CRP≤3.2 between week 52 to week 78 and 41.9% maintained DAS28-
CRP<2.6. For comparison, in the methotrexate and placebo group these figures 
were 64.9% and 42.9% respectively. 
 
5.3.2 Patient-reported outcomes 
5.3.2.1 Secondary outcomes: HAQ-DI and SF-36 
Improvements in patient function were seen in both groups at week 52 (ΔHAQ-DI -
0.31 vs. -0.4, p=0.381 in the methotrexate and placebo and methotrexate and 
etanercept groups respectively). These were maintained at week 78. Improvements 
in physical function in both groups were greater than that in mental function with no 
significant between group differences (Week 52 ΔSF36 PCS 6.69 vs. 8.10 and 
ΔSF36 MCS. 2.99 vs. 0.97 in the methotrexate and placebo and methotrexate and 
etanercept groups) (table 5.2). 
5.3.2.2 Exploratory outcomes: MCID HAQ-DI and normal HAQ-DI 
No between group differences were seen in the proportion of patients with a 
reduction in HAQ-DI ≥ MCID (ΔHAQ-DI ≥ 0.22 units at week 52: 58.3% vs. 59.5%, 
unadjusted OR (95% CI) 1.05 (0.47, 2.37); adjusted OR  (95% CI)1.08 (0.47, 2.49), 
p=0.854 and at week 78: 62.5% vs. 58.1%, unadjusted OR (95% CI) 0.83 (0.38, 
1.84); adjusted OR (95% CI) 0.85 (0.38, 1.88), p=0.682 in the methotrexate and 
placebo and methotrexate and etanercept groups respectively). The proportions 
achieving normal function were also similar between the two groups (HAQ-DI ≤0.5 
at week 52: 44.5% vs. 51.5%; unadjusted OR (95% CI) 1.32 (0.60, 2.91); adjusted 
OR (95% CI) 1.37 (0.58, 3.26), p=0.474 and at week 78: 48.6% vs. 46.1% 
unadjusted OR (95% CI) 0.91 (0.42, 1.97); adjusted OR (95% CI) 0.86 (0.37, 2.02), 
p=0.735 in the methotrexate and placebo and methotrexate and etanercept groups). 
The site adjustment for these comparisons pooled sites 2-4. 
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5.3.3 Imaging outcomes 
5.3.3.1 Secondary outcome: Radiographic findings 
The SDC in mTSS for this study was calculated to be 3 units. In both groups 
radiographic non-progression was high. At week 52, progression ≤SDC was 95.5% 
and 93.1% in the methotrexate and placebo and methotrexate and etanercept 
groups respectively (table 5.2). At week 78 this was 80.0% and 87.1% in each 
group (p=0.598).  
 
5.3.3.2 Secondary outcome: Ultrasound findings 
In the subset of patients with ultrasound data  at baseline (methotrexate and 
placebo n=46; methotrexate and etanercept n=48), 66.7% (30/45) in the 
methotrexate and placebo group and (62.2%) in the methotrexate and etanercept 
group had ultrasound synovitis (GS>1 and PD>0) in at least one joint. Baseline total 
ultrasound scores did not differ substantively between the groups (median (IQR) 
GS: methotrexate and placebo =12 (7, 17) vs. methotrexate and etanercept =14 (9, 
22); PD: methotrexate and placebo =3 (1, 5) vs. methotrexate and etanercept =3 (0, 
9); erosion score methotrexate and placebo =1.0 (0.0, 2.0) vs. methotrexate and 
etanercept =1.0 (0.0, 2.5) (n=44)).  
 Of these, 35.7% vs. 27.5% of patients in the methotrexate and placebo and 
methotrexate and etanercept groups respectively had ultrasound synovitis in at 
least one joint at week 52 and 38.0% vs. 41.6% at week 78. Neither the total GS 
score nor the total PD scores differed between the two groups at weeks 52 or 78. In 
both groups the number of ultrasound detected bone erosions was low with no 
significant between group differences seen at weeks 52 or 78 (table 5.2). 
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Table 5.2 Combined results from analyses of multiply imputed datasets of primary and secondary efficacy outcomes at weeks 52 and 78. 
 
Outcome MTX+PBO 
n=55 
MTX+ETN 
n=55 
Unadjusted (95% CI) Adjusted (95% CI) p 
Week 52 
NTSJ  
28.1% 32.5% OR 1.23 (0.54, 2.84) OR 1.32 (0.56, 3.09)* 0.522 
ACR 2010 remission (Boolean) 
22.5% 26.7% OR 1.26 (0.50, 3.13) OR 1.24 (0.49, 3.12)* 0.653 
ACR 2010 remission (SDAI≤3.3) 37.0% 47.5% OR 1.54 (0.69, 3.41) OR 1.57 (0.68, 3.61) 0.287 
DAS44CRP 
-1.32 -1.45 -0.13 (-0.56, 0.30) -0.11 (-0.47, 0.26) 0.554 
Pain VAS# 
-12.0 (-36.8, -0.6) -30.4 (-54.3, -1.8) -18.4 (-35.2, -1.6)† -7.9 (-20.7, 4.9)† 0.222 
Fatigue VAS# 
-16.2 (-35.1, 9.9) -21.4 (-41.8, -0.4) -5.2 (-21.6, 11.2)† -8.5 (-27.0, 10.0)† 0.363 
Physician VAS# 
-23.2 (-32.2, -13.4) -27.6 (-36.8, -16.8) -4.4 (-11.8, 3.0)† -2.4 (-6.2, 1.4)† 0.203 
EMS# 
-50.0 (-79.8, -14.8) -48.0 (-116.6, -15.7) 2.0 (-27.5, 31.5)† -6.7 (-15.3, 1.90)†  0.126 
HAQ-DI  
-0.31 -0.40 -0.10 (-0.30, 0.11) -0.09 (-0.29, 0.11) 0.381 
SF36 MCS  
2.99 0.97 -2.02 (-7.09, 3.05) 0.29 (-4.05, 4.64) 0.893 
SF36 PCS  
6.93 8.10 1.16 (-3.36, 5.68) 2.17 (-4.17, 4.60) 0.922 
EQ-5D# 
0.113 (0.000, 0.245) 0.128 (-0.024, 0.250) 0.016 (-0.11, 0.14)† 0.052 (-0.063, 0.166)†* 0.373 
1
6
7
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ERO 
0.37 0.23 -0.14 (-0.47, 0.19) -0.13 (-0.44, 0.18) 0.408 
JSN 
0.54 0.68 0.14 (-0.36, 0.64) 0.25 (-0.24, 0.74) 0.308 
mTSS 
0.91 0.90 0.00 (-0.64, 0.63) 0.12 (-0.47, 0.72) 0.676 
ERO# 
0.00 (0.00, 0.52)  0.00 (0.00, 0.47) -0.00 (-0.15, 0.15)† 0.00 (-0.15, 0.15)†* 1.000 
JSN# 
0.13 (0.00, 1.13) 0.41 (0.00, 0.96) 0.29 (-0.23, 0.80)† 0.22 (-0.22, 0.66)† 0.327 
mTSS# 
0.50 (0.00, 1.66) 0.52 (0.00, 1.16) 0.02 (-0.46, 0.51)† 0.08 (-0.52, 0.68)† 0.791 
Progression ≤0.5 54.4% 48.0% OR 0.77 (0.32, 1.87) OR 0.71 (0.29, 1.76)* 0.462 
Progression ≤SDC 95.5% 93.1% OR 0.67 (0.09, 4.84) OR 0.40 (0.04, 3.75)* 0.423 
S GS>1PD>0 
35.7%, n=46 27.5%, n=48 OR 0.68 (0.28, 1.68) OR 0.63 (0.23, 1.72) 0.372 
US total GS score# 
-1.0 (-6.4, 5.0) -3.7 (-12.8, 2.3) -2.7 (-8.1, 2.7) -1.6 (-5.6, 2.4) 0.426 
US total PD score# 
-2.0 (-4.8, 0.0) -3.0 (-8.0, 0.0) -1.0 (-3.5, 1.6) 0.0 (-0.4, 0.4) 1.000 
US total number of erosions# 
0.0 (-0.1, 1.0), n=46 1.0 (0.0, 2.1), n=48 1.0 (-0.5, -2.5) 0.96 (-0.40, 2.32) 0.164 
Week 78 
NTSJ  
28.1% 24.6% 0.84 (0.34, 2.05) 0.94 (0.37, 2.41) 0.904 
Achieved 26 weeks of 
remission 
18.3% 14.5% OR 0.76 (0.28, 2.10) OR 0.85 (0.30, 2.41)* 0.756 
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ACR 2010 remission (Boolean) 
20.5% 20.9% OR 1.03 (0.40, 2.63) OR 1.04 (0.37, 2.89) 0.947 
ACR 2010 remission (SDAI≤3.3) 38.5% 39.5% OR 1.05 (0.45, 2.41) OR 1.08 (0.45, 2.59) 0.867 
DAS44CRP 
-1.33 -1.29 0.04 (-0.46, 0.54) 0.05 (-0.34, 0.44)  0.794 
Pain VAS# 
-19.6 (-40.7, -4.6) -21.9 (-45.6, -1.6) -2.3 (-19.6, 15.0) 9.1 (-4.8, 23.1)† 0.195 
Fatigue VAS# 
-17.7 (-37.1, 8.4) -19.0 (-46.3, 1.2) -1.4 (-17.9, 15.2) -3.6 (-23.9, 16.8)† 0.725 
Physician VAS# 
-23.9 (-31.4, -10.5) -23.1 (-37.4, -11.3) 0.8 (-8.2, 9.7) 0.5 (-5.3, 6.3)† 0.871 
EMS# 
-42.8 (-85.4, -0.3) -29.9 (-86.2, -1.2) 12.9 (-13.2, 39.0)† 1.8 (-14.8, 18.4)† 0.826 
HAQ-DI 
-0.37 -0.34 0.02 (-0.20, 0.24) 0.04 (-0.17, 0.26) 0.688 
SF36 MCS  
2.94 2.48 -0.46 (-5.48, 4.57) 1.42 (-3.10, 5.95) 0.533 
SF36 PCS  
7.06 6.50 -0.56 (-4.35, 3.24) -0.98 (-4.77, 2.80) 0.607 
EQ-5D# 
0.151 (-0.004, 0.276) 0.102 (-0.002, 0.236) -0.049 (-0.156, 0.057)† -0.029 (-0.130, 0.073)†* 0.576 
ERO 
0.60 0.50 -0.11 (-0.55, 0.34) -0.10 (-0.54, 0.34) 0.653 
JSN 
0.99 0.87 -0.11 (-0.61, 0.39) -0.03 (-0.52, 0.46) 0.901 
mTSS 
1.59 1.37 -0.22 (-0.90, 0.46) -0.10 (-0.74, 0.54) 0.761 
ERO# 
0.11 (0.00, 0.71) 0.02 (0.00, 0.81) -0.09 (-0.55, 0.36)† 0.00 (-0.22, 0.22)†* 1.000 
JSN# 
0.52 (0.04, 1.44) 0.62 (0.04, 1.21) 0.11 (-0.46, 0.68)† -0.12 (-0.62, 0.38)† 0.644 
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mTSS# 
0.97 (0.45, 2.27) 1.09 (0.36, 1.97) 0.13 (-0.55, 0.81)† 0.15 (-0.48, 0.77)† 0.642 
Progression ≤0.5 35.9% 35.8% OR 0.99 (0.36, 2.74) OR 0.99 (0.27, 3.00)* 0.982 
Progression ≤SDC 80.0% 87.1% OR 1.69 (0.53, 5.37) OR 1.39 (0.41, 4.76)* 0.598 
US GS>1PD>0 
38.0%, n=46 41.6%, n=48 OR 1.16 (0.49, 2.75) ** 0.740 
US total GS score# 
1.9 (-6.0, 7.8) -0.1 (-5.6, 3.6) -2.0 (-7.2, 3.2) -1.6 (-6.2, 2.9) 0.472 
US total PD score# 
-2.0 (-3.9, 0.0) -1.5 (-7.7, 0.1)  0.5 (-1.9, 3.0) 0.6 (-1.0, 2.2) 0.434 
US total number of erosions# 
0.1 (0.0, 2.1), n=46 1.1 (0.0, 3.0), n=48 1.1 (-0.4, 2.5) 0.53 (-0.72, 1.78) 0.399 
 
Mean (SD) or median (IQR) changes from baseline and between-group differences (95% CI) are presented for continuous variables; 
proportions and odds ratios (95% CI) are presented for nominal variables; results were adjusted for baseline values and study site unless 
otherwise indicated. 
ACR, American College of Rheumatology; DAS44CRP, disease activity score based on RAI and SJC44; EQ-5D-3L, Euroqol 5-
dimensional 3-level response standardised health outcome tool; EMS, early morning stiffness; ERO, erosion score; ESR, erythrocyte 
sedimentation rate; ETN, etanercept; GS, grey scale; HAQ-DI, Rasch-transformed health assessment questionnaire disability index 
score; JSN,  joint space narrowing score; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; NTSJ, no tender or 
swollen joints; PBO, placebo; PD, power Doppler; RAI, Ritchie Articular Index; RAQoL, Rasch-transformed rheumatoid arthritis quality of 
life score; RF, rheumatoid factor; SE, shared epitope; US, ultrasound; VAS, visual analogue scale  
#Results of quantile regression; median (1st quartile, 3rd quartile) are presented for each group.  
*Site adjustment pooled sites 2-4 to avoid model separation due to sparse data; **Unadjusted results presented as ultrasound data only 
available at a single site, and adjusting for baseline values caused analysis model to fail.  
†Difference between medians
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Table 5.3 Sensitivity analyses of primary efficacy outcome at week 52.  
 
Outcome Analysis MTX+PBO MTX+ETN Unadjusted (95% CI) Adjusted (95% CI) p 
Week 52 
NTSJ remission NRI*  27.3% (15/55) 27.3% (15/55) 1.00 (0.43, 2.31) 1.06 (0.45, 2.49) 0.898 
 NRI, no additional meds** 34.5% (10/29) 41.2% (14/34) 1.33 (0.48, 3.71) 1.33 (0.45, 3.86) 0.598 
 Complete case 29.4% (15/51) 35.4% (17/48) 1.32 (0.57, 3.06) 0.90 (0.35, 2.31) 0.822 
 Per protocol 35.9% (14/39) 28.6% (10/35) 0.62 (0.23, 1.69) 0.70 (0.24, 1.98) 0.497 
 
Results were adjusted for baseline values and study site unless otherwise stated.  
ETN, etanercept; meds, medications; MTX, methotrexate; NTSJ, no tender or swollen joints; PBO, placebo 
*Non-response imputed for patients who withdrew from study treatment or were lost to follow-up before week 52 
**Patients were excluded if they had received oral Prednisolone, IA or IM steroid, or DMARDs other than MTX and/or ETN
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Table 5.4 Analyses of secondary efficacy outcomes at weeks 52 and 78 (observed data only). 
 
Outcome MTX+PBO MTX+ETN Unadjusted (95% CI) Adjusted (95% CI) p 
Week 52 
ACR 2010 remission (Boolean) 
23.5% (12/51) 28.3% (13/46) OR 1.28 (0.51, 3.18) OR 1.32 (0.53, 3.33)* 0.551 
ACR 2010 remission (SDAI≤3.3) 38.0% (19/50) 48.9% (22/45) OR 1.56 (0.69, 3.53) OR 1.88 (0.78, 4.50) 0.158 
DAS44CRP 
-1.34 (1.19), n=50 -1.40 (1.03), n=46 -0.07 (-0.52, 0.39)† -0.12 (-0.50, 0.26) 0.533 
Pain VAS# -12.0 (-37.0, -2.0), 
n=51 
-31.0 (-58.0, -5.0), 
n=45 
-19.0 (-37.0, -1.0)† -8.9 (-20.5, 2.8)† 0.133 
Fatigue VAS# -16.0 (-36.0, 11.0), 
n=51 
-25.0 (-41.0, -4.0), 
n=45 
-9.0 (-25.5, 7.5)† -10.3 (-27.9, 7.4)† 0.251 
Physician VAS# -23.0 (-32.0, -13.0), 
n=50 
-28.0 (-35.0, -17.0), 
n=45 
-5.0 (-12.9, 2.9) -3.2 (-7.0, 0.7)†  0.103 
EMS# -50 (-70, -25), n=49 -55 (-120, -20), n=47 5.0 (-16.0, 26.0)† -6.7 (-14.5, -1.2)† 0.095 
HAQ-DI  
-0.29 (0.57), n=49 -0.44 (0.47), n=46 -0.14 (-0.36, 0.07) -0.14 (-0.35, 0.08) 0.202 
SF36 MCS  
4.24 (14.51), n=45 1.65 (8.20), n=41 -2.59 (-7.72, 2.53) 0.83 (-3.59, 5.25) 0.709 
SF36 PCS  
6.92 (9.74), n=45 9.85 (10.66), n=41 2.94 (-1.44, 7.31) 2.15 (-2.12, 6.41) 0.319 
EQ-5D# 0.123 (0.000, 0.244), 
n=49 
0.159 (0.000, 0.240), 
n=42 
0.036 (-0.09, 0.16)† 0.069 (-0.047, 0.185)†* 0.239 
ERO 
0.41 (0.88), n=40 0.22 (0.64), n=30 -0.18 (-0.56, 0.19) -0.19 (-0.58, 0.20) 0.335 
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JSN 
0.56 (1.08), n=40 0.62 (1.28), n=30 0.06 (-0.50, 0.62) 0.19 (-0.34, 0.72) 0.472 
mTSS 
0.97 (1.38), n=40 0.84 (1.47), n=30 -0.12 (-0.81, 0.56) 0.01 (-0.63, 0.65) 0.975 
ERO# 0.00 (0.00, 0.50), n=40  0.00 (0.00, 0.48), n=30 0.00 (-0.21, 0.21)† 0.00 (-0.23, 0.23)† 1.000 
JSN# 0.32 (0.00, 1.03), n=40 0.40 (0.00, 0.93), n=30 0.08 (-0.33, 0.50)† 0.11 (-0.34, 0.56)† 0.628 
mTSS# 0.49 (0.00, 1.79), n=40 0.50 (0.00, 1.02), n=30 0.01 (-0.50, 0.52)† 0.00 (-0.58, 0.57)† 0.996 
Progression ≤0.5 55.0% (22/40) 46.7% (14/30) OR 0.72 (0.28, 1.85) OR 0.70 (0.26, 1.82)* 0.459 
Progression ≤SDC 95.0% (38/40) 93.3% (28/30) OR 0.74 (0.10, 5.55) OR 0.53 (0.06, 4.86)* 0.572 
US GS>1PD>0 
34.9% (15/43) 28.6% (12/42) OR 0.75 (0.30, 1.87) OR 0.70 (0.25, 1.94) 0.495 
US total GS score# -1.0 (-7.0, 5), n=43 -4.0 (-13.0, 3.0), n=42 -3.0 (-9.2, 3.2) -1.6 (-5.6, 2.5) 0.444 
US total PD score# -2.0 (-4.0, 0.0), n=43 -2.9 (-7.0, 0.0), n=42 -1.0 (-3.5, 1.7) 0.0 (-0.44, 0.44) 1.000 
US total erosions# 0.0 (0.0, 1.0), n=43 1.0 (0.0, 2.0), n=39 1.0 (-0.7, 2.7) 1.0 (-0.7, 2.7) 0.234 
Week 78 
NTSJ remission 
30.0% (15/50) 25.0% (12/48) OR 0.78 (0.32, 1.89) OR 0.90 (0.35, 2.32) 0.822 
Achieved 26 weeks of 
remission 
19.6% (10/51) 16.0% (8/50) OR 0.78 (0.28, 2.18) OR 0.86 (0.30, 2.47)* 0.777 
ACR 2010 remission (Boolean) 
22.0% (11/50) 22.9% (11/48) OR 1.05 (0.41, 2.72) OR 1.12 (0.42, 2.97) 0.826 
ACR 2010 remission (SDAI≤3.3) 39.1% (18/46) 41.9% (18/43) OR 1.12 (0.48, 2.61) OR 1.21 (0.50, 2.92) 0.667 
DAS44CRP 
-1.33 (1.09), n=48 -1.33 (1.31), n=45 0.00 (-0.49, 0.49) 0.08 (-0.30, 0.46) 0.676 
Pain VAS# -22 (-41.0, -6.0), n=49 -23.0 (-50.0, - -1.0 (-9.4, 17.4)† 11.8 (-0.9, 24.4)† 0.068 
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3.0),n=47 
Fatigue VAS# -18.0 (-37.0, 4.0), 
n=50 
-21.0 (-47.0, -
3.0),n=47 
-3.0 (-19.3, 13.3)† -7.7 (-22.5, 7.2)† 0.308 
Physician VAS# -24.0 (-32.0, -13.0), 
n=47 
-25.0 (-38.0, -16.0), 
n=44 
-1.0 (-9.2, 7.2)† 0.8 (-4.1, 5.7)† 0.754 
EMS# -45 (-80, -13), n=48 -30 (-110, -5), n=47 15.0 (-11.1, 41.1)† -0.2 (-12.7, 12.3)† 0.972 
HAQ-DI 
-0.39 (0.65), n=48 -0.37 (0.45), n=47 0.02 (-0.21, 0.25) 0.04 (-0.19, 0.27) 0.712 
SF36 MCS  
4.01 (13.88), n=45 3.04 (9.65), n=44 -0.97 (-6.02, 4.08) 1.45 (-3.05, 5.94) 0.524 
SF36 PCS  
6.80 (9.40), n=45 8.04 (7.76), n=44 1.24 (-2.39, 4.88) 0.71 (-2.87, 4.30) 0.694 
EQ-5D# 0.157 (0.000, 0.280), 
n=47 
0.102 (0.000, 0.240), 
n=47 
-0.055 (-0.169, 0.059)† -0.026 (-0.108, 
0.057)†* 
0.543 
ERO 
0.64 (1.22), n=39 0.47 (0.95), n=32 -0.17 (-0.70, 0.36) -0.29 (-0.81, 0.22) 0.254 
JSN 
0.94 (1.12), n=39 0.92 (1.42), n=32 -0.02 (-0.62, 0.59) -0.04 (-0.62, 0.54) 0.890 
mTSS 
1.58 (1.86), n=39 1.39 (1.58), n=32 -0.19 (-1.02, 0.64) -0.32 (-1.06, 0.42) 0.387 
ERO# 0.00 (0.00, 0.50), n=39 0.00 (0.00, 0.49), n=32 0.00 (-0.24, 0.24)† 0.00 (-0.26, 0.26)† 1.000 
JSN# 0.49 (0.00, 1.42), n=39 0.50 (0.00, 1.02), n=32 0.00 (-0.49, 0.50)† -0.16 (-0.66, 0.34)† 0.535 
mTSS# 0.95 (0.42, 2.03), n=39 1.02 (0.47, 1.80), n=32 0.07 (-0.71, 0.85)† 0.08 (-0.51, 0.67)† 0.792 
Progression ≤0.5 38.5% (15/39) 34.4% (11/32) OR 0.84 (0.32, 2.22) OR 0.90 (0.31, 2.60)* 0.842 
Progression ≤SDC 79.5% (31/39) 87.5% (28/32) OR 1.81 (0.49, 6.66) OR 1.74 (0.45, 6.77)* 0.423 
US GS>1PD>0 
38.1% (16/42) 41.5% (17/41) OR 1.15 (0.48, 2.77) OR 1.03 (0.42, 2.56) 0.944 
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US total GS score# 2.0 (-6.0, 8.0) 0.0 (-5.0, 4.0) -2.0 (-7.5, 3.5) -1.4 (-5.8, 3.0) 0.540 
US total PD score# -2.0 (-3.0, 0.0) -1.0 (-8.0, 0.0) 1.0 (-1.3, 3.3) 1.0 (-1.1, 3.1) 0.338 
US total erosions# 0.0 (0.0, 2.0), n=42 1.0 (0.0, 3.0), n=38 1.0 (-0.2, 2.2) 0.3 (-0.9, 1.4) 0.678 
 
Mean (SD) or median (IQR)  changes from baseline and between-group differences (95% CI) are presented for continuous variables; 
proportions (n) and odds ratios (95% CI) are presented for nominal variables; results were adjusted for baseline values and study site 
unless otherwise stated.  
ACR, American College of Rheumatology; DAS44CRP, disease activity score based on RAI and SJC44; ERO, Euroqol 5-dimensional 3-
level response standardised health outcome tool; EMS, early morning stiffness; ERO, erosion; ESR, erythrocyte sedimentation rate; ETN, 
etanercept; GS, grey scale; HAQ-DI, Rasch-transformed health assessment questionnaire disability index score; JSN, joint space 
narrowing; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; NTSJ, no tender or swollen joints; PBO, placebo; PD, 
power Doppler; RAI, Ritchie Articular Index; RAQoL, Rasch-transformed rheumatoid arthritis quality of life score; RF, rheumatoid factor; 
SE, shared epitope; SF36 MCS,  short-form 36 mental component score,  SF36 MCS,  short-form 36 physical component score US, 
ultrasound; VAS, visual analogue scale. 
#Results of quantile regression; median (1st quartile, 3rd quartile) are presented for each group; * Site adjustment pooled sites 2-4 to avoid 
model separation due to sparse data; †Difference between medians.
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Table 5.5 Combined results from analyses of multiply imputed datasets of exploratory efficacy variables at weeks 2, 12, 26, 52 and 78.  
 
Outcome MTX+PBO 
n=55 
MTX+ETN 
n=55 
Unadjusted OR (95% CI) Adjusted OR (95% CI) p 
Week 2 
DAS44CRP<1.6   
5.5% 27.7% 6.55 (1.77, 24.26) 8.79 (2.02, 38.29)* 0.004 
DAS44CRP≤2.4 32.1% 55.8% 2.67 (1.22, 5.86) 3.20 (1.30, 7.88) 0.012 
DAS28CRP<2.6  
9.2%   38.5% 6.21 (2.13, 18.12) 8.87 (2.53, 31.17)* 0.001 
DAS28CRP≤3.2 22.2% 55.5% 4.37 (1.90, 10.07) 6.03 (2.22, 16.36)* <0.001 
Week 12 
DAS44CRP<1.6  
38.5% 43.0% 1.21 (0.56, 2.63) 1.30 (0.57, 3.00) 0.534 
DAS44CRP≤2.4 65.2% 77.9% 1.88 (0.81, 4.41) 1.84 (0.77, 4.40) 0.173 
DAS28CRP<2.6  
43.8% 65.1% 2.39 (1.10, 5.21) 2.49 (1.12, 5.54) 0.026 
DAS28CRP≤3.2 65.1% 78.0% 1.90 (0.82, 4.44) 1.89 (0.76, 4.70) 0.172 
Week 26 
DAS44CRP<1.6  
36.8% 56.5% 2.23 (1.01, 4.90) 2.297 (1.03, 5.13) 0.043 
DAS44CRP≤2.4 67.8% 84.2% 2.53 (0.99, 6.49) 2.78 (1.02, 7.56)* 0.046 
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DAS28CRP<2.6  
49.3% 67.5% 2.14 (0.98, 4.71) 2.12 (0.94, 4.75) 0.069 
DAS28CRP≤3.2 62.7% 81.5% 2.62 (1.06, 6.47) 2.51 (0.98, 6.43) 0.055 
Week 52 
     
DAS44CRP<1.6  
53.0% 57.1% 1.18(0.54, 2.58) 1.13 (0.49, 2.62) 0.770 
DAS44CRP≤2.4 77.8% 83.7% 1.47 (0.55, 3.94) 1.50 (0.53, 4.25)* 0.448 
DAS28CRP<2.6  
62.5% 68.8% 1.39 (0.60, 3.24) 1.32 (0.58, 3.04) 0.508 
DAS28CRP≤3.2 75.1% 84.5% 1.82 (0.67, 4.91) 1.84 (0.65, 5.24)* 0.250 
Week 78 
DAS44CRP<1.6   
60.5% 51.6% 0.70 (0.30, 1.62) 0.65 (0.27, 1.54) 0.329 
DAS44CRP≤2.4 80.1% 82.5% 1.18 (0.41, 3.37) 1.18 (0.41, 3.43)* 0.755 
DAS28CRP<2.6  
61.4% 58.3% 0.88 (0.39, 1.98) 0.88 (0.39, 2.00)* 0.761 
DAS28CRP≤3.2 81.3% 76.0% 0.73 (0.26, 2.03) 0.71 (0.25, 2.01)* 0.522 
 
ETN, etanercept; MTX, methotrexate; PBO, placebo. 
Results were adjusted for baseline values and study site unless otherwise stated. 
*Site adjustment pooled sites 2-4 to avoid model separation due to sparse data
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Table 5.6 Analyses of exploratory efficacy variables at weeks 2, 12, 26, 52 and 78 (observed data only).  
 
Outcome MTX+PBO MTX+ETN Unadjusted OR (95% CI) Adjusted OR (95% CI) p 
Week 2 
DAS44CRP<1.6 
5.5%   (3/54) 27.8% (15/54) 6.54 (1.77, 24.18) 8.83 (2.03, 38.34)* 0.004 
DAS44CRP≤2.4 31.5% (17/54) 55.6% (30/54) 2.72 (1.24, 5.97) 3.29 (1.33, 8.14) 0.010 
DAS28CRP<2.6 
9.3%   (5/54) 38.9% (21/54) 6.24 (2.14, 18.19) 9.21 (2.61, 32.47)* 0.001 
DAS28CRP≤3.2 22.2% (12/54) 55.6% (30/54) 4.38 (1.90, 10.10) 6.24 (2.29, 17.02)* <0.001 
Week 12 
DAS44CRP<1.6 
36.5% (19/52) 42.6% (23/54) 1.29 (0.59, 2.81) 1.40 (0.60, 3.23) 0.433 
DAS44CRP≤2.4 63.5% (33/52) 77.8% (42/54) 2.02 (0.86, 4.74) 1.96 (0.81, 4.72) 0.133 
DAS28CRP<2.6 
42.3% (22/52) 64.8% (35/54) 2.51 (1.15, 5.50) 2.63 (1.18, 5.91) 0.018 
DAS28CRP≤3.2 63.5% (33/52) 77.8% (42/54) 2.02 (0.86, 4.74) 2.02 (0.80, 5.07) 0.135 
Week 26 
DAS44CRP<1.6 
36.5% (19/52) 56.9% (29/51) 2.29 (1.04, 5.05) 2.36 (1.05, 5.31) 0.038 
DAS44CRP≤2.4 67.3% (35/52) 84.3% (43/51) 2.61 (1.01, 6.76) 2.90 (1.05, 7.97)* 0.040 
DAS28CRP<2.6 
48.1% (25/52) 68.6% (35/51) 2.36 (1.06, 5.28) 2.31 (1.02, 5.25) 0.046 
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DAS28CRP≤3.2 61.5% (32/52) 82.4% (42/51) 2.92 (1.17, 7.26) 2.81 (1.09, 7.21) 0.032 
Week 52 
DAS44CRP<1.6 
54.0% (27/50) 58.7% (27/46) 1.21 (0.54, 2.72) 1.14 (0.48, 2.69) 0.766 
DAS44CRP≤2.4 78.0% (39/50) 84.8% (39/46) 1.57 (0.55, 4.47) 1.56 (0.52, 4.71)* 0.428 
DAS28CRP<2.6 
64.0% (32/50) 71.7% (33/46) 1.43 (0.60, 3.39) 1.36 (0.55, 3.38) 0.502 
DAS28CRP≤3.2 76.0% (38/50) 87.0% (40/46) 2.11 (0.72, 6.17) 2.17 (0.70, 6.79)* 0.180 
Week 78 
DAS44CRP<1.6 
62.5% (30/48) 51.1% (23/45) 0.63 (0.27, 1.43) 0.60 (0.26, 1.41) 0.242 
DAS44CRP≤2.4 81.3% (39/48) 82.2% (37/45) 1.07 (0.37, 3.06) 1.12 (0.38, 3.26)* 0.841 
DAS28CRP<2.6 
62.5% (30/48) 57.8% (26/45) 0.82 (0.36, 1.89) 0.85 (0.36, 1.97)* 0.699 
DAS28CRP≤3.2 81.3% (39/48) 75.6% (34/45) 0.71 (0.26, 1.93) 0.72 (0.26, 1.99)* 0.532 
 
ETN, etanercept; MTX, methotrexate; PBO, placebo.  
Results were adjusted for baseline values and study site unless otherwise stated. 
* Site adjustment pooled sites 2-4 to avoid model separation due to sparse data 
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Figure 5.3 Proportions of patients in (a) LDAS28-CRP and (b) DAS28-CRP 
remission and (c) LDAS44-CRP and (d) DAS44-CRP remission 
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Legend: 
Methotrexate + Placebo (n=55)    
Methotrexate+ Etanercept (n=55)    
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5.3.4 Changes in medication  
Changes in DMARD therapy and additional glucocorticoid requirements were also 
analysed. In total  32.7% (18/55) and 30.9% (17/55) of patients in the methotrexate 
and placebo and methotrexate and etanercept groups respectively required a 
change in DMARD during the study period.  Between baseline and week 52, 
changes were made in 18% (10/55) and 5% (3/55) of patients in the methotrexate 
and placebo and methotrexate and etanercept groups; and between weeks 52 and 
78 in 16% (9/55) and 25% (14/55) of patients. The number of additional csDMARDs 
used was similar between the groups. Biological DMARDs were added in three 
patients in the methotrexate and placebo group. (tables 5.7 to 5.9)  
In each group approximately 50% of patients received at least one steroid injection 
during the trial period. The cumulative doses were similar in both groups (figure 
5.4).                
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Table 5.7 Total additional synthetic or biological DMARD therapy from baseline to 
week 78 
 
DMARD (% (n)) MTX + PBO 
(n=55) 
MTX + ETN 
(n=55) 
Methotrexate (subcutaneous) 9.1% (5) 10.9% (6) 
Sulphasalazine  20.0% (11) 21.8% (12) 
Hydroxychloroquine  10.9% (6) 10.9% (6) 
Leflunomide  1.8% (1) 0 
Etanercept  3.6% (2) 0 
Adalimumab  1.8% (1) 0 
Total number of patients requiring 
change in DMARDs 
32.7% (18) 30.9% (17) 
DMARD, disease-modifying antirheumatic drug; ETN, etanercept; MTX, 
methotrexate; PBO, placebo. 
 
 
Table 5.8 Additional synthetic or biological DMARD therapy from baseline to week 
52 
 
DMARD  (% (n)) MTX + PBO 
(n=55) 
MTX + ETN 
(n=55) 
Methotrexate (subcutaneous) 9.1% (5) 1.8% (1) 
Sulphasalazine initiated 3.6% (2) 1.8% (1) 
Sulphasalazine + hydroxychloroquine 7.3% (4) 1.8% (1) 
Adalimumab initiated 1.8% (1) 0 
Total number of patients requiring 
change in DMARDs 
18% (10) 5% (3) 
DMARD, disease-modifying antirheumatic drug; ETN, etanercept; MTX, 
methotrexate; PBO, placebo. 
In one patient in the MTX and ETN arm, injections were stopped prematurely. 
The patient had a subsequently flare of inflammatory arthritis which was 
treated with sulphasalazine and the patient was withdrawn from the study.  
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Table 5.9 Additional synthetic or biological DMARD therapy from week 52 to week 
78 
 
DMARD (% (n)) MTX + PBO 
(n=55) 
MTX + ETN 
(n=55) 
Methotrexate (subcutaneous) 0 9.1% (5) 
Sulphasalazine initiated 9.1% (5) 10.9% (6) 
Hydroxychloroquine initiated 3.6% (2) 1.8% (1) 
Sulphasalazine + hydroxychloroquine 0 7.3% (4) 
Leflunomide initiated 1.8% (1) 0 
Etanercept initiated 3.6% (2) 0 
Total number of patients requiring 
change in DMARDs 
16% (9) 25% (14) 
  
DMARD, disease-modifying antirheumatic drug; ETN, etanercept; MTX, 
methotrexate; PBO, placebo 
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Figure 5.4 Steroid use during the study period 
ETN, etanercept; IA, intra-articular; IM, intramuscular; MTX, methotrexate; 
PBO, placebo 
Nine patients in the methotrexate and PBO group received a steroid injection 
(intra-articular or IM) between the week 38 and week 52 visits compared to 7 
in the methotrexate and ETN group. Six in the methotrexate and PBO group 
required IA injection during this period compared to 5 in the methotrexate and 
ETN group.      
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5.3.5 Predictors of outcome 
In a post hoc analysis of baseline predictors of outcome, earlier reduction in DAS28-
CRP was seen in the anti-CCP positive compared to anti-CCP negative patients. 
Improvement in disease activity scores were higher in anti-CCP positive patients at 
week 2, controlling for treatment, study site and baseline DAS28-CRP (adjusted 
difference (95% CI) at week 2: -0.86 (-1.23, -0.49), p<0.001 and week 26: -0.92 (-
1.46, -0.38), p=0.001). This difference was no longer seen at week 12 (-0.36 (-0.89, 
0.17), p=0.179) or week 52 (-0.40 (-0.97, 0.17), p=0.163). These trends did not 
differ significantly between the two treatment groups (interactions all p>0.2).  
The trend was reversed to an extent in the methotrexate and placebo group at week 
78 (adjusted difference 0.48) compared to the methotrexate and etanercept group 
(adjusted difference -0.97: interaction -1.45 (-2.53, -0.37), p=0.009). It should be 
noted however that in each of the groups there were few anti-CCP negative 
patients; only those whose anti-CCP status was known at baseline were included in 
these comparisons (methotrexate and placebo: anti-CCP negative n=10, anti-CCP 
positive n=42; methotrexate and etanercept: anti-CCP negative n=15, anti-CCP 
positive n=39). The numbers in each group were too small to determine a difference  
in NTSJ.  
In patients fulfilling the 1987 ACR RA classification criteria, 66% vs. 68% of the 
methotrexate and placebo and methotrexate and etanercept groups respectively 
had a DAS28-CRP<2.6 at week 52. The proportions of those not fulfilling the criteria 
who achieved DAS28-CRP <2.6 was similar in both groups (69% and 60%). 
The 2010 ACR/EULAR RA classification criteria were fulfilled in the majority of 
patients. In both, all patients who did not fulfil the ACR/EULAR 2010 criteria 
(methotrexate and placebo: 4/4 and methotrexate and etanercept: 3/3) achieved a 
DAS28-CRP<2.6 at week 52. Of those who fulfilled the 2010 ACR/EULAR 
classification criteria, proportions achieving remission was similar in both groups 
(67% and 60%). 
The association between DAS28-CRP<2.6 at 12 weeks and outcome at 78 weeks 
was also analysed. Controlling for study site and treatment, patients with DAS28-
CRP<2.6 at week 12  were more likely to have a DAS28-CRP<2.6 at week 78 (OR 
(95% CI) 3.53 (1.46, 8.53), p=0.005). There was no substantive difference in 
radiographic progression (adjusted difference in median ΔmTSS (95% CI) -0.06 (-
0.58, 0.47), p=0.825) according to DAS28-CRP<2.6. Those with DAS28-CRP<2.6 
at 12 weeks had significantly lower HAQ-DI values (mean difference -0.53 (-0.72, -
0.34), p<0.001).  
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5.3.6 Adverse events  
The number of adverse events was comparable between the groups (events per 
100 patient years methotrexate and placebo=417.3; methotrexate and 
etanercept=451.6). Although there was a greater number of SAEs in the 
methotrexate and etanercept group (16.4 per 100 patient years compared to 3.7 in 
the methotrexate and placebo group), the majority were related to medical or 
surgical procedures. Only two were considered to be possibly related to study 
medication and of these only one was thought to be possibly related to etanercept. 
This was in a patient who had persistently elevated inflammatory markers and 
ongoing weight loss despite good control of her inflammatory arthritis. Following 
further investigations she was diagnosed with metastatic breast cancer four months 
after baseline and study medication was discontinued. There was also one 
malignancy described in the methotrexate and placebo group – a case of non-
Hodgkin’s lymphoma (NHL). This patient completed the trial and no specific 
treatment was required for the NHL during the study period. (table 5.10)  
In total 195 infectious episodes were recorded: 105 in 37 patients in the 
methotrexate and placebo group and 90 in 43 patients in the methotrexate and 
etanercept group. Most were due to upper respiratory tract or pulmonary infections 
(71.4% (75/105) vs. 77.8% (70/90) in the methotrexate and placebo and 
methotrexate and etanercept groups respectively). Two infections were reported as 
severe. Both of these were pulmonary infections and both in the methotrexate and 
etanercept group. All other infections were reported as mild or moderate in severity 
(table 5.11). 
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Table 5.10 Adverse events experienced by participants during follow-up 
 
 MTX+PBO 
n=55 
MTX+ETN 
n=55 
Number of patients who experienced an 
AE 
55 (100.0%) 53 (96.4%) 
Maximum severity of AE experienced   
Mild 231/338 (68.3%) 236/358 (65.9%) 
Moderate 104/338 (30.8%) 107/358 (29.9%) 
Severe (including SAEs) 3/338 (0.9%) 15/358 (4.2%) 
Total number of AEs 338 358 
Total patient-years of follow-up 80.99 79.27 
Number of AEs per 100 patient-years 417.3 451.6 
Patient expectation of event   
Expected (listed in PIS) 256/338 (75.7%) 263/358 (73.5%) 
Severity*   
Mild 231/338 (68.3%) 236/358 (65.9%) 
Moderate 104/338 (30.8%) 107/358 (29.9%) 
Severe (including SAEs) 3/338 (0.9%) 15/358 (4.2%) 
Number of patients who experienced an 
SAE 
3/55 (5.5%) 9/55 (16.4%) 
Total number of SAEs 3 13 
SAEs by category - relation to study 
drug: 
    
Dermatology/skin   1 - probably not 
Gastrointestinal  1 - probably not 
Infection - pulmonary/upper respiratory  2 - 1 probably 
not, 1 possibly 
Malignancy - haematological 1 - probably not  
Malignancy - metastatic  1 - possibly 
Musculoskeletal/soft tissue  1 – not related 
Neurology 1 – probably not   
Pain - cardiovascular   1 – probably not 
Pain - musculoskeletal   1 – not related 
Surgical and medical procedures 1 – not related 5 – not related 
 
AE, adverse event; PIS, patient information sheet; SAE, serious adverse event
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Table 5.11 Adverse events - infections 
 
Placebo Mild Moderate Severe Total 
Auditory/ Ear 5 2 0 7 
Dermatology/ Skin 0 2 0 2 
Gastrointestinal 6 4 0 10 
General 1 0 0 1 
Lymphatic 0 2 0 2 
Ocular 1 0 0 1 
Pulmonary/ Upper respiratory 57 18 0 75 
Renal / Genitourinary 5 2 0 7 
Total 75 30 0 105 
Etanercept Mild Moderate Severe Total 
Auditory/ Ear 1 1 0 2 
Dermatology/ Skin 3 0 0 3 
Gastrointestinal 1 2 0 3 
General 0 3 0 3 
Lymphatic 1 0 0 1 
Ocular 1 0 0 1 
Pulmonary/ Upper respiratory 48 20 2 70 
Renal / Genitourinary 5 2 0 7 
Total 60 28 2 90 
Combined treatment groups Mild Moderate Severe Total 
Auditory/ Ear 6 3 0 9 
Dermatology/ Skin 3 2 0 5 
Gastrointestinal 7 6 0 13 
General 1 0 0 1 
Lymphatic 0 5 0 5 
Ocular 1 0 0 1 
Pulmonary/ Upper respiratory 2 0 0 2 
Renal / Genitourinary 105 38 2 145 
Auditory/ Ear 10 4 0 14 
Total 135 58 2 195 
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5.4 Discussion 
The EMPIRE study was the first double-blind, placebo-controlled RCT that 
compared methotrexate monotherapy with methotrexate and etanercept 
combination in early IA.  Whilst the study was designed prior to the development of 
the 2010 ACR/EULAR RA classification criteria, 12 the principles of the trial 
embodied those of the 2010 classification criteria – aiming to identify and treat 
patients with RA in the earliest phases of the disease continuum. Of all the trial 
participants only 41% fulfilled the 1987 criteria whilst the majority of patients (94%) 
fulfilled the 2010 ACR EULAR classification criteria.  
The primary outcome, NTSJ at week 52, was similar between the two groups 
(approximately 30%). Whilst the DAS responses were as expected, the proportion 
of patients achieving NTSJ was lower than initially predicted in the etanercept group 
(60%). The primary endpoint was chosen as it was thought that complete 
normalisation of disease could be achieved in this early population. It is possible 
that NTSJ may have been too strict an outcome and that no swollen joints alone 
may have been a more realistic target. On ultrasound, synovitis at week 52 (GS>1 
and PD>0) was only seen in about 30% of patients.   
The use of methotrexate and etanercept as combination therapy has been used in 
several studies of patients with RA according to the 1987 ACR criteria.180 333 372 In 
the COMET study, 180  the proportion of patients achieving remission (study primary 
endpoint) was significantly higher using the combination therapy compared to 
methotrexate monotherapy (one year DAS28-ESR remission: 50% vs. 28% (effect 
difference (95% CI) 22,05% (13.96-30.15%, p<0.0001). Remission was higher with 
shorter disease duration (≤ 4 months), with between-group differences remaining  
significant (69.8% vs. 34.7% (p<0.05)).35 In the PRIZE study of early DMARD naïve 
RA (mean disease duration six months),339 methotrexate and etanercept was used 
as induction therapy - DAS28-ESR remission was achieved in 70.5% of patients. In 
the EMPIRE study, proportions with DAS28-CRP<2.6 and DAS28-CRP ≤3.2 were 
high in both groups. At one year, DAS28-CRP<2.6 was 68.8% and 62.5% with 
methotrexate and etanercept and methotrexate monotherapy respectively. It is 
likely that the high responses seen were partly due to the fact that the results were 
based on DAS28-CRP rather than DAS28-ESR, which is known to yield slightly 
lower values.373 374 Other possible explanations for the relatively high clinical 
responses in this study, particularly in those receiving methotrexate monotherapy, 
may be that these patients had relatively early disease with a low disease burden 
(although the majority fulfilled the 2010 ACR/ EULAR RA classification criteria, most 
did not fulfil the 1987 ACR criteria). Results from the PROMPT study showed that in 
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anti-CCP positive patients, methotrexate delayed progression to RA.213  It is 
possible that these were methotrexate responsive patients given that a high 
proportion were anti-CCP positive. In this study there was also a ‘treat-to-target’ 
component, in that methotrexate was increase at regular intervals to a maximum 
dose of 25mg/week if NTSJ was not achieved. At week 52, although the 
combination therapy group stopped etanercept, additional DMARDs were allowed 
in both groups if required. Another possible which may have played a role in the 
clinical outcomes of these patients, which has not been addressed in this study, is 
their immunological profile. Higher proportions of baseline naïve T cells have been 
found to correlate with remission induction in patients receiving methotrexate 
monotherapy. 375  
In both groups functional  and radiographic outcomes were also high with almost 
50% achieving normal function and 80-90% achieving radiographic non-progression 
by week 78.  Notably, direct between-study comparisons cannot be made given the 
heterogeneity in study designs, patient populations and clinical outcomes. 374 
Clinical responses remained high between weeks 52 and 78, suggesting that 
remission induction with a bDMARD and maintenance with methotrexate 
monotherapy, as described by Quinn et al.182 and in other studies including BeSt291 
and OPTIMA,2 may be a possible treatment strategy in some patients. There was, 
however, a slight reduction in proportions in remission in the methotrexate and 
etanercept group on withdrawal of the TNFi, suggesting that not all patients may be 
able to achieve this. In the HIT HARD study, 230 the initial improvement in DAS at 
week 24 with methotrexate and adalimumab was also lost when adalimumab was 
withdrawn. It is likely that a proportion of patients will need to continue with 
bDMARD therapy.  Biological DMARD dose reduction, as described in the PRIZE 
340 and PRESERVE232 studies, may be an option. In this study, the improvement in 
clinical responses in the methotrexate monotherapy group is likely due to the 
additional DMARD therapy which was allowed after week 52.  
The speed of response with combination therapy was remarkable with almost 30% 
achieving a DAS44-CRP<1.6 and 40% a DAS28-CRP<2.6 at week 2 after a single 
injection. This degree of early response was likely due to the relatively mild disease 
and short symptom duration. There is evidence to suggest that early disease 
control is associated with significantly better long-term clinical 350 and radiographic 
outcomes.35 From the exploratory analyses of this study, those with a DAS28-
CRP<2.6 at week 12 were more likely to have a DAS28-CRP<2.6 and better 
function at week 78. The longer-term outcomes of these two treatments groups are 
still to be determined.  
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In this study methotrexate was started at 10mg weekly and increased at regular 
intervals to a maximum dose of 25mg weekly if tolerated. The impact of starting 
methotrexate at a higher dose on the speed of response would be of interest. 
Overall both treatments were well tolerated. There were no new safety signals. The 
findings support the benefit of early methotrexate therapy with dose escalation. 
Clinical responses were achieved earlier with methotrexate and etanercept and 
clinical and imaging responses were maintained in the majority of patients on 
stopping etanercept. The value of this combination therapy, however particularly 
with cost consideration, still need to be determined. Presently in patients with RA, 
early diagnosis and treatment with csDMARDs and glucocorticoids, escalating 
therapy using a treat-to-target type approach remains the mainstay of treatment.209 
Ideally, understanding which patients would receive the greatest benefit in the 
short- and longer-term with initial intensive induction therapy with a bDMARD and 
the possibility of bDMARD and drug-free remission would be of importance.  
5.5 Limitations  
This study has its limitations. In terms of other options for induction therapy, it has 
not addressed the role of other combination csDMARDs and glucocorticoids which 
have demonstrated efficacy in these patients. 363  
Another limitation relates to that of missing data. The calculation of sample size was 
based on the primary outcome allowing for a 10% drop-out. There was clinical data 
for 51/55 (93%) of patients in the methotrexate and placebo group but for 48/55 
(87%) in the methotrexate and etanercept group. This fell just below the 10% 
margin. Data analysis using multiple imputation to account for missing data 
however was no different to that for the observed-case only analysis.  
5.6 Conclusions 
In summary, in this group of patients with DMARD-naïve early IA, after one year of 
treatment, almost a third had no tender, swollen joints. A high proportion achieved 
DAS28-CRP<2.6  and low ultrasound synovitis. In conclusion, whilst clinical 
responses with methotrexate and etanercept were more rapid, the combination 
therapy was not superior to methotrexate monotherapy in achieving the primary 
outcome.  
192  
 
Chapter 6 Use of clinical, genetic, serological and imaging 
biomarkers in anti-CCP positive patients with nonspecific 
musculoskeletal symptoms to identify early IA in the 
secondary care 
This longitudinal study sought to address the use of anti-CCP antibodies, together 
with other biomarkers, to predict progression to early IA in secondary care. 
6.1 Introduction 
The body of evidence from the literature and results from the clinical trials detailed 
in the previous chapters support the call for early DMARD therapy to achieve 
optimal disease control, prevent joint destruction and preserve function. Early 
diagnosis is therefore essential.  
In patients presenting with clinically apparent IA, the 2010 ACR/EULAR RA 
classification criteria12 were developed to identify patients requiring DMARD therapy 
early.  There has also been increasing interest in the earlier phase of the disease - 
in patients at risk but without clinical synovitis.13 In the so called ‘pre-clinical’ phase 
of RA, several studies have found increased levels of circulating autoantibodies 
including ACPA and RF.376-381  
In clinical practice, ACPA is often measured as  antibodies to synthetic cyclic 
citrullinated peptide. Anti-CCP are more specific than RF for RA and have been 
documented in the sera of RA patients up to 14 years prior to disease onset when 
they were asymptomatic blood donors.376 377 Other markers that have been 
associated with the development of RA include smoking, prolonged EMS, the 
presence of shared epitope and raised inflammatory cytokines.99 160 378 382-384 MSK 
imaging with ultrasound has also been shown to detect low level joint inflammation 
in cases of clinical examination.385  
The year or two leading up to the development of clinical RA has sometimes been 
described as phase of imminent RA.386 ACPA levels and an expansion in ACPAs to 
a number of citrullinated proteins (epitope spreading) has been documented during 
this period.387 388  
The hypothesis of this study was that anti-CCP positive patients with new non-
specific MSK symptoms would represent a population enriched for the development 
of IA. Identifying patients during this early phase would allow early diagnosis and 
allow for early treatment thus optimising treatment outcomes. 
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The first study aim was to determine the proportion of anti-CCP positive individuals 
presenting with new onset non-specific MSK symptoms progressing to IA and the 
time to progression. The second aim was to develop a scoring system to predict 
progression to IA using clinical, serological and imaging parameters in this these 
patients.    
6.2 Patients and methods  
Patients were recruited from primary care services and from rheumatology clinics in 
Yorkshire, UK. The primary care recruitment was adopted by the UK National 
Institute of Health Research Clinical Research Network (NIHR CRN) and the study 
was approved by the local ethics committee. Patients over 18 years with new onset 
MSK symptoms presenting to their GPs or other health professionals (e.g. podiatry 
or physiotherapy) were invited to participate. All participants signed informed 
consent before taking part. For those referred from primary care, the anti-CCP test 
was performed centrally at the Leeds Rheumatology Department using a standard 
commercially available anti-CCP2 test (Immunocap 250, Phadia and later Bioplex, 
Bio-rad). Those with a positive test were invited to a attend a dedicated research 
clinic at Chapel Allerton Hospital, Leeds.  Patients from the Leeds rheumatology 
early arthritis clinic and those referred from other rheumatologists in Yorkshire were 
eligible to take part in the study if they had no clinical evidence of inflammatory joint 
swelling (deemed IA) and were anti-CCP antibody positive. The following were 
exclusion criteria: a history of IA diagnosed by a rheumatologist; presence of 
clinically detected IA at baseline confirmed by a rheumatologist; use of DMARD 
therapy.  
 
6.2.1 Assessments 
Patient assessments were done at baseline, then three monthly for the first year, 
and then as clinically indicated until they developed IA (defined by the presence of 
≥ 1 tender and swollen joint confirmed by a rheumatologist). Patients could also be 
seen between these time-points if they developed new joint symptoms. 
Assessments were carried out by rheumatologists who completed the eligibility 
criteria and performed the clinical examinations. 
 
6.2.1.1 Clinical and demographic assessments 
The following demographic and clinical parameters were documented at baseline: 
age, gender, joint symptoms in the upper and lower extremities, the presence of 
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intermittent symptoms, duration of EMS in minutes, history of first degree relative(s) 
with RA, smoking history, alcohol intake, body mass index (BMI), tenderness of the 
small joints of the hands and feet (wrists, MCP, PIP, mid-tarsal and/or MTP joints),  
the RAI (scores 0-78), 44 swollen joint count and pain VAS. 
 
6.2.1.2 Biomarkers 
A number of biomarkers were also measured at baseline. Shared epitope status 
was considered positive if one or two copies of the following human leukocyte 
antigen (HLA)-DRB1 alleles were present:  HLA- DRB1*01, DRB1٭04, and 
DRB1٭10.58 389 For RF and anti-CCP antibody tests, the laboratory machines and 
therefore the reference ranges changed partway through recruitment. The cut-off 
for immunoglobulin M (IgM) RF positivity was initially 40 IU/ml and later <20 IU/ml. 
For anti-CCP, the cut-off was initially 7 IU/ml initially (anti-CCP2; Immunocap 250, 
Phadia) and later 2.99 IU/ml (anti-CCP2, Bioplex, Bio-rad). High-level RF or anti-
CCP levels were defined according to the 2010 ACR / EULAR criteria by a cut-off of 
> 3 times the upper limit of normal.12 High sensitivity C reactive protein (hs-CRP) 
was also performed and a level of  ≥ 2 mg/dl, which has been associated with RA 
disease activity, was considered positive.89 Ultrasound assessments were 
performed (Philips HDI 5000 machine 15-8 MHz transducer) by a rheumatologist 
experienced in MSK ultrasound. Findings in the wrists, MCPs, and PIPs were 
reported using standard OMERACT definitions to define synovitis.356 The EULAR-
OMERACT system (a 0-3 semi-quantitative scale) was used for scoring. PD signal 
was reported positive with the presence of intra-articular Doppler signal (PD ≥ 1).357 
Intra-reader reliability for the ultrasound assessor has been reported to be 
excellent, with 100% agreement between two repeated assessments of the 
presence of PD signal in 33 joints.390  
For sample size, the potential predictive value of the variables collected in the first 
100 patients were assessed, based on an estimated progression to IA of 40-50%. 
This would enable an estimation of the unadjusted hazard ratios (HR) for the 
potential predictors and to develop a simplified clinically-relevant four-variable 
model. For cox regression analyses, published rules of thumb recommend 10 
events per variable.391 
 
6.2.2 Statistical analysis 
Univariable cox regression analyses were used to obtain unadjusted HR to assess 
the association between baseline variables with time to progression to IA. 
Continuous variables were dichotomised using clinically relevant cut-offs. In 
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addition to those listed above, the following cut-offs were used: ≥12 months for 
symptom duration, ≥30 minutes for EMS, ≥25 for BMI and ≥50mm for pain VAS. In 
each case variables were coded so that the HR was positive. When selecting 
variables for the multivariable model, HR ≥1.5 was considered substantive. Cases 
were treated as censored after their last follow-up if they had not progressed to IA.  
For development of a risk stratification score, variables were considered for 
inclusion in the multivariable model of time to progression to IA if a) they were 
potentially available in clinical practice and b) they were related to the outcome to a 
substantive degree (HR ≥1.5). Once the model was fitted, individual variables were 
given scores derived from their regression coefficients, rounded to the nearest 0.5 
interval and multiplied by 2. Patients’ total scores depended on which risk factors 
were present at baseline. Risk categories were then defined according to the 
proportions of patients that progressed at each score level. 
6.3 Results 
The baseline demographic and clinical characteristics are presented in table 6.1. In 
total 100 patients were included - 29 from primary care referrals and 71 from 
rheumatology clinic referrals. Figure 6.1 presents a flow chart of participants. 
Patients who met inclusion criteria at the point of referral but subsequently were 
found to have IA at the baseline were excluded (n=21). The median follow-up 
period for the 100 patients included in the analysis was 19.8 months (1st 
quartile=7.6, 3rd quartile=34.4; range 0.1-69.0). Fifteen patients were lost to follow-
up from the research clinic. For all of these patients, confirmation was obtained 
from their GPs or clinical records that they had not developed IA. Using the point of 
last patient or GP contact to determine the duration of follow-up, all but one of the 
patients had been followed for at least 12 months. 
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Table 6.1 Baseline demographic, clinical, and imaging characteristics of 100 anti-
CCP positive patients with non-specific MSK symptoms. Values presented are 
n/N (%) unless otherwise indicated. 
 
Characteristic 
 
No inflammatory arthritis at 
baseline (n=100) 
Age years* 
51.2 (11.9), 24 to 77 
Gender female 
72/100 (72.0%) 
Shared epitope one copy 
two copies 
46/86 (53%) 
17/86 (20%) 
FDR with RA yes 
25/94 (27%) 
Smoker ever 
70/99 (71%) 
Alcohol consumer no 
17/75 (23%) 
BMI score* 
≥25 
29.0 (6.5), 18.3 to 44.7 
54/76 (71%) 
Anti-CCP 
 
level 
low positive 
high positive 
246 (61, 825), 9 to 13400 
17/100 (17%) 
83/100 (83%) 
RF 
 
level** 
low positive 
high positive 
21 (0, 103), 0 to 1000 
15/100 (15%) 
31/100 (31%) 
Autoantibody status low positive RF 
and anti-CCP 
high positive RF 
or anti-CCP 
14/100 (14%) 
 
86/100 (86%) 
hsCRP level** 
≥2 mg/dl 
2.9 (0.9, 10.5), 0.1 to 30 
43/74 (58%) 
Symptom duration months** 
≥12 months 
22.7 (8.2, 42.4), 1.4 to 327.7 
66/97 (68%) 
Intermittent symptoms present 
20/97 (21%) 
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Tenderness of small joints count (0-34)**, 
range 
present 
0.5 (0.0, 3.0), 0-18 
50/100 (50%) 
Symptoms in upper and 
lower extremities 
present 
37/100 (37%) 
EMS minutes** 
≥30 minutes 
10 (0, 38), 0 to 270 
39/100 (39%) 
Pain VAS mm** 
≥50mm 
24 (9 to 51), 0 to 100 
25/91 (27%) 
 
*mean (SD), range **median (1st quartile, 3rd quartile), range. FDR, first 
degree relative; BMI, body mass index; Anti-CCP, anti-cyclic citrullinated 
peptide antibodies; RF, rheumatoid factor; hsCRP, high sensitivity C reactive 
protein; EMS, early morning stiffness; VAS, visual analogue scale. 
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6.3.1 Progression to inflammatory arthritis  
After a median of 7.9 months (IQR 3.2, 14.5; range 0.1-52.4), 50 patients 
progressed to clinically detected IA. Thirty four progressed within the first 12 
months of follow-up and 44 within the first 24 months (figure 6.1). Of those who 
progressed to IA, 43 fulfilled the 2010 ACR/EULAR RA classification criteria. The 
remaining patients had undifferentiated IA. The median follow-up of those who did 
not progress was 30.3 months (IQR 22.5, 45.1; range 7.7-69.0). 
 
6.3.1.1 Univariable Cox regression analysis 
There were two clinical parameters which were substantively associated with an 
increased risk of progression to IA: EMS lasting ≥30 minutes and tenderness of 
small joints (table 6.2).  For cut-off points for EMS, 30 and 60 minutes were both 
considered and showed similar predictive values. The 30 minutes cut-off was 
chosen as it was thought to be more sensitive.43 There was no evidence that the 
risk of developing IA was substantively associated with symptom duration, BMI, 
pain VAS or high sensitivity CRP (hsCRP). 
The following biomarkers were associated with an increased risk of progression to 
IA: positive RF, high positive anti-CCP or RF, presence of shared epitope, and 
positive ultrasound PD signal.  
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Figure 6.1 Flowchart of the study patients 
IA, inflammatory arthritis; **details of the 15 patients lost to follow-up from the 
research clinic, obtained from their clinical records or with their general 
practitioners, showed that none had developed IA at their last clinic 
appointments.       
Baseline assessment 
N=121 patients 
IA at baseline 
N = 21 
No IA at baseline 
N= 100 
No IA at 12 months 
N = 66* 
*includes 1 lost to follow-up 
IA at 12 months 
N = 34 
 
 
No IA at 24 months 
N = 56* 
*includes 5 lost to follow-up 
and 10 who had not reached 
24 months 
 
IA at 24 months 
N = 44 
 
No IA at any time 
N = 50** 
**includes 15 lost to follow-up 
IA at any time 
N = 50 
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Table 6.2 Associations between baseline demographic, clinical and imaging 
characteristics and time to development of inflammatory arthritis in anti-CCP 
positive patients with non-specific MSK symptoms. 
 
Baseline characteristics Progression to IA  
 
n/N (%) who 
developed 
IA 
Months to 
IA (mean) 
HR (95% CI) 
Symptom 
duration 
<12 months 
≥12 months 
15/31 (48) 
35/66 (53) 
33.3 
35.8 
reference 
1.05 (0.57, 1.92) 
Intermittent 
symptoms 
absent 
present 
37/77 (48) 
12/20 (60) 
37.5 
31.0 
reference 
1.27 (0.66, 2.44) 
Symptoms in 
upper and 
lower 
extremities 
absent 
present 
28/63 (44) 
22/37 (60) 
39.3 
32.6 
reference 
1.38 (0.79, 2.41) 
EMS 
 
<30 minutes 
≥30 minutes 
27/61 (44) 
23/39 (59) 
38.7 
32.0 
reference 
1.70 (0.97, 2.98) 
<60 minutes 
≥60 minutes 
37/78 (47) 
13/22 (59) 
39.4 
27.3 
reference 
1.92 (1.02, 3.63) 
FDR with RA yes  
no 
11/25 (44) 
37/69 (54) 
40.3 
35.3 
reference 
1.25 (0.64, 2.46) 
Smoker never 
ever 
12/29 (41) 
38/70 (54) 
41.1 
35.3 
reference 
1.26 (0.66, 2.42) 
Alcohol 
consumer 
yes 
no 
30/58 (52) 
9/17 (53) 
35.2 
31.2 
reference 
1.27 (0.60, 2.69) 
BMI ≥25 
<25 
28/54 (52) 
11/22 (50) 
36.4 
26.5 
reference 
1.13 (0.55, 2.30) 
Tenderness 
of small 
joints 
absent 
present 
19/50 (38) 
31/50 (62) 
43.9 
30.9 
reference 
1.83 (1.03, 3.24) 
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Pain VAS ≥50mm  
<50mm 
11/25 (44) 
34/66 (52) 
41.6 
36.0 
reference 
1.26 (0.64, 2.50) 
hsCRP <2 mg/dl 
≥2 mg/dl 
15/31 (48) 
24/43 (56) 
35.8 
33.3 
reference 
1.27 (0.66, 2.42) 
Anti-CCP +ve 
++ve 
7/17 (41) 
43/83 (52) 
43.7 
35.9 
reference 
1.43 (0.64, 3.19) 
RF -ve 
+ve 
++ve 
21/54 (39) 
9/15 (60) 
20/31 (65) 
45.2 
29.4 
25.9 
reference 
1.69 (0.77, 3.69) 
2.04 (1.10, 3.78) 
Autoantibody 
status 
-ve or +ve RF 
and +ve anti-
CCP 
++ve RF and/or 
++ve anti-CCP 
4/14 (29) 
 
46/86 (53) 
51.1 
 
35.0 
reference 
 
2.17 (0.78, 6.04) 
Shared 
epitope 
absent 
present 
6/23 (26) 
33/63 (52) 
20.3 
15.5 
reference 
2.47 (1.03, 5.90) 
Power 
Doppler 
signal 
absent 
present 
28/67 (42) 
22/33 (67) 
42.2 
26.3 
reference 
1.88 (1.07, 3.29) 
 
-ve, negative; +ve, low positive; ++ve, high positive (3x upper limit of normal); 
anti-CCP, anti-cyclic citrullinated peptide antibodies; BMI, body mass index; 
CI, confidence interval; EMS, early morning stiffness; FDR, first degree 
relative; HR,  hazard ratio; hsCRP, high sensitivity C reactive protein; RF, 
rheumatoid factor; VAS, visual analogue scale.   
  
202  
 
6.3.1.2 Multivariable Cox regression 
Variables were considered for inclusion in the multivariable models of progression if 
they were substantively associated with progression to IA in the univariable analysis 
(HR≥1.5) and possibly available in clinical practice. Initially, ultrasound was chosen 
over the shared epitope due to its wider availability in the UK.  The use of shared 
epitope as a predictive factor however was also explored with and without PD, 
allowing for differences in the availability of each test in different countries (tables 
6.3 and 6.4, and figure 6.2). 
The first model of progression to IA (PD model) included 100 patients, 50 of whom 
progressed over 69 months of follow-up. The independent variables were EMS ≥30 
minutes, presence/absence of small joint tenderness, high level RF and/or anti-
CCP, and PD. Time-varying covariates were added to each model to test the 
proportional hazards assumption392 and found to be satisfied. Harrell’s C was used 
to assess the predictive strength of the model.393 This assesses whether ordering of 
the predicted progression times is concordant with the observed data. A value >0.5 
indicates predictive ability better than random chance, and a value of 1 represents 
perfect concordance. Harrell’s C for this model was 0.67 (0.59, 0.74). All four 
variables were substantively associated with risk of progression to IA (HR≥1.5) 
although none to a statistically significant degree (table 6.2). The model residuals 
however revealed two unduly ‘influential’ patients (dfbeta>2/√N). Both had low 
positive anti-CCP antibody levels and had no PD signal present on ultrasound but 
progressed to IA. Excluding these two patients, the HRs increased and EMS, 
antibody levels, and PD were all independently associated with time to progression.  
The risk score of this model ranged from 0-5 (table 6.3). The proportion of patients  
progressing to IA using this risk score suggested that patients could be divided into 
three risk groups (table 5). Anti-CCP positive patients with none of the four risk 
factors at baseline could be considered at low risk (0/5 progressed). Those scoring 
1-2 points could be pooled into a moderate risk group (31% of 29 patients 
progressed), and those scoring ≥ 3 could be pooled into a high risk group (62% of 
66 patients progressed). Of those who progressed the majority did so within the first 
12 months (table 6.4). The 3 different risk groups and their Kaplan-Meier IA-free 
survival curves over the period up to 69 months of follow-up are shown in figure 
6.2A.  
Alternative models which included shared epitope were constructed and found to 
have similar predictive ability (tables 6.3 and 6.4, figures 6.2B - 6.2C). Using shared 
epitope instead of PD yielded a model with similar predictive ability to that of the PD 
model (Harrell’s C=0.66 (0.58, 0.74)) (table 6.3). The 92 patients with shared 
epitope available were included in this model, 46 of whom progressed to IA. All four 
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independent variables were substantively associated with the outcome (HR>1.5). 
The resulting risk score ranged from 0-4. Fewer patients however were found to be 
at high or low risk using this model (table 6.4). With both PD and shared epitope, 
the predictive strength remained moderate (Harrell’s C=0.65 (0.58, 0.73)). In this 
model the adjusted effects of EMS and antibody status were reduced (both HR≈1.5) 
compared to PD and shared epitope (both HR≈1.8). The resulting risk score ranged 
from 0-5. None the 11 patients in the low risk group (score 0 or 1) progressed to IA. 
Follow up of these patients ranged between 18 and 55 months. In the high risk 
group (score 4 or 5), 72% (18/25) progressed to IA, 56% (14/25) within 12 months 
of presentation. Excluding both PD and shared epitope, the predictive strength 
remained moderate (Harrell’s C=0.65 (0.58, 0.73)). In this model, antibody status 
was the dominant predictor (HR=2.46). The resulting risk score ranged from 0-4 
(table 6.3). None of the 5 patients in the low risk group (score 0) progressed to IA, 
compared to 40% (16/40) of those at moderate risk and 62% (24/55) of those at 
high risk (table 6.4, figure 6.2D). The discriminatory power of model was similar to 
the model that included shared epitope.
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Table 6.3 Results of multivariable Cox regression models of time to progression to inflammatory arthritis 
 
Multivariable Cox-regression predictors Excluding outliers HR (95% CI) All subjects (95% CI) 
(95% CI) B: score 
Power Doppler model 
n=98 n=100  
Tenderness of small joints present 
1.39 (0.77, 2.53), p=0.277 1.56 (0.87, 2.81) 0.44: 1 
EMS ≥ 30 minutes 
1.85 (1.02, 3.35), p=0.043 1.75 (0.97, 3.16) 0.55: 1 
High level RF and/or anti-CCP 
4.52 (1.07, 19.15), p=0.040 1.83 (0.98, 3.42) 0.82: 2 
Power Doppler present 
1.84 (1.04, 3.27), p=0.037 1.51 (0.83, 2.74) 0.56: 1 
Shared Epitope model 
n=90 n=92  
Tenderness of small joints present 
1.54 (0.83, 2.87), p=0.173 1.68 (0.91, 3.11) 0.52: 1 
EMS ≥ 30 minutes 
1.61 (0.86, 3.00), p=0.135 1.54 (0.84, 2.84) 0.43: 1 
High level RF and/or anti-CCP 
3.40 (0.77, 14.96), p=0.105 1.68 (0.57, 5.00) 0.52: 1 
Shared epitope present 
1.58 (0.72, 3.49), p=0.257 1.87 (0.84, 4.14) 0.62: 1 
Power Doppler + Shared Epitope model 
n=90 n=92  
Tenderness of small joints present 
1.54 (0.82, 2.88), p=0.178 1.69 (0.91, 3.13) 0.52: 1 
2
0
4
 
205  
 
EMS ≥ 30 minutes 
1.56 (0.83, 2.92), p=0.167 1.49 (0.81, 2.77) 0.40: 1 
High level RF and/or anti-CCP 
3.04 (0.68, 13.6), p=0.147 1.47 (0.48, 4.47) 0.38: 1 
Power Doppler present 
1.92 (1.06, 3.50), p=0.033 1.89 (0.84, 4.24) 0.63: 1 
Shared epitope present 
1.57 (0.70, 3.49), p=0.272 1.84 (1.02, 3.32) 0.61: 1 
Model without Power Doppler or Shared 
Epitope 
n=98 n=100  
Tenderness of small joints present 
1.42 (0.78, 2.57), p=0.252 1.56 (0.87, 2.81) 0.44: 1 
EMS ≥ 30 minutes 
1.86 (1.03, 3.37), p=0.039 1.75 (0.98, 3.13) 0.56: 1 
High level RF and/or anti-CCP 
4.86 (1.16, 20.43), p=0.031 2.46 (0.87, 6.99) 0.90: 2 
 
Duration of follow-up = 69 months  
Scores for each predictor were derived from the regression coefficients, rounded to nearest 0.5 then multiplied by 2, to give a total risk score 
ranging from 0-5.  
B, regression coefficient; HR, hazard ratio; CI, confidence interval; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide 
antibodies; EMS, early morning stiffness. 
 
2
0
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Table 6.4 Proportions of patients progressing to inflammatory arthritis (IA) within 12 or 24 months of referral, or at any time during follow-up, 
according to their risk score at baseline 
Risk score Proportion (n/N) of patients who progressed to IA: Risk category:  
 
% progressed 
Within 12 months  Within 24 months  At any time  
Power Doppler in model 
0 
0/5 (0%) 0/5 (0%) 0/5 (0%) Low:  0% 
1 
1/3 (33%) 1/3 (33%) 1/3 (33%) Mod:  31% 
2 
6/26 (23%) 8/26 (31%) 8/26 (31%) 
3 
10/34 (29%) 14/34 (41%) 19/34 (56%) High:  62% 
4 
11/23 (48%) 15/23 (65%) 16/23 (70%) 
5 
6/9 (67%) 6/9 (67%) 6/9 (67%) 
Shared Epitope in model 
0 
0/3 (0%)  0/3 (0%)  0/3 (0%)  Low:  0% 
1 
0/11 (0%)  1/11 (9%) 2/11 (18%) Mod:  40% 
2 
10/32 (31%) 13/32 (41%) 15/32 (47%) 
3 
12/33 (36%) 17/33 (52%) 20/33 (61%) High:  63% 
4 
8/13 (62%) 9/13 (69%) 9/13 (69%) 
2
0
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Power Doppler and Shared Epitope in model 
0 
0/3 (0%)  0/3 (0%)  0/3 (0%)  Low:  0% 
1 
0/8 (0%)  0/8 (0%)  0/8 (0%)  
2 
7/25 (28%) 9/25 (36%) 11/25 (44%) Mod:  50% 
3 
9/31 (29%) 14/31 (45%) 17/31 (55%) 
4 
10/19 (53%) 13/19 (68%) 14/19 (74%) High:  72% 
5 
4/6 (67%) 4/6 (67%) 4/6 (67%) 
Neither Power Doppler or Shared Epitope in model  
0 
0/5 (0%) 0/5 (0%) 0/5 (0%) Low:  0% 
1 
1/4 (25%) 1/4 (25%) 1/4 (25%) Mod:  40% 
2 
9/36 (25%) 13/36 (36%) 15/36 (42%) 
3 
12/35 (34%) 17/35 (49%) 21/35 (60%) High:  62% 
4 
12/20 (60%) 13/20 (65%) 13/20 (65%) 
 
2
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Figure 6.2 Conditional probability of inflammatory arthritis (IA)-free survival over up 
to 69 months of follow-up, according to categories of risk derived from 
exploratory risk scores for progression to IA. 
 
Crosses indicate censoring due to loss to follow-up (n=15) or duration of 
follow-up <69 months without progression to IA (n=35). The majority of those 
who progressed did so within the first 12 months (dotted line). Four different 
models are presented (A power Doppler; B shared epitope; C power Doppler 
& shared epitope; D neither power Doppler nor shared epitope). Black 
line=high risk of progression to IA; mid-grey=moderate risk; light grey=low risk. 
 
C 
D 
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6.4 Discussion 
Early identification and treatment of patients with RA is crucial since joint damage 
occurs early and therapy is most effective during the early stages of the disease. 
With the wider availability of anti-CCP testing, identifying individuals with disease 
specific antibodies during the ‘at risk’ period before the development of clinical IA 
has become a possibility. Predicting transition to clinical disease in these patients is 
important to initiate therapy. 
In this cohort of anti-CCP positive patients with non-specific MSK symptoms, half 
developed IA. Most progressed within 12 months of presentation (median 7.9 
months) corresponding to what has been labelled imminent RA. Those progressing 
to IA had some distinctive clinical features and biomarker profiles at baseline. 
Clinically, they were more likely to report EMS ≥ 30 minutes and to have small joint 
tenderness at presentation. They were also more likely to have high positive RF 
and/or anti-CCP and to have a positive shared epitope or PD on ultrasound scan.  
The results of this study support the findings of other studies in which the presence 
of anti-CCP antibodies has been associated with an increased risk of developing 
IA.160 378 394 395 The proportion of patients in this cohort progressing to IA (50%) is 
higher than that reported in another study of individuals at risk (35%).160 Different 
inclusion criteria may be one factor accounting for the difference between the 
studies. In the previous study for example, only 83% of patients were anti-CCP 
positive.160 In both cohorts there were some variables that showed similar predictive 
ability - prolonged EMS, small joint involvement, and antibody status. However, 
there were other variables that were only reported to predict development of IA in 
the study by van de Stadt et al – e.g. symptom duration < 12 months, first degree 
relative with RA, and no alcohol intake.160 In previous studies, the value of imaging 
biomarkers to predict the development of IA have been inconsistent. In one study, 
the use of ultrasound was predictive of the development of IA at a joint but not a 
patient level. Other imaging modalities including MRI have also shown features of 
subclinical inflammation in patients with ACPA positive arthralgia, 396 with the ability 
to predict the development of IA in a small cohort of patients with arthralgia and 
inflammatory symptoms. 134 In a prospective pilot study, subclinical arthritis has also 
been visualised on macrophage positron emission tomography (PET) in ACPA- 
positive arthralgia with a subgroup of PET-positive patients developing features of 
an IA within a two year follow up period.397  
This study highlights the potential role of biomarkers in patients at risk of developing 
RA.  The simplified risk score which has been developed using variables potentially 
available in clinical practice may help to identify patients presenting with non-
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specific MSK symptoms and a positive anti-CCP. Prolonged EMS, physician-
defined tenderness of the small joints of the hands and feet, and a positive RF and 
anti-CCP antibodies have face validity having previously been shown to be 
predictors of persistent and erosive arthritis, 79 as well as the transition from UA to 
RA. 80 Although MSK ultrasound is not available in all rheumatology services, it is 
becoming more accessible in clinical practice. 
In addition, to allow for differences in biomarker availability, the risk scores were 
performed with and without power Doppler and shared epitope. The predictive 
performance of the four derived models were similar with regard to the low risk (0% 
in all models) and the high risk (62 to 72% progression) categories. The model 
which included both power Doppler and shared epitope, however, allowed a greater 
number of patients to be classified in the low risk group. The results would suggest 
that the simplified model using clinical data and antibodies may be used at 
presentation and those with moderate risk may be referred for additional 
assessments.  
6.5 Limitations  
The current study has its limitations. Whilst it is one of the larger prospective 
cohorts of patients at risk that are followed up from an early phase of non-specific 
MSK symptoms  and anti-CCP positivity and to the development of IA, the number 
of patients is still relatively small for full multivariable analyses. It has however 
allowed, for the first time, the development of a potential model incorporating 
clinical, serological and imaging parameters to determine progression to RA  in 
patients at risk. The ultrasound findings highlights its potential role in the 
assessment and stratification of patients at risk.  
6.6 Conclusions 
In summary, this study confirms that patients with nonspecific MSK symptoms and 
anti-CCP antibodies are at risk of developing RA. The risk score which has been 
derived from this cohort is a step towards identify these patients at an early stage. 
This model will need to be confirmed in a larger cohort.  
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Chapter 7 Use of anti-CCP antibodies in patients with new 
nonspecific musculoskeletal symptoms to identify 
patients  at risk of early IA in primary care  
 
In this chapter, the use of anti-CCP antibodies has been explored as a tool to 
identify patients with new, nonspecific musculoskeletal symptoms in primary care at 
increased risk of developing IA.  
7.1 Introduction  
From cross sectional studies anti-CCP are present in approximately one percent of 
the population.376 398 Their presence has also been associated with a high risk of 
subsequent development of RA. 367 399 Anti-CCP antibodies however can be found 
more than 10 years prior to disease onset.377 The risk of developing RA in anti-CCP 
positive individuals from the general population has been estimated at 5% over a 5 
year period, 376 meaning that this test is unlikely to be of value as a screening tool. 
However, in retrospective studies, in the years just prior to diagnosis, the predictive 
value of CCP testing has been found to be much higher, with a positive predictive 
value (ppv) of 85% noted within 1.5 years of symptom onset.377 
It is also recognised that people with RA often have MSK complaints which may not 
be sufficiently suggestive of an inflammatory arthritis (IA) (from herein referred to as 
‘nonspecific symptoms’) in the months or years prior to development of RA.  Joint 
pain, muscle cramps, stiffness, loss of motor control and weakness are described 
as the first symptoms in people with RA and anti-CCP positive arthralgia.400 The 
majority of people present to their general practitioners (GPs) first. It has been 
estimated that people with RA visited their GPs on average four times before being 
referred to a specialist for a diagnosis.401 Identifying individuals with new nonspecific 
symptoms with the anti-CCP antibody may therefore provide an enriched case 
selection for imminent RA. 
In 2009, the National Audit Office estimated the prevalence of RA in adults in 
England at 580 000 with an incidence of 26 000 new cases per year.401  The 
estimated cost of RA to the UK National Health Service was approximately £560 
million a year and the cost of work-related disability and sick leave was estimated at 
£1.8 billion a year. Delays in treatment have been associated with increased joint 
damage and poorer function.  8 78In contrast, early identification has been associated 
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with improved clinical outcomes, health-related quality of life and work ability.322 
Thus very early identification and targeted treatment of individuals at risk of 
imminent RA19 has the potential to be cost effective. 
In this study we aimed to show that individuals present with new-onset, nonspecific 
MSK complaints in the pre-clinical phase of RA, and that these individuals can be 
identified by performing an anti-CCP antibody test. This should identify anti-CCP 
positive individuals at risk of rapid progression to RA who would otherwise not be 
referred, allowing assessment of individuals at risk of IA at the earliest opportunity. 
The primary hypothesis was that a higher proportion of individuals with new-onset 
nonspecific MSK symptoms have anti-CCP antibodies compared to the general 
population. The secondary hypothesis was that the presence of the anti-CCP 
antibody in individuals with nonspecific MSK symptoms would help to identify those 
at risk of rapid progression to RA. 
7.2 Patients and methods  
This was a longitudinal prospective cohort study adopted by the NIHR CRN.402 It 
was initially conducted in West, North and North East Yorkshire and later opened to 
recruitment across the U.K. Individuals were recruited between July 2007 and 
March 2015. GPs, MSK physicians, physiotherapists, nurse practitioners and other 
health professionals were asked to refer individuals aged ≥18 years with any new 
MSK complaint, whom they were not already planning to refer to a rheumatology 
unit with an IA, for an anti-CCP test. For purpose of this study, a new MSK 
complaint was defined as any joint/ MSK symptom, including (but not limited to) 
rotator cuff tendonitis, subacromial bursitis, carpal tunnel syndrome, tendonitis e.g. 
epicondylitis, which the patient had not previously reported to their GP. Individuals 
with documented IA were excluded.  
Individuals consenting to study participation were instructed to go to their GPs/ local 
phlebotomy centres to give a blood sample.  The serum was sent to Chapel Allerton 
Hospital, Leeds for the anti-CCP antibody tests to be performed. This was done 
using second generation CCP assays. Anti-CCP positivity was determined using 
machine-specific cut-offs - initially using an Immunocap 250 (Phadia) (reference 
range <7U/mL) and later a Bioplex 2200 (Bio-rad) machine (reference range 
<2.99U/mL). They were also asked to complete a questionnaire and provide 
information on previous or current MSK diagnoses and mark their symptoms on a 
diagram. The questionnaire was updated during the course of the study to request 
details for information on family history of RA and smoking.   
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Individuals with positive anti-CCP antibody test results were contacted by the 
Rheumatology Department and offered an outpatient appointment at the CCP Clinic 
at Chapel Allerton Hospital for clinical assessments, blood tests and imaging with X-
rays and other imaging modalities. Individuals with negative anti-CCP tests 
continued to be followed up with their GPs. They were also contacted via 
telephone/post 12 months after consenting to the study and sent a questionnaire. 
Follow up was therefore wither after a period of 12 months or until the development 
of clinical synovitis If necessary, GPs and rheumatology departments were also 
contacted for relevant diagnoses.  
 
7.2.1 Outcomes  
The primary outcome was the proportion of individuals with new-onset nonspecific 
MSK symptoms who were anti-CCP positive. Secondary outcomes included the 
number of anti-CCP positive individuals who progressed to IA, in particular RA 
(according to the 2010 ACR/EULAR RA classification criteria12), and the time to IA 
diagnosis. Other outcomes of interest included the initial presenting complaint of all 
individuals (anti-CCP positive and negative), as this may help to determine whether 
there is a symptom complex that would prompt autoantibody testing. 
 
7.2.2 Statistical analysis 
Statistical analyses were performed using SPSS 21 and Stata IC 13. For the 
analyses, the date of the anti-CCP test was used as the baseline date. 
Demographic characteristics, prevalence of anti-CCP positivity, progression to IA 
and the associations with joint involvement were calculated using Pearson’s chi 
square tests. A one-sample binomial test was used to assess whether the 
proportion of individuals with anti-CCP antibodies was higher amongst those 
presenting with new MSK pain compared to the estimated proportion in the general 
population (1%). Of the individuals tested, only those who completed the follow up 
period were included in the analyses addressing time to IA or RA diagnosis. Median 
time to IA development was compared using a log rank test. Sensitivity and 
specificity for the anti-CCP antibody test were calculated together with the 95% 
confidence intervals (Wilson method). Binary logistic regression was used to assess 
the association between the involvement of specific joint types and the risk of being 
anti-CCP positive.  
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7.3 Results 
In total 2195 individuals were referred of whom 2028 individuals with new 
nonspecific MSK symptoms were enrolled (figure 7.1).  
 
 
Figure 7.1 Study recruitment 
Patients referred 
(n= 2195) 
Excluded (total =167) 
-Ineligible (n=156) 
No/insufficient blood sample and/ 
or no consent form (n=143) 
IA/RA diagnosis (n=5) 
Other (n=8) 
-Eligible but not recruited (n=11) 
Declined participation (n=11) 
Total recruited 
(n=2028) 
No follow up data (total =414) 
- Moved and unable to obtain follow up 
information (n= 38) 
- Not yet due 12 month follow up 
questionnaires (n=376) 
Total with follow up information 
(n=1614) 
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The mean (SD) age was 49.2 (13.6) years and the majority were female (75.9%). Of 
these, 2.8% (57/2028) were anti-CCP positive, a significantly higher proportion than 
the estimated 1% for the general population (95% CI 2.1% to 3.6%, p<0.001). There 
were no differences in demographic features between anti-CCP positive and anti-
CCP negative individuals. Individuals had a range of MSK and associated 
conditions with no significant differences between those who were anti-CCP positive 
or negative (table 7.1).   
Of those who were antibody positive, 47.4% (27/57) were subsequently diagnosed 
with an IA – 1 with UA, 24 with RA and 2 with polymyositis. Of those who were 
tested anti-CCP negative and completed at least 1 year of follow up, 1.3% (20/1559) 
were diagnosed with an IA – 1 with undifferentiated IA, 13 with RA and 6 with 
psoriatic arthritis (PsA) (table 7.2). The relative risk (RR) (95% CI) for ever 
developing IA in the anti-CCP positive group was 36.8 (22.0 to 61.7, p <0.001 and 
the RR for developing RA was 50.4 (27.1 to 93.8), p<0.001) (table 7.2). The 
sensitivity and specificity for the development of any IA in the anti-CCP positive 
individuals were 57.4% (43.3% to 70.5%), and 98.1% (97.3% to 98.7%) 
respectively, and the ppv and negative predictive value (npv) were 47.4% (35.0% to 
60.1%) and 98.7% (98.0% to 99.2%). The sensitivity, specificity, ppv and npv for 
progression to RA were 64.9% (48.8% to 78.2%), 97.9% (97.1% to 98.5%), 42.1% 
(30.2% to 55.0%) and 99.2% (98.6% to 99.5%) respectively. 
Median duration of follow up of anti-CCP positive individuals with MSK symptoms 
(to IA diagnosis or last assessment) was 11.5 months (IQR 1.5 to 28.2; range: 0.3 to 
79.1 months). The median time for progression to IA in the 25 anti-CCP positive 
individuals was 1.8 months (95% CI: 1.2 to 2.3, IQR 1.0-4.3, range 0.3 to 16.1). The 
majority (25/27 (92.6%)) were diagnosed within 12 months of the anti-CCP test. In 
the anti-CCP negative individuals, median time to IA diagnosis or last follow up of 
was 13.8 months (IQR: 12.5; 21.5, range 1.2 to 84.4 months) and median time to IA 
diagnosis was 5.1 months (95% CI: 4.2 to 5.8; IQR 2.9; 13.5, range 1.2 to 27.2, 
p=0.002 for anti-CCP positive vs. anti-CCP negative); 75% (15/20) were diagnosed 
within 1 year of having the test. The RR for developing IA within 12 months in the 
anti-CCP positive group was 45.5 (25.4 to 81.6), p<0.001 and RR for developing RA 
within 12 months: 66.8 (32.2 to 138.4), p<0.001) (figures 7.2 and 7.3). 
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Table 7.1 Baseline characteristics of individuals with new non-specific MSK 
symptoms 
 
Characteristic Anti-CCP 
negative (n=1971) 
Anti-CCP 
positive (n=57) 
p 
Female (n) 76.2% (1502)  66.7% (38)  0.097 
Age (years) mean (SD; range ) 49.2 (13.6; 18-90) 49.2 (13.3; 24-80) 0.986 
RA FDR (n (%)) 32.0% (369/1153) 28.0% (14/50) 0.552 
Smoker 
Never smoked 
Ex-smoker 
Current smoker 
 
50.6% (171/338) 
33.1% (112/338) 
16.3% (55/338) 
 
34.6 % (18/52) 
48.1% (25/52) 
17.3% (9/52) 
 
0.072 
Current or previous diagnoses    
Osteoarthritis/ multiple 
mechanical joint pain 
17.6% (337/1917) 9.1% (5/55) 0.101 
Gout 1.0% (20/1917) 1.8% (1/55) 0.581 
Hypermobility 0.7% (14/1917) 0% (0/55) 0.525 
Arthralgia/ Arthritis NOS/ other 
joint problems 
5.4% (103/1917) 1.8% (1/55) 0.245 
Tendinopathies * 24.4 % (468/1917) 21.8% (12/55) 0.658 
Nerve entrapment e.g. CTS 13.1% (252/1917) 7.3% (4/55) 0.201 
Bone conditions e.g. 
osteoporosis 
0.7% (14/1917) 0% (0/55) 0.525 
Polymyalgia rheumatica 0.3% (5/1917) 0% (0/55) 0.705 
Fibromyalgia 1.3% (25/1917) 0% (0/55) 0.394 
Muscular pain 0.6% (11/1917) 0% (0/55) 0.573 
Other conditions** 2.1% (40/1917) 5.5% (3/55) 0.092 
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Values presented are % (n/N) unless indicated otherwise. 
Anti-CCP, anti-cyclic citrullinated peptide; CTS, carpal tunnel syndrome; FDR, 
first degree relative; MSK, musculoskeletal; NOS, not otherwise specified; RA, 
rheumatoid arthritis; *include rotator cuff tendonitis, tennis elbow/golfer’s elbow 
and trigger finger; ** other self-reported disease from patient questionnaires 
which included diagnoses of hypothyroidism, chronic fatigue syndrome, 
Raynaud’s phenomenon, Crohn’s disease and vitamin B12 deficiency. 
 
Table 7.2 Outcomes of anti-CCP positive and negative individuals with new 
nonspecific MSK symptoms 
 
 Anti-CCP negative 
(n=1557)* 
Anti-CCP positive 
(n=57) 
No IA % (n) 98.7% (1537) 52.6% (30) 
UA % (n) 0.1% (1) 1.8% (1) 
RA % (n) 0.8% (13) 42.1% (24) 
PsA or IA with Psoriasis % 
(n) 
0.4% (6) 0% (0) 
CTD % (n) 0% (0) 3.5% (2) 
 
IA, inflammatory arthritis; RA, rheumatoid arthritis; PsA, psoriatic arthritis; UIA, 
undifferentiated inflammatory arthritis; *patients who had reached their 12 
month follow-up time point (1557/1971)
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Figure 7.2 Kaplan-Meier graph: Time to IA progression in anti-CCP positive 
and anti-CCP negative individuals with MSK symptoms 
anti-CCP, anti-cyclic citrullinated peptide antibody; IA, inflammatory arthritis; 
MSK, musculoskeletal symptoms 
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Figure 7.3 Kaplan-Meier graph: Time to RA progression in anti-CCP positive 
and anti-CCP negative individuals with MSK symptoms 
anti-CCP, anti-cyclic citrullinated peptide antibody; RA, rheumatoid arthritis; 
MSK, musculoskeletal symptoms 
 
 
Analyses of location of symptoms, showed that individuals with pain affecting the 
regions of the wrists and/or hands or the feet were more likely to be anti-CCP 
positive (RR 2.9 (1.2 to 7.3, p=0.024) for wrists and/or hands and RR 2.1 (1.2 to 3.6, 
p=0.008) for feet).  Those with shoulder symptoms were also more likely to have a 
positive anti-CCP result (RR 2.1 (1.2 to 3.7, p=0.010)) (table 7.3).  The association 
between the location of symptoms and progression to RA was not analysed as the 
number of patients per variable would be too small.403 404 
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Table 7.3 Associations between joint symptoms and anti-CCP positivity in 
individuals with new nonspecific MSK symptoms 
Joint involved  % (n/N) who are 
anti-CCP positive 
RR (95% CI), p 
Neck Absent 2.9% (40/1364) reference 
 Present 2.5% (15/608) 0.9 (0.5, 1.6); p=0.627 
Back Absent 3.6% (48/1352) reference 
 Present 1.1% (7/620) 0.3 (0.1, 0.7);p=0.008 
R or L shoulder Absent 2.2% (25/1116) reference 
 Present 3.5% (30/856) 2.1 (1.2, 3.8);p=0.010 
R or L elbow Absent 3.1% (40/1297) reference 
 Present 2.2% (15/675) 0.7 (0.4, 1.2);p=0.184 
R or L wrist and/or 
hand 
Absent 1.0% (5/483) reference 
 Present 3.4% (50/1489) 2.9 (1.2, 7.3);p=0.024 
R or L hip Absent 3.4% (41/1208) reference 
 Present 1.8% (14/764) 0.6 (0.3, 1.1); p=0.075 
R or L knee Absent 3.3% (28/836) reference 
 Present 2.4% (27/1136) 0.8 (0.5, 1.4);p=0.442 
R or L ankle Absent 3.1% (41/1333) reference 
 Present 2.2% (14/639) 0.8 (0.4, 1.4);p=0.377 
R or L foot Absent 2.2% (27/1224) reference 
 Present 3.7% (28/748) 2.1 (1.2, 3.6); p=0.008 
L, left; MSK, musculoskeletal symptoms, R, right 
 
222 
 
 
7.4 Discussion 
At the time of performing this work,  this was the first prospective cohort study 
addressing the prevalence of anti-CCP in individuals with new non-specific MSK 
symptoms without clinical synovitis and the progression to IA. In this cohort of 
individuals referred from primary care, 2.8% were anti-CCP antibody-positive with 
47% progressing to IA mainly RA, the majority within one year or antibody testing.  
Several retrospective studies have identified the presence of RA associated 
autoantibodies in individuals with RA prior to disease onset with a rise in 
prevalence in the years just prior to diagnosis. 376 377 In a large population study, the 
prevalence of RA was found to be 19% in RF positive individuals.405 Findings from 
the Nurses’ Health Study showed a sensitivity and specificity of 28% and 100% 
respectively in a single pre-RA diagnosis serum sample tested for anti-CCP 
antibodies. Higher antibody levels were associated with a shorter time to diagnosis. 
394 In another cohort of 147 individuals with arthralgia without IA, of whom 50 were 
CCP positive, 52 RF positive and 45 positive for both antibodies, 45% developed 
RA after a median 28 months. The presence of ACPA, but not RF or shared 
epitope, was associated with disease progression. 395  
In recent years, there has been increasing focus on work addressing individuals at 
risk of developing RA.13 Other methods have also been evaluated for identifying 
these individuals early. Liang et al. have explored the possibility of an internet-
based method for identifying people with symptoms of an inflammatory polyarthritis 
of less than 12 weeks. In this study, 43 244 people took the online questionnaire.406 
Of these 60 took a self-scoring algorithm for IA, 48 screened positive, 24 were 
evaluated and 3 diagnosed with IA. Of the 24 people, 17 completed a follow up 
questionnaire at 1 year – 3 were diagnosed with RA and were on methotrexate. 
An important question that would need careful consideration prior to implementing 
any case finding strategy is that of cost–effectiveness.  On the one hand, there is 
the cost of the disease, which is associated with irreversible joint damage and 
increased morbidity, the cost of treatment and societal costs including potential job 
loss.401 This needs to be balance against the cost of performing investigations in 
order to finding early treatable RA and preventing disease progression.  
Testing of individuals with nonspecific symptoms for anti-CCP provides a relatively 
easy and simple method for identifying individuals at risk at an early stage. Another 
possibility would be to refine the group to be tested and referred. Hand involvement 
has been reported to be more common in individuals who progress to RA. 400 In our 
cohort, symptoms involving the wrists and/or hands, feet and the shoulders were 
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associated with anti-CCP positivity. In the previous chapter, a history of EMS, the 
presence of polyarticular pain, RF or inflammatory markers has been reported to 
increase the positive predictive value of anti-CCP in individuals with early RA.407 In 
another cohort, anti-CCP positive individuals with symmetric arthralgia of small 
joints and EMS, 60% progress to RA.395 The presence of anti-CCP together with 
inflammatory symptoms, the presence of shared epitope and imaging with 
ultrasound  have been shown to enable identification of individuals with RA at an 
early stage.19  
Whilst the majority of anti-CCP positive individuals who progressed to IA in this 
study were classified as RA, two individuals were later diagnosed with Jo-1 
polymyositis, one with high level anti-CCP antibodies and one with a borderline 
result. Studies suggest that the autoimmune process in ACPA-associated diseases 
may begin at mucosal sites e.g. the lung.408 These two individuals may have an 
overlap of RA and polymyositis. The possibility of a pathogenic link between 
polymyositis and ACPA with lung involvement in both, however, is an interesting 
one.    
7.5 Limitations 
The study has its limitations. These findings have been compared to an estimated 
1% based on blood donor cohorts.376 398 Whilst this may be a reasonable 
approximation of anti-CCP positivity in the general population, it is known that 
screening of donors exclude individuals with medical conditions and may therefore 
underestimate the population prevalence of the antibody. Despite this, findings from 
this study suggest that individuals with rapid progression to IA may be identified. 
Another limitation is that participants in this study have mainly been recruited from 
Yorkshire, U.K. The antibody prevalence may differ in other populations and ethnic 
groups. Of the individuals who progressed to RA, approximately one third were 
anti-CCP negative. Whilst anti-CCP positivity has been associated with more 
severe destructive disease, the study confirms the need for additional biomarkers 
for the diagnosis of seronegative RA and other inflammatory arthritides e.g. PsA. 
The joint symptoms and associated conditions were all self-reported from patient 
questionnaires. It is possible that there may be a bias towards under-reporting as 
patients may have only reported what they may have perceived as relevant to the 
study. 
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7.6 Conclusions 
In this study selecting individuals with new nonspecific MSK symptoms without 
clinical synovitis enriched the prevalence of anti-CCP positivity to 2.8%, with anti-
CCP positive individuals being found to be at high risk of rapidly developing an 
inflammatory arthritis, in particular RA. The cost-effectiveness of this approach will 
need to be determined. 
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Chapter 8 Discussion, future directions and conclusions 
 
This final chapter presents a summary of the findings from this thesis, discussing 
the results in context of the recent literature and potential research questions 
arising from the thesis.  
8.1 Overview 
Review of the literature and evidence from clinical practice have shown that 
outcomes of patients with IA are significantly improved when treated early8 78 with 
effective DMARD therapies,187 followed by regular monitoring and, where 
necessary, DMARD escalation to achieve a treatment target (ideally remission).222 
In a recent study of patients with early inflammatory polyarthritis, early sustained 
remission was associated with lower all-cause mortality.409  
Notably, of the DMARDs, use of bDMARDs178 have been highly effective in 
achieving disease control in  patients with IA.  Their use is supported by a wealth of 
evidence from clinical trials confirming their efficacy. 187 223 With the cost of these 
drugs remaining an important point of consideration,207 however, many treatment 
guidelines place them after failure of one or more csDMARDs.188 410 Questions 
regarding the benefit of bDMARD therapy in the early phases of the disease also 
remained unanswered. 
The importance of early treatment has in turn placed increasing emphasis on the 
need for early diagnosis. Several biomarkers have been identified in patients in the 
early stages of the disease. The genetic marker, shared epitope, has long been 
associated with patients with RA. Serological markers including RF and ACPA have 
been shown to be present in the preclinical phase of the disease. Imaging with 
ultrasound has also been shown to be more sensitive than clinical examination for 
detecting synovitis. Use of these biomarkers in clinical practice in patients at-risk of 
IA, however, have not yet been well established. 
This thesis has addressed the management of RA across the IA disease 
continuum, looking at (1) the treatment of IA, particularly focusing on the role of 
bDMARD in early disease, and (2) the diagnosis of IA,  focusing on the 
identification of patients at-risk before developing clinically apparent disease (figure 
8.1). 
First the thesis provided an up-to-date systematic review of the literature of RCT 
evidence of the efficacy of all available bDMARDs and emerging bsDMARDs along 
the IA continuum, from patients with UA to those with established RA, to underpin 
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guidance for treatment recommendations for the use of these agents.209 Two RCTs 
then addressed the use of bDMARDs in patients with early DMARD naïve IA, an 
area in which the evidence for their use was less clear. One of the RCTs was in 
patients with early RA and the other included patients with UA. Both incorporated a 
treat-to-target approach within their study designs.  
The thesis also aimed to explore the use of biomarkers available in clinical practice 
for the early identification of patients with IA in secondary care and the specific use 
of anti-CCP in primary care to identify a cohort of patients at greater risk of 
developing IA (with the eventual aim of enabling earlier intervention). 
 
8.1.1 Thesis synopsis 
Chapter Three: Systematic literature review of the efficacy of biological DMARDs in 
patients along the inflammatory arthritis disease continuum 
This SLR confirmed the efficacy of bDMARDs particularly in combination with 
methotrexate.  With studies showing superior long-term clinical and radiographic 
outcomes using combination therapy with a bDMARD and a csDMARD, this 
remains the optimal treatment approach. In situations where patients may not 
tolerate methotrexate or another csDMARD, bDMARD monotherapy may be 
considered. In general, studies also showed earlier improvement in signs and 
symptoms with more intensive initial treatment strategies compared to step-up 
approaches. In patients with insufficient response to methotrexate or other 
csDMARDs, however, outcomes were similar once bDMARDs were added. 
Radiographic progression was also lower with therapies that included a bDMARD. 
High clinical response rates and less radiographic progression were also seen in 
clinical trials which incorporated treat-to-target type strategies - many of these also 
included glucocorticoids. Biological DMARD- and drug-free remission was 
achievable in some patients with IA, particularly with early bDMARD use. Newer 
therapies have also begun to emerge,  with the first published RCT showing 
efficacy of CT-P13, the first infliximab bsDMARD in RA.   
Chapter Four: Infliximab vs. intravenous methylprednisolone with methotrexate as 
induction therapy in DMARD naïve early RA 
Results from this chapter (the IDEA study) showed that first-line therapy with 
methotrexate and high dose IV steroid in early DMARD naïve RA, together with a 
treat-to-target approach, resulted in little damage progression. Methotrexate and 
infliximab was not superior to methotrexate and high dose IV steroid in inhibiting 
radiographic progression, however there was a trend towards earlier clinical 
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responses, with significantly earlier achievement of DAS28 remission and greater 
reduction in synovitis on ultrasound in the bDMARD group.  
Chapter Five: Etanercept with methotrexate vs. methotrexate monotherapy in 
DMARD naïve early IA  
In this RCT of DMARD naïve early IA, almost a third of patients had no tender and 
no swollen joints after one year of treatment. A high proportion also achieved 
DAS28-CRP<2.6  and low levels of ultrasound synovitis. Combination therapy with 
methotrexate and etanercept was not superior to methotrexate monotherapy in 
achieving the primary outcome, however clinical responses were more rapid in the 
methotrexate and etanercept combination therapy group.  
Chapter Six: Use of clinical, genetic, serological and imaging biomarkers in anti-
CCP positive patients with nonspecific musculoskeletal symptoms to identify early 
IA in the secondary care 
This longitudinal cohort study confirmed that patients with nonspecific MSK 
symptoms and anti-CCP antibodies are at risk of developing IA with 50% of patients 
having progressed to IA, the majority within the first year of follow-up. A risk score 
was derived using a combination of clinical features, serology and ultrasound 
imaging or shared epitope as a genetic marker to risk stratify patients with the 
potential to develop IA.  
Chapter Seven: Use of anti-CCP antibodies in patients with new nonspecific MSK 
symptoms to identify patients at risk of early IA in primary care  
In this prospective cohort study of patients in primary care, 2.8% of patients with 
new nonspecific MSK symptoms were found to be anti-CCP positive. Of these a 
significant proportion (47%) developed IA, the majority within one year of having the 
blood test done. 
8.2 Discussion   
The following section will discuss the  work from this thesis  in context of the recent 
literature especially work that was done contemporaneously or since the thesis 
studies were completed. It will also address areas related to, but outside the scope 
of this body of work. These will be discussed under two main headings: (1) update 
of IA treatment and (2) update of early IA diagnosis.   
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8.2.1 Update of IA treatment 
Since the work of this thesis, several new therapies have emerged. All thus far 
have only been examined in clinical trials in established RA.  A few new studies 
have also been published on treatment strategies in early IA/RA. This section will 
therefore seek to examine the literature that may give clues on therapies and new 
strategies that will impact the early disease continuum regimens. This will be 
discussed under three main subheadings (1) new therapies, (2) treatment 
strategies in early IA  and (3) how should IA be treated, in the light of the body of 
work arising from this thesis. 
 
8.2.1.1 New therapies  
8.2.1.1.1 Emerging Biological DMARDs 
Despite current treatment options, some patients continue to have refractory 
disease, leaving scope for newer therapies. Sarilumab, a fully human anti-IL-6Rα 
monoclonal antibody, can bind both soluble and membrane-bound IL-6Rα thereby 
inhibiting IL-6 mediated inflammatory signalling. Following an initial dose-ranging 
portion of a two-part phase II/III RCT,411 the second part of the study was 
conducted comparing subcutaneous sarilumab 150mg, 200mg or placebo every 
two weeks with methotrexate in patients with moderate to severe MTX-IR RA.412 
Both sarilumab groups met their co-primary endpoints, showing significantly greater 
improvements than placebo: ACR 20 responses at week 24: 58%, 66.4% vs 33.4%, 
p<0.0001), HAQ-DI at week 16: -0.53,-0.55 vs -0.29, p<0.0001 and mTSS at week 
52: 0.90, 0.25 vs 2.78, p<0.00001 in the sarilumab 150mg, 200mg and placebo 
groups respectively. Serious infections were documented in 2.6%, 4.0% and 2.3% 
of the three groups. Laboratory abnormalities were similar to those reported in other 
studies of IL-6 blockade, with neutropaenia, elevated liver transaminases and 
increases in fasting cholesterol in a proportion of patients.413 414  
Newer therapies targeting other sites along the inflammatory cascade have also 
been investigated. One such therapy is granulocyte-macrophage colony-stimulating 
factor (GM-CSF). GM-CSF is a pro-inflammatory cytokine that is involved in the 
differentiation and survival of macrophages and neutrophils. In a phase 2 double 
blind RCT, treatment with mavrilimumab, a fully human monoclonal antibody 
targeting GM-CSF receptor-α, resulted in significantly greater reduction in DAS28-
CRP  ≥ 1.2 at 12 weeks (primary outcome) than placebo.415 No significant adverse 
events were noted. In the phase 2b EARTH-EXPLORER 1 study of moderate to 
severe csDMARD-IR RA, groups receiving mavrilimumab 30mg, 100mg and 150mg 
every other week. The study met its co-primary endpoints of mean change in 
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DAS28-CRP  from baseline at 12 weeks and ACR 20 at 24 weeks.416 The safety 
profile was acceptable. There were no serious infections in the mavrilimumab 
100mg and 150mg groups but two cases of pneumonia – one in each of the 
mavrilimumab 30mg and placebo groups. 
8.2.1.1.2 Biosimilar DMARDs 
The drug armamentarium continues to grow with the emergence of the biosimilar 224  
DMARDs.315 Since the introduction of the first bsDMARD, CT-P13, 346 several 
others have come to the fore. These include two rituximab biosimilars, CT-P10417 
and PF-05280586.418 In a phase 1 trial in TNFi-IR RA, CT-P10 has showed 
equivalent pharmacokinetic and pharmacodynamic properties to rituximab. Efficacy, 
in terms of the ACR 20, 50 and 70 and EULAR responses, and safety profiles were 
also similar up to 24 weeks. Studies of PF-05280586 have shown similar in vitro 
structure and functionality to rituximab. A phase I/II clinical trial in TNFi-IR RA (NCT 
01526057) is underway. For the etanercept biosimilar, GP2015, in vitro binding to 
TNFα,  and pharmacokinetic properties and efficacy in animal models were similar 
to the innovator product.419  
Several bsDMARDs have undergone phase 3 clinical trials. In a double blind RCT, 
189 RA patients with active RA (2010 ACR/EULAR classification criteria) on stable 
dose methotrexate with a CRP ≥10 mg/L were randomized to BOW015 or innovator 
infliximab.420 Therapeutic  equivalence was seen between the biosimilar and the 
innovator compounds (ACR 20 at week 16: 85.0% and 85.5% in the ITT 
populations  (95% CI for the difference: -11.2% to 10.3%). The pharmacokinetics, 
proportion of anti-drug antibodies and adverse events were also similar between 
the two groups. Another infliximab biosimilar, SB2, also demonstrated equivalence 
to infliximab in terms of ACR20 responses to week 30 in patients with moderate to 
severe MTX-IR RA. Its pharmacokinetics, immunogenicity and safety profile were 
also similar to infliximab.421 In an RCT evaluating the efficacy of an etanercept 
biosimilar, HD203, 294 RA patients  were randomized to receive HD203 or Enbrel 
®, both in combination with methotrexate. The ACR20 at week 24 of 83.5% and 
81,4% in the HD203 and Enbrel® groups respectively (difference (95% CI) 2.12 (-
7.65, 11.89), p=0.67), demonstrating equivalence in efficacy. There was no 
significant between group difference in adverse events.422 Another etanercept 
biosimilar, SB4, also showed equivalent ACR responses to its reference etanercept 
at week 24. The safety profile was comparable between the two groups.423  
At present only one bsDMARD – the infliximab biosimilar CT-P13 (Remsima ® or 
Inflectra ®) - is approved by the European Medicines Agency. The similarities in 
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efficacy, safety and immunogenicity between this and other bsDMARDs and their 
innovator products in the clinical trials is promising.  
Due to the complex nature of these compounds and their production, bsDMARDs 
are not identical to the originator product. Registry data and ongoing 
pharmacovigilance will therefore be vital to provide long-term information  on the 
efficacy and safety of these drugs. The questions around starting a bsDMARD or 
switching between a bsDMARD and its innovator also still need to be addressed. A 
large RCT, the NOR-SWITCH study, is currently underway to evaluate the impact 
of substituting the originator infliximab for the biosimilar compound across several 
indications including RA, psoriatic arthritis, spondyloarthropathy, Crohn’s disease, 
ulcerative colitis and chronic plaque psoriasis.424 Initial reports of its use in clinical 
practice suggest that its efficacy profile is similar to infliximab.425 
8.2.1.1.3 Small molecules 
Whilst the biological and biosimilar DMARDs look to target extracellular signaling, 
there have also been advances in research into novel small molecules directed at 
intracellular pathways.426 The focus of these therapies in RA have mainly been on 
inhibiting intracellular protein tyrosine kinases which include JAKs and spleen 
tyrosine kinase (SYK). These enzymes are responsible for protein phosphorylation 
thereby modifying downstream protein signaling and nuclear protein transcription.   
There are four members of the JAK family – JAK1, JAK2, JAK3 and tyrosine kinase 
2 (Tyk2). JAK2 is mainly expressed on haematopoetic cells while the other three 
are more widely expressed. JAKs are associated with cytokine receptors. Cytokine 
binding causes signaling through their associated signal transducer and activator of 
transcription factors (STATs) – the JAK-STAT pathway. Tofacitinib is the first and 
only JAK inhibitor that has been approved for the treatment of RA. It preferentially 
inhibits JAK3 and/ or JAK1, down-regulating several cytokines including interleukins 
2, 4, 7, 9, 15 and 21. The main advantage of this drug is its availability in an oral 
form. Several published RCTs have confirmed clinical efficacy of tofacitinib in 
combination with methotrexate or other csDMARDs in MTX- naïve, DMARD-IR and 
TNFi-IR RA.317 427-429 As monotherapy, in DMARD-IR RA, higher ACR responses 
and greater improvement in function was achieved with tofacitinib than placebo. 
The proportion of patients achieving DAS28-4variable(ESR)  remission was similar 
in the tofacitinib 5mg and 10mg groups.427 Inhibition of radiographic progression, 
however, has been demonstrated in MTX-IR RA with the tofacitinib 10mg but not 
the 5mg dose.430 The drug has been approved for use by the United States (US) 
food and drug administration431 as well as in several other countries including 
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Switzerland, Russia and Japan for the treatment of adults with moderate to severe 
active RA who have had inadequate response or are intolerant to methotrexate. 
Long-term efficacy and safety profiles need to be established. Thus far, pooled data 
from phase 2 and 3 clinical trials and long-term extension studies in moderate to 
severe RA has shown the overall risk of infection and mortality to be similar to that 
of the biological therapies (serious infections (95% CI) 3.09 (2.37-2.39) per 100 
patient-years and all-cause mortality (95% CI)  0.30 (0.20-0.44) per 100 patient-
years.432 Serious infections were higher in patients with low lymphocyte counts 
(<0.5 x103/mm3). Whilst it was unclear whether this was the cause or due to the 
infection, regular monitoring of lymphocyte counts has been advised whilst on 
treatment. Higher rates of herpes zoster infection has also been documented with 
this agent (239 cases of 4879 tofacitinib-treated patients;  4.4 per 100 patient-years 
(95% CI 3.2-6.0) compared to 1.5 per 100 patient years (95% CI 0.5-4.6) in the 
placebo treated patients in the phase 3 trials).433 Complicated herpes zoster, 
however, was rare.   
Several other JAK kinase inhibitors are also undergoing phase 2 and 3 clinical 
trials.434 One of these is the JAK 1 and JAK 2 inhibitor, baricitinib. In a phase IIb 
study in MTX-IR RA, the proportion of patients in the combined baricitinib 4mg and 
8mg groups achieved significantly higher ACR20 responses than placebo at week 
12 (76% vs. 41%, p<0.001).435 ACR 50 and 70 responses and DAS28, SDAI and 
CDAI remission were also higher in the baricitinib groups. Serious infections were 
described in two patients receiving baricitinib. There were no reported cases of 
opportunistic infections, tuberculosis, herpes zoster or death. Recently, results from 
two phase 3 RCTs, RA-BUILD and RA-BEACON, have been published in patients 
with moderate-to-severely active csDMARD-IR RA, and in TNFi-IR RA in patients 
continuing background csDMARD therapy.436 437 In RA-BUILD, there were 
significantly greater improvement in clinical responses and function at weeks 12 
and 24 with baricitinib 2mg and 4mg compared to placebo, with responses seen as 
early as one week after starting. Radiographic progression was also significantly 
lower in both baricitinib groups, with least progression in the baricitinib 4mg group. 
In RA-BEACON, improvements in clinical outcomes and function were also higher 
in the baricitinib groups compared to placebo, with greatest benefits seen in the 
baricitinib 4mg group. Whilst there were numerically more reported cases of Herpes 
zoster in the baricitinib 4mg group in this study, the proportion of serious adverse 
events including serious infections in both studies was not significantly higher than 
in those receiving placebo. 
SYK, another group of cytoplasmic tyrosine kinases, is expressed in most 
haematopoetic cells, including macrophages, neutrophils, B cells, naïve T cells and 
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mast cells. It is also found on platelets and some other non-haematopoetic cells 
including osteoclasts.438 439 It acts downstream to B cell receptors and Fc receptors. 
Though intracellular signaling, SYK can affect cell survival, proliferation, 
differentiation and cytokine release in immune cells440 and in non-immune cells e.g. 
osteoclasts has a role in cell differentiation and function. In two phase 2 clinical 
trials in MTX-IR RA, fostamatinib a SYK-inhibitor, showed significantly higher ACR 
20, 50 and 70 responses and DAS28 responses compared to placebo,441 442 
however in another, in bDMARD non-responders, the primary endpoint (ACR20 at 
week 12 for fostamatinib and methotrexate vs. placebo and methotrexate) was not 
met.443 In early DMARD-IR or DMARD-naïve RA, fostamatinib monotherapy was 
superior to placebo but less effective than adalimumab monotherapy in achieving 
clinical responses. 444 In a phase 3 trial of MTX-IR RA,  ACR responses at week 24 
were higher in the two fostamatinib groups that placebo but improvements were not 
as great as in the phase 2 trials. Radiographic progression was similar between the 
groups. 445 A phase 3 trial of a single TNFi-IR RA showed significantly higher 
ACR20 responses at week 24, but only in the group receiving fostamatinib 100mg 
bd compared to placebo.446 Diarrhoea, hypertension and headache were frequently 
reported adverse events. Following the results of these trials, the companies 
developing this drug has decided to put further studies on hold.444-446  
 
8.2.1.2 Treatment strategies  
Since the SLR in chapter 3, there have also been new strategies trials in early and 
established IA. 
8.2.1.2.1 Treatment strategies in established RA 
The multicenter non-inferiority TACIT trial compared combination csDMARD 
therapy to TNFi in patients with csDMARD-IR RA who would be eligible to 
bDMARD therapy according to UK NICE guidelines162.447 In this pragmatic open-
label RCT, 214 patients were randomised to receive additional csDMARD therapy 
followed by TNFi therapy at 6 months in cases of nonresponse, or immediate TNFi 
therapy switching to another TNFi at 6 months in cases of nonresponse. The study 
met its primary endpoint with a  ΔHAQ-DI at 12 months of -0.45 in the csDMARD 
group and -0.3 in the TNFi group, mean difference (95% CI) -0.14 (-0.29 to 0.01). 
This was below the pre-specified non-inferiority margin of 0.22. Clinical responses 
were achieved earlier in patients in the TNFi group, but at 12 months there were no 
significant between group differences, findings similar to those of the RACAT 
trial.242 There were 28 serious events (10 in the csDMARD group and 18 in the 
TNFi group. The number of patients with infections involving several body systems 
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were also higher in the TNFi group (54 vs. 30). Overall, however, number of 
adverse events was higher in the csDMARD group (635 vs. 465 in the csDMARD 
vs TNFi groups respectively). This study therefore highlights the benefits of treat-to-
target. Whilst there was a higher number of infections with bDMARD use, multiple 
csDMARD use was also associated with an increase in adverse events.  
Studies have also looked at bDMARD-free remission in established disease. In the 
open-label non-randomised HONOR trial, 75 patients with disease duration 
approximately 7.5 years, in DAS28-ESR remission (<2.6) for ≥ 6 months on stable 
dose methotrexate and adalimumab (without glucorticoids or NSAIDs) could 
choose to withdraw or continue adalimumab.448 At 12 months, 48 % who withdrew 
adalimumab (n= 52) maintained DAS28 remission vs. 83% in those who continued 
treatment (n=23). Greater depth of remission (DAS28-ESR ≤1.98) at treatment 
discontinuation was the main factor for remission maintenance. Of importance, 
control of disease activity could be re-established on restarting adalimumab and 
there was no radiographic progression and no loss of function with bDMARD 
withdrawal. This study adds to the body of evidence that bDMARD-free remission is 
achievable, even in patients with established disease. It also highlights the 
importance of achieving tight control of disease activity to enable bDMARD 
withdrawal – a treatment goal which is more easily attained in early disease. 
8.2.1.2.2 Treatment strategies in early IA 
There have also been several RCTs looking at remission induction strategies in 
early disease. In the U-ACT-EARLY strategy study, 317 patients with early DMARD 
naïve RA were randomised to receive tocilizumab and methotrexate, tocilizumab 
monotherapy and methotrexate monotherapy. Patients were seen monthly and 
treatment escalated if remission was not achieved. If in sustained remission 
(defined by a DAS28 <2.6 and SJC ≤4, sustained for ≥23 weeks, with the exception 
of ≤2 visits where the DAS28 could be ≥2.6 but <3.2) treatment was tapered and 
reintroduced at flare (DAS28 >2.6). Sustained remission was achieved in 86%, 
84% and 44% in the tocilizumab and methotrexate, tocilizumab monotherapy and 
methotrexate monotherapy groups respectively (p <0.002 for the tocilizumab and 
methotrexate vs the methotrexate and tocilizumab vs methotrexate, p=0.62 for 
tocilizumab and methotrexate vs. tocilizumab).   
In the SLR in Chapter 3, several studies showed that, in patients in whom remission 
or low disease activity was achieved, bDMARD therapy may be successfully 
withdrawn. This was particular so in early disease.2 449 450 Since then, the AVERT 
trial of MTX-naïve anti-CCP positive early RA,  has been published.451 In this RCT, 
the first to address drug free remission as a primary endpoint, a small but 
 234 
 
significant proportion of patients were able to successfully stop all therapy. Drug 
free remission after 12 months of DMARD therapy (DAS 28 (CRP) < 2.6 at 12 and 
18 months) was achieved in 7.8%, 12.4% and 14.8% in the methotrexate, 
abatacept, and methotrexate and abatacept groups respectively (OR (95% CI) for 
methotrexate and abatacept vs. methotrexate: 2.51 (1.02, 6.18), p=0.045 and for 
abatacept vs. methotrexate : 2.04 (0.81, 5.14)).  Factors predicting sustained 
remission on treatment withdrawal were lower mean symptom duration at baseline, 
DAS28(CRP), HAQ-DI and DAS28 (CRP) < 2.6 over time during the treatment 
period – features once again highlighting the importance of early treatment.   
Tapering csDMARDs has also been addressed in the tREACH trial.452 In this RCT 
which incorporated a treat-to-target strategy, patients receiving combination 
csDMARDs with glucocorticoids achieved earlier control of disease activity than 
those receiving methotrexate monotherapy with glucocorticoids however outcomes 
in both groups were similar at two years. Function, measured by the HAQ-DI score, 
however, was significantly better in the combination csDMARD group. In both, 
approximately 50% of patients achieved sustained remission but those in the 
combined csDMARD group required less TNFi therapy (21% vs. 38%). Those 
achieving sustained remission, a DAS < 1.6 at two consecutive visits, were eligible 
to taper DMARD therapy. Of those who did, 43% in both groups had a flare of 
disease activity (defined as an increase in DMARD therapy after tapering had 
commenced). Approximately 19% achieved drug free remission at the end of the 
two year period. Radiographic progression was low in both groups. 
 
8.2.1.3 How should IA be treated  
Findings from the SLR in chapter 3 together with the recently published studies, 
confirm the efficacy of bDMARDs in patients across the IA disease continuum from 
patients with UA to those with established RA and from DMARD-naïve through to 
those that had failed previous bDMARDs, in particular the TNFi therapies.  
With evidence highlighting the importance of treating patients at the earliest 
opportunity, several clinical trials have addressed the impact of bDMARD use as 
first-line therapy. These have compared combination therapy with methotrexate and 
a bDMARD to methotrexate monotherapy, 182 230 to other treatment combinations 
e.g. triple csDMARD therapy241 and to methotrexate with high dose oral or IV 
steroid. The more recent trials have also incorporated some form of treat-to-target 
strategy. 183 293 296 337 Overall, these have shown more rapid clinical responses with 
the use of bDMARD therapy but ultimately similar results in the non-bDMARD 
groups when treatment was escalated in the non-responders. This was seen 
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particularly in patients with early disease and when adopting a treat-to-target 
approach, escalating therapy when a treatment target (remission or low disease 
activity) was not met. These findings were supported by the results from the IDEA 
and EMPIRE studies (chapters  4 and 5 respectively).17 18 Furthermore, the ability 
to de-escalate bDMARD therapy is greatest in patients who achieve disease control 
early. 
The data therefore, first and foremost, support the need for early effective 
treatment. In addition, clinical and radiographic outcomes are improved with regular 
monitoring of disease activity and escalating therapy as part of a treat-to-target type 
approach. Regarding treatment choice, bDMARDs are highly effective therapies 
and have the potential for earlier clinical responses, lower radiographic progression, 
and the possibility of tapering and stopping therapy. A proportion of patients 
however will respond to csDMARD therapy and bDMARD therapies are still 
relatively costly. In the main, therefore, bDMARDs are only available to patients 
with active disease following failure of one or more cs-DMARD (depending on the 
governing body authorising their use).162 
The results from the SLR on bDMARD efficacy (Chapter 3),16 together with one on 
DMARD safety189 and the efficacy of sDMARDs and glucocorticoids, 453 were used 
to inform the 2013 EULAR recommendations on DMARD therapy for patients with 
RA. These are summarised in table 8.1. 209 The guidelines advocate the use of 
early treatment with csDMARDs and glucocorticoids, regular monitoring of disease 
activity, and treating-to-target. In patients in whom response to csDMARD therapy 
is inadequate, timely commencement of bDMARD therapy are advocated. With less 
data on the infliximab biosimilar DMARD, CT-P13 and the tsDMARD, tofacitinib, 
recommendations for their use are following treatment failure of the more 
established cs- and bDMARDs.209  
Over the past two decades, the treatment and treatment principles of IA have 
undergone many changes. It is likely that treatment strategies will continue to 
evolve with the newer emerging therapies and the work being done to gain further 
insights into the disease and treatment responses. These will be discussed in 
section 8.3.1 on future directions on the treatment of early IA.  
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Table 8.1 2013 update of the EULAR recommendations for the management of 
rheumatoid arthritis with synthetic and biological DMARDs (from Smolen et al. 
ARD 2014209) 
1. Therapy with DMARDs should be started as soon as the diagnosis of RA is 
made 
2. Treatment should be aimed at reaching a target of remission or low disease 
activity in every patient 
3. Monitoring should be frequent in active disease (every 1-3 months); if no 
improvement by at most 3 months after the start of treatment or the target 
has not been reached by 6 months, therapy should be adjusted 
4. MTX should be part of the first treatment strategy in patients with active RA 
5. In case of MTX contraindications (or early intolerance), sulphasalazine or 
leflunomide should be considered as part of the (first) treatment strategy 
6. In DMARD-naïve patients, irrespective of the addition of glucocorticoids, 
csDMARD monotherapy or combination therapy of csDMARDs should be 
used. 
7. Low-dose glucocorticoids should be considered as part of the initial 
treatment strategy (in combination with one or more csDMARDs) for up to 6 
months, but should be tapered as rapidly as clinically feasible 
8. If the treatment target is not achieved with the first DMARD strategy, in the 
absence of poor prognostic factors, change to another csDMARD strategy 
should be considered; when poor prognostic factors are present, addition of 
a bDMARD should be considered 
9. In patients responding insufficiently to MTX and/or other csDMARD 
strategies, with or without glucocorticoids, bDMARDs, (TNF inhibitors, 
abatacept or tocilizumab, and, under certain circumstances, rituximab) 
should be commenced with MTX 
10. If a first bDMARD has failed, patients should be treated with another 
bDMARD; if a first TNF inhibitor therapy has failed, patients may receive 
another TNF inhibitor or a biological agent with another mode of action 
11. Tofacitinib may be considered after biological treatment has failed 
12. If a patient is in persistent remission after having tapered glucocorticoids, 
one can consider tapering bDMARDs, especially if this treatment is 
combined with a csDMARD 
13. In cases of sustained long-term remission, cautious reduction of the 
csDMARD dose could be considered, as a shared decision between patient 
and physician 
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14. When therapy needs to be adjusted, factors apart from disease activity, 
such as progression of structural damage, comorbidities and safety issues, 
should be taken into account 
DMARD, disease-modifying antirheumatic drug; EULAR, European League 
against Rheumatism; MTX, methotrexate; RA, rheumatoid arthritis; TNF, 
tumour necrosis factor 
 
8.2.2 Update of early IA diagnosis 
Early treatment requires early disease identification. There are several stages along 
the IA disease continuum at which this may be achieved. Much  work thus far has 
been done to determine the progression from UA  to RA.80 210 367 The development 
of the 2010 ACR/EULAR RA classification criteria were developed to identify, 
among patients with IA, those with early RA, in particular those at greatest risk of 
developing persistent and /or erosive disease. These criteria have been shown to 
be more sensitive, although somewhat less specific, than the 1987 ACR criteria for 
the classification of RA.454-458 They have also enabled earlier identification of 
patients starting DMARD therapy.454 455 459 In a recent study, the use of these 
criteria have been assessed as a potential tool to help triage patients referred from 
primary care with possible IA.460 In this eight month prospective study, 143 referrals 
were included - 71 met the triage criteria and 72 did not. Of the patients whose 
referrals met the triage criteria and attended their rheumatology clinic 
appointments, 40% (25/63) were diagnosed with RA, compared to 2% (1/49) where 
the triage criteria were not fulfilled. The median wait time for a rheumatology 
appointment in each of the two groups was 7.9 weeks and 45.4 weeks respectively. 
Work from this thesis had addressed the earlier phases along the disease 
continuum - in patients with systemic autoimmunity associated with RA and 
symptoms without clinical arthritis (groups c+d13 using terminology proposed by the 
EULAR study group for risk factors for RA (table 8.2)).13  
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Table 8.2 Phases up to the development of RA 13 
 
(a) Genetic risk factors for RA 
(b) Environmental risk factors for RA 
(c )Systemic autoimmunity associated with RA 
(d) Symptoms without clinical arthritis 
(e) Unclassified arthritis 
(f) RA 
The term ’arthritis’ is used to denote clinically apparent soft tissue swelling or fluid 
(not bony overgrowth alone). 
(a) to (e) can be used in a combinatorial manner for example, an individual may 
have (a)+(b), or (a)+(b)+(c) or (a)+(b)+(d) etc. 
 
Initial estimates suggested that  approximately 1% of the general population are 
anti-CCP positive, with progression to IA occurring over a variable period of time, 
possible more than 10 years after initial antibody detection.376 In clinical practice, 
screening asymptomatic individuals for serological markers (group d)13 for the 
development of RA would therefore not be feasible. 
In a recent analysis from the European Perspective Investigation of Cancer in 
Norfolk (EPIC-Norfolk) UK cohort study, 18628 individuals aged 40-79 years were 
tested for anti-CCP. 461 Anti-CCP positivity in this population sample was 2.1%, with 
previous or current smokers (OR (95% CI) 1.29 (1.02 to 1.55) and 1.6 (1.95 to 
2.13)) and older age (OR (95% CI) 1.01 (1.00 to 1.03)) associated with antibody 
positivity.  There was a 10 fold increase of anti-CCP positive individuals 
progressing to IA within the following 3-10 years compared to those who were anti-
CCP negative,  supporting evidence for the role of anti-CCP in identifying an at-risk 
population. 
The results from chapter 7 showed that testing for anti-CCP in patients presenting 
with new nonspecific MSK symptoms in primary care enable the identification of an 
anti-CCP positive cohort at high risk of rapid progression to IA. Overall, there was a 
2.8% anti-CCP positivity in patients with new nonspecific MSK symptoms with 
approximately 45% developing IA, the majority within 12 months.  
Requesting anti-CCP tests has become more widely used in secondary care and in 
some primary care centres. In Alberta, Canada, for example,  some patients are 
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referred for rheumatology assessment on the basis of a positive anti-CCP test.462 
Over a three year period, it was noted that 11614 referrals were received and 
accepted for a rheumatology consultation via the Central Referral and Triage 
service in the Calgary Heath Region. Of these, 4.5% (568/11614) were referrals for 
a positive anti-CCP test. A proportion were thought to have RA by the referring 
clinician and in the majority (81.3% (61/75)), the diagnosis was confirmed. In 
addition, RA was diagnosed in half (120/239) of those that were termed unresolved 
or non-RA.  
The cohort study described in chapter 6 was one of the first prospective studies to 
address the role of anti-CCP in early IA diagnosis in secondary care. In this study of 
anti-CCP positive patients with MSK symptoms, half developed IA over a 6 year 
follow-up period, with a third showing disease progression within the first year. The 
clinical findings together with the use of serological markers, shared epitope, 
ultrasound scans of the wrists and hands and/or the genetic marker, enabled 
further risk stratification for disease progression.  
The number of patients in this study however was relatively small. Findings from 
the study will therefore need to be validated in a larger cohort.  
Improved understanding of the pathogenesis of the IA has led to the discovery of 
several new antibodies. The role of these and other biomarkers in this patient group 
also needs to be explored. Some of these will be discussed below. 
 
8.2.2.1 Anti-CarP antibodies  
The identification of antibodies to citrullinated proteins has improved our 
understanding of the RA. The presence of ACPAs, often measured using the anti-
CCP2 test, has been associated with disease progression19 367 395 and a more 
severe disease course, thus assisting with RA diagnosis and prognosis. 
Since its discovery, antibodies to other neo-self epitopes generated though 
processes of post-translational modification have been described.463 Antibodies to 
carbamylated proteins have also been found in patients with IA.464 Through the 
non-enzymatic process of carbamylation, cyanate reacts with lysine to produce 
homocitrulline.465 Interestingly, whilst homocitrulline and citrulline are structurally 
very similar, not all ACPA and anti-CarP antibodies have been found to be cross-
reactive.466 Anti-CarP antibodies have been documented in both anti-CCP positive 
(49%-73%) and in anti-CCP negative (8%-14%) RA patients.467  
Anti-CarP antibodies have also been detected in the sera of symptomatic blood 
donors prior to RA diagnosis, evidence for their presence during the preclinical 
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phase of the disease468 and may therefore play an important role in identifying 
ACPA negative patients at risk of disease progression. Presence of this antibody 
has also been associated with a greater risk of joint damage.98  
 
8.2.2.2 Malondialdehyde-acetaldehyde  
More recently, antibodies to a new post-translationally modified protein, 
malondialdehyde-acetaldehyde (MAA) have been described in RA.469 Reactive 
oxygen species can cause membrane lipid peroxidation, with the formation of highly 
reactive aldehydes that can modify peptides, in particular the amine of lysine 
residues, resulting in the formation of MAA products. Alterations in proteins by 
these MAA adducts can have deleterious effects on protein function and can alter 
inflammatory processes. These are produced during oxidative stress and may be 
associated with inflammation.470  
These antibodies have been seen in several conditions including diabetes mellitus 
and coronary artery disease.471 472 Thiele et al also found an increased 
concentration of MAA-modified proteins in the synovial tissue of patients with RA 
compared to OA.469 In RA synovium they co-localised with citrullinated proteins. 
Levels of antibodies to MAA have been found to be significantly higher in RA 
patients than in controls. They have been associated with RF and ACPA positivity 
and some measures of disease activity. No cross-reactivity has been seen between 
anti-MAA antibodies and ACPAs, suggesting that these are different antibody 
systems. IgG anti-MAA antibodies have been detected in 88% of ACPA-negative 
patients. Whilst they are not specific for RA, they may be another clinically useful 
biomarker for the disease.  
 
8.2.2.3 Magnetic resonance imaging 
Preliminary work has been done evaluating the use of MRI as an imaging 
biomarker in patients with symptoms but without clinical synovitis. One of the first 
studies looked at synovial histology and compared dynamic contrast-enhanced 
knee MRI scans of 13 arthralgia patients who were positive for IgM RF and/or 
ACPA and six healthy controls. Synovial volume, maximal enhancement and rate of 
enhancement and enhancement shape curve distribution of the knees were found 
to be similar between the two groups.473  
A subsequent cross-sectional study looked at MRI changes in small joints of the 
wrists, hands and feet. The mean combined inflammation scores (synovitis plus 
bone marrow oedema using the rheumatoid arthritis magnetic resonance imaging 
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score (RAMRIS)) of painful MCP and PIPs, wrists and MTPs were found to be 
higher in patients with anti-CCP positive arthralgia than those of asymptomatic 
controls but lower than anti-CCP positive RA patients (mean combined scores of 
the MCPs and PIPs: 0.1, 0.7 and 3.7 (p<0.001) in controls, anti-CCP positive 
arthralgia and anti-CCP positive RA patients respectively; mean scores of the 
wrists: 0.9, 2.3 and 10.3 respectively (p<0.001) ; and of the MTPs: 0.5, 0.9 and 3.8 
respectively (p=0.10)). In this study, however, relatively small number of joints per 
region were scanned (in the anti-CCP-positive patients: MCPs (n=4), PIPs (n=3), 
wrist (n=3) and MTPs (n=10)), and whist the patients received contrast-enhanced 
scans, the controls were scanned without contrast.396  
A longitudinal study of 28 anti-CCP positive arthralgia patients with three years of 
follow-up addressed the predictive value of MRI for progression to IA. MRI synovitis 
was found in the majority of patients (93%).474 Surprisingly, the median (IQR) 
cumulative MRI score in those who progressed was significantly lower than those 
who did not (9.0 (6.3-13.8) vs. 20.0 (10.8-21.8), OR (95% CI)  0.87 (0.76-0.99, 
p=0.03) although at a joint level, there was a trend towards earlier progression to IA 
in patients with a RAMRIS synovitis score of 2. Of note, low levels of imaging 
synovitis was also found in the four controls, and in both patients and controls, 
those who were older tended to have higher total MRI scores.  
In another study in patients with arthralgia and inflammatory symptoms (irrespective 
of autoantibody status), MRI scans were perform on the unilateral wrist, MCP joints 
2-4 and MTP joints 1-5 of 93 patients.134 MRI inflammation was defined by a 
combined RAMRIS score of synovitis, bone marrow oedema and tenosynovitis ≥3. 
In total, 44% were found to have subclinical inflammation. Patients with MRI 
inflammation were more frequently anti-CCP antibody positive than those without 
MRI inflammation (anti-CCP positivity: 22% (9/41) vs. 7.7% (4/52), p= 0.049). Ten 
out of 29 patients (34.5%) with MRI inflammation developed an IA within at least 
two months of follow-up.  
Overall these studies, all of which have been performed using 1.5T MRI scanners, 
have demonstrated the presence of subclinical synovitis and tenosynovitis in 
patients with symptoms without clinical synovitis, particularly in those who were 
auto-antibody positive. Longer follow-up in large cohorts however are needed to 
determine the role of MRI in identify patients at risk of IA disease progression. 
Positive findings in patients who did not progress and in controls475 also highlights 
the need for further work in determining cut-off’s of MRI scores for defining 
synovitis. Preliminary work in this regard has recently been presented on a cohort 
of 193 individuals without joint symptoms who underwent contrast enhance 1.5T 
MRI of the dominant wrist, MCTs and MTPs. Using a RAMRIS score ≥1, MRI-
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detected synovitis was seen in 48%, bone marrow oedema in 58% and 
tenosynovitis in 17%. In most individuals scores were low but a correlation between 
anatomical site and age was seen. Reference values have been calculated based 
on these.476 
 
8.2.2.4 Positron emission tomography 
Whilst ultrasound and MRI are able to detect synovial thickening, they are not 
always able to determine the metabolic activity of the tissue. Grey scale on 
ultrasound, for example, is not able to differentiate active from chronic synovitis, 
and enhancement on contrast MRI may be due to capillary permeability and 
hypervascularisation rather than synovial inflammation. 
Positron emission tomography (PET) is another modality that has been investigated 
for imaging arthritis. The radioligand 18F-fluorodeoxyglucose (18F-FDG) 
accumulates in metabolically active cells and can visualise synovitis in established 
RA.477 Macrophage-specific tracers, e.g. (R)-11C-PK11195 (1-(2-chlorophenyl)-N-
methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide),  which may be more 
specific for inflammation, has also been shown in one study, to detect subclinical 
synovitis in patients with RA.478 PET tracer uptake correlated significantly with 
CD68 staining of macrophages from synovial biopsies of the affected joint. In 
another study of 22 ACPA-positive arthralgia patients, increased uptake of (R)-11C-
PK11195 was seen in the hand or wrist of four patients. Two RA control patients 
also had increased tracer uptake in clinically inflamed joints but none of the six 
healthy volunteers had enhanced uptake. After two years, nine developed synovitis 
including all four patients who had baseline PET-positive findings.397 Further work in 
this area in larger cohorts will help determine whether this may be another tool to 
aid early IA diagnosis. 
8.3 Future Directions 
Whilst there has been a rapid expansion of knowledge and understanding in the 
field of early IA, there are still areas for further research to improve management of 
this disease. These will be discussed under three main headings, addressing (1) 
the treatment of early IA, (2) diagnosis of early IA and the potential for (2) 
prevention in early IA.   
 
8.3.1 Treatment of early IA 
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Over the past two decades there has been a surge of new therapies for the 
treatment of IA including bDMARDs, bsDMARDs and small molecules (discussed in 
section 8.2.1.1). All have undergone clinical trials in patients with RA who have 
failed one or more csDMARD or TNFi. Information from open-label extension 
studies following these trials and from registries will be important to provide long-
term efficacy and safety data on these drugs. Their efficacy in early IA, in particular 
DMARD-naïve IA, still need evaluation.  
With the number of new therapies, in particular the bsDMARDs, it is likely that the 
cost of these highly effective therapies will decrease.  Whilst bsDMARDs are not 
identical to their originator bDMARD, their efficacy and safety profiles from clinical 
trial data look promising. It is possible that, in time to come, bDMARD or bsDMARD 
induction strategies followed by treatment reduction and maintenance with fewer 
drugs may become more cost-effective options for treating IA. 
The newer drugs also target different sites in the immune system, increasing the 
types of therapies available. Routes of administration also differ, with the small 
molecules offering the possibility of oral therapy. The increasing number of options 
raises the question regarding the optimal choice of DMARD for an individual 
patient. Ideally treatment should be tailored such that the right drug is given to the 
right patient at the outset. Evidence from clinical trials and experience in clinical 
practice highlight the fact that response to treatment in patients with IA is variable. 
Thus whilst csDMARD therapy, including methotrexate monotherapy, may be the 
treatment of choice in a sizeable proportion of patients (approximately 40%),183 240 
others may benefit from early bDMARD therapy or other combinations of DMARD 
therapies. Identifying  patients who will respond to a particular DMARD or DMARD 
strategy would allow for safer, more effective treatment, and potentially the 
achievement of bDMARD free - or even drug-free remission.  
One study addressing the immunological changes in early RA has shown that 
baseline T-cell analysis may predict response to methotrexate.375 In this group of 
patients with DMARD naïve early RA, higher naïve T cell frequency was associated 
with remission. Analyses of synovial tissue samples in patients with established RA 
looking at gene expression, histology and cellular analysis, have also been done.479 
480  Several histological phenotypes - lymphoid, myeloid, low inflammatory and 
fibroblast patterns – have been described in patients with RA. Synovial histology 
findings, together with analyses of serum biomarkers in patients from the ADACTA 
trial which compared adalimumab and tocilizumab monotherapy in MTX-IR RA,275 
suggest that molecular and cellular differences may enable prediction of response 
to therapy. Patients with a so-called ‘myeloid phenotype’ have been found to have 
high levels of intracellular adhesion molecule (ICAM) 1. The presence of both 
 244 
 
‘myeloid phenotype’ and ICAM 1have associated with a better clinical response to 
TNFi therapy. The lymphoid and fibroid phenotypes, however did not show 
correlation with response to treatment. Further research of large cohorts in early RA 
e.g. the Pathobiology of Early Arthritis Cohort (PEAC)429 will be helpful in providing 
further insights into the early phases of the disease and possibly the identification of 
synovial and systemic biomarkers to predict treatment responses in different patient 
groups.481 
One may also learn from other areas of medicine where one condition may have 
several treatment options but where individual responses differ and a need for so-
called ‘personalised’ medicine is required. In the field of oncology, a new approach 
to clinical trial design has been suggested in which novel treatment evaluation 
occurs alongside the evaluation of a biomarker within a phase II/III study setting.482 
This type of study would answer three questions (1) does the new therapy provide 
a signal of response in different biomarker-defined populations, (2) if so, are 
outcomes definitively improved and (3) is this restricted to the biomarker-defined 
populations. Because this study design would allow the evaluation of multiple 
treatment and biomarkers, a large number of patients would fulfil study inclusion 
criteria. As an adaptive trial design, any new treatment which proved ineffective 
could be stopped and new biomarkers that appeared promising could be added and 
patients restratified. New treatments would be compared to placebo or standard 
care. Patients who do not wish to receive new therapies would therefore also be 
able to participate in the study and receive conventional therapy and be stratified 
according to whether they were biomarker positive or not. The FOCUS4 study of 
patients with metastatic colorectal cancer is the first multicenter parallel biomarker-
stratified RCT which is currently underway.  
Extrapolating this biomarker-stratified trial design to clinical trials in IA may be a 
method that would help evaluate novel therapies and biomarkers to determine 
optimal individual treatments. Alternatively the active arms may compare different 
treatment strategies (e.g. bDMARD and methotrexate vs. triple therapy with 
methotrexate, sulphasalazine and hydroxychloroquine) rather than a new therapy to 
standard therapy or placebo. An example of a biomarker stratified RCT is illustrated 
in figure 8.1.
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Figure 8.1 Biomarker stratified randomized controlled trial, adapted from Kaplan et al., Journal of Clinical Oncology 2013482 
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8.3.2 Diagnosis of early IA 
The work on early diagnosis in this thesis (chapters 6 and 7)  highlights the need for 
a cost-effective care pathway to identify patients with IA early. Delays in treatment 
have been associated with increasing joint damage and function.8 78 In 2009, the 
U.K. National Audit Office estimated that the cost of RA to the NHS was 
approximately £560 million per annum and that of work-related disability and sick 
leave approximately £1.8 billion a year.401 Identifying at-risk individuals during an 
early treatable stage has the potential to reduce the long-term costs (both health 
related and those due to work-related disability). It may be health-service 
dependent, and therefore differ in different countries. In places where primary care 
is the main first point of patient contact, further work in this area will need to 
continue fostering close collaboration with GPs and health professionals to identify 
patients at risk of IA in the earliest stages.483 Expanding on the research outlined in 
chapters 6 and 7 and the use of additional biomarkers described in section 8.2 may 
further refine the means to identify and stratify patients at risk of IA in both primary 
and secondary care, working towards the development of a cost-effective clinical 
decision tool. 
Thus far, most of the discussion in patients at risk has focused on patients with 
symptoms without clinical arthritis. Family members of patients with RA form 
another at-risk group. Twin studies suggest that genetic factors contribute about 
60% to the development of RA,51 53 and over 100 genetic loci have been associated 
with the condition.484 The risk of RA in FDRs has been estimated be 3-9 time higher 
than that of the general population.485 Whilst population screening would not be 
cost-effective, studying family members, a group at increased risk of developing 
RA, 486-488 may provide further insights into early disease diagnosis. In a large US  
multicentre prospective cohort study of RA FDRs, 55% (538/1058) had one or more 
copies of the shared epitope and 15.9% were autoantibody positive (anti-CCP 
1.7%, IgM-RF 4.7%, IgG-RF 6.2% and IgA-RF 3.8%).489 During the initial follow up 
period, four FDRs developed RA (6.7 cases per 1000 person-years), an incidence 
rate for RA similar to that described in previously evaluated FDR cohorts.486 Work 
similar to that described in chapter 7 is currently underway testing FDRs for the 
presence of anti-CCP antibodies. A larger national study (PReVeNT RA) is also 
being undertaken to establish a national register of FDRs of patients with 
established RA.490 The study aims to assess various factors including genetic and 
lifestyle and other biomarkers of the disease.  
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8.3.3 Prevention of early IA  
Whilst clinical trials of DMARD therapy in early IA have shown good clinical and 
radiographic results, 236 238 288 289 a proportion of patients will continue to have 
ongoing disease. Earlier therapy has been associated with improved clinical 
outcomes, less  joint damage, a higher chance of achieving remission and lower 
mortality rates.8 26 78 491 Not only is earlier treatment important for clinical response, 
but is has been hypothesised that there may be a period very early on in which the 
disease process may be altered or even  reversed.148 A recent study of two early 
arthritis cohorts showed that the effect of time of treatment initiation on achieving 
drug-free free remission was non-linear with the highest change of achieving this 
being early in the disease course, 492 suggesting that there may be a ‘window of 
opportunity’ for IA treatment. 
Immunological findings also suggest a window in the pre-clinical period during 
which a number of changes occur. In at-risk cohorts have demonstrated that ACPA 
and RF levels rise during the phase just before the development of clinical 
disease.376 377 Abnormal IgG galactosylation has also been shown prior to RA 
disease onset, possibly suggesting a process of post-translational modification 
rendering these antibodies more pathogenic.493 Rise in antibody levels has been 
associated with an increase in cytokine and chemokines, including some which are 
targeted by current RA therapies, including TNFα, IL-1 and ILF-6, just before 
disease onset. High antibody levels have also been associated with an epitope 
spreading (an increase in the number of citrullinated epitopes) 386 494 and isotype 
switching,  resulting in greater diversity in antibody structures and  function. 
Notably, whilst many ACPA isotypes are present before diagnosis, isotype 
distribution does not seem to expand significantly from progression from UA to 
RA381 suggesting that most of the changes occur during the preclinical phase.495 
Avidity maturation has also been shown to occur before disease onset with 
stabilisation at disease onset.496 99  
It is likely, therefore, that if a window of opportunity for intervention truly exists for 
modifying the disease, that it would be at a very early stage, possibly within the pre-
clinical phase. Clinical trials have begun to address the potential for IA prevention. 
In 2010 Bos et al. treated 83 anti-CCP or IGM-RF positive patients with arthralgia 
with two dose of IM dexamethasone or placebo. Whilst the glucocorticoid reduced 
ACPA and RF levels, progression to clinical IA was not prevented.497 The first RCT 
addressing the use of  bDMARDs in IA prevention was initiated in 2009. In the 
PRAIRI study (prevention of clinically manifest rheumatoid arthritis by B cell 
directed therapy in the earliest phase of the disease), RF or ACPA positive patients 
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without clinically apparent IA and either elevated CRP or evidence of synovitis on 
imaging were randomised to receive a single dose of rituximab or placebo The 
primary outcome is the difference in number of patients who develop RA at 4 
years.498 In the U.K., the APIPPRA (Arthritis Prevention In the Pre-clinical Phase of 
RA with Abatacept) trial, a multicentre RCT comparing abatacept to placebo in 
patients, seropositive for RF and/or anti-CCP at risk of RA, has just begun.499 The 
results of these trials will be of value not only in their primary outcomes but also to 
further the understanding of the immunological changes of the disease and help to 
inform future studies. 
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8.4 Conclusions 
Work undertaken in this thesis has focused on the diagnosis and treatment of early 
inflammatory arthritis, particularly with the use of bDMARDs.  
Early effective DMARD therapy and the use of treat-to-target strategies (with 
regular monitoring of disease activity and treatment escalation if disease control is 
not achieved) are two important principles in the management of patients with IA. In 
terms of therapies, bDMARDs have transformed patient outcomes in early IA. 
Studies identified in a SLR of bDMARDs in IA, and two RCTs - one in early RA (the 
IDEA study) and the other in early IA (the EMPIRE study) - have demonstrated 
rapid induction of clinical responses, improvement in function and prevention of 
joint damage with bDMARD therapy. Induction with bDMARDs has also enabled 
the potential for treatment de-escalation and DMARD-free remission. Whilst the 
effects of csDMARDs were somewhat slower, their use has been associated with 
similar long-term clinical outcomes, particularly within a treat-to-target approach in 
early disease. At present, the majority of guidelines therefore still place bDMARDs 
after failure of one or more csDMARD(s). 
The emergence of novel therapies, however, including newer biological and 
biosimilar DMARDs and small molecules, continue to increase the armamentarium 
of therapy. It is possible that with the number of available therapies, the cost of 
these highly effective drugs will fall and that bDMARD induction strategies may 
become a possible treatment option. With the increasing number of available 
therapies, research addressing biomarker responses to treatment are also 
becoming increasingly important to enable a more tailored treatment approach for 
an individual patient.  
The importance of early treatment has also placed greater emphasis on early 
diagnosis. Cost-effective clinical decision tools for early diagnosis are needed. The 
use of anti-CCP antibodies in patients with new MSK symptoms has enabled the 
identification of individuals at risk of rapid progression to IA. Together with 
biomarkers available in clinical practice including MSK ultrasound, patients may be 
further risk stratified for the development of clinical IA.  
Studies addressing treatment during the very earliest phase of the disease - in at-
risk individuals will  improve the understanding of pathogenesis of the disease. 
These may have the potential to alter and in future possibly lead to the prevention 
of inflammatory arthritis.  
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